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ABSTRACT 
 
TITLE:  Post-tuberculosis lung damage in Malawian adults 
AUTHOR: Dr Jamilah Meghji 
 
INTRODUCTION: 
Pulmonary tuberculosis (PTB) remains an important risk factor for chronic lung disease (CLD) in sub-
Saharan Africa (sSA), but our understanding of the nature of post-TB lung damage, its evolution over 
time, and the associated morbidity remains limited. This information is needed to inform clinical care 
and health system approaches to the management of those surviving PTB disease.   
 
METHODS: 
A general review of the literature on CLDs in sSA, TB disease and epidemiology, and post-TB lung 
damage and its associated morbidity were completed, followed by a systematic review of the 
prevalence and pattern of post-TB structural lung pathology.  
 
Primary data presented in this thesis were drawn from two studies based in urban Blantyre, Malawi. 
The first was a cross-sectional survey of respiratory abnormalities amongst adults in the community 
which was completed as part of the Burden of Obstructive Lung Disease (BOLD) initiative. The second 
was a prospective cohort study of HIV-positive and negative adults completing treatment for PTB 
which aimed to describe a) the prevalence of respiratory pathology at TB treatment completion using 
symptoms, quality of life scores, spirometry and high-resolution CT imaging, and b) the relationships 
between post-TB lung damage at treatment completion and adverse outcomes over 1-year of follow-
up.   
 
RESULTS: 
The systematic review identified 39 studies of variable quality describing post-TB structural lung 
damage. A lack of prospective data, and data from sSA and HIV-positive groups was noted. Few studies 
related structural damage to symptoms, spirometry, or morbidity.  
 
The BOLD data estimated a high burden of respiratory symptoms and abnormal spirometry amongst 
adults aged ≥18 years in urban Blantyre: 11.8% reported ≥1 symptom, and 4.8% had airway 
obstruction. The prevalence of the low-FVC pattern of abnormal spirometry varied according to the 
reference range used for standardisation, from 9.0% (local reference range) to 38.6% (NHANES III 
reference range).  
 
A considerable burden of residual lung pathology was seen amongst 405 adults completing treatment 
for PTB in Blantyre: 60.7% had ongoing weekly/monthly respiratory symptoms, and 34.2% of 
participants had abnormal spirometry at PTB treatment completion. Participants had a median of 1.4 
lobes of abnormal parenchyma on CT imaging. Moderate-severe bronchiectasis was seen in 44%, and 
9.6% had ≥1 ‘destroyed’ lobe. The burden of pathology was lower in HIV-positive vs. HIV-negative 
adults, but patterns of abnormality were similar. The odds of ongoing respiratory symptoms or an 
impaired quality of life at 1-year were over three-fold higher amongst those with both extensive 
structural damage and abnormal spirometry at PTB treatment completion.  
 
CONCLUSION: 
Post-TB lung damage is a common but neglected form of CLD amongst both HIV-positive and negative 
adults in Malawi, and occurs against a high background prevalence of respiratory symptoms and 
abnormal spirometry in the community. Severe forms are associated with considerable ongoing 
morbidity including persistent symptoms and reduced quality of life. Further work is required to 
understand the range of patterns of post-TB lung damage, and their relationship with long-term 
outcomes such as respiratory exacerbations and mortality. However, this is a neglected population 
and interventions to maximise their health following PTB treatment completion are required.
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1 INTRODUCTION 
In this brief introductory chapter, the context and rationale for the body of work presented in this 
thesis is described followed by an outline of the content of each of the chapters.  
1.1 MALAWI 
Malawi is a land-locked country in sSA with an estimated population of 18 million people.1 48% of the 
population was aged under 15 years in 2016.2 Rapid growth is ongoing as a result of high total fertility 
rates (4.4 children per woman), and falling under-5 mortality rates (234 deaths/1000 live births in 1992 
vs. 63 deaths/1000 live births in 2015-16). Forecasts based on the 1998 Malawi population census 
predict that growth will continue at a rate of 3.2-3.4% per annum through to 2023, with the largest 
increases expected in young and older adults.3 Malawi remains largely rural, with 82% of men and 81% 
of women living in rural areas.2 However, in keeping with patterns seen across sub-Saharan Africa, 
rural to urban migration is ongoing and urban populations are expanding. Blantyre is the second city 
in Malawi. It is located in the densely populated Southern region, and has an estimated population of 
over 1 million, many of whom live in rapidly growing informal settlements around the city centre. The 
city is situated in the Shire highlands, in a hilly area, and sits at an altitude of 780 – 1612m from sea 
level.  
Malawi is an economically vulnerable country. Agriculture is the dominant sector but suffered heavy 
blows due to flooding in 2014/15 and drought in 2015/16. Energy shortages hamper growth, with 
electricity access available to only 4% of rural and 49% of urban households, and frequent supply 
shortages seen in recent years.2 Inflation stabilized from 218% in 2016 to 12.3% in 2017 as a result of 
good harvests,4 but poverty remains widespread and is particularly marked in rural areas where wealth 
indices are low. The Gross national income (GNI) per capita was $320 in Malawi in 2016, compared to 
the UK where the GNI was $42,370 in the same year.1 Although 91% of households in urban areas fall 
into the highest two national wealth quintiles, it must be noted that this is a relative measure and that 
even these ‘wealthy’ households have limited resources and expenditure. The proportion of men and 
women who were employed in the week prior to the 2016 Demographic Health Survey (DHS) was 73% 
and 54% respectively in urban and rural areas. Educational attainment throughout the country 
remains low – only 26% of women and 36% of men aged 15-49 years have at least some secondary 
education, and 72% of women and 83% of men are literate.2  
The burden of tuberculosis (TB) is high in Malawi, and is addressed by a strong and well-functioning 
TB National Treatment Programme (NTP). The most recent TB prevalence survey in 2014 reported a 
national prevalence of microbiologically confirmed PTB of 452/100,000 (95% CI: 312-593), and smear 
positive PTB of 220/100,000 (95% CI: 142-297).  Nationally, 16,959 confirmed cases of TB disease were 
notified in 2016, of which 53% were HIV co-infected.5 TB treatment services in Malawi are 
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decentralized – treatment registration and monitoring is provided by TB officers within local health 
centres, with referral to hospitals only as required. TB diagnostics are largely limited to sputum smears 
in community settings, with XPert MTB/RIF and chest radiography available only at tertiary centres on 
referral. Sputum culture is routinely performed at the National Reference Laboratory for retreatment 
cases, but is not generally available for new cases. In most settings TB management is provided 
separately to other medical services.  Drugs are provided free of charge to patients on a 2-weekly basis 
during the first 2-month intensive phase of treatment, and monthly thereafter, in order to support 
compliance and regular review. Direct observation of treatment is not performed on site, but all 
patients are asked to appoint a guardian to sign for medications as they are taken in the home setting. 
In the event of a patient not attending for follow up, health centres are mandated to follow individuals 
in the community using the contact details provided. Treatment success (patients classified as having 
treatment cure or completion) was reported for 81% amongst new / relapsed TB cases registered 
during 2015.5 That is, 4 out of 5 patients registered for TB treatment in Malawi are thought to survive 
to treatment completion, with microbiological cure or clinical resolution confirmed. 0.4% of new cases 
and 4.8% of retreatment cases were documented to have MDR in the national drug resistance survey 
in 2010-11.6 
Malawi has a generalized HIV epidemic with an estimated national prevalence amongst those aged 
15-49 years of 11.2% (10.5-11.9%) in women and 7.1%(6.7-7.5%) amongst men in 2016.7 Estimated 
annual incidence is 4.15/1000 population for adults aged 15-49 years. Data from Blantyre, obtained 
through a recent self testing programme, suggest a peak prevalence amongst those aged 40-49 years 
of 22.5% (95% CI 19.4%– 25.8%).8 However Malawi is a country with a strong and forward looking HIV 
strategy: it was the first country to adopt Option B+ whereby all pregnant women are provided with 
antiretroviral treatment (ART) at diagnosis which is continued for life, and an early adopter of the ‘Test 
& Treat’ strategy with early initiation of ART for all individuals receiving a positive HIV diagnosis. ART 
uptake is correspondingly high. Anti-retroviral drugs are provided free to all patients, and the current 
first line regimen includes tenofavir, lamivudine and efavirenz, and can be used concurrently with 
standard TB treatment. Co-trimoxazole is also provided free of charge to all patients. CD4 counts are 
varyingly performed in patients at HIV diagnosis. Viral loads are not yet widely available and whilst 
recommended for those who develop TB disease and are already HIV positive and on ART with good 
compliance, to investigate for treatment failure, this is not routinely done. Isoniazid Preventative 
Therapy (IPT) was not in programmatic use for the majority of this study, but was introduced in 
December 2017. 
1.2 POST-TUBERCULOSIS LUNG DAMAGE 
Non-communicable diseases (NCDs) are a key driver of morbidity and mortality worldwide: The Global 
Burden of disease studies estimate that chronic diseases were responsible for 69% of all deaths 
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(38.3/54.9 million) globally in 2013,9 and 61.5% (1.47 /2.39 billion) of all disability adjusted life years 
lost worldwide in 2016.10 Cancer, cardiovascular diseases, chronic respiratory disease, and diabetes 
have been highlighted as areas of concern, and target 3.4 of the Sustainable Development Goals (SDG) 
demands a one-third reduction, relative to 2015 levels, in the probability of dying between 30 years 
and 70 years of age from these diseases by 2030. Progress to date has, however, remained slow – the 
effect of NCDs is felt disproportionately by those living in low and middle income countries (LMICs), 
and rates of decline are stagnating in many of these countries such that they are likely to miss this SDG 
target by tens of years.11  
The ongoing high burden of chronic lung diseases (CLDs) in LMICs is of particular concern. Many known 
risk factors for respiratory disease are poverty associated and common in these settings. These include 
limited in utero growth as a result of poor maternal health, recurrent respiratory infections in 
childhood, and exposure to indoor and outdoor air pollution, tobacco smoke, HIV infection, and TB 
disease across the life course. Despite the widespread nature of these risk factors, data on the 
epidemiology, nature and outcomes of respiratory disease in these settings remains limited, such that 
the development of health services for prevention and management is extremely challenging.  
Residual lung damage after pulmonary tuberculosis may be a particularly important but neglected 
type of chronic lung disease in many LMICs. Despite many years of concerted effort, WHO estimates 
suggest that there were 10.4 million incident cases of active tuberculosis (TB) disease in 2016, one 
quarter of which occurred in the African region, where TB remains a disease of young adults and the 
majority of incident cases are seen in those aged 15-44 years.12 Amongst those started on treatment 
for drug sensitive disease globally, it is thought that >80% survive with treatment cure / completion. 
TB management programmes have traditionally discharged these ‘TB survivors’ from health services 
as ‘cured’ at the end of standard short-course therapy, with no ongoing follow-up, but evidence for 
lasting post-TB sequelae amongst this group is growing. This is particularly evident for individuals who 
have completed treatment for pulmonary tuberculosis disease (PTB) who appear to be at increased 
risk of persistent abnormal spirometry after treatment completion, with significantly increased odds 
of residual airway obstruction and spirometric restriction demonstrated in several systematic 
reviews.13-15  
Despite growing concerns that post-TB lung damage may be a key form of chronic respiratory 
pathology in LMICs, our knowledge of this condition remains limited: few studies have attempted to 
comprehensively characterise post TB lung pathology, to describe the evolution of damage over time, 
or to measure its associated morbidity and mortality. Data on the nature and impact of post-TB lung 
damage amongst HIV infected adults and those living the sub-Saharan African (sSA) setting are 
particularly scarce.  
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This PhD was completed in response to the need to address the high burden of CLDs in LMICs, and the 
indication that post-TB lung damage may be an important but neglected contributor to CLD in this 
setting. Its overall aim was to review and document the current body of literature on post-TB lung 
damage, and to establish a representative cohort of adults completing PTB disease in sSA amongst 
whom the prevalence, pattern and impact of post-TB lung damage could be measured, and placed in 
the context of the community burden of CLD.  
1.3 THESIS STRUCTURE 
This thesis starts with a broad review of the literature that summarises the scientific context for the 
novel work described in the following chapters. In Chapter 2 the burden of NCDs in sSA and Malawi in 
particular, the epidemiology and clinical management of tuberculosis disease, mechanisms of 
tuberculosis related lung damage, and the nature and impact of post-TB lung damage are reviewed. 
Approaches to the measurement of lung damage and patient centred outcomes in CLDs are discussed. 
Chapter 2 identified a need for a systematic review of the literature on the prevalence and pattern of 
structural post-TB lung damage, which was done and is presented in Chapter 3.  
Chapter 4 describes a population-based cross-sectional study of chronic symptoms and spirometry 
amongst adults in urban Blantyre which was done to understand the burden of chronic respiratory 
disease amongst ‘well’ adults in the community in Blantyre, and provide a comparator for the cohort 
study described in Chapter 5.  
Chapter 5 is the centrepiece of this thesis and describes a prospective cohort study of adults 
completing treatment for pulmonary TB in Blantyre. This study measured the prevalence and pattern 
of post-TB lung pathology amongst HIV-positive and negative adults at TB treatment completion, and 
its evolution over a 1-year follow up period, and explored the association between severe residual 
lung damage and patient outcomes.  
Finally, Chapter 6 is a general discussion that draws together the findings of all the Chapters and 
outlines implications for future research and policy.  
The three chapters (3, 4 and 5) that describe the novel work of this thesis are written as standalone 
studies in accordance with the relevant PRISM and STROBE guidelines, each with introduction, 
methods, results, discussions and conclusions sections. Although this makes for long individual 
chapters – particularly Chapter 5 – it is hoped that this consistent approach and alignment with 
international reporting guidelines will be helpful to the reader.  
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2 LITERATURE REVIEW 
This Chapter provides a broad review of the literature on NCDs and TB, and summarises the scientific 
context for the novel work described in later sections of this thesis. 
Literature describing the burden and patterns of chronic lung disease (CLD) in sSA is scarce. A general 
overview of this literature is given here, with a focus on Malawi.  
In contrast, the body of literature on tuberculosis is vast – although the Mycobacterium tuberculosis 
organism was not discovered by Robert Koch until 1882, the disease has been present for centuries 
and there exists a great catalogue of pure science, clinical and public health work describing the 
condition. In this introduction I have focused mainly on the literature most relevant to TB related 
respiratory damage, including brief overviews of the epidemiology, diagnosis and management, and 
current understandings of the mechanisms of TB-related lung damage. Existing data on the nature of 
post-TB lung damage (PTLD) and its associated morbidity are outlined, and gaps in our knowledge 
highlighted. Lastly, potential approaches to the measurement of post-TB lung damage in resource 
poor settings, which have informed the work described in subsequent chapters, are discussed.  
2.1 CHRONIC LUNG DISEASE IN SUB-SAHARAN AFRICA 
Non-communicable diseases (NCDs) are widely recognized as leading causes of morbidity and 
mortality worldwide – the Global Burden of Disease study 2013 estimated 38.3 million (95% CI: 37.2 – 
29.4m) NCD related deaths in 2013, with 4.2 million (95% CI: 4.0 – 4.7m) of these attributed to chronic 
lung diseases. The importance of tackling high burden NCDs has been enshrined in the Sustainable 
Development Goal target 3.4, which requires a one-third reduction, relative to 2015 levels, in the 
probability of dying between 30 years and 70 years of age from cancers, cardiovascular diseases, 
chronic respiratory diseases, and diabetes by 2030.  
2.1.1 RISK FACTORS FOR CHRONIC LUNG DISEASE IN SSA 
At the time of starting this PhD few data were available on the burden of CLDs in the sSA region, but 
many acknowledged risk factors for chronic respiratory damage are known to converge here. These 
include poverty-related in-utero and early childhood exposures, biomass fuel exposure, a rapidly 
increasing prevalence of smoking, chronic HIV-infection, and of course a persistently high incidence of 
pulmonary tuberculosis.16   
There is strong evidence of in-utero and early childhood exposures constraining lung growth in the 
early years of life. Many risk factors for reduced growth are poverty-associated and common in low 
resource settings, including maternal malnutrition, maternal smoke and pollution exposure, fetal 
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prematurity and intrauterine growth restriction, and early childhood lower respiratory tract 
infections.17 Longitudinal studies suggest that children with impaired lung development as a result of 
these factors go on to have lower lung function in adulthood.17 The broad impact of these insults on 
general health may explain the association between low FVC volumes and mortality which has been 
observed amongst asymptomatic adults,18 and the higher and earlier incidence of cardiac and 
metabolic comorbidities experienced by young adults with impaired lung function, as they age. 19 
It is thought that 1/3 of the world’s population use solid fuel combustion for cooking, heating and 
lighting. The majority of these individuals live in low and middle income countries (LMICs): data from 
Malawi suggest that even in urban settings, individual level exposures to pollutants released by 
biomass used including PM2.5 and CO frequently exceed WHO recommended ranges.20 Biomass fuel 
exposure has been associated with childhood respiratory tract infections, chronic obstructive 
pulmonary disease (COPD), and respiratory malignancy, and is thus a major risk factor for CLDs in sSA. 
The growing prevalence of tobacco use in sSA is of also concern: a 2009 review of tobacco use in Kenya, 
the Gambia, Uganda and Liberia found a prevalence of current smoking of between 5-54% depending 
on the population sampled, with male dominance noted throughout.21 Tobacco consumption in many 
LMICs is increasing, and it has been estimated that by 2030, 70% of global tobacco related deaths will 
occur in developing countries.22 Uptake of tobacco monitoring and prevention policies in many of 
these regions have however been slow.23 Malawi remains particularly vulnerable – its economy 
remains reliant on exports of tobacco crop, and perhaps in relation to this Malawi has only limited 
cigarette taxation, no smoke-free policies, no health warnings on tobacco products, and no tobacco 
advertising bans in place.22 
HIV infection is known to increase the incidence of severe respiratory tract infection across all age 
groups, and in advanced immunosuppression is associated with opportunistic respiratory infections 
such as Pneumocystis jirovecii (PCP), Cryptococcus neoformans, and Histoplasma capsulatum.24  
Chronic HIV infection has also been associated with CLDs – increased odds of airway obstruction and 
accelerated rates of lung function decline have been demonstrated in HIV-positive western cohorts, 
as well as a high incidence of pulmonary hypertension25. It has been suggested that this is the result 
of immune activation and subsequent immune senescence caused by chronic HIV-disease, both 
directly and through associated chronic/recurrent bacterial and viral infections.26 High rates of 
obliterative bronchiolitis have been detected amongst adolescents with vertically acquired HIV in sSA, 
with the same underlying mechanism postulated here.27 
2.1.2 BURDEN OF CHRONIC LUNG DISEASE IN SSA 
Despite the presence of multiple risk factors for CLD in sSA, and the resulting suspicion of a high burden 
of disease in this setting, few robust data on the epidemiology of disease in this region were available 
until the start of The Burden of Obstructive Lung Disease (BOLD) initiative in 2005.28 This was a multi-
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country programme of work primarily designed to measure the prevalence of chronic obstructive 
pulmonary disease (COPD) amongst adults >40-years around the world, using standardized 
community sampling approaches, questionnaires, and spirometry procedures in multiple study sites, 
with centralized quality control and data analyses.  
Data for the first 12 sites was published in 2007, and included findings from Cape Town, South Africa 
where the prevalence of moderate-severe airway obstruction was found to be particularly high at 
19.1%, compared to prevalence estimates of 5.9 – 14.3% from sites in Western Europe and North 
America.29 This finding sparked much concern, and resulted in BOLD studies being initiated at several 
other African sites for comparison.   
In fact,  data from Tunisia, Morocco, Nigeria, and Malawi have shown a much lower prevalence of 
obstruction than that seen in Cape Town – the estimated population prevalence of obstruction ≥GOLD 
stage II (FEV1/FVC ratio<0.7 and FEV1 <80%)  was 7.9% in Morocco and 4.2% in Tunisia,30 31 and the 
prevalence of any obstruction (FEV1/FVC ratio<0.7) was 6.7 – 8.7% in Nigeria,32 8.7% in rural Malawi 
and 4.2%  in urban Malawi.33 34 The dominant pattern of abnormality observed across these sites was 
instead a low FVC pattern, or a picture of reduced lung volume. If standardized against a Caucasian 
American population using the National Health and Nutrition Examination Survey III (NHANES III) 
reference ranges, the population prevalence of reduced FVC was estimated at 70.4 – 72.8% in Nigeria, 
38.6% in urban Malawi, and 34.8% in rural Malawi.33-35 These findings suggest that it is small lungs, 
rather than obstructed airways, which is the dominant deficit in the African setting.  
There remains much debate about the underlying cause of this low FVC pattern. It is possible that 
black African populations have lower ‘normal’ lung volumes compared to Caucasian Americans due to 
genetic differences. However, some have argued that optimal lung volumes are likely similar across 
ethnic groups, with the low lung volumes observed in the African setting reflecting widespread in utero 
or early childhood exposures which have prevented optimal lung development.36 This will be discussed 
in greater detail below.  
Although the burden of airway obstruction may be lower across sSA than initially suspected, where 
obstruction is seen, exposures other than tobacco may be important risk factors in this setting. Never-
smokers made up 1/3 of those with airway obstruction across 14 of the earliest BOLD study sites,37 
and many had high exposures to biomass fuel and occupational dusts. An association between poverty 
and obstructive FEV1/FVC ratios has been demonstrated both within and between populations from 
14 LMIC sites, which is independent of smoking.38  
Outside of these BOLD studies, there have been few large-scale robust efforts to document patterns 
of CLDs across the sSA region. Existing data are therefore focused largely on clinical symptoms and 
spirometry deficits, with little attention paid to the structural lung pathology underlying these 
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abnormalities and the specific respiratory diagnoses they relate to. If mortality related to CLDs in sSA 
is to be reduced, further work in this area is required.   
2.1.3 BURDEN OF CHRONIC LUNG DISEASE IN MALAWI 
As highlighted in the introduction above, much of the primary data presented in this thesis is drawn 
from Malawi, and a more detailed description of existing data on the burden of CLDs in Malawi is 
therefore given below.  
 URBAN MALAWI 
Data from the BOLD study completed in urban Blantyre in Malawi in 2014 were analysed as part of 
this PhD, and are presented in detail in Chapter 4 of this thesis. In summary, this study showed that 
amongst an age and gender stratified sample of 1059 adults from Chilomoni district of urban Blantyre, 
11.8% (SE 1.2%) reported respiratory symptoms including cough, sputum production, exertional 
breathlessness, or wheeze. 72.8% (749/1029) of participants completed ATS standard spirometry, 
amongst whom 4.3% (SE 1.1) of men and 4.1% (SE 1.1) of women were found to have post-
bronchodilator obstruction, and 38.6% were found to have a reduced FVC pattern of deficit using 
NHANES III reference ranges.34 Increasing age and lower socioeconomic situation (SES) were 
associated with airway obstruction in multivariate models, whilst a low FVC pattern was more 
common in those with a reduced BMI. No associations were demonstrated between HIV status, 
biomass exposure, smoking or self-reported previous TB disease, and either pattern of abnormal 
spirometry.  
 RURAL MALAWI 
Data from two further studies have examined the burden of respiratory symptoms and spirometric 
deficits amongst adults in rural Malawi, and confirm a high background burden of chronic respiratory 
symptoms / impairment within the general Malawian population  
Recently published findings from a community based prevalence survey in a rural area in southern 
Malawi (Chikwawa) showed that amongst 1481 adults aged over 18 years, 12.6% reported at least one 
respiratory symptom, with cough in 11.1%, regular sputum production in 2.6%, and breathlessness 
and wheeze both reported by 1.6% of participants.33 Self-reported previous TB (reported by 3.2% of 
the cohort) was associated with increased odds of respiratory symptoms (OR 2.50, 95% CI 1.04 – 
15.58). The prevalence of airway obstruction was 8.7% (95% CI 7.0-10.7%) and a low FVC pattern of 
deficit was seen in 34.8% (95% CI 31.7-38.0) using NHANES III reference ranges. Female gender, 
increasing age, and previous TB disease were associated with lower FEV1 and FVC volumes. Smoking 
was associated with lower FEV1 volumes. Biomass exposure was reported by 99.8% of the study 
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population, and directly measured in 1144 study participants, but in multivariable models neither 
particulate matter (PM2.5) nor carbon monoxide (CO) levels were associated with either FEV1 or FVC.  
Figures from a second rural study available for Malawi are rather higher – a population proportion 
sampling approach was used to select 5670 households from 27 clusters defined by local health 
centres in Dowa and Ntchisi in central Malawi in 2014/15. A total of 15795 adults ≥15 years old  were 
interviewed from across these households, and 22.5% reported some combination of chronic cough, 
shortness of breath, or wheeze within the last 12months.39 Out of those patients reporting chronic 
respiratory symptoms, only 18% (648/3554) had a respiratory diagnosis recorded in their health 
passport (including bronchitis, COPD, asthma or lower respiratory tract infection), highlighting the 
unmet need for chronic respiratory services in this setting.  
Variation in the burden of symptoms reported by these studies may relate to the format of the 
questions used and duration of time over which symptoms were recorded, but all confirm the finding 
of a high burden of chronic respiratory symptoms and perhaps respiratory pathology within the 
general population in Malawi.   
 NATIONAL DATA 
The final source of data on the burden of chronic respiratory pathology in Malawi comes from the 
National TB prevalence survey, which was completed in 2014 and included 31,579 adults ≥15 years.40 
This study was focused on collecting data relevant to the diagnosis of TB, rather than chronic 
respiratory pathology. As such, questionnaires focus on current symptoms, in comparison to the BOLD 
questionnaires used in the studies above, which ask about symptoms experienced in recent months. 
Nevertheless, amongst adults included in the prevalence survey, current cough for at least 2 weeks 
was reported by 3.7%, and any TB symptoms (including cough, breathlessness, night sweats, fever or 
weight loss) for 1 week by 8.6% of participants. The overall prevalence of ever-smoking was 16%, with 
much higher rates of current smoking amongst men (18.1%) compared to women (3.6%). 
In addition to symptom data, the national prevalence survey included imaging with chest x-ray (CXR) 
for all survey participants, whether symptomatic or not. Images were read by 1 radiologist and 1 
physician in the field and classified according to the categories defined below (Table 1), with central 
re-reads performed for 10% of the normal images and the majority of the abnormal images, for quality 
control.  On initial field review, 95.8% of patients were thought to have normal CXRs, and only 4.2% 
had abnormal CXRs. This proportion of those suspected of having abnormal films was higher in men 
than women (4.4 vs. 2.4%). The majority of abnormal scans were attributed to TB disease (76.4%, 
1016/1330). However, the accuracy of this field interpretation is likely limited: rereading of 10% of the 
normal films led to 5.3% of them being reclassified as abnormal, and over half of the abnormal films 
were reclassified as normal on central review, and sub-optimal image quality was noted in the survey 
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report40 Given these limitations, and the difficulty in using the case definitions employed to 
differentiate between signs of acute and old PTB, these data are likely of limited use in understanding 
the population burden of chronic structural lung damage and post-TB lung damage specifically in 
Malawi. No other population or survey level imaging data from Malawi were identified on review of 
the literature. 
Table 1: CXR classification in National TB prevalence survey (n=31,561) 
Field Category Description of category (verbatim, from the NTP manual) 
Field 
reading 
results, 
n (%) 
Central re-reading results 
 
Normal No abnormality detected 30,231 (95.8%) 
3627 re-read 
 
Normal: 3434 (94.7%) 
TB: 49 (1.4%) 
Other lung disease: 66 (1.8%) 
Cardiac disease: 35 (1.0%) 
Other: 10 (0.0%) 
Non interpretable: 33 (1.0%) 
Abnormal –  
TB related 
CXR images that showed abnormalities usually with 
pulmonary TB. 
 
Eg. Cavitation, apical involvement, parenchymal 
opacities with or without pleural effusion, parenchymal 
opacities with mediastinal or hilar lymph node 
enlargement, isolated lymphadenopathy, diagonal 
parenchymal involvement, miliary parenchymal 
mottling, and involvement of typical tubercular sites 
such as apices and upper segments of lower lobes plus 
isolated pleural effusion and pneumothorax. 
1016 
(3.2%) 
 
1168 re-read 
 
Normal: 586 (50.2%) 
TB: 273 (23.4%) 
Other lung disease: 189 (16.2%) 
Cardiac disease: 72 (6.2%) 
Other: 20 (1.7%) 
Non interpretable: 28 (2.4%) 
Abnormal –  
not TB related 
CXR images that were significantly abnormal but the 
radiologist is certain that the cause is non-tubercular.  
 
Eg. Emphysema, classic bronchiectasis, classic lobar 
consolidation with air bronchograms (bacterial 
pneumonia), spiculated or stellate masses (malignancy), 
canon ball metastases or other vascular abnormalities. 
312 
(1.0%) 
Non-
interpretable 
CXR images where significant abnormality existed but 
the radiologist was not sure whether the cause is 
tubercular or non-tubercular.  
Eg. Non-homogeneous opacities, bizarre patterns. 
2 (0.0%) N/a 
 
 
2.2 TUBERCULOSIS EPIDEMIOLOGY AND MANAGEMENT 
As mentioned above, pulmonary tuberculosis (PTB) remains one of a series of risk factors for chronic 
lung damage which may be encountered over the life course in the sSA setting. The relationship 
between PTB and CLD is the central focus of this thesis, and a brief overview of the epidemiology, 
clinical presentation and management of tuberculosis disease is therefore given below. 
2.2.1 MYCOBACTERIUM TUBERCULOSIS 
Discovered in 1882 by Dr Robert Koch, Mycobacterium tuberculosis (MTB) is an aerobic bacterium with 
a thick lipid rich cell wall, and a slow dividing time of 15-20 hours. Humans are the only known reservoir 
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of the organism. It is a respiratory transmitted infection, spread between individuals in air droplets 
inhaled into the lungs.  
2.2.2 EPIDEMIOLOGY 
WHO estimates suggest that there were 10.4 million incident cases of active TB disease in 2016, with 
30 high TB burden countries accounting for 87% of all incident cases, and the largest number of cases 
seen in India, China, the Philippines and Pakistan. It is thought that 10% of incident TB cases (range 8-
12%) in 2016 occurred among people living with HIV, with the proportion of HIV co-infection cases 
highest in the African region (30% HIV co-infection, range 24-35%).  
Incidence rates of TB disease vary widely between countries (Figure 1), with the rate across the WHO 
African region thought to lie at 254/100,000 (Range 227-284). Globally, TB incidence rates are falling, 
but progress is slow with an average rate of decline between 2000-2016 of 1.4%. 
Figure 1: Global estimates of TB incidence rates*, per 100,000 population 
 
*Estimates of incident cases drawn from National TB Prevalence survey data and TB notification rates in high and middle 
income countries with well performing national surveillance programmes, with adjustment for estimated underreporting and 
under diagnosis based on expert opinion and ancillary data.  
 
WHO estimates of global TB related deaths are drawn from a combination of vital registration data, 
mortality surveys, and modelling based on TB incidence and case-fatality rates, and suggest that TB 
remains the 9th leading cause of death worldwide, responsible for 1.3 million (range: 1.2-1.4m) deaths 
amongst HIV-negative and 374,000 (range: 325-427,000 deaths) amongst HIV-positive people in 2016. 
Mortality rates are again unevenly distributed, with 85% of TB deaths seen in the WHO Africa and 
South-East Asia regions. The average case fatality rate (the number of TB deaths, divided by the 
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number of incident cases) for TB was 16% globally in 2016, but remains >20% in the majority of 
countries in the WHO African region.12  
Global estimates suggest that tuberculosis prevalence remains higher in men than women, with a ratio 
of between 1.3 to 2.1 across the WHO regions,12 41 and evidence of reduced access to available health 
care services amongst men in many resource-poor settings.42 43 Estimates of TB incidence in the African 
region suggest that the majority of cases are seen in young adults, between the ages of 15 – 44years.12 
Modelling studies, which include primary tuberculin skin test (TST) data from 37 countries, suggest 
that 23% of the global population or 1.7 billion people had latent TB infection in 2014.44  
Of note - tuberculosis is a disease driven by social determinants, with risk factors for transmission, 
development of active disease, and poor access to treatment common amongst those living in 
poverty.45 Significant declines in disease and mortality were seen in the early 20th century as a result 
of economic growth, improvement in working conditions, and public health interventions to improve 
nutrition, housing and sanitation, even prior to the arrival of anti-tuberculosis chemotherapy in the 
1940s.46 However, the HIV epidemic of the late 1980s and 90s, ongoing funding limitations, and 
challenges providing public health services during the dissolution of the Soviet Union led to an upsurge 
in cases and TB mortality, such that the WHO declared tuberculosis a global emergency in 1993.47 
Perhaps the most striking feature of the TB epidemic which is seen today is how gradual progress has 
been, since then. 
2.2.3 SPECTRUM OF TUBERCULOSIS DISEASE 
For public health and clinical purposes, TB disease is classically thought of as either ‘latent’ or ‘active’. 
However, in reality TB disease is likely a spectrum based on the balance between mycobacterial 
burden and the host immune response (Figure 2).  
Figure 2: Schematic to illustrate the spectrum of TB disease, from MTB exposure to active pulmonary disease48 
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On entering the lung, the MTB organism is phagocytosed by the alveolar macrophage, but evades 
destruction by preventing fusion of the phagosome with the lysosome, and rather begins to replicate. 
Over time, the organism gains access to the lung parenchyma, either through translocation of infected 
macrophages across the alveolar epithelium, or by direct movement of the mycobacteria into the lung 
tissue. As infected dendritic cells and inflammatory monocytes are recognized by the pulmonary 
lymph nodes, the host T-cell response is triggered, T and B cells are recruited, and granuloma form at 
the site of infection.  
In the context of a competent immune response the mycobacterial burden is contained, granuloma 
remain intact and a controlled state – or latent TB infection – is established. Individuals remain 
asymptomatic, and are not infective but typically have evidence of an acquired T-cell response to 
infection which is evident on Tuberculin skin test (TST), or serum Interferon gamma release assay 
(IGRA).  
If the host immune response is inadequate and the bacterial burden increases, the granuloma may fail 
to contain the infection, resulting in dissemination of mycobacteria within the respiratory tract or 
through the blood stream to other organs. Early in this process, individuals may remain asymptomatic 
with ‘subclinical’ disease – several population based prevalence surveys have found that up to half of 
those with prevalent culture-positive disease identified on screening are clinically asymptomatic.49 
However, in the absence of treatment, the mycobacterial burden grows leading to symptomatic 
pathology and active disease. In the absence of TB treatment, mortality from active disease is 
invariably high with case fatality rates estimated at 70% for smear positive and 20% for smear negative 
HIV uninfected adults.50  
In those with latent infection, the lifetime risk of progression to active disease or ‘reactivation’ is 
thought to lie between 5 – 15%,51 with the highest risk seen in the early years after infection. Whilst it 
is clear that reactivation is more common in those with compromised immunity,52 for example those 
with HIV co-infection in whom the risk is as high as 10% per year, investigation into the contribution 
of mycobacterial factors and host genetic susceptibility / immune response to reactivation rates are 
ongoing.53 Neither of the LTBI tests – TST or IGRA – are able to predict future development of active 
disease.48  
The symptoms associated with active TB disease depend on the site of mycobacterial dissemination 
and replication. The most common manifestation of disease is pulmonary tuberculosis, with 
extrapulmonary tuberculosis (EPTB) disease accounting for only 8-24% of notified cases across the 
WHO regions in 2016.12 Respiratory symptoms of PTB disease include cough, sputum production, 
haemoptysis, chest pain and breathlessness. Constitutional symptoms of active disease include weight 
loss, fever and night sweats.  
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2.2.4 DIAGNOSIS OF TUBERCULOSIS DISEASE  
Tests of the adaptive T-cell immune response – TST and IGRA –are used to determine whether an 
individual has previously encountered the MTB pathogen, and are markers of pathogen exposure only. 
In the Mantoux TST, 0.1ml of tuberculin (a purified protein derivative of MTB) is injected intradermally 
in to a patient’s forearm and the extent of the resulting skin induration is used to quantify the host 
immune response to this protein. For IGRA assays, a whole blood sample is taken and mixed with 
antigens derived from MTB, and either the number of cells producing interferon-gamma (IFN-g) or the 
amount of IFN-g produced is measured. Both of these assays are expected to be positive if an 
individual has previously encountered MTB and has a host immune reaction which is ‘primed’ to the 
pathogen, whether or not they currently carry the infection.  As such, these tests are unable to 
differentiate between latent and active disease. 
Detection of active TB disease instead relies on four main technologies – imaging techniques, 
microscopy, culture, and molecular methods – the sensitivity and specificity of which are shown in 
Figure 3. 
Culture remains the gold standard for detection of active TB disease, liquid media are increasingly 
used in the automated BACTEC Mycobacteria Growth Indicator Tube (BACTEC MGIT) system.54 
Although sensitivity of culture is high, and isolation of the MTB organism allows drug sensitivity testing 
for resistant disease, samples take 10-21 days to be processed, and culture is usually only available in 
central reference or research laboratories such that wide spread use in low and middle income settings 
remains limited. In practice, TB management services in these settings remain largely reliant on smear 
microscopy with direct visualization of mycobacteria using either conventional microscopy, or the 
more sensitive fluorescence microscopy. Smear microscopy is a technique that is more easily 
decentralized, and can be performed on the same day, but requires investment in quality control to 
maintain standards. Sensitivity remains much lower than that of culture.  
The emergence of molecular techniques in recent years has significantly changed practice. The Xpert 
MTB/RIF assay is an automated cartridge based nucleic acid amplification test, which can be 
performed on sputum and other biological samples, with a 2-hour turn around period. It is expensive 
assay, costing around $17,000 for the initial unit and $10 for each single-test cartridge used, but 
sensitivity is higher than that of sputum smear testing, and includes concurrent assessment of 
Rifampicin resistance. WHO authored a policy update in 2013, conditionally recommending the use of 
XPert MTB/RIF as the first-line diagnostic test in all adults and children with suspected active TB 
disease, particularly in those with HIV co-infection.55  By the end of 2016, 28/48 high TB burden 
countries had national algorithms including Xpert MTB/RIF as the initial diagnostic test for all TB 
suspects.12  
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The lipoarabinomannan (LAM) urinary assay is the first truly point-of-care test for advanced TB disease 
to have emerged in recent years. LAM is a component of the M.tuberculosis cell wall, and is found in 
the urine of those who have disseminated TB disease with renal involvement. It has been shown to 
have high sensitivity for TB disease in those with advanced HIV infection and CD4 counts <100 cells/uL, 
in whom disseminated disease is more common.56 It is currently recommended by WHO as a 
diagnostic tool in HIV infected adults with CD4 counts <100 cells/u, or those with unknown counts. A 
recent multicentre randomized control trial demonstrated a mortality benefit when LAM was used as 
a screening tool for disseminated TB disease amongst HIV-infected adults admitted to hospital with 
low CD4 counts, severe anaemia, or clinically suspected TB disease.57  
Use of chest x-ray as a stand-alone diagnostic tool has been somewhat limited to date. Until recently 
radiography was available largely in secondary and tertiary health care settings only, and sensitivity / 
specificity of chest imaging for active TB disease was limited by reader inconsistency. However, 
increasing use of Computer Aided Diagnostics (CAD), which rely on automated reading and 
interpretation of images, will allow standardized interpretation and may improve performance in 
coming years, and if used together with digital CXR, may make the use of chest radiographs for 
decentralized screening and diagnosis increasingly feasible.  
Figure 3: Diagnostic tools for active TB disease, reviewed by WHO48 
 
TAT: Turn around time 
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2.2.5 EMPIRICAL TB TREATMENT 
It is worth noting that in the context of imperfect diagnostics, clinicians in both high and low burden 
settings have long initiated empirical treatment for TB disease where there is reasonable clinical 
suspicion of disease, but no microbiological or pathological confirmation. Thresholds for empirical 
treatment are known to vary widely between settings, with factors such as the background prevalence 
of tuberculosis, presence of HIV co-infection, patient stability, access to clinical investigations, 
probability of a one-off patient encounter, and perhaps the individual physicians own training and risk 
perceptions influencing the decision to start treatment.58 As such, the accuracy of clinical judgements 
in the diagnosis of pulmonary TB disease are likely to vary widely between regions. 
Some evidence of accuracy of clinical diagnosis can be drawn from a recent meta-analysis of 5 studies, 
which compared the accuracy of the 2007 WHO algorithm for the clinical diagnosis of smear negative 
pulmonary TB, with sputum culture confirmed disease as the gold standard. This study showed a 
pooled sensitivity of 69% (66-72%) and specificity of 69% (66-72%) for the algorithm, against culture, 
suggesting that when formal guidelines are followed the accuracy of clinical diagnosis is likely limited.59 
A wider spectrum of accuracy is likely in real-life settings where the algorithm is likely incompletely 
followed and clinical judgements may vary. Previous work from Malawi has shown that amongst 352 
smear-negative patients registered for treatment in Lilongwe – prior to the introduction of molecular 
diagnostics – approximately 1/3 were shown to have microbiologically confirmed PTB disease when 
extensively investigated, 1/3 show clinical behaviour very similar to that of those with 
microbiologically confirmed PTB and are thought likely to have true smear negative disease, and the 
remaining patients with likely non-TB diagnoses had a very high mortality,60 suggesting that at least in 
this time and in this setting, rates of false positive diagnosis amongst smear negative patients were 
perhaps limited.  
2.2.6 ACTIVE CASE FINDING 
Despite ongoing investments in TB health services, improvements in diagnostics, and the use of 
empirical treatment as deemed appropriate, it is clear that there remains a diagnostic gap: in addition 
to the 6.3 million new and relapse TB cases reported globally in 2016, it is thought that there were an 
additional 4.1 million unreported cases of active disease.12  Post-mortem studies suggest a high 
prevalence of undiagnosed TB disease amongst unwell patients dying in hospital, with up to 45% of 
TB cases identified amongst HIV-infected adults remaining undiagnosed at time of death.61 
A 2008 systematic review of 58 observational studies investigating barriers to treatment for TB disease 
identified substance / alcohol abuse, poverty, low access to health care facilities, rural residence, old 
age, and poor knowledge about TB as risk factors for treatment delays. Health system capacity / 
approach limitations were also highlighted as barriers to prompt diagnosis and treatment initiation, 
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with patients with smear negative or EPTB disease, or who used traditional or private practitioners 
first experiencing longer delays.62 Recurrent visits to the same health care provider for investigation 
was a widespread issue, together with the stigma associated with a TB diagnosis and its association 
with HIV disease.  
This diagnostic gap poses a public health challenge as it facilitates onwards transmission of disease 
from infectious untreated individuals, and is also detrimental to the health of the individual patient. 
Active case finding aims to address this gap, with screening of either whole communities in high TB 
incidence settings or specific high risk populations for active disease, in order to decrease time to 
treatment and minimize ongoing disease transmission. In various settings, it has been shown to 
decreased incident disease,63 and has been endorsed by the WHO End-TB strategy as a means to 
promote early diagnosis and treatment.64 
2.2.7 TUBERCULOSIS TREATMENT 
Although MTB was discovered in 1882, the advent of anti-tuberculosis drug therapy came only in the 
1940s when streptomycin and para-aminosalicylic acid (PAS) were shown to be effective. In fact the 
discovery of the four first-line drugs which continue to form the backbone of modern short-course TB 
treatment dates back to the same period: Pyrizinamide was discovered in the late 1940s, isoniazid in 
1951, ethambutol in 1961, and the rifamycins in 1956.65 
WHO currently recommends six-months of therapy for drug sensitive disease, with an initial 2-month 
‘intensive’ phase of treatment with rifampicin, isoniazid, pyrazinamide, and ethambutol, followed by 
a 4-month ‘continuation’ phase with with rifampicin and isoniazid alone. Whilst extension of therapy 
beyond 6-months is not recommended for any patients by WHO, various national guidelines advocate 
a further prolonged continuation phase in those with extensive disease or cavitation, or persistently 
positive microbiology.66 Traditionally the response to drug treatment is thought to be biphasic, with 
early killing of replicating bacteria, followed by slower killing of a subpopulation of slowly dividing or 
sequestered ‘persistent’ organisms.  Although the majority of smear positive patients are seen to have 
converted to become culture negative by the end of the intensive treatment phase, trials conducted 
to date which have attempted to shorten treatment regimens to less than 6-months have failed, with 
increasing rates of relapse seen.66  
Combination therapy has long been used in TB treatment to minimize the risk of drug resistance and 
treatment failure. Drug resistance in MTB is conferred by mutations, rather than acquisition of new 
DNA,48 which are thought to occur at a spontaneous rate of approximately 1 mutation every 107 - 1010 
divisions for each of the four first-line drugs. Using these four drugs in combination, the chances of 
any single organism developing resistance to all four drugs is thought to be minimal. In addition, each 
of the drugs has a different mode of action, with rifampicin having the most marked bactericidal effect. 
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2.2.8 DRUG RESISTANT DISEASE 
Drug resistance can be detected by phenotypic culture-based approaches, as well as molecular based 
methods to detect the genetic mutations.  WHO estimates from 2016 suggest that globally, 4.1% of 
new cases (95% CI 2.8 – 5.3%), and 19% of retreatment cases (95% CI; 9.8 – 27%) had rifampicin 
resistant (RR) tuberculosis disease, or multidrug resistant (MDR) where resistance to both isoniazid 
and rifampicin are detected. It is thought that 6.2% (95% CI: 3.6 – 9.5%) of these organisms are 
extensively drug resistant (XDR), with additional resistance to a fluoroquinolone (Eg. levofloxacin or 
moxifloxacin) and to at least one of the three injectable second line drugs (Amikacin, capreomycin or 
kanamycin). The countries with the highest numbers of cases of MDR / RR disease, accounting for 47% 
of the overall burden, are China, India and Russia.12  
Treatment regimens for MDR-TB require a larger number of drugs delivered for a prolonged period, 
with use of individualized regimens based on drug-susceptibility testing. Traditionally, treatment 
regimens lasting at least 20-months were recommended. However in 2016, based on the results of 
the STREAM trial which demonstrated comparable effects of 9-month treatment regimen compared 
to the 20-month treatment regimen within rigorous clinical trial conditions,67 the WHO now 
recommends a 9-12month treatment regimen for MDR disease using 7 drugs for the initial 4 months, 
followed by 4 drugs for at least a further 5 month period.68 Despite this reduced duration, pill burdens 
and drug side effects experienced during treatment for resistant disease are often profound.  
2.2.9 TREATMENT OUTCOMES 
TB treatment outcomes are classified according to standard WHO definitions (Table 2). In drug 
sensitive disease treated with standard short course therapy, ‘treatment success’ was reported for 
83% of cases treated in 2015.12 Programmatic data suggest that outcomes are much worse in the 
context of drug resistance with only 54% of patients with MDR/RR-TB and 30% of those with XDR-TB 
achieving treatment success.   
Table 2: WHO TB treatment outcome definitions69 
Outcome Definition 
Cured 
A pulmonary TB patient with bacteriologically confirmed TB at the 
beginning of treatment who was smear- or culture-negative in the last 
month of treatment and on at least one previous occasion. 
Treatment completed 
A TB patient who completed treatment without evidence of failure BUT 
with no record to show that sputum smear or culture results in the last 
month of treatment and on at least one previous occasion were negative, 
either because tests were not done or because results are unavailable. 
Treatment failed A TB patient whose sputum smear or culture is positive at month 5 or later during treatment. 
Died A TB patient who dies for any reason before starting or during the course of treatment. 
Lost to follow-up A TB patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more. 
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Not evaluated 
A TB patient for whom no treatment outcome is assigned. This includes 
cases “transferred out” to another treatment unit as well as cases for 
whom the treatment outcome is unknown to the reporting unit. 
Treatment success The sum of cured and treatment completed. 
 
There remains some controversy over when TB treatment outcomes should be defined. Standard 
WHO treatment outcomes which are assigned at the point of treatment completion have been 
criticised for their failure to include relapse after this time point as a type of treatment failure, 
particularly in the context of MDR treatment.70 However, the inclusion of relapse within standard 
outcome definitions would require ongoing follow-up of all TB patients for at least 1-year following 
treatment completion. With current resource constraints this may prove challenging – or impossible - 
for many National TB treatment programmes in resource-poor settings, and as such treatment 
outcome definitions continue to be determined at the point of treatment completion.  
2.2.10 RECURRENT TB DISEASE 
Recurrent TB disease after successful treatment completion can be the result of either endogenous 
reactivation following inadequate initial treatment, or exogenous reinfection. Rates of relapse are 
thought to be highest soon after completion of the initial TB treatment episode. A systematic review 
of 15 early tuberculosis trials found relapse rates of between 3 - 8% across the studies, with 78% of 
relapse episodes occurring within the first 6-months following completion of the initial TB treatment 
regimen,67 and 91% occurring within the first 1-year.  
A recent population based retrospective cohort study of 1869 individuals who had been successfully 
treated for smear positive TB in Cape Town, South Africa between 1996-2008 used molecular strain 
typing to differentiate between relapse and reinfection, and confirmed the early dominance of the 
former. Within this study, 10.9% of individuals experienced a recurrent episode of smear positive TB 
disease during follow-up, with a median time to disease of 21 months. Amongst those with recurrent 
disease for whom sputum samples were available for both disease episodes, 49% were identified as 
relapse and 51% recurrence. Reinfection accounted for only 20% of cases within the first year after 
the initial treatment episode, but 66% of recurrent cases thereafter.71  
There remains some uncertainty about the extent of lasting immunity conferred by an initial TB 
disease episode.73 Ongoing latent infection is thought to confer some protection against progression 
to active disease following re-exposure amongst HIV-negatives, but the same pattern has not been 
demonstrated amongst HIV positives.74 An episode of active TB disease may also confer lasting 
protection, as it is increasingly thought that cells involved in the innate immune response become 
‘trained’ at both the mucosal level within the lung and through their development within the bone 
marrow after an episode of active disease,75 76 such that a more effective innate immune response is 
mounted on subsequent exposures.77  
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2.2.11 IMPACT OF HIV CO-INFECTION 
HIV co-infection, seen in approximately 10% of incident TB cases globally in 2016, impacts both TB 
epidemiology, and clinical presentation, diagnosis and management.   
HIV infection leads to impairment of T-cell dependent immune responses early in disease, and in more 
advanced stages reduces the total number of CD4 T-cells,48 such that the ability of the host immune 
response to contain MTB infection is reduced. As such, the risk of developing active TB disease from 
both exogenous infection, and endogenous reactivation of latent infection rises in HIV co-infected 
adults.78 This increased risk manifests early in HIV disease, with some studies showing a doubling of 
risk within the first 1-year following HIV seroconversion.79 Annual risks of reactivation of latent to 
active TB disease are estimated at 10% per year in HIV infected adults, in contrast to the 10% lifetime 
risk quoted for HIV-negative individuals.80  
Patients with HIV co-infection are more likely to develop EPTB or disseminated disease than HIV-
negative individuals, particularly at lower CD4 counts.81 Whilst pulmonary disease remains the most 
common pattern of TB disease in both groups, its appearance on chest radiographs at lower CD4 
counts has been widely documented as ‘atypical’ with more individuals showing non-cavitatory 
infiltrates, miliary disease, pleural effusions, or even normal appearances, compared to HIV negative 
adults.81-83  In the context of active PTB disease, HIV positive individuals are more likely to be smear-
negative.84  
Clinical management of drug sensitive TB disease in those with HIV co-infection relies on the same 
drug regimens presented above, for the same 6-month duration. Introduction of antiretroviral 
treatment (ART) amongst ART-naïve HIV-infected patients with concurrent TB disease is known to 
increase the risk of developing an immune reconstitution inflammatory syndrome (IRIS), particularly 
within the first 3-months pf TB treatment and amongst those with CD4 counts <100 cells/mm3.78 
However, despite this risk, early introduction of ART within 2 weeks of TB treatment initiation has 
been shown to significantly reduce mortality, except in the context of TB or cryptococcal meningitis, 
and is therefore widespread practice in resource poor settings today.85  
Given the increased risk of reactivation from latent to active TB disease in the context of HIV infection, 
WHO guidelines currently recommend the use of isoniazid preventative therapy (IPT) in HIV infected 
individuals with no evidence of active disease, regardless of CD4 count and TST result, for at least 36 
months in settings of high TB incidence and transmission.86  
2.2.12 INTERNATIONAL TARGETS 
Despite the ongoing challenges to the prevention, diagnosis, and management of TB outlined above, 
target 3.3 of the Sustainable Development Goals includes an explicit objective to end the epidemic of 
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multiple infectious diseases, including tuberculosis, by 2030. The WHO End TB strategy published in 
2015 sets out the indicators and targets required to meet this ambitious objective. The central pillars 
of this agenda include a focus on health systems with integrated, patient-centred approaches to 
treatment and prevention, social and political action to address key social determinants of disease, 
and recognition of the urgent need for research to provide new tools or diagnosis and treatment of 
disease.64 Much progress is required however, if this objective is to be met. In the foreseeable future 
it is likely that high rates of TB transmission and active disease will persist.  
2.3 TUBERCULOSIS RELATED LUNG DAMAGE: MECHANISMS & 
DETERMINANTS 
As can be seen from the above, globally there remains an ongoing high burden of active TB disease, 
with a concentration in resource poor settings. Although mortality remains high, over 80% of 
individuals successfully complete first-line treatment for drug sensitive disease,12 and it is on this group 
of individuals that this PhD was focused. Crucial to understanding the nature of the residual lung 
pathology that they may be left with, after treatment, is some appreciation of the mechanisms and 
drivers of the TB-related lung damage during disease.  
Research into the immune mechanisms underlying TB related lung damage has been limited by the 
lack of an accurate animal model for disease, with no non-human primates or other models which 
completely mimic the TB related pathology seen in humans, and limited opportunities to perform 
biopsies of sites of infection and disease within the infected human lung. However, our current 
understanding suggests that much of the pulmonary pathology seen is a result of the host immune 
response to infection which causes both tissue destruction and aberrant healing mechanisms, and is 
influenced by a combination of pathogen, environmental and host factors. An overview of existing 
literature on the mechanisms of TB related lung damage and drivers of this pathology is presented 
below.   
2.3.1 MECHANISMS OF LUNG DAMAGE 
 GRANULOMA FORMATION 
Within the lung, MTB is phagocytosed by the alveolar macrophage but resists destruction by 
preventing fusion of the phagosome with the acidic lysosome,87 and instead initiates replication. 
Initiation of an inflammatory cascade follows, and together with other inflammatory cells (T-cells, B-
cells, NK cells, granulocytes) localised granulomata are formed at sites of infection within the lung.87 
Impairment of alveolar macrophage phagosomal proteolysis in HIV-infected adults in the early years 
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of ART treatment has been demonstrated, and likely contributes to the increased risk of TB disease 
amongst HIV-infected populations.88   
Granulomata are highly organised structures that form within the lung, with alveolar macrophages – 
many of which differentiate into foamy macrophages with high lipid content – at the core and a fibrous 
coating / density of lymphocytes found more peripherally.  It is in many ways the balance of the 
immune response at the level of the granuloma which determines the extent of tissue destruction: in 
some cases, stable granulomata which ‘wall off’ mycobacteria with no ongoing lung tissue destruction 
are seen, whilst in others ongoing activity with necrosis occurs at the core of the lesion with extensive 
destruction of alveolar tissue. Diverse granuloma stages and behaviours can be seen within the lung 
of a single infected individual, suggesting that immune responses mediating their formation and the 
MTB response is highly localised,87 and perhaps accounting for the heterogeneous patterns of residual 
lung damage seen even within a single patient in different lung lobes.  
 LUNG DESTRUCTION WITH CAVITATION 
Cavitation with connection to the airways is in the interest of the MTB organism as it allows spread of 
disease through expectoration of caseous material that contains live organisms. However, the process 
through which lung cavities are formed remains unclear. Classically, they have been thought to be the 
result of caseation and alveolar destruction at the core of granulomata with rupture through the wall 
of an adjacent airway. However, other data suggest that cavities arise from areas of lipoid pneumonia 
which form in the lung, distinct from granulomata.89 The role of Matrix Metalloproteinases (MMPs) in 
this process of lung destruction is increasingly recognised. MMPs are a group of enzymes responsible 
for the degradation of extra-cellular matrix components. Upregulation of MMP genes with increased 
secretion of MMP in the lung has been shown in the context of TB disease, with a lack of corresponding 
increase in the levels of the tissue inhibitors of metalloproteases (TIMPS), producing a local 
environment in which fibrin collagens and elastin in the lung are destroyed.90  
 ABERRANT HEALING WITH FIBROSIS 
Changes in lung architecture which are seen following TB disease are not due to tissue destruction 
alone, but also related to aberrant healing with architectural distortion and fibrosis / parenchymal 
scarring. Whilst less important for disease transmission during active TB disease, these processes may 
be highly relevant in producing residual pathology and ongoing disability after disease resolution. Data 
on the processes underlying these healing responses are less extensive, but it has been hypothesised 
that dysregulation of fibrogenic cytokines including TNF-a, TGF-ß and IL-1ß (which is implicated in the 
fibrosis seen in idiopathic pulmonary fibrosis) may be associated with higher levels of lung fibrosis in 
response to TB disease.89  
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 AIRWAY DAMAGE WITH BRONCHIECTASIS 
Tuberculosis is a well-known cause of bronchiectasis, but literature on the mechanisms underlying the 
airway damage it produces are scarce: the TB immunology research community has historically 
focused more on mechanisms underlying TB related parenchymal changes such as fibrosis and 
cavitation, perhaps because these are more readily visible on chest x-ray and due to the public health 
importance of cavitation for TB transmission. However, calls for increasing research into the causal 
mechanisms of bronchiectasis and heterogeneity of airway damage in response to an infective insult 
are ongoing within the respiratory community.91 92 It is possible that much of the bronchiectasis seen 
in the context of TB infection is related to the remodelling described above, and is ‘traction’ 
bronchiectasis, but it is possible that TB disease causes local and systemic inflammation which may 
lead to airways pathology independently of this architectural distortion.  
2.3.2 DETERMINANTS OF LUNG DAMAGE 
 MYCOBACTERIAL FACTORS 
Animal models suggest that MTB strains differ in their virulence, the immune responses they trigger, 
and how they respond to oxidative stress. However, there are no data from human studies 
demonstrating a link between MTB strain type and disease phenotype at the individual or population 
level, such that the relationship between mycobacterial strain and localised lung pathology remains 
unclear.93  Calls for increasing systems biology approaches that investigate genotypic diversity and 
environmental exposures together to better understand this process are ongoing.  
Of note, it cannot be assumed that a single individual is exposed to a single MTB organism which 
behaves in a uniform way through the lung. it has been suggested that even within a genetically 
homogeneous mycobacterial population in a single human host, phenotypic diversity may exist in 
distinct granulomata in the lung, and may account in part for the diverse patterns of lung pathology 
seen within a given individual.94 The presence of mixed strain infections and genetic diversity between 
respiratory samples taken from individual hosts has also been reported in autopsy studies, suggesting 
that there may be genotypic diversity within a single host also.95 The impact of these variations on the 
nature and extent of lung damage seen is not clear.   
 ENVIRONMENTAL EXPOSURES 
The potential for an environmental exposure to modify the pulmonary reaction to MTB is clearly 
demonstrated in the context of silica exposure.  Amongst male gold miners in South Africa silicosis has 
been shown to be both a risk factor for incident TB disease,96 and associated with slower / incomplete 
resolution of imaging after miliary TB disease.97 The hypothesis is that the already inflammatory / pro 
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fibrotic environment which is seen in the lung with silicosis compounds the local immune response 
triggered by TB, to give a more marked effect.  
As mentioned above, smoking is a common exposure in resource poor settings and likely has a direct 
effect on lung development and decline, but its relationship with TB related lung damage is less clear.  
Smoking is thought to increase the incidence of TB disease. Perhaps the largest epidemiological study 
supporting this was a case-control study comparing the prevalence, in India, of ever-smoking and 
causes of death in 45,000 deceased adult males compared to 35,000 controls, published in 2003.98 
This study showed a relative risk of tuberculosis related death of 4.5 (95% CI 4.0-5.0) amongst urban 
ever-smokers compared to never-smokers, and a similar ratio of 4.2 (3.7-4.8) amongst rural ever vs. 
never smokers. The prevalence of current/previous TB disease amongst living ever smokers within the 
same population was noted to be higher than that amongst never smokers suggesting that this 
increased mortality in smokers may be due to increased TB incidence in this group, as well as worse 
outcomes amongst those with disease. A dose-response ratio was observed, with a higher prevalence 
of current/previous TB disease amongst those with a greater intensity of cigarette or bidi1 use, perhaps 
suggesting a causal relationship between smoking and TB disease. In vivo murine studies have 
demonstrated increased susceptibility to MTB disease following cigarette smoke exposure, and 
cellular studies suggest alterations in macrophage, neutrophil and T-cell behaviour / differentiation 
with cigarette smoke exposure,99 such that there is a plausible but as yet unconfirmed biological 
mechanism underlying this relationship. However, despite these data suggesting increased 
susceptibility to TB disease amongst smokers, and our existing understanding of smoking as an 
independent risk factor for COPD, no literature on the influence of smoking on the residual lung 
damage which persists after TB disease itself has been identified.  
Bacterial co-infection may be another key factor influencing the host immune response to MTB 
infection. The lung is no longer thought of a sterile site, but one that is colonised by a range of 
bacterial, fungal, and viral organisms. The relationship between the prevalence, diversity, and burden 
of the lung microbiome and both tuberculosis disease / tissue responses remains largely unclear: the 
influence of the pulmonary microbiota on the rate of progression to active TB disease, its impact on 
the local immune response to mycobacterial infection, and its relationship to residual lung pathology 
remain poorly defined. Because the pulmonary microbiome is an exposure that changes over time, it 
is possible that the microbiome seen in the lung both prior to diagnosis, and the changes that occur 
during treatment in response to antibiotic pressure from the TB treatment (especially from the 
rifamycins, which have a broad spectrum of activity) are important in determining treatment response 
and sequelae.100  
                                                                
1 Hand rolled cigarette widely smoked in South Asia, typically made of unprocessed tobacco wrapped in leaves 
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 HOST FACTORS 
Literature on the relationship between host genetic polymorphisms and localised immune responses 
/ lung pathology seen with TB infection are sparse. However, genetic polymorphisms are well known 
to be linked to the prevalence and progression of other respiratory conditions including COPD, and a 
role in determining the response to TB disease has been hypothesised.89  
HIV co-infection is well known to be a key determinant of the extent and patterns of TB related lung 
damage: as described above imaging appearances during active disease are related to the degree of 
immune function, with classic findings of upper zone cavitation / fibrosis seen in those with preserved 
immune function, and atypical often more subtle features of airspace opacification / effusions / 
lymphadenopathy seen in those with advanced immune suppression.83 A recent study has 
demonstrated different sputum MMP profiles between HIV infected and HIV negative TB patients, 
with higher levels of MMP-1 seen in HIV negatives with extensive cavitation on chest x-ray,101 
suggesting that differential MMP responses may be one mechanism underlying these differences.  
 DURATION OF THE HOST IMMUNE RESPONSE 
Recent imaging studies have used Positron Emission Tomography and Computerized Tomography 
(PET-CT) imaging to demonstrate ongoing areas of high metabolic activity with increased 18F-
fluorodeoxyglucose (FDG) uptake suggestive of high glucose metabolism within lung lesions, even 
after completion of TB treatment.  A prospective cohort study of 99 HIV-negative patients completing 
TB treatment in Cape Town demonstrated marked diversity in the treatment response of lung lesions 
between and within individuals: at the point of treatment completion, 72% of individuals still had 
lesion(s) with moderate-high intensity uptake on PET, with 28% of those cured showing at least one 
lung lesion with increased FDG uptake compared to baseline imaging. Amongst 50 patients re-imaged 
1-year after TB treatment completion, only 8 of whom were diagnosed with recurrent disease, the 
majority had incomplete resolution of their metabolic activity. Patterns of imaging in those with 
ongoing high FDG uptake were largely consistent with TB related disease rather than other causes.102 
These data confirm the heterogeneity of response to TB treatment between lung lesions within 
individuals as above, and suggest that TB related metabolic activity continues long after TB treatment 
completion.  
The reason for this remains unclear - the relationship between sputum MTB-RNA tested by GeneXpert 
and PET lesion intensity within the study above was weak only (p=0.08), but it remains possible that 
persistent viable mycobacteria drive ongoing metabolic activity within lung lesions after treatment 
completion. The current 6-month duration of standard short course treatment for a first episode of 
pulmonary tuberculosis was determined by acceptable rates of disease relapse / recurrence after 
cessation of therapy, rather than a measure of the timing of sterilisation of disease, and rates of 
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recurrence within 2 years of treatment completion for an initial episode are variably quoted as 2.6-
9.7% within multi-site trials.102 It may be the case that a significant number of patients do not achieve 
sterilisation with current short course TB treatment, and the ongoing high metabolic activity seen in 
lung lesions even after PTB treatment completion is a response to persistent, viable mycobacteria. 
Regardless of the reason for these ongoing lesions – whether this be a feature of persistent 
mycobacterial disease or an aberrant and protracted host immune response to disease that has been 
sterilised – the persistence of inflammation beyond the point of treatment completion is a key factor 
which may influence the patterns of residual post-TB lung damage, and their evolution over time.   
2.4 POST-TB LUNG DAMAGE: NATURE & SEVERITY 
Just as our understanding of the mechanisms driving TB related lung damage are incomplete, so our 
understanding of the nature of the residual lung damage that persists after treatment completion 
remains limited. Existing data on the patterns, prevalence, and evolution of post-TB lung damage are 
outlined below. 
2.4.1 SPIROMETRIC DEFICITS 
Much of the interest in post-TB lung damage to date has focused on the residual spirometric deficits 
that persist after TB disease. Three reviews of papers investigating this relationship have been 
published since 2011. The first by Erlich et al. included 8 epidemiological studies from South Africa 
that investigated the relationship between PTB and lung function parameters – this was not a 
systematic review, the methods of literature selection are not clearly described, and the studies 
included varyingly reported on FEV1, FVC, and patterns of spirometric deficits.15 However, amongst 
them, a reduction in FVC in conjunction with an obstructive FEV/FVC ratio – that is a mixed pattern of 
spirometric deficit – was the most common picture seen, and the OR for airway obstruction following 
TB disease treatment was 2.6-8.9.  In 2013 Allwood et al. performed a systematic review of English 
language studies describing the relationship between PTB and airway obstruction only - they identified 
19 studies for inclusion, 3 of which were from South Africa and 1 from Lesotho, with no data from 
elsewhere on the African continent.13 The three large population-based surveys included here (BOLD, 
PLATINO & PREPCOL) again confirmed a significant association between previous PTB and airway 
obstruction (OR 1.37 – 2.94). Finally, Byrne et al. performed a systematic review of studies describing 
the relationship between PTB and airway obstruction or bronchiectasis. The search strategy used here 
was somewhat unusual in that it identified only studies containing the MESH term ‘respiratory tract 
disease’ in addition to tuberculosis, and it is perhaps for this reason that it identified only 9 studies 
describing airway obstruction, with 1 study from South Africa and none from other African countries. 
However, again, the positive association between previous TB and airway obstruction was 
confirmed.14  
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Although none of these reviews were able to perform meta-analyses to measure the overall strength 
of association between TB disease and residual spirometric deficits due to the heterogeneity of studies 
included, their findings have been reinforced by more recent findings from the large multi-centre 
Burden of Obstructive Lung Disease (BOLD) study. Here, spirometry data were collected from age and 
gender standardised populations from 19 sites around the world with measurements taken from 
14,050 individuals. Early publications from the  BOLD network showed that across the 14 original 
country sites, a surprising 23.6% (302/1282) of adults ≥40 years identified as having airway obstruction 
with FEV1/FVC ratio<LLN for age were never smokers,37 with a particularly high prevalence of 
moderate to severe airway obstruction (19.1%) seen  in Cape Town where 11.9% of patients reported 
previous PTB disease.103 A subsequent individual level regression analysis of data from all BOLD study 
sites investigated the relationship between self-reported previous TB disease (defined as a positive 
answer to the question “Has a doctor or other health care provider ever told you that you have 
tuberculosis?”) and residual obstruction or restriction amongst adults ≥40 years, showed that amongst 
the low-middle income sites, the adjusted OR for obstruction was 3.11 (95% CI: 2.30–4.21) with a 
similarly high aOR for spirometric restriction of 3.19 (95% CI: 1.70–5.99) in those who had had previous 
TB compared to those who had not. Heterogeneity was marked for the low FVC estimates (I2 79%) 
compared to the obstruction data (I2 0%), for unclear reasons, but the pattern of findings was similar 
when continuous spirometric data were used: previous TB was associated with both decreased 
FEV1/FVC (β=−3.43, 95% CI −5.05–−1.80) and decreased FVC (β=−0.15, 95% CI −0.23–−0.06).104 These 
analyses were controlled for age, sex, BMI and pack-years of smoking, but were not standardized or 
stratified for HIV status. They are restricted to adults ≥40years, and rely on self-reported previous TB 
to define exposure, but the scale of this study and the strengths of the associations seen very much 
support the influence of TB disease on long term spirometric outcomes. 104  
These data then include both individual clinical studies and large population level surveys, studies that 
have defined TB exposure using both self-report and microbiological / clinical diagnosis, and both 
cohort and cross-sectional studies. All have been consistent in identifying increased odds of both 
obstruction and spirometric restriction following treatment for TB disease.  
Reduced FEV1 volumes are known to predict mortality both amongst those with COPD, and the general 
population, with causes including respiratory failure as well as cardiovascular disease.105 Recent data 
suggest that the FVC may be an additional, or even more important, driver of mortality even in the 
absence of persistent symptoms or an underlying diagnosis of lung pathology.18 106 Whilst the studies 
on which these findings are based draw largely on data from non-TB populations in high resource 
settings, it is plausible that a comparable increase in mortality may be seen in relation to spriometric 
deficits in the post-TB population also.   
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2.4.2 STRUCTURAL PATHOLOGY 
Whilst there has been much focus on spirometric deficits remaining after TB disease, no systematic 
reviews of residual structural lung damage were found in the literature prior at the time of starting 
this PhD. A systematic review was therefore completed as part of this PhD, and was published in 2016 
(PLoS ONE 11(8): e0161176. Doi: 10.1371/journal.pone.0161176). Findings from this review are 
presented in Chapter 3 below, and are not therefore presented here.  
2.4.3 RELATIONSHIP BETWEEN IMAGING AND SPIROMETRY 
The majority of the studies of post-TB lung damage to date have measured lung pathology using either 
imaging or spirometry only, rather than focusing on the relationship between these parameters. The 
limited number of studies describing the relationship between these parameters are described below. 
 CHEST X-RAY STUDIES 
In her cross sectional study of 127 non-smoking adults who had previously completed PTB treatment 
6-18 months previously in Mexico city, Baez Saldana demonstrated a negative correlation between 
post-TB spirometric values (absolute and % predicted FEV1 and FVC) and the total extent of pathology 
(any pattern) seen on chest x-ray (range 0-20).107 For each unit increase in the radiology score, a 
decrease in FVC of 2.48% predicted (95% CI: -3.45 to -1.50%) and in FEV1 of 2.92% (95% CI: -3.87 to -
1.97%) was observed. Amongst the cohort, the dominant patterns of abnormal spirometry were 
obstruction in 24% and restriction in 17%, and 97% of patients had some degree of radiographic 
abnormality including parenchymal fibrosis, bronchiectasis, and emphysema, but the relationship 
between these various imaging patterns and the spirometric deficits seen were not described, and 
dominant clinical disease phenotypes such as COPD or bronchiectasis were not allocated.   
De la Mora also performed a cross sectional study in Mexico, inviting patients who has completed TB 
treatment in the past 3-years to attend for assessment, and comparing imaging findings in patients 
with (n=24) and without (n=46) fixed airway obstruction on spirometry following treatment 
completion. Those with airway obstruction had more lung quadrants affected by fibro-cavitatory 
changes, residual lung cavities, and mediastinal retraction/deviation on chest x-ray than those 
without.  
In the prospective cohort study of 92 patients with biopsy / microbiologically proven TB pleural 
effusions conducted by Lai et al.  in Taiwan, it was shown that at 6 and 12 months after the start of 
anti-TB treatment, patients with residual pleural thickening of at least 10mm seen on chest x-ray had 
lower FVC than those without thickening (FVC 73.6% vs. 81.4% at 6m, p<0.01 / 75.4% vs. 83.2% at 
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12m, p<0.01), although it should be noted that the extent of the pleural thickening seen was not 
recorded, and despite the reduction these FVC volumes are only marginally reduced.108 
 CT IMAGING STUDIES 
Three studies were identified which related details of CT imaging findings to spirometric abnormalities 
amongst individuals with pulmonary TB disease.  
The first study recruited 595 patients with ‘destroyed lung’ - parenchymal tissue destruction and 
anatomical distortion following TB disease – who were identified from 21 hospitals in Korea at 
unspecified times following PTB treatment, and compared their imaging and spirometry findings. The 
median age of the cohort was 65 years and traction bronchiectasis was seen in 80% (333/419) of 
imaged patients. Amongst this group of patients, those with more lobes destroyed had lower % 
predicted FEV1 and FVC volumes.109 
In their study of 101 adults self-presenting to hospital in India with symptoms and a history of previous 
TB disease, Panda et al. showed a high prevalence of spirometric deficits (1% pure obstruction, 40% 
restrictive, 35% mixed deficit) with 55% of patients having an FEV1<60% predicted. The extent of 
fibrosis, cavitation, and bronchiectasis were higher in patients with severe FEV1 limitation (<60% 
predicted), but summary measures of the extent of any radiological abnormality across the lung were 
not associated with spirometry results.110 
Lastly, Lee et al investigated 97 patients who were found to have had spontaneously healed PTB within 
an ongoing population-based cohort study of 8697 adults in Korea, based on radiological sequelae of 
PTB seen on chest x-ray, and a positive IGRA blood test. These patients had a higher prevalence of 
airway obstruction compared to the rest of the population (13.4% vs. 7.4%, p<0.05). CT imaging and 
spirometry in this group showed that amongst the 82 patients with a positive IGRA, both the total 
number of lobes affected by TB sequelae and the extent of emphysema, were positively associated 
with the presence of spirometric airway obstruction (p=0.0461 & p=0.0084).111  
Findings from these studies are consistent in suggesting that more extensive structural pathology is 
correlated with a greater extent of spirometric abnormality following PTB disease, and that 
fibrocavitatory disease, bronchiectasis, emphysema, and pleural thickening dominate. However, we 
still have little understanding of whether these patterns vary between those with spirometric 
obstruction or restriction, or whether there are distinct phenotypes of post-TB lung damage who have 
had heterogeneous responses to the lung insult of TB disease.   
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2.4.4 IMPACT OF HIV CO-INFECTION 
Imaging data from the point of TB diagnosis consistently show that HIV infection modifies the pattern 
of chest x-ray changes seen in the context of active TB infection, and that HIV positivity is associated 
with less marked cavitatory lung damage and ‘atypical’ imaging appearances.83 However, there is a 
remarkable paucity of data on the relationship between HIV infection and post-TB lung damage. 
Only two studies reporting on the relationship between HIV infection and patterns of residual 
spirometric impairment following TB disease were identified, both of which suggest no statistically 
significant association between HIV and ongoing spirometric deficits: Hnidzo et al showed no 
difference in the lung volumes observed amongst HIV infected / uninfected gold miners with the same 
number of previous episodes of TB disease in South Africa,112 and Mbatchou et al. showed no 
univariate association between HIV infection and lung function impairment following TB treatment 
amongst 296 adults treated for PTB in Cameroon within the preceding 3-years.113  
Only one imaging study which included disaggregated imaging data for both HIV-infected (n=12) and 
uninfected (n=98) patients following PTB treatment completion was identified.114 In this study in 
Thailand, all patterns of radiographic abnormality were more common in HIV-negative compared to 
HIV-positive adults following TB treatment completion, however differences were statistically 
significant for reticular fibrotic change only which was seen in 70% (69/98) of HIV negative and 25% 
(3/12) of HIV positive patients.  
Given the well documented ‘atypical’ findings seen on chest imaging in HIV infected adults at TB 
diagnosis, the lack of evidence for differences in the nature / severity of post-TB lung damage between 
HIV-positive and negative groups is surprising. Data from high-income settings suggest that HIV 
disease is directly associated with increased odds of airway obstruction, and a more rapid decline in 
lung function over time,25 independently of TB disease, and it may be the case that reduced amounts 
of TB-related lung damage amongst HIV-infected adults is somewhat offset by the direct impact of 
HIV-disease on the lung. However, further investigation of these relationships is required. Factors such 
as the timing of ART initiation and the degree of immune-compromise at the time of TB disease must 
be considered.  
 
2.5 POST-TB LUNG DAMAGE: CHANGE OVER TIME 
There are few prospective data tracking lung function or imaging after TB treatment completion, and 
as such we have a limited understanding of how post-TB lung damage evolves over time. Only two 
studies aiming to map changes in spirometry over time after PTB treatment were identified. In his 
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study amongst male adult gold miners in South Africa, Hnidzo et al. compared the spirometry 
measurements taken at varying intervals from a clinical / radiological / microbiologically defined 
episode of TB disease.112 Improvement was seen from 13-18 months from TB treatment completion, 
with ‘stabilisation’ at an average reduction of 153ml in absolute FEV1 and 96ml in absolute FVC 
volumes after this point. When FEV1 was considered as % predicted rather than an unstandardized 
volume, the % predicted loss seems to increase with time from disease episode resulting in more 
obstruction over time. However, these are cross-sectional data from different individuals at different 
time points from TB disease treatment rather than true prospective data tracking change in spirometry 
in the same individuals over time and were obtained from a very specific population of male gold 
miners with concurrent occupational exposures such that they cannot be extrapolated.  
In a smaller study of 115 patients who had performed 162 pulmonary function tests within 5-years of 
TB treatment completion identified from a tertiary referral hospital in Taiwan, Chung et al used their 
data to construct partial models predicting lung function over time, controlling for age, weight and 
height. The median age across the cohort was 59.3 years. These models suggest a biphasic relationship 
with nadir lung function at 18-months after treatment completion (Figure 4), but again it should be 
noted that the number of repeated measures included into these models was limited, the sample size 
small, and 26% of the cohort had had at least 1 non-tuberculous mycobacteria isolate, such that again 
data from this study cannot be extrapolated.  
Figure 4: Predicted change in FEV1 and FVC over time from TB treatment completion (Chung et al.) 
 
 
Only one imaging study with repeated chest imaging after PTB treatment completion was identified – 
this was based in Romania and used repeat chest x-rays to determine the proportion of retreatment 
patients who had cavitation at the start of treatment, the end of treatment, and 6-months after this. 
Although the study findings suggested a resolution of cavitation over time, with prevalence falling 
from 84% (36/43) at treatment initiation to 68.8% (22/32) 6-months after treatment completion, the 
study was limited by marked loss to follow up and a limited highly selective sample population.115 
Given the limited amount of prospective imaging and spirometry data available, the extent of 
respiratory recovery or ongoing decline experienced after PTB disease remains unclear, and the 
heterogeneity of responses within the patient population poorly defined. Understanding this change 
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over time will be key to understanding outcomes of those surviving PTB treatment, and determining 
whether / what ongoing support patients require.116  
2.6 POST-TB LUNG DAMAGE: MORBIDITY & MORTALITY 
Perhaps of greatest relevance to patients is the impact that any residual post-TB lung damage may 
have on their lives and livelihoods. Existing data on the relationship between post-TB lung damage 
and outcomes including impairment of quality of life, persistent respiratory symptoms, reduced 
functional capacity, rates of ongoing respiratory exacerbation and hospitalization, and mortality are 
presented below. Also, of relevance in low-resource, high TB prevalence settings are the risks of TB 
retreatment associated with symptomatic post-TB lung damage, and the financial impact of disease. 
Existing data on the relationship between PTLD and these outcomes are also reviewed.   
2.6.1 MORBIDITY  
Only 7 studies describing the morbidity related to post-TB lung damage measured using spirometry or 
imaging were identified – the majority included cross sectional data, and reported on a single measure 
of morbidity only (Table 3). 
Table 3: Spirometry / imaging studies reporting patient centred outcomes in relation to spirometric or imaging deficits 
Study Location Patient 
population 
Exposure  Outcome Findings 
Imaging studies 
Godoy et al. 
117 
Brazil 18 patients, 
completing MDR 
TB treatment 
Extent of 
CXR 
damage 
6-minute walk 
distance 
100% (3/3) of those with Grade 
III damage failed to reach 
expected distance, compared to 
64% (7/11) of those with Grade I 
damage (no statistical 
comparison between groups) 
 
Banu Rekha 
et al. 118 
India 198 patients who 
had first episode 
of PTB median 
16.5yrs previously 
Extent of 
CXR 
Pathology 
SGRQ score No statistically significant 
difference in symptoms, activity, 
impact, or overall SGRQ score 
between in those with 2 vs. >2 
CXR damaged zones on imaging 
Rhee et al.109 Korea 595 patients with 
≥1 destroyed lung 
lobe following 
previous PTB 
 
Number of 
lobes 
destroyed 
on CXR 
Respiratory 
exacerbation rate 
Number of exacerbations per 
year increases with number of 
lobes destroyed.  
Panda et al. 
110 
India 105 patients 
completing PTB 
treatment, first 
episode 
CT imaging 
findings 
Any dyspnoea 
(mMRC1-4) 
Positive correlation between 
extent of fibrosis, bronchiectasis, 
nodules, summary pathology 
scores, and presence of 
dyspnoea.  
 
Ryu et al. 119 Korea 169 patients with 
TB destroyed lung 
(median 25-50% 
of the lung 
destroyed) at 
median 31m post-
treatment 
completion 
N/a Hospitalisation 
Pneumonia 
Death, all cause 
Death, respiratory 
 
64% (108/169) hospitalised 
57% (96/169) pneumonia 
episode 
28% (47/169) died, all cause  
68% (32/47) of deaths 
respiratory 
No comparison group, median 
31m follow up.  
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Spirometry studies 
Baez Saldana 
et al.107 
Mexico 127 patients, 
median 11 (6-
18m) post 
treatment 
completion 
FEV1 & FVC MRC dyspnoea 
scores 
Negative correlation between 
MRC dyspnoea scores and FEV1 
and FVC values (absolute & % 
predicted) in univariate analyses 
 
Pasipanodya 
et al. 120 
 
USA 105 patients 
completing PTB 
treatment 
FEV1, FVC, 
Ratio, 
MEF25-75 
SGRQ scores Negative correlation between 
symptom, activity, impact and 
total SGRQ scores and all 
spirometric measures 
SGRQ: St George’s Respiratory Questionnaire; MRC: Medical Research Council 
 
Two studies investigating the relationship between post-TB lung damage and quality of life, measured 
using the St George’s Respiratory Questionnaire (SGRQ), were identified. These were both cross 
sectional studies but had different findings: no relationship was demonstrated between the extent of 
imaging pathology and quality of life amongst 198 patients who had completed PTB treatment in India 
a median of 16.5 years previously in the study by Banu-Rekha et al.,118 but a negative correlation was 
seen between spirometric indices and the SGRQ scores in the study by Pasipanodya in the USA which 
measured these parameters at the time of TB treatment completion.120  
Two studies investigating the relationship between the extent of PTLD and dyspnoea both showed a 
negative correlation, with increased breathlessness seen in those with more extensive imaging 
pathology or spirometric deficits.107 110 Only one study looking at the relationship between the extent 
of structural pathology and the 6-minute walk test was identified – this was performed in 18 patients 
completing MDR TB treatment only, but suggests that there may be reduced walking distance in those 
with extensive pathology on x-ray.117 
It is of note that the only two studies identified which investigated the rate of respiratory 
exacerbations occurring in relation to post-TB lung damage had been conducted in patients with 
extensive lung destruction. Ryu et al. identified 169 patients between 1994-2009 who had had TB 
disease a median of 25 years previously, and who now had destruction of at least half of a hemithorax 
on CXR or CT imaging. Patients were followed for a median of 31 months (0-172 month) and during 
this period 56.8%(96/169) experienced a pneumonia, 29.6%(50/169) experienced respiratory failure, 
and the overall mortality was 27.8%(47/169).119 Rhee et al. recruited 595 patients with a median of 
2.6 lobes destroyed, and showed the number of exacerbations experienced per year increased with 
the total number of lobes destroyed.109 Both studies were vulnerable to significant selection bias given 
recruitment from existing hospital patients only, as well as a survival bias given patients were 
identified many years after the initial TB disease episode. Nevertheless, they suggest that those with 
extensive post-TB lung damage are at risk of recurrent respiratory exacerbations. Unfortunately no 
data on the risk of respiratory exacerbations amongst adults with milder forms of PTLD were identified 
in the literature, but the suggestion that a broad range of chronic lung pathology may increase risk of 
respiratory admissions in resource poor settings is supported by recent data from a case-control study 
of risk factors for hospitalization with pneumonia amongst adults in Blantyre, Malawi, which showed 
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that adults with a previous history of chronic respiratory symptoms (usual cough or sputum, 
breathlessness or wheeze) or respiratory diagnosis (emphysema, asthma, chronic bronchitis) were at 
increased odds of admission with pneumonia in this setting.20  
None of the studies identified here reported on patient experiences of stigma, in relationship to post-
TB lung disease. Previous work from Malawi has suggested that cough, HIV and TB disease are often 
conflated in public opinion,43 with activities surrounding screening of patients with cough for HIV and 
TB disease compounding this view, with the result that chronic cough can be highly stigmatizing in this 
setting. It may be that this is highly relevant to patient experiences of ongoing respiratory symptoms 
following PTB disease. 
In addition, no studies comparing the morbidity experienced in relation to post-TB lung damage 
between HIV-positive and HIV-negative groups were identified.  HIV infected individuals are known to 
be at increased risk of severe acute respiratory tract infections across all age groups - the bacterial 
pathogens causing these infections are likely similar to those seen in HIV uninfected adults, with an 
additional risk of opportunistic infections also.24 In addition, HIV is a known to be an independent risk 
factor for chronic airway, parenchymal, and pulmonary vascular disease, both increasing the incidence 
of abnormalities, and in the case of chronic airway obstruction accelerating the rate of lung function 
decline.24 It is plausible that the morbidity experienced by HIV positive individuals with residual lung 
pathology at TB treatment completion is different from that experienced by HIV negative individuals, 
particularly with respect to the rate of ongoing infections and decline in lung function, and this merits 
further investigation. 
Taken together, the data identified here do suggest that post-TB lung damage may well be associated 
with long-term adverse patient outcomes including impaired quality of life, ongoing breathlessness, 
functional impairment, and respiratory exacerbations. However, rigorous prospective data are 
required to confirm these results, in both HIV positive and negative groups, and will be needed to 
support interventions to mitigate these outcomes in this population.   
2.6.2 MORTALITY 
Data from both resource rich and resource poor settings suggest an increased mortality amongst 
adults, even after completion of treatment for active TB disease. 
A recent prospective study of 10,662 adults undergoing treatment for TB disease in Vietnam, with a 
median 2.9 year follow up duration, showed a mortality rate of 8.9% across the duration of the study, 
with 60% of deaths occurring in the period after treatment completion, and an age and gender 
standardized mortality ratio amongst those treated for TB disease of 4.0 (95% CI: 3.7-4.2) compared 
to household controls.121 Older data from a cohort of 124 Malawian adults diagnosed and treated for 
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PTB during 1995 who had their outcomes ascertained 6-years later showed that 46% of individuals 
had died in the period following treatment completion – although the majority of the cohort had 
advanced HIV disease, high rates of mortality were seen even amongst the HIV- uninfected group.122  
Data from the US suggest an increased mortality in adults completing treatment for PTB, compared to 
those diagnosed as having latent TB infection, after treatment completion. State-wide registries from 
3 states (Texas, Massachusetts & Seattle) were used to compare age, gender, ethnicity/race, nativity 
and HIV standardized mortality rates between adults who had completed treatment for TB between 
1993-2002 and those who had received a diagnosis of latent TB infection during the same period, with 
a duration of follow up between 6-16 years. A total of 11135 individuals were followed over 119 772 
person-years of follow up. Causes of death were not assessed, but adjusted mortality rates were 
8.3/1000 vs. 1.2/1000 person-years for those treated for PTB compared to those diagnosed with latent 
disease, and the adjusted mortality hazard was 7.2 times higher for the PTB group compared to the 
latent TB infection group.123  
Together, these studies suggest a lasting, ongoing impact of a treated TB disease episode, beyond the 
point of TB treatment completion. Potential mechanisms underlying this increased mortality were 
explored in a systematic review of the causes of death amongst TB patients after treatment 
completion, conducted in 2011.124 This included 22 studies – largely retrospective, with a range of 
follow up from 202 days to 7 years – and showed that in low income, high prevalence settings, HIV 
disease especially with advanced immunosuppression, smear negative disease and malnutrition were 
identified as risk factors for case fatality. In wealthier countries with a lower disease burden, 
socioeconomic features including alcohol and drug abuse, comorbidities often associated with age 
(renal disease, diabetes, respiratory morbidity) and extensive or cavitatory disease on chest x-ray were 
associated with mortality. It is possible that residual lung damage following PTB treatment is a factor 
contributing to ongoing mortality in resource poor settings, but no studies directly assessing this 
relationship were identified in the literature.  
2.6.3 RISK OF TB RETREATMENT 
 RISK OF RECURRENT PTB DISEASE 
The risk of incident TB disease is known to be higher in those who have already been treated for PTB, 
compared to those who have never been treated. A recent review of prevalence survey data used to 
evaluate the impact of the ZAMSTAR study125 – a large community based intervention study of TB 
control strategies in 24 communities in Zambia and South Africa – showed that 18.5%(165/894) of 
sputum MGIT positive TB cases identified came from patients who had previously been treated for 
disease, that those who had been previously treated had a higher burden of cough (43% vs. 34%), and 
that amongst the HIV-negative individuals screened, TB disease prevalence was higher in those who 
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reported previous PTB compared to those that were treatment naïve (3.32/100 vs. 1.78/100 in South 
Africa, and 0.88/100 vs. 0.34/100 in Zambia).126 The reasons underlying the higher prevalence of TB 
disease amongst adults who had previously been treated may include ongoing exposure to the same 
set of risk factors: individuals with repeat episodes may have a genetic milieu that increases risk for 
disease, patterns of social interaction that consistently increase rates of exposure, and long-standing 
socioeconomic conditions that compromise their ability to clear mycobacteria when exposed. As 
discussed above, there may also be a certain amount of disease relapse following incomplete 
resolution of the original infection.  
However, it is reasonable to ask whether residual lung damage is a contributing factor here. Structural 
lung damage in which the local pulmonary immunity is disrupted may make it harder for individuals 
to both clear an initial episode of disease, and for them to contain mycobacteria inhaled with re-
exposure. This hypothesis is perhaps supported by greater difference in TB prevalence between those 
that have / have not had previous PTB amongst the HIV negatives compared to HIV-positives within 
the ZAMSTAR prevalence data,125 in whom we suspect residual TB related lung damage to be more 
marked. Other potentially supportive data for the role of structural respiratory damage in impairing 
the host ability to combat mycobacterial disease comes from studies in the gold mining populations 
of south Africa, in whom the odds of MTB disease has been shown to increase with the degree of 
silicosis, and and in whom NTM disease is associated with previous TB disease, focal radiological 
scarring, and the degree of silicosis.96  Mechanistic work to understand the biological mechanisms 
through which the immune response to TB exposure is altered in the structurally damaged lung, as 
well as epidemiological studies to compare recurrence rates in those with / without post-TB lung 
damage will be required to further understand this.  
 RISK OF EMPIRICAL RETREATMENT 
In addition to potentially increasing the rate of true TB disease relapse or reinfection, PTLD may 
increase the risk of empirical or inappropriate TB retreatment. As shown above, there is a suggestion 
in the literature that individuals with residual lung damage following PTB treatment have a higher 
prevalence of ongoing respiratory symptoms. Management of persistent respiratory symptoms, which 
may include chronic cough and sputum production, is challenging in resource poor settings with 
limited access to diagnostics, and may result in empirical TB retreatment in the absence of true TB 
disease recurrence.  
No studies investigating the performance of clinical screening tools or clinician led empirical TB 
diagnoses in retreatment patients were identified in the literature. Similarly, no prospective data 
describing the proportion of adults with chronic respiratory symptoms /persistently positive TB 
symptom screens following an initial episode of PTB disease, and the clinical management of these 
symptoms have been identified. However, data from a prospective observational study in Harare, 
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Zimbabwe from 2011-2013 showed that 36% (118/328) of symptomatic patients who had been 
started on TB retreatment for a presumed recurrent episode of TB disease infact had no 
microbiological evidence of disease after extensive testing with Xpert, MODS, and liquid and solid TB 
culture of sputum. This study also showed that of those within this group who received an X-ray 39/53 
had evidence of long-term structural lung pathology including bronchiectasis and atelectasis. It may 
be the case that some of these individuals had residual lung damage from a previous episode of 
disease, which let to ongoing chronic respiratory symptoms and may have resulted in empirical 
retreatment.127  
Given the recent calls to increase our focus on active case finding for recurrent TB disease amongst 
patients who have already had an episode of disease as a means of better controlling transmission128, 
better understanding of the impact of chronic symptoms on treatment decisions, and the accuracy / 
role of screening techniques including symptom screening / chest x-ray use in patients who have 
already had an episode of PTB disease is required.  
2.6.4 FINANCIAL IMPACT 
The high costs incurred by patients and their households, both prior to diagnosis and during TB 
treatment, have been well documented, even in settings where TB care is provided for ‘free’ within 
existing public health services.129 More recently, these costs were shown to be associated with adverse 
patient outcomes – in a study in Lima, Peru, patients experiencing ‘catastrophic’ costs prior to/during 
treatment (defined as 20% of annual household income, and experienced by 39% of households) had 
an increased incidence of adverse patient outcomes (defined as death, treatment default or failure, 
or disease recurrence within 2-years).130 Mitigating the economic impact of TB disease has since been 
included in the WHO End TB strategy, with an aim that no TB-affected family should face catastrophic 
costs due to TB by 2020.64 
To date, however, there has been little attention paid to the ongoing direct / indirect costs incurred 
by families after TB treatment completion, with recent reviews of TB related patient costs including 
data from pre-diagnosis and treatment periods only.129 It is indeed likely that out of pocket expense 
and loss of income are most pronounced early in TB disease, and existing data suggest that these 
decline towards the latter stages of treatment.131 However, it is possible that ongoing costs persist at 
a low but still meaningful way beyond treatment completion in relation to residual physical morbidity 
or difficulty regaining employment. Global burden of disease calculations which aim to quantify the 
disability and quality adjusted life years (DALYs & QALYs) experienced in relation to TB disease, and 
which are used to calculate the cost-benefit of TB screening and prevention interventions currently 
consider the TB disease state to end at the point of TB treatment. However, if ongoing costs related 
to residual disability are widespread, this approach may require review.9 132 133  
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2.7 POST-TB LUNG DAMAGE: MEASUREMENT OF DISEASE 
AND OUTCOMES 
As highlighted above, no comprehensive measurement frameworks or severity scores, which included 
multiple respiratory parameters and have been validated against patient outcomes, have been 
identified for post-TB lung damage. In the absence of validated measurement tools for this condition, 
approaches taken to the measurement of disease and outcomes in other lung diseases including 
bronchiectasis, COPD, and pneumonia are reviewed here. This literature has been used to guide the 
approach to the assessment of post-TB lung damage used in Chapter 5 below.  
In addition, existing work on the measurement of chronic lung disease in Africa has identified many 
challenges, for example with the standardization of measurements and selection of reference ranges 
for comparison. These challenges will also be discussed below. 
2.7.1 MEASUREMENT OF LUNG PATHOLOGY 
In order to determine which aspects of post-TB lung damage may be relevant to patient outcomes, 
the clinical parameters included within key prognostic scores used in bronchiectasis and COPD, and 
the outcomes against which they have been validated were reviewed (Table 4). 
Table 4: Prognostic respiratory scores / outcome validated scores 
Prognostic tool Clinical parameters included Outcome of interest 
Non-CF bronchiectasis 
FACED score 
Martinez-Garcia, 
2013134 
 
Age >70 yrs 
mMRC dyspnoea score ≥3 
FEV1 <50% predicted 
>2 lobes affected on CT 
Chronic pseudomonas colonisation 
5-year all cause mortality 
Bronchiectasis 
severity index 
(BSI) 
Chalmers, 2014135 
Age 
BMI 
FEV1 % predicted 
Previous hospital admission 
Previous exacerbations 
MRC dyspnoea score 
Colonisation with pseudomonas / other bacterial 
organism 
Radiological severity - ≥3 lobes / cystic bronchiectasis 
Hospital admission 
4-year all cause mortality 
Chronic Obstructive Pulmonary Disease (COPD) 
CODEX index 
Almagro, 2014136 
Charlson index of comorbidity 
mMRC dyspnoea score 
FEV1% predicted 
Previous severe exacerbations 
3-month & 1-year all cause mortality 
Hospital admissions 
BODE score 
Celli, 2004137 
FEV1 % predicted 
BMI 
MRC dyspnoea score 
6-minute walking distance 
1-year all cause mortality 
 
DOSE score 
Jones, 2009138 
MRC dyspnoea score 
FEV1% predicted 
Current smoking 
Previous exacerbation frequency  
Clinical COPD questionnaire score 
Current respiratory failure (SO2<92%) 
Current 6-minute walk distance 
Health care use / hospitalisation 
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ADO score 
Puhan, 2009139 
Age 
MRC dyspnoea 
FEV1 % predicted 
3-year all cause mortality 
Each of these prognostic scores was noted to include multiple respiratory parameters to capture 
disease severity, based on the finding that individual measures of respiratory disease have poor 
prognostic power. The use of multiple parameters to characterize respiratory disease is further 
supported by the increasing focus on disease phenotyping across parameters within the literature for 
many of these disease conditions.142 143  
Spirometry was a widely used measure of respiratory impairment, with imaging parameters appearing 
as a key feature in bronchiectasis prognostic scores. The degree of breathlessness was found to have 
prognostic relevance in both COPD and bronchiectasis, and age, BMI, and comorbidities were relevant 
for outcome in various scores.  Several of these scores include the number of previous respiratory 
exacerbations as a predictor of long term outcome. Measurement of this parameter is unlikely to be 
appropriate in the assessment of post-TB lung damage, given our interest in new pathology caused by 
the recent TB episode rather than long standing progressive disease. Similarly, although respiratory 
colonization with pseudomonas / other pathogens is a strong predictor of outcome in bronchiectasis, 
the availability of respiratory culture is limited in many resource poor settings including Malawi, such 
that measurement of this parameter is unlikely to be feasible.  
2.7.2 INTERPRETATION OF SPIROMETRY DATA 
From this review it is clear that measurement of spirometry is key to the assessment of PTLD. However, 
several controversies exist in the approach taken to standardizing spirometry data and defining 
patterns of deficit, and the literature on these issues will be reviewed here.  
 SELECTION OF THE REFERENCE RANGE 
When presenting spirometry data, it is important to describe how far from normal the volumes 
measured are. Conventionally this is achieved by standardising FEV1 and FVC volumes, relative to the 
normal values which might be expected from a patient of that age / height / gender. However, there 
is much debate over which reference population these ‘normal’ values are drawn from, and whether 
standardized data should be presented as a % predicted values or z-scores. Four different sets of 
reference ranges for ‘normal’ lung volumes are available for use in the Malawian setting: NHANES III 
Caucasian, NHANES III African American, GLI-2012, and local Malawian reference ranges.34 144 145 The 
populations from which these reference ranges were derived, key features about the models used to 
generate ‘normal’ curves, and the normal values available for each of these reference ranges are 
outlined below (Table 5). Of note – all of these reference ranges are derived from cross sectional data 
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from individuals of different ages, rather than prospective cohort data following individuals up over 
time to truly document change with increasing age, so all are subject to a cohort effect.  
Table 5: Comparison between spirometry reference ranges 
Reference range Derivation  Model Available 
parameters  
NHANES III 
Caucasian 
(Hankinson, 1999)144 
898 male / 1383 female Caucasians, 
aged 8-80yrs. 
 
Asymptomatic lifelong non-smokers 
 
Model includes age and 
standing height. Mean values 
of FEV1 and FVC derived for 
2yr age and 2cm height 
intervals  
 
2 linear models for each 
gender generated, for young 
/older adults (cut point at 
20yrs for males / 18 yrs 
female) 
Predicted & LLN 
values for: 
FEV1, FEV6, FVC, 
PEF, FEF25-75, 
FEV1/FVC 
 
NHANES III 
African American 
(Hankinson, 1999)144 
1027 male / 1481 female African-
Americans, aged 8-80yrs. 
 
Asymptomatic lifelong non-smokers 
Includes a correction term for 
lower observed lung volumes, 
and marginally lower 
FEV1/FVC ratio in African 
Americans. 
Predicted & LLN 
values for: 
FEV1, FEV6, FVC, 
PEF, FEF25-75, 
FEV1/FVC 
GLI-2012 
(Quanjer, 2012)145 
Asymptomatic life long non-smokers 
with data available on sex, age, height, 
self-reported ethnicity, and spirometry, 
aged 3-95yrs (31,856 males / 42,331 
females) 
 
Regression performed separately for 4 
groups: Caucasian, Black, SE Asian, NE 
Asian, and final model includes 
adjustment for each of these. An 
‘other’ category added, averaging the 
results of these groups.  
 
Data for black adults derived from 4 
African American cohorts including 
1520 males / 2025 females 
Height (to 1dp) and age (to 
1dp) standardised 
 
Single curve generated for all 
age groups, using a spline 
 
African American scores lower 
than Caucasian scores: 
FEV1 -13.8-14.7%  
FVC -14.4-15.5% 
Ratio -0.6-0.8% 
Z-scores & LLN 
values for: 
FEV1, FEV6, FVC, 
PEF, FEF25-75, FEF 
75, FEV1/FVC 
 
 
 
Local Malawi 
reference ranges 
(unpublished)34 
 
Post-bronchodilator spirometry from 
healthy non-smokers 
 
242 males / 383 females 
 
Urban Blantyre, 2013-2014 
Height  and age (rounded to 
0dp) standardised 
Predicted & LLN 
values for: 
FEV1, FEV6, FVC 
PEF, FEF25-75, 
FEV1/FVC 
 
Much of debate surrounding which of these reference ranges to use centres on the role of ethnicity in 
determining normal lung function. The relationship between ethnicity and lung volumes is highly 
confounded by socioeconomic situation (SES) and the associated early life exposures – that is, low SES 
is independently associated with ethnicity within / between countries, and is also an independent 
predictor of lung volumes. Because SES is not reported in the large prediction models used to generate 
the reference ranges above, and as few studies have compared lung volumes across ethnically similar 
individuals from diverse socioeconomic backgrounds, or ethnically diverse individuals from similar 
socioeconomic and environmental backgrounds, it has proved difficult to identify the independent 
impact of these variables on lung function.36 
Theoretical arguments against an ethnically driven variation in lung volumes, and therefore against 
using ethnic corrections for lung volume standardisation are based on the premise that ‘normal’ lung 
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volumes have presumably evolved to be maximally efficient for the body’s function, and that there is 
no biological reason why this efficient fixed point should differ between ethnic groups. Some have 
argued that rather than being data driven, the assumption of different ‘normal’ volumes between 
ethnic groups is deeply rooted in 19th century writings on slavery and concepts of the racial ‘inferiority’ 
of black individuals.146 In addition, many argue that the notion of distinct and homogenous categories 
of ethnicity and race is a social rather than biological construct – the genetic heterogeneity between 
black individuals in Africa is marked, and there are likely to be many distinct genetic sub categories 
within this ‘ethnic’ group, which cannot be captured in simple ethnicity corrections. In addition, even 
if we accept that there is one universal set of norms for lung volumes, use of the Caucasian reference 
ranges described above to represent these norms assumes that the populations from whom these 
reference ranges were derived lived in optimal environments for the development of lung function, 
but we have no data on the SES or maternal health of individuals included in these derivation cohorts 
on which to base this assumption.  
Theoretical arguments in favour of using ethnic corrections may include that different ethnic groups 
have widely observed different body characteristics: it is possible that these are genetic / endogenous 
and have evolved over time in response to long-term differences in environment to become ‘norms’, 
and variation in ‘normal’ lung volumes may be one such characteristic. In addition, many note that 
there is much less variation in the FEV1/FVC ratio between ethnicities than the variation seen in the 
FEV1 and FVC volumes themselves, suggesting that perhaps it is the ratio which is the efficient ‘fixed 
point’ to which we have all evolved, with variation in absolute lung volumes around this.  
Given this complexity, the selection of which reference range to use is largely a judgement based on 
the intended purpose of the data collected, and the impact of over/under estimation of abnormality 
which would result. In the BOLD study described in Chapter 4 below, the main aim was to compare 
general findings in the Malawian population with those of other populations, in other settings, and 
the widely used NHANES III Caucasian reference range was therefore chosen for ease of comparison. 
However, in the cohort study presented in Chapter 5 below, the main aim was to describe differences 
within a Malawian cohort, rather than with reference to an external group. A reference range with 
maximal sensitivity to differences between Malawian individuals was therefore required. As will be 
discussed in Chapter 4, infact the NHANES III has high expected lung volumes and tends to classify a 
large proportion of Malawian as having abnormally small lungs, such that it has limited discriminative 
ability between individuals in this setting.34 In theory the Malawian reference range would be ideal for 
an internal comparison, but confidence in the predictive models used to derive this range is limited: 
the R2 values for FEV1 and FVC in males and females within the model ranged from 0.31-0.45, 
suggesting that the ‘fit’ of the predictive models for this population is poor and explains only between 
31-45% of the variation in the true lung volumes observed. Use of these equations to derive normal 
values is therefore unlikely robust. Finally, both the GLI and NHANES III African-American equations 
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are derived from US based African American populations, and set the expected age/height 
standardised lung volumes rather lower than NHANES III Caucasian reference range. These therefore 
provide more conservative estimates of abnormality, and are likely to make identification of those 
with clearly limited lung volumes from within this cohort more robust. The GLI equations are more 
widely used and employ z-scores / LLN values, such that they take into account the distribution of 
observed data in the reference population, as well as the mean predicted value.145 ‘Normal’ values 
derived from GLI-2012 ‘Black’ reference group were therefore selected for use for all primary data 
analysis within the cohort study described in Chapter 5 below.  
 MEASURING DISEASE SEVERITY: Z-SCORES VS. % PREDICTED VALUES 
Whilst use of % predicted scores to interpret the severity of spirometry deficits is widespread in clinical 
practice, it is in some ways statistically flawed – although this approach takes into account the 
predicted mean value for a group of patients of a specific height, age and gender, it does not account 
for the expected variation around this normal value for a given group. In contrast, z-scores are 
measures which are standardised according to the data distribution seen within the reference 
population: a reading which is 1 z-score away from the ‘expected’ value is the equivalent of 1 standard-
deviation from the mean. Because they take into account both the mean ‘normal’ estimate, and the 
expected variation within the reference group for any individual, z-scores are perhaps statistically 
more appropriate measures of severity. 
Whilst % predicted scores were used for the BOLD data analysis presented in Chapter 4 below, in 
keeping with the methods used by BOLD studies in other settings, analysis of data collected from the 
post-TB cohort described in Chapter 5 instead used z-scores.  
 DEFINING PATTERNS OF ABNORMALITY 
Spirometry data are most accurately presented as continuous variables, with % predicted values or z-
scores used as a measure of abnormality. However, for ease of interpretation and in keeping with 
clinical practice, spirometry results are instead often classified into those that are normal / abnormal, 
and into patterns of deficit. 
A fixed FEV1/FVC ratio of 0.7 has been classically used as the cut off to define airway obstruction in 
the literature. However, this ratio is known to vary with age, with a non-linear decline from early 
adulthood even amongst normal ‘well’ individuals. Use of a fixed ratio cut off of 0.7 therefore tends 
to underdiagnose obstruction in younger patients, and over diagnose in older patients. In addition, 
although average ratio values remain constant at a given age / height across all ethnicities (except SE 
Asians), the expected scatter of values varies between ethnicities and age groups and use of a fixed 
ratio does not account for this. Similarly, absolute % predicted cut offs have been used to define 
‘abnormal’ FEV1 or FVC volumes. However, these are controversial: as explained above, % predicted 
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values ignore variation in the distribution of data around the average reading for patients of a given 
age / height, and as such are misleading measures of abnormality. Perhaps related to this, the % 
predicted cut points at which lung volumes are considered abnormal vary widely between patient 
guidelines and are poorly supported by relationships with patient outcomes (Table 6).147 
Table 6: FEV1 severity classification, amongst those with reduced FEV1/FVC ratios 
 ATS/ERS GOLD 2017 GLI 2012 
Mild ≥70% ≥80% >60% 
Moderate 60-69% 50%≤ ≤ FEV1<80% 40-60% 
Mod-Severe 50-59%   
Severe 35-49% 30%≤ ≤ FEV1<50% <40% 
Very severe <35% <30%  
Instead of using fixed % predicted values and a constant FEV1/FVC ratio to define abnormality across 
the whole population, lower limit of normal (LLN) values which take into account both the location 
and spread of data can be used to define abnormality at the individual level.148 A LLN cut off of 5% or 
the 5th percentile can be used to identify measurements which are greater than 1.64 standard 
deviations or z-scores away from the mean in a reference population of individuals with the same age 
/ height / gender. Classifying all measurements which fall outside of this range as abnormal accepts a 
false +ve rate of 5% for all patients, whereby 5% of a normal population would be mistakenly classified 
as having abnormally low readings. The result of using the LLN cut offs for abnormality rather than 
fixed % predicted cut offs is that where ‘normal’ data have wider spread amongst patients of a given 
age / gender / height, fewer people are classified as abnormal. This is particularly relevant for older 
age groups where the spread of data tends to be wider, standard deviations are larger, and the LLN is 
lower than the 80% fixed cut off used in GOLD, such that fewer older individuals will be classified as 
having abnormal lung volumes if the LLN approach is used.145 
 DESCRIBING PATTERNS OF DEFICIT 
Spirometry alone is capable of detecting airway obstruction, as this defined by the presence of a 
reduced FEV1/FVC ratio alone. Use of the term ‘obstructed’ to describe those with a low ratio on 
spirometry is likely an appropriate reflection of underlying lung pathology. However, use of the term 
‘restriction’ to describe spirometry readings where the FEV1/FVC is preserved but FVC volume reduced 
is likely misleading as true restrictive pathology is defined by a reduced total lung capacity (TLC), and 
diagnosis therefore requires formal measurement of lung volumes, rather than spirometry alone. In 
the context of post-TB lung damage in particular, it is not possible to make assumptions about the 
degree to which a low FVC measurement represents a low TLC and true underlying restrictive 
pathology: the true prevalence of restrictive pathology within this cohort is not known and the positive 
predictive value of a low FVC for this is therefore unclear. In addition, a reduced FVC can be the result 
of severe obstruction with gas trapping causing increased residual volumes (RV) / reduced expired 
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volumes, whilst in others the presence of a normal/slightly high ratio with proportionately reduced 
FEV1 and FVC may be caused by submaximal inspiratory or expiratory effort rather than true 
underlying lung pathology. For all of these reasons, use of the terms ‘restriction’ to describe those 
with a low FVC is likely misleading within this patient group, and the term ‘low FVC’ may be more 
accurate. In keeping with this, it is not possible to define a group with mixed disease using spirometry 
only within this group – both restrictive and obstructive pathologies can cause reduction in FVC, such 
that it is not possible to determine the degree of restrictive pathology in a patient who is obstructed, 
using spirometry alone.   
 MEASURING REVERSIBILITY 
Reversibility describes a proportional change in lung volumes in response to bronchodilation, but the 
definition of this varies between guidelines with different denominators used for calculation: the 
ATS/ERS guidelines suggest that any change in volume is measured in reference to the best pre-
bronchodilator FEV1 value, whilst the GLI-2012 guidelines suggest use of the FEV1 predicted value 
(Table 7). However, both of these measures use changes in % predicted values and absolute volumes 
to define reversibility, and as the ATS/ERS classification is more widely recognised, this definition was 
considered more appropriate for use in further analyses presented here. 
Table 7: Reversibility criteria 
 ATS/ERS 2005 GLI-2012 
None n/a Increase <9% of FEV1 predicted AND <200ml increase 
Indeterminate n/a Increase 9-12% of FEV1 predicted OR >200ml increase 
Clear >200ml increase AND Increase >12% of baseline FEV1 value Increase >12%  of FEV1 predicted 
 
2.7.3 SCORING OF CXR & CT IMAGING DATA 
Only one CXR scoring system designed and validated specifically for a post-TB population was 
identified on review of the post-TB lung damage literature presented above, and in the systematic 
review which will be described in Chapter 3 below. In their cross-sectional study of 127 Mexican adults 
who had completed PTB treatment a median of 11 months previously, Baez-Saldana et al. developed 
a simple imaging severity score, whereby the lung fields of each image were divided into quadrants, 
scored from 0(normal) to 5(severe abnormality), and then these scores summed across the lung fields. 
This severity score was found to be negatively correlated with absolute and % predicted values of FEV1 
and FVC following PTB disease. Unfortunately, this scoring system applies to CXR imaging only, is 
relatively broad and simple, and does not measure specific patterns of parenchymal, airway and other 
pathology seen. It was therefore not felt to be appropriate for use in the analyses to be performed in 
the cohort study of post-TB patients presented in Chapter 5 below, and it was felt necessary to 
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generate new scoring system instead. The chronic lung disease most closely related to post-TB lung 
damage in which imaging appears to play a key role in prognostication / management is 
bronchiectasis, and approaches to the measurement of lung damage in bronchiectasis are therefore 
reviewed below.  
The two radiological scoring systems for bronchiectasis severity in widest use at the time of starting 
this project were the Bhalla and Reiff scores. The Bhalla score was developed in 1991 to measure 
structural abnormalities in patients with cystic fibrosis, and the Reiff score subsequently developed in 
1995 to quantify the pattern, severity and distribution of damage in patients with bronchiectasis with 
a range of aetiologies, with the BRICS scoring tool developed during the course of this study.149 150 
(Table 8) 
Table 8: Existing CT bronchiectasis scoring systems 
Name of score Variables measured Options 
Reiff, 1995149 
 
Extent of involvement 0: Absent 
1: ≤1 BP segment 
2: ≥ 2 BP segments 
Severity of dilatation 0: Normal 
1: Lumen < 2x vessel diameter 
2: Lumen 2-3 x vessel diameter 
3: Lumen  >3 times vessel diameter 
Severity of bronchial wall 
thickening 
0: normal 
1: 0.5x vessel diameter 
2: 0.5-1 x vessel diameter 
3: >1 x vessel diameter 
Type of bronchiectasis Cylindrical 
Varicose 
Cystic 
Dominant site Central  
Peripheral 
Mixed 
Lobar distribution Widespread (5-6 lobes) 
Predominant UK 
Predominant ML 
Predominant LL 
Both ML and LL equally involved 
Bhalla,  1991 Severity of dilatation 0: Normal 
1: Lumen slightly >vessel diameter 
2: Lumen 2-3 x vessel diameter 
3: Lumen  >3 times vessel diameter 
Peribronchial thickening 0: Absent 
1: Wall thickness = vessel diameter 
2: Wall thickness 1-2x vessel diameter 
3:  Wall thickness >2x vessel diameter  
Extent of bronchiectasis 
involvement 
0: Absent 
1:1-5 BP segment 
2: 6-9 BP segments 
3: >9 BP segments 
Extent of mucus plugging As above 
Extent of sacculations / abscesses As above 
Generation of bronchial divisions 
with Bx / plugging 
0: Absent 
1: Up to 4th generation 
2: Up to 5th generation 
3: Up to 6th generation / distal 
Number of bullae 0: Absent 
1: Unilateral (not >4) 
2: Bilateral (not >4) 
3: >4 
Emphysema 0: Absent 
1: 1-5 BP segments 
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2: >5 BP segments 
Collapse / consolidation 0: Absent 
1: Subsegmental 
2: Segmental 
BRICS, 2017150 Bronchial dilatation 0: Absent 
1: Lumen slightly >vessel diameter  
2: Lumen 2-3 x vessel diameter 
3: Lumen  >3 times vessel diameter 
Number BP segments with 
emphysema 
0: Absent 
1: 1-5 BP segments 
2: >5 segments 
Variations of these scores have been used in multiple studies investigating patient outcomes in 
relation to imaging measures of bronchiectasis severity (Table 9). The patient cohorts included in these 
studies were different to the likely post-TB population in the Malawian context: all were based in 
resource rich settings, the aetiology of bronchiectasis was different / diverse, average ages were 
higher, and patients were mostly recruited from specialist respiratory units / hospitals at which they 
were being seen for respiratory symptoms. Despite these differences, is it plausible that similar 
parameters may be clinically relevant to outcomes amongst post-TB patients in resource poor settings. 
Reviewing these studies, the parameters most consistently associated with adverse patient 
parameters were: the numbers of lobes affected by bronchiectasis, the overall radiographic extent of 
bronchiectasis, the severity of airway dilatation, and the extent of bronchial wall thickening and 
emphysema. These imaging features were therefore all included in the CT scoring tool designed for 
use in the cohort study of this PhD (Chapter 5).  
Table 9: Studies investigating patient outcomes in relation to imaging appearance, amongst patients with bronchiectasis  
Study Study design Patient population / inclusion criteria 
CT scoring 
method 
Patient 
centred 
outcome 
Imaging features 
associated with outcome 
Sheehan 
2002151 
Prospective 
cohort 
Median 28m 
follow up (6-
74m) 
Single centre 
UK (1991 – 
1999) 
N=48 
 
Chronic sputum 
production, 2x HRCTs 
with PFTs within 2m of 
each 
Modified 
Bhalla score 
Change in 
FEV1 
between 
scans 
Univariate: baseline 
bronchiectasis extent, 
bronchial wall thickening, 
airway plugging score 
Multivariate – bronchial 
wall thickening only 
Onen 
2006152 
Prospective 
cohort with 
4yr follow up  
Single centre 
Turkey (2000-
2005) 
N = 98 
Mean age 68yrs 
75% non-smokers, 28% 
previous PTB 
 
Previous respiratory 
admission, both HRCT 
and PFT results available 
Radiographic 
extent of 
disease 
(1/2/3) – 
based on BP 
segments 
affected & 
pattern 
All cause 
mortality 
 
16 deaths 
(16% 
mortality) – 
all were 
respiratory 
 
Univariate & multivariate: 
radiographic extent of 
disease 
Martinez 
Garcia  
2007134 
Prospective 
cohort 
2yr follow up 
Single centre 
Spain (2003-
2005) 
N=76 
Mean age 70yrs 
Non smokers only, 20% 
post-TB 
 
CT Bx affecting more 
than 1 lobe or with cystic 
pattern, in a stable phase 
Modified 
Bhalla score 
Rate of FEV1 
decline 
Univariate & multivariate: 
no Imaging features 
(overall score, presence of 
cylindrical or cystic 
disease) were statistically 
significant predictors of 
FEV1 decline 
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Loebinger 
2009153 
Prospective 
cohort 
14yr follow up  
Single centre 
UK (1994-2007) 
 
N=91 
Mean 51yrs (SD 12yrs) 
56% idiopathic, 22% post 
infection 
77% never smokers 
 
Clinically diagnosed Bx, 
confirmed on CT imaging 
Modified 
Bhalla score 
 
All cause 
mortality 
 
27 deaths 
(30% 
mortality) - 
70% were 
respiratory 
 
Univariate model - Bx 
extent, dilation severity, 
wall thickness, large airway 
plugging, mosaicism, 
emphysema 
Multivariate model, CT 
variables only – bronchial 
wall thickness, emphysema 
Multivariate model, all 
covariates – no CT features 
significant 
Martinez-
Garcia 
2013154 
Retrospective 
cohort 
5yr follow up 
7 centres 
Spain (Dec 
2005) 
N=819 
Mean age 59yrs  
 
CT diagnosis of Bx, and 
clinical symptoms 
Number of 
lobes 
affected  
 
All cause 
mortality 
 
20% 
mortality – 
43% 
respiratory 
Univariate & multivariate: 
number of lobes affected 
significant 
Goeminne 
2013155 
Prospective 
cohort 
Mean follow up 
5.2yrs 
Single centre 
Belgium (2006-
2012) 
N=245 
Median age 68yrs 
 
‘Clinically significant’ Bx, 
with CT confirmation 
Number of 
lobes 
involved + 
worst 
pattern seen 
All cause 
mortality 
 
20% 
mortality – 
58% from 
respiratory 
cause 
Multivariate: number of 
lobes affected significant 
Chalmers 
2014135 
Prospective 
cohort 
4yr follow up 
Single centre 
UK (2008-2012) 
N=608 
78% aged 50-79yrs 
14% post TB 
 
CT diagnosis of Bx, and 
clinical symptoms 
Modified 
Reiff score 
 
Score ≥3 
used as cut 
off (3 lobes 
/cystic Bx) – 
as per AUC / 
Youden’s 
index 
All cause 
mortality 
62 deaths 
(10% 
mortality) 
Exacerbation 
frequency 
Hospital 
admissions 
Quality of 
life 
Univariate: radiological 
severity ≥3 associated with 
admissions and weakly 
associated with quality of 
life 
Multivariate: radiological 
severity score ≥3 
associated with hospital 
admissions 
Bedi 
2017150 
Cross sectional 
study 
Single centre 
UK (2006-2013) 
N=184 
Median age 65 years 
 
CT diagnosis of Bx and 
clinical symptoms, 
idiopathic / post infective 
aetiology. Limited 
smoking history only.  
Bhalla & 
modified 
Reiff scores 
FEV1<50% 
Sputum 
purulence 
Hospital 
admissions 
Multivariate: severity score 
for bronchial dilatation 
associated with FEV1<50%, 
BP segments with 
emphysema associated 
with sputum purulence 
and hospital admissions 
Bx: bronchiectasis; BP: Bronchopulmonary segment 
 
2.7.4 MEASUREMENT OF QUALITY OF LIFE 
Quality of life emerged as a key outcome measured in the existing literature on PTLD, and that from 
other chronic lung diseases. The most widely used tool for the measurement of respiratory related 
quality of life is the St George’s Respiratory Questionnaire (SGRQ). Developed in the UK in 1992, the 
SGRQ is standardized health-related quality of life assessment tool designed specifically for use in 
patients with chronic respiratory disease.138 It includes 50 items with 76 weighted responses, with a 
focus on respiratory symptoms and their physical and psychosocial impact.156 It has been shown to be 
reliable and valid across multiple chronic respiratory pathologies including COPD and bronchiectasis. 
The long form of the questionnaire, which asks about the frequency of symptoms over the preceding 
3-months has been shown to have superior psychometric properties to versions which ask about 
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symptoms over a shorter duration of time. The questionnaire generates data on individual questions, 
which are combined and weighted using a standard algorithm to generate a symptom, activity, impact, 
and summary score. Each of these four scores ranges from 0 (no symptoms) to 100 (maximal 
symptoms), such that a lower score indicates a superior quality of life. The mean total score amongst 
healthy individuals with no history of respiratory disease is quoted at 6 (IQR: 5-7) in the original SGRQ 
manual.156 
In the literature review above, only 2 studies which had used the SGRQ to assess health related quality 
of life following PTB disease were identified. In a 2007 study by Pasipanodya et al., SGRQ results 
amongst 106 patients from multiple ethnic backgrounds who had completed at least 5-months of 
treatment for culture confirmed PTB were compared with those of patients diagnosed with latent TB 
infection (LTBI) within the same health care unit in Texas, USA (n=207). Comparison was also made 
between the SGRQ and the Medical Outcome Study (MOS) questionnaire (a well validated general 
HRQoL questionnaire that includes data on physical function, general health, and other aspects of 
physical / emotional wellbeing) in 50 patients to assess construct / content validity of the SGRQ in this 
post-TB population. Study findings suggested that the SGRQ was a valid quality of life measure within 
this patient group: those who had been treated for PTB had higher SGRQ scores than those with LTBI;  
both the SQRQ total and sub-scores were correlated with age standardized pulmonary function results 
including FEV1, FVC, FEV1/FVC ratio in both the PTB and LTBI groups; and the SGRQ and MOS scores 
were highly correlated, except for the symptom score, which is perhaps unsurprising given the 
respiratory focus of the SGRQ/ the more general focus of the MOS. An additional finding of interest 
was that differences in scores between PTB and LTBI groups persisted even when controlling for 
spirometry, which suggests that the SGRQ may capture aspects of quality of life outside of pure 
respiratory pathology/ physiology. Of note, the data suggested some cultural variation in results, with 
higher scores observed amongst White American compared to foreign-born / non-white participants 
in the same setting.157 
Only one other study, investigating the relationship between structural lung damage and quality of 
life using the SGRQ in a post-TB population was identified in the literature. In this cross-sectional study 
in India, lung function, CXR and the SGRQ were preformed in 198 patients who had been treated for 
TB a mean of 16.5 years previously 118. The symptom, activity, impact, and overall SGRQ scores were 
slightly higher in those with abnormal CXRs, more pathology on CXR (damage of >2 vs. 2 CXR zones) 
or worse FEV1 scores (≤80% predicted vs. >80% predicted), but these differences were generally not 
statistically significant.  
Of note – whilst not respiratory focused, the EQ-5D-3L is a short quality of life questionnaire that 
assesses 5 domains of health (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression), together with a measure of self-reported general health reported on a Visual 
Analogue Scale (VAS) scaled from 0-100, which has previously been validated for use amongst TB 
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patients in Malawi.158 159 It is quick to complete and provides a broader assessment of general quality 
of life than the SGRQ, can be used for post-hoc validation of the SGRQ, and importantly can be used 
for cost-effectiveness analyses, and as such is used in the cohort study described in Chapter 5 below.  
2.7.5 MEASUREMENT OF FUNCTIONAL CAPACITY 
The most widely used sub-maximal test of functional capacity is the six-minute walking test (6MWT). 
This is a self-paced test with patients asked to walk continuously along a 30m flat corridor for a 6-
minute period, following standardized instructions. It is considered a sub-maximal exercise test in that 
whilst it does push patients to their peak oxygen requirement (VO2 peak) it requires lower ventilation 
than a cardio-pulmonary exercise test. The primary outcome of the test is the total distance covered 
by the patient in the 6-minute study window (6-minute walking distance, 6MWD). Exercise intensity 
is known to be a key predictor of the 6-minute walking distance and reflects the ‘effort’ put into the 
test.160 This is calculated as the % of maximum heart rate reached – or the end of test heart rate 
divided by the maximum heart rate, with the latter approximated as (220 – patient age).  
Models which have sought to design prediction equations for the 6MWD using parameters such as 
height, age, sex, and weight have been limited in their ability to explain the observed variation in 
walking distance achieved between patients.160 A 2014 ERS / ATS review found that at a single time 
point, the walking distance has been shown to have only weak to moderate correlation with health 
related quality of life measures and pulmonary function measures (FEV1, FVC, diffusing capacity of the 
lung for carbon monoxide (DLCO)) across multiple forms of chronic lung disease.161 In fact, the main 
value of the walking distance has been shown to be is its correlation with long-term adverse patient 
outcomes over time including mortality and hospitalization, and therefore its prognostic implications. 
The minimum important distance for the 6MWD reported in the literature – that is, the change in 
distance walked which is observed over time and likely clinically meaningful – is thought to be 
approximately 30-metres.161 
Only one study in which 6-minute walk tests were performed in post-TB patients was identified in the 
literature: this was conducted in Brazil and included 18 patients treated for MDR TB only, amongst 
whom no statistically significant relationship was demonstrated with the extent of pathology seen on 
CXR.117 No accepted norms or cut offs for the 6MWD were identified within the literature for the post-
TB population.  
2.7.6 DEFINITION OF ACUTE RESPIRATORY EXACERBATIONS 
Challenges in defining respiratory exacerbation in chronic lung disease are widely recognized – no 
biomarkers for exacerbation are available, and objective confirmation of a deterioration in patients 
symptoms is often difficult.162 Some of the most commonly used definitions of infective exacerbations 
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in bronchiectasis and COPD are outlined below (Table 10). These chronic respiratory conditions were 
chosen as both airway obstruction and bronchiectasis were expected to be common in the post-TB 
population. Although fibrotic change was also thought likely, the pattern and nature of this was felt 
likely to be different to the fine reticular change often observed in the interstitial lung diseases, and 
definitions of exacerbations seen in the latter were therefore not reviewed.  
Table 10: Potential definitions of acute respiratory event or respiratory exacerbation 
Source Definition 
Bronchiectasis 
Pasteur et al., 2010163 
British Thoracic Society 
A change in one or more of the common symptoms of bronchiectasis (increasing 
sputum volume or purulence, worsening dyspnoea, increased cough, declining lung 
function, increased fatigue/malaise) or the appearance of new symptoms (fever, 
pleurisy, haemoptysis, requirement for antibiotic treatment). 
Hill et al, 2017164 
EMBARC working group 
 
A deterioration in three or more of the following key symptoms for at least 48 h: 
cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or 
exercise tolerance; fatigue and/or malaise; haemoptysis  
AND a clinician determines that a change in bronchiectasis treatment is required. 
COPD 
Wedzicha et al, 2007165 
 
An acute worsening of respiratory symptoms associated with a variable degree of 
physiological deterioration 
GOLD, 2007 
An event in the natural course of the disease characterized by a change in the patient’s 
baseline dyspnoea, cough, and/or sputum that is beyond normal day-to-day variations, 
is acute in onset, and may warrant a change in regular medication in a patient with 
underlying COPD 
GOLD 2017166 An acute worsening of respiratory symptoms that result in additional therapy 
These definitions have been developed largely for use in resource rich settings, and amongst patients 
with pre-existing diagnoses of chronic respiratory disease who may be well informed about their 
respiratory health. The features included within these definitions include change in symptoms, change 
in physiology, a time-frame over which these changes were observed, and health seeking with a 
change in clinical management. Reporting of each of these parameters may be problematic in resource 
poor settings or when dealing with a patient population with limited education or health literacy. 
Symptom descriptions may vary / be less precise, ascertainment of time frames may be challenging, 
and issues around health service access may influence health seeking.165 Medical documentation is 
often more limited in these settings, such that events are difficult to ascertain from health records. In 
such contexts, simpler definitions are required. 
2.7.7 MEASUREMENT OF FINANCIAL IMPACT 
As explained above, adults completing treatment for PTB may continue to experience economic costs 
as a result of persistent morbidity and ongoing health service use. No validated tools for the 
measurement of post-treatment costs were identified on review of the literature, but at the start of 
this PhD the STOP-TB partnership were in the process of developing a cost questionnaire for TB 
patients.167 This questionnaire includes questions on both direct and indirect patient costs: direct costs 
include the medical expenses (Eg. investigation and medication costs) and non-medical expenses (Eg. 
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transport, accommodation, food) incurred by patients and their households through the process of 
health care seeking, whilst indirect costs relate to lost income due to time away from work during health 
care seeking. This tool was therefore used as the basis for data collected in Chapter 5 below.  
Of note, recall bias in the reporting of income and expenditure, particularly when data are collected 
some months after the event have been widely reported in the economic literature. ‘Dissaving’ is an 
alternate concept recently proposed in the literature, as a more reliable measure of patient and 
household costs – it includes the use of savings, selling of assets, and borrowing of money by the 
household to cover health related costs or lost income, and is thought to be the final consequence of 
catastrophic costs. It may be more memorable than income levels or expenditure, 168 and is therefore 
also included in Chapter 5 below.  
2.8 SUMMARY 
Despite the WHO declaration of TB as a global emergency in the 1990s, there remain an estimated 
10.4 million incident cases of TB disease per year, with incidence rates of 254/100,000 population per 
year in the African region. Although incidence rates are falling, progress is slow with an average rate 
of decline of only 1.4% per year. Despite the ambitious targets set out in the SDGs and the end-TB 
strategy, TB disease is therefore likely to remain a pressing public health priority in the decades ahead.  
In recent years, much emphasis has been placed on reducing TB related mortality – national 
surveillance systems are mandated to report predominantly on microbiological and mortality 
outcomes, with little focus on morbidity. However, in 2015 treatment success rates of up to 83% of 
registered cases of drug sensitive disease were reported, suggesting that by far the majority of 
individuals treated for TB disease survive to 6-months with either microbiological cure or clinical 
recovery. Given these numbers, some focus on the long-term outcomes of survivors is warranted.   
We now have good evidence that PTB disease leads to lung damage which persists after completion 
of treatment. These data are particularly strong when residual damage is measured using spirometry 
– the odds of airway obstruction in those who have had previous PTB compared to those who have 
not are 1.37 – 8.9 higher in numerous studies, with 1.70 - 5.99 times higher odds of restrictive 
spirometry demonstrated within the BOLD studies. However, there have been limited attempts to 
describe the structural pathology underlying abnormal spirometry after PTB disease, there is an 
absence of prospective data describing the evolution of pathology over time, and we have few data 
on the relationship between residual post-TB lung damage and ongoing morbidity. Whilst there is 
some suggestion that those with more extensive residual damage may be at risk of reduced quality of 
life, impaired functional capacity, and increased respiratory exacerbations in long term, these data are 
far from robust. The relationship between post-TB lung damage and mortality, risk of recurrent TB 
disease / empirical retreatment, and ongoing economic impact are poorly defined. Lastly, there 
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remain many gaps in our understanding of post-TB lung damage amongst those who are HIV co-
infected, who account for 30% of TB cases in the African region.  
A key challenge for future work in this area is the lack of consistency in terminology used between 
studies when describing post-TB lung damage, and the lack of validated tools for measurement of both 
disease and outcomes. Consensus agreement on the terminology and measurement tools to be used 
for future work in this area are required, but a comprehensive understanding of what this damage 
looks like and how it behaves is first needed.   
Finally, the population in Malawi may be particularly vulnerable to the effects of post-TB lung damage. 
Almost 17,000 new cases of TB disease are reported annually, and over half of TB patients at HIV co-
infected. The population is economically vulnerable with limited educational opportunities, and there 
is a high burden of background respiratory impairment on which the additional insult of PTB disease 
is experienced, with 11.8 – 22.5% of adults reporting respiratory symptoms and over 40% of adults 
having abnormal spirometry using NHANES III reference ranges. In this setting, the impact of residual 
post-TB lung damage and any disability related to this may be profound.  
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3 SYSTEMATIC REVIEW OF POST-TB 
STRUCTURAL LUNG DAMAGE 
3.1 INTRODUCTION 
As highlighted in the literature review above, the majority of large studies seeking to describe post-TB 
lung damage to date have focused on describing the prevalence of residual abnormal spirometry: 3 
reviews and data from the international BOLD studies have provided strong evidence that PTB disease 
is associated with increased odds of persistently abnormal lung function after treatment completion. 
However, no comparable reviews of the patterns of structural lung damage were identified in the 
literature. In response to this a systematic review of the prevalence and patterns of post-TB structural 
lung damage was completed, and was published in 2016 (PLoS ONE 11(8): e0161176. Doi: 10.1371/ 
journal.pone.0161176).169 The findings of this review, which was updated in January 2018, are 
presented below. 
3.2 METHODS 
3.2.1 SYSTEMATIC REVIEW PROTOCOL, JULY 2016 
The original review protocol was designed in accordance with PRISMA guidelines, and was registered 
with the National Institute of Health Research (NIHR) Prospero register (CRD42015027958) with the 
stated research question of “What is the prevalence and pattern of imaging defined (CT or CXR) 
respiratory pathology in adults, following treatment for pulmonary TB disease?”.  
Only studies in which unselected consecutive participants with pleural, miliary, or pulmonary TB had 
been recruited, where CXR or CT had been performed after the completion of a full medical TB 
treatment regimen, and where the prevalence of abnormal imaging or the severity of residual 
structural lung damage had been reported were included. Studies describing the prevalence of 
radiological abnormalities amongst a subset of patients completing PTB treatment, for example those 
with confirmed airway obstruction or ongoing symptoms, were excluded to avoid selection bias. 
Cohort studies, cross-sectional studies and randomised control trials (RCTs) were eligible for inclusion. 
There were no limits on publication date. Only studies published in English were included.  
Original literature searches were conducted in Medline, Pubmed, Scopus, Web of Science, and the 
Cochrane Library using the search terms shown in Table 1. Reference lists from published reviews and 
reference and citation lists of papers meeting inclusion criteria were reviewed to identify additional 
articles.  
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Table 1: Template for literature search: Pulmonary, pleural or military tuberculosis AND [CXR imaging OR CT imaging]  
Criteria Search terms 
Pulmonary, pleural, or miliary 
tuberculosis 
“Tuberculosis, pulmonary”[MESH] OR “tuberculosis, miliary[MESH] OR “tuberculosis, 
pleural”[MESH] OR "pulmonary TB" OR "pulmonary tuberculosis" 
CXR Imaging “thoracic radiography"[MESH] OR “chest x-ray" OR "chest radiograph" OR "CXR"  
CT imaging “computed tomography”[MESH]  OR "CT" OR "comput* tomography" 
The title and abstract of all identified studies were screened by two independent reviewers (JM & HS). 
Full text review was performed on all selected articles. Studies restricted to paediatric populations, in 
whom PTB has a varied presentation, or patients with non-HIV related immunosuppression 
(chemotherapy, malignancy etc.) where imaging was likely to be affected by comorbidities, were 
excluded. Data from the control arms of trials of adjuvant immunomodulatory therapies, in which 
patients received medical TB treatment only, were included. A standardized data extraction form was 
used to determine the primary outcome of interest, which was the prevalence of abnormal imaging 
after TB treatment. Information was collected on the patterns of imaging pathology, study 
characteristics, participant characteristics, treatment regimens, and the modality and timing of 
thoracic imaging (Table 2). The proportion of studies that presented a measure of association between 
imaging findings and other clinical parameters including spirometry, functional capacity, respiratory 
symptoms, or health-related quality of life was recorded.  
Table 2: Study data extracted 
Category Data collected 
Study characteristics Author 
Year of publication 
Country 
Study design 
Study dates (month/year) 
Patient characteristics Pattern of TB disease – pleural, pulmonary, miliary 
First episode / retreatment 
Microbiological evidence for disease 
Drug sensitivity of organism 
HIV status of participants 
Treatment outcome 
Participant age 
Other inclusion / exclusion criteria used 
TB treatment received Duration of treatment 
Treatment regimen 
Imaging findings Timing of imaging, post treatment completion 
Imaging modality – CXR / CT imaging 
Number of imaging readers 
Definitions of imaging findings used 
% prevalence of the following: overall normal / abnormal imaging, cavitation, bronchiectasis, 
fibrosis, lung destruction, pleural thickening, other 
Severity scores used 
Severity score results 
Associated outcomes Patient centred outcomes measured (Symptoms, health related quality of life, functional 
capacity) 
Lung function measured 
Relationship of associated factors to imaging described 
 
63 
 
Disagreements in study selection and data extraction were resolved by discussion. Subgroup analyses 
were conducted to explore the effect of different manifestations of disease (pleural vs. pulmonary), 
imaging modality (CXR vs. CT), and multidrug-resistant (MDR) disease on the primary outcome.  
Study quality was determined using a modified version of the Newcastle-Ottowa score,170 which 
included assessment of selection bias, adequacy of follow-up, the accuracy with which baseline TB 
disease and treatment completion were determined, the quality and standardisation of imaging 
interpretation, and the exclusion of those with structural lung disease preceding TB-disease. Whilst 
there is no formal recommendation for multiple readers in radiology research, this is the norm in the 
imaging literature, as the amount of variation between readers can be used by to quantify levels of 
‘uncertainty’ in imaging interpretation. It was therefore felt to be an important marker of study quality 
and was included in our evaluation.  A maximum score of 5 was possible for cohort studies, and 4 for 
cross-sectional studies where no follow-up was required (Table 3) 
Table 3: Modified Newcastle-Ottowa score for assessment of study quality 
Study characteristic 
 
Study performance Score 
Selection of study cohort Truly representative of the average TB patient in the community* 
Somewhat representative of the average TB patient in the community 
Selected groups  
No description of the derivation of the cohort 
1 
Assessment of exposure  Secure record of TB disease and treatment* 
Structured interview recording of TB disease and treatment 
Written self report of TB disease and treatment 
No description of how exposure ascertained 
1 
Demonstration that 
outcome not present at 
start 
Imaging performed prior to TB diagnosis, with exclusion of those with prevalent 
lung disease* 
Statement of exclusion of those with known preceding lung disease 
1 
Assessment of outcome Independent blind assessment by 2 readers with definitions of imaging findings 
(severity score or individual features) given* 
1 reader only 
No description of readers, or no definitions given 
1 
Adequacy of follow-up§ ≤20% of those starting treatment & surviving lost to follow up, with subjects lost 
unlikely to introduce bias* 
Loss to follow up >20% of those who survived treatment 
No statement on follow-up 
1 
*Studies awarded a point only when this highest standard achieved for each study parameter 
§Only applicable to cohort studies in which patient follow-up required 
3.2.2 SYSTEMATIC REVIEW UPDATE, JANUARY 2018 
The search above was repeated for the period from June 2016 -  January 2018, in order to ensure up 
to date findings. Because during the course of the PhD it became clear that the term ‘sequelae’ is 
frequently used in the literature to denote residual morbidity following TB disease, including lung 
pathology, an additional search using this term was performed in January 2018 (Table 4). 
Table 4: Template for additional literature search: Pulmonary, pleural or military tuberculosis AND [sequel*]  
Criteria Search terms 
Pulmonary, pleural, or miliary 
Tuberculosis 
“Tuberculosis, pulmonary”[Mesh] OR “tuberculosis, miliary[Mesh] OR “tuberculosis, 
pleural”[Mesh] OR "pulmonary TB" OR "pulmonary tuberculosis" 
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Respiratory sequelae sequel* 
This update was performed in Pubmed only and was again limited to English language publications, 
with article review and data extraction performed by one reviewer (JM) only.  
3.3 RESULTS 
3.3.1 ARTICLES IDENTIFIED 
The initial search performed in July 2016 identified 10,740 articles, with 6909 articles remaining after 
removal of duplicates. Title and abstract review identified 309 articles for full text review, of which 
277 were excluded for reasons including non-consecutive patient recruitment (n=48), imaging prior to 
treatment completion (n=162), and failure to report the absolute prevalence or severity of residual 
lung damage (n=35). Reference and citation searches identified 5 further articles for inclusion, giving 
a total of 37 articles. Repetition of this search for the period from June 106 to January 2018 identified 
an additional 192 articles, with no duplicates. Only 13 new articles were left after title and abstract 
review, of which none remained for inclusion after full text review.  
The additional search performed using the term ‘Sequel*’ in January 2018 identified 288 articles, with 
52 of these remaining after abstract / title review. Six of these were duplicates of papers already 
identified by the two searches above, and were therefore discarded. Full texts were reviewed for 37 
or the remaining 46 articles, and 2 of these were thought to be eligible for inclusion.  
A summary of the reasons for exclusion across these three sections of the review is given in Table 5, 
and the PRISMA diagram for the initial and updated searches given in Figure 1. The total number of 
articles identified which provide data on the prevalence and pattern of post-TB structural lung damage 
was 39.  
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Figure 1: Prisma diagram for systematic review 
 
 
 
Table 5: Reasons for rejection at full-text review for the original search (July 2016), updated search (Jan 2018), and separate 
search with the term “sequelae” 
 Original (n=309) 
Update* 
(n=13) 
Sequelae* 
(n=46) 
Total articles 
receiving full 
text review 
(n=368) 
Excluded  
Imaging prior to treatment completion  158 4 0 162 
Prevalence of abnormal imaging not given  32 3 9 44 
Non-consecutive patients recruited  44 4 14 61 
Not original research 19 2 8 29 
Case report/series 11 0 3 14 
Additional treatments given 1 0 0 1 
No treatment received 0 0 1 1 
Paediatric study 1 0 0 1 
Modelling / ex vivo studies 2 0 1 3 
Not English 1 0 0 1 
Unable to locate full article 8 0 8 16 
Added  
Citation review 1 0 0 1 
Reference review 4 0 0 4 
Total 37 0 2 39 
*One reviewer only 
 
3.3.2 STUDY CHARACTERISTICS 
Of the 39 studies identified, the majority were from the Americas (n=13), South East Asia (n=10), the 
Western Pacific (n=7) and Europe (n=6) (Table 6). Despite being the WHO region which contributed 
25% of incident TB cases in 2016, Africa is significantly under-represented – only 2 studies were 
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conducted on the continent, both of which were done in South Africa, and of which 1 focused on MDR 
disease171 and the other on pleural disease.172 We did not identify any robust data on residual 
structural lung damage following drug sensitive pulmonary TB in Africa.  
Table 6: Geographical distribution of studies, by WHO world region 
WHO World Region Total number of studies Country (number of studies) 
Americas 13 Brazil (6), Mexico (2), Martinique (1), USA (3), Canada (1) 
South East Asia 10 India (7), Indonesia (2), Thailand (1) 
Europe 6 Turkey (3), Spain (2), Romania (1) 
Western Pacific 7 Taiwan (5), Malaysia (1), Hong Kong (1) 
Africa 2 South Africa (2) 
Eastern Mediterranean 1 Saudi Arabia (1) 
 
Study publication dates spanned the period 1973-2017. Treatment regimens varied widely in the 
earlier studies, but even post 1995 when ‘standard’ first line treatment regimens were adopted, 
significant variation in the drugs used and treatment duration were seen. 11 studies did not specify 
the treatment regimen used.    
There were 16 prospective cohort studies with patients recruited at TB diagnosis and imaged upon 
treatment completion, one prospective cohort study where imaging was performed 1 year post 
treatment completion173 and one where imaging was performed 6-months after treatment 
completion. There were 6 cross-sectional studies, 4 of which performed imaging at various time points 
after treatment completion, and 9 retrospective cohort studies, which performed imaging upon 
treatment completion. Data from 6 RCTs were included: data from both study arms were included for 
two treatment regimen trials174 175 and a study investigating the effect of Vitamin-D and L-arginine 
supplementation 176, but data from the control arms only were included from trials investigating 
prednisolone use172 177, and a trial of M. vaccae immunomodulation 115. All RCTs performed imaging at 
treatment completion, and 1 also performed serial imaging 6-months later172.  
Only seven studies used CT imaging to describe structural pathology. Five of these were conducted in 
the Americas, all were prospective cohort studies, and all performed imaging at treatment completion. 
Only one study of pleural disease used both CXR and CT imaging 172.  
3.3.3 PATIENT CHARACTERISTICS 
The total number of patients in all included studies was 4096, with disaggregated data available for 76 
HIV-infected individuals only. The median number of participants per study was 56 (range 13-1080). 
We identified 26 studies focused on PTB, 1 on the sequelae of miliary TB, 10 restricted to pleural TB, 
and 2 which included patients with varying patterns of intrathoracic TB. Patients with microbiological 
confirmation of TB disease only were included in 22/39 studies, with 6 studies failing to describe the 
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baseline microbiology of patients at diagnosis. Of the studies that specified the pattern of drug 
sensitivity (15/39), we identified 3 studies imaging patients treated for multidrug resistant disease 
using CXR in South Africa,171 India,178 and Brazil.117 The majority of studies did not specify whether they 
included patients who had completed a first or retreatment treatment regimen (25/39). Of those that 
did describe this, 8 studies included patients completing their first episode of treatment, 2 included 
retreatment patients,115 117 and 4 included both groups. The marked heterogeneity between studies 
made meta-analysis of their findings inappropriate. 
3.3.4 IMAGING 
The majority of studies used CXR imaging only (32/39), with 6 studies using CT only, and only 1 study 
using both CXR and CT to image patients following pleural disease.172  29 studies performed imaging 
at TB treatment completion, 2 did not specify the timing of imaging, and the remainder imaged 
patients from 6m to 18yrs post completion. The approach to image reporting varied widely between 
studies – several studies (15/39) did not document the number of readers reviewing each image, and 
only 17/39 used 2-3 readers per image. In addition, many studies (11/39) did not provide definitions 
or a reference for the radiology terminology or scoring system used when to describe image findings.   
3.3.5 STUDY FINDINGS – PULMONARY TB STUDIES 
Of the 27 studies reporting the sequelae of pulmonary and miliary TB, prevalence estimates for 
radiographic pathology were given in 17 CXR (Table 7) and 5 CT studies (Table 8), and varied widely. 
Findings are summarised in Table 9 below. Twelve CXR studies reported the prevalence of cavitation 
(8.3-83.7%), 3 reported fibrosis (prevalence 25.0-70.4%) and 4 reported bronchiectasis (prevalence 
4.3-11.2%). The CT-based studies generally reported a lower prevalence of cavitation (7.4-34.6%), and 
a higher prevalence of bronchiectasis (35.0-86.0%) and fibrosis (70.0-92.6%), than studies using CXR 
imaging.  
A more diverse range of pathologies was noted on CT imaging: pleural thickening was reported in 3 
studies (prevalence 0.1-50.0%, n=99), features potentially suggestive of ongoing inflammation such as 
nodules were seen in all 5 studies (prevalence 25.9-55.8%, n=193), consolidation was reported in 4 
studies (3.7-19.2%, n=119), emphysema was seen in in 2 studies (prevalence 15.4-45.0%, n=72). 
Mosaicism was documented in 1 study only where it was observed in all patients with concurrent 
cavities (11/11) and a third of patients without cavities (3/9), and no change in prevalence was 
observed over the course of treatment.179  
The prevalence of cavitation was higher in studies of re-treatment patients (68.8-83.7%), and those 
treated for MDR disease (51.5-69.7%), compared to those with fully sensitive, mixed, or unspecified 
sensitivities (8.3-49.7%). Only 1 study performed repeat imaging; this demonstrated a reduction in the 
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prevalence of cavitation during the 6-month follow-up period from the end of TB treatment, but the 
findings were limited by a small sample size and 25% loss to follow-up115. 
Table 9:  Range of prevalence estimates of imaging patterns on CXR or CT following pulmonary or miliary TB  
Imaging pattern 
CXR imaging CT imaging CXR imaging in patients with MDR disease 
Number of 
studies 
(number of 
patients) 
n=15 (3517) 
% prevalence 
range 
Number of 
studies 
(number of 
patients) 
n=5 (193) 
% prevalence 
range 
Number of 
studies 
(number of 
patients) 
n=2 (78) 
% prevalence 
range 
Normal imaging 11 (2365) 0 – 86.4% -  2 (78) 0 – 6.1 % 
Cavitation 11 (2902) 8.3 – 83.7 % 4 (173) 7.4 – 34.6 % 2 (78) 51.5 – 69.7 % 
Bronchiectasis 4 (670) 4.3 – 11.2 % 5 (193) 35.0 – 86.0 % - - 
Fibrosis 3 (551) 25.0 – 70.4 % 4 (119) 70.0 – 92.6 %  - - 
Pleural thickening 2 (1520) 6.9 – 21.2% 3 (99) 0 – 50.0 % - - 
Nodules - - 5 (193) 25.9 – 55.8 % - - 
Consolidation - - 4 (119) 3.7 – 19.2 % - - 
Tree in bud   4 (166) 0 – 20.0%   
Ground glass   2 (79) 1.9 – 7.4%   
Emphysema / 
bullae - - 2 (72) 15.4 – 45.0 % - - 
Mosaicism   1 (20) 70.0%   
Architectural 
distortion   1 (74) 91.0%   
A broad range of severity scores were used to quantify residual damage in 14 studies of PTB sequelae, 
only one of which was validated for scoring post-TB damage rather than active PTB disease (Table 
10).107 
3.3.6 STUDY FINDINGS – PLEURAL DISEASE 
The only radiological feature consistently reported in studies of pleural TB sequelae was the presence 
of residual pleural thickening, but the thoracic area covered by this thickening was not routinely 
reported. Residual thickening >10mm was seen in 19.6-46.0% of patients in 5 studies (n=310) (Table 
11). One study reported both CXR and CT findings following pleural TB, with mild pleural thickening 
>2mm seen in 50.0% (18/36) on CXR, and 60.0% (21/35) on CT172. 
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Table 11: Studies of residual pleural thickening (RPT) on completion of treatment for TB pleural effusion 
Imaging Author, Year Country Study design Patients HIV status 
Prevalence of 
pathology (%) 
Qualit
y 
score  
CXR Kunter, 2002180 Turkey 
Retrospective 
cohort 47 
Not 
specified 
RPT>2mm: 
63.8% 
RPT>10mm: 
25.5% 
2/5 
 CXR Uskal, 2005181 Turkey 
Retrospective 
cohort 121 
Not 
specified 
RPT>2mm: 
52.1% 3/5 
 CXR Wong, 2005182 Hong Kong 
Retrospective 
cohort 70 
Not 
specified 
RPT>10mm: 
41.4% 2/5 
 CXR Barbas, 1991183 Brazil 
Prospective 
cohort 44 
Not 
specified 
RPT>2mm: 
52.3% 2/5 
 CXR de Pablo, 1997 184 Spain 
Prospective 
cohort 56 Mixed 
RPT>2mm: 
42.9% 
RPT>10mm: 
19.6% 
3/5 
 CXR Frye, 1997185 America  
Retrospective 
cohort 20 Positive Any RPT: 65.0% 3/5 
 CXR Galarza, 1995 177 Spain RCT - steroid use* 60 Negative Any RPT: 8.3% 2/5 
 CXR Wyser, 1996 172 South Africa RCT - steroid use* 36 Negative 
RPT>2mm: 
50.0% 4/5 
CXR Lai, 2009108 Taiwan Prospective cohort 87 
Not 
specified 
RPT>10mm: 
22.9% 4/5 
CT Wyser, 1996172 South Africa RCT - steroid use* 35 Negative 
RPT>2mm: 
60.0% 4/5 
 CT Seiscento, 2007186 Brazil 
Prospective 
cohort 50 
Not 
specified 
RPT>10mm: 
46.0% 3/5 
*Date from study arm including steroids excluded 
 
3.3.7 RELATIONSHIP BETWEEN IMAGING CHANGES AND OTHER 
RESPIRATORY PARAMETERS 
Although several studies described spirometry following PTB disease, only 2 studies directly related 
physiological impairment to imaging findings. The first showed a statistically significant inverse 
correlation between both FEV1 (forced expiratory flow in 1-second) and FVC (forced vital capacity), 
and the extent of radiographic abnormality on CXR in 127 adults who were a median of 11 months 
(IQR 6-18 months) post completion of TB treatment107. The second described imaging findings in 
patients with (n=24) and without (n=46) fixed airway obstruction on spirometry following treatment 
completion. Those with airway obstruction had had more previous episodes of TB (1.9+/-0.7 vs. 1.4+/-
0.6, p=0.009), but had more fibrocavitatory changes evident on CXR imaging.187  
The only study to relate imaging findings to functional capacity included 18 patients completing 
treatment for MDR-TB, and found a higher level of impairment amongst those with more marked 
radiographic damage: 64% of those with Grade I damage (7/11) failed to reach an expected 6-minute 
walking distance, compared to 100% of patients with Grade III damage (3/3). However, the findings of 
this study were limited by a small sample size and a lack of statistical testing.117 Only one study 
described the relationship between imaging findings and patient quality of life. This was a cross-
sectional study of 198 patients who had been treated for TB a mean of 16.5 years previously, and 
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found no statistically significant difference in the symptoms, activity, impact, or overall St George’s 
Respiratory Questionnaire scores between those with pathology affecting 2 vs. >2 CXR zones.188 
These studies have been described in greater detail in the general thesis literature review, given 
above.  
3.4 DISCUSSION 
The key findings from this systematic review of structural lung damage in adults completing medical 
treatment for PTB are the high prevalence of residual structural abnormalities seen on imaging, but 
the lack of validated scores for the measurement of this damage. Differences in both the prevalence 
estimates and patterns of damage seen in CXR and CT based studies were noted, as well as the high 
burden of residual damage amongst those treated for MDR disease, but data from HIV-infected adults 
and the sSA region are limited. Few prospective studies have documented change over time or the 
level of morbidity experienced in relation to this residual damage.  
 RESIDUAL STRUCTURAL LUNG DAMAGE IS COMMON FOLLOWING PTB 
DISEASE 
Data from both the CXR and CT imaging studies suggest a high burden of residual structural pathology, 
which persists following PTB treatment completion. Cavitation was the feature most commonly 
reported on 11/15 CXR studies, perhaps in relation to the public health importance of this feature for 
smear positivity and ongoing transmission of disease, and was documented in 8.3 - 83.7% of cases. 
The range of pathologies reported on CT imaging studies was much wider, and included a high burden 
of both airway (Bronchiectasis: 35.0 – 86.0 %, Tree-in-bud: 0-20%) and parenchymal pathology 
(Fibrotic change: 70.0 – 92.6 %, consolidation: 3.7 – 19.2%, ground glass: 1.9 – 7.4%, emphysema: 15.4 
– 45.0%, and mosaicism: 70.0%).   
The high burden of bronchiectasis is of particular interest. Tuberculosis is a known cause of airway 
pathology,189 but these data suggest that at least a third of patients completing PTB treatment may be 
left with this pattern of damage. This is of concern given data from resource rich settings suggesting 
that bronchiectasis is associated with adverse long term outcomes including reduced quality of life, 
increased rates of respiratory exacerbation, and mortality,134 135 150 152-155 The high prevalence of other 
risk factors for bronchiectasis including HIV disease and early childhood infection in many high TB-
incidence settings may compound this burden of disease,190 and yet few imaging data from non-TB 
populations are available to describe the background burden of bronchiectasis in resource-poor 
settings, and few guidelines for clinical management have been developed for these settings. Amongst 
the 5 CT studies reporting the prevalence of this pathology, none were based in sSA or included HIV-
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infected adults, and the extent and severity of damage was not reported. This requires further 
investigation.  
The high prevalence of potential signs of ongoing inflammation, including tree-in-bud airway change, 
consolidation and ground glass infiltrate, and perhaps nodules even after treatment completion is also 
of note, and supports the finding of ongoing inflammatory activity documented of the PET-CT studies 
performed in post-TB populations and described in the literature review above.102 The evolution of 
these patterns of pathology were not described in the CT studies identified in this review, such that it 
remains unclear whether they represent resolving inflammation or ongoing active disease. Again, this 
requires further investigation.  
Lastly, it is of note that mosaicism – reported in one study only – had a high prevalence of 70%. 
Mosaicism is defined in the Fleischner guidelines as ‘a patchwork of regions of differing attenuation’ 
within the lung parenchyma,191 with the areas of lower attenuation conventionally scored. A degree 
of parenchymal heterogeneity can be seen in normal individuals, with up to 20% showing mild 
mosaicism on inspiratory scans. What constitutes a ‘normal’ percentage of low attenuation in the lung 
tissue has been shown to vary from the apices to bases of the lung fields, and from central to 
peripheral regions, and is highly dependent on how complete the patient’s inspiratory effort was at 
time of imaging, such that there are no absolute cut-offs for normal. High amounts of lung attenuation 
can be caused by two main groups of pathology. The first is primary small airways disease – the small 
airways are those with an internal diameter <2mm, between the 8th generation of the airways and the 
terminal bronchioles, and are only visible on CT imaging when pathologies such as primary damage 
with an inflammatory or constrictive bronchiolitis, involvement of the small airways in an interstitial 
process such as hypersensitivity pneumonitis, or involvement in a large airways process such as 
bronchiectasis or asthma are present. Relative lucency of parenchyma is caused by obstruction of the 
small airways, with gas trapping distal to the point of obstruction +/- shunting and decreased perfusion 
through vessels in these areas. The second situation in which the lung tissue develops low attenuation 
is in pulmonary hypertension, where there are regional differences in lung perfusion through 
pulmonary vessels and hence a ‘patchy’ density is seen on imaging.192 Further studies investigating the 
prevalence and extent of this pattern are required – if widely seen, investigation of the cause may be 
warranted.  
 THE BURDEN OF POST-TB LUNG DAMAGE IS LIKELY HIGHER FOLLOWING 
MDR-TB DISEASE 
A limited amount of data on the residual lung damage experienced by patients treated for MDR PTB 
disease was identified. However, the prevalence of cavitation was higher on the two CXR studies 
performed in these groups (51.5-69.7%), compared to those with fully sensitive, mixed, or unspecified 
disease (8.3-49.7%).  
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This is likely a result of the longer time taken for culture conversion and treatment of multidrug 
resistant disease. The physical, social and economic impacts of MDR-TB disease are known to be 
high,193 and the potential impact of marked residual pulmonary impairment on top of this may be 
significant. Globally an estimated 4.1% (95% CI: 2.8–5.3%) of new TB cases and 19% (95% CI: 9.8–27%) 
of previously treated cases had MDR/RR-TB in 2016,12 and the burden of post-TB lung damage 
amongst this patient population requires further investigation.  
 THE QUALITY OF EXISTING CT IMAGING DATA IS LIMITED 
CT imaging is likely to be the more accurate modality for the measurement of structural pathology. As 
described here, the 5 CT studies identified in this review provide useful information about this 
pathology, but their findings must be interpreted with caution. The majority of these studies were 
completed in the Americas and were restricted to HIV-negative / HIV-unknown individuals only, and a 
total of 193 individuals only were included across them all. These studies largely reported on the 
presence of pathology, rather than its extent or severity, making it difficult to understand the 
importance of their findings. Finally, prevalence estimates of pathology were noted to vary widely 
between studies, and in the absence of standardized reporting tools, and high quality reporting 
systems, it is not clear whether this represents the true variation between individuals, or rather 
differences in the approach taken to measurement.  
No validated reporting tools for chest CT imaging following PTB treatment completion were identified 
in this review. Rigorous and standardized approaches to the scoring of CT imaging in the post-TB 
population are required to allow us to more accurately document post-TB structural pathology, and 
to understand the heterogeneity of pathology within and between populations. 
 FEW DATA ARE AVAILABLE ON THE OUTCOMES ASSOCIATED WITH 
STRUCTURAL DAMAGE 
Few studies attempted to examine the relationship between lung damage and patient functional 
capacity, symptom burden, and quality of life. The available data suggest that exercise capacity may 
decrease with increasing extents of structural pathology, but sample sizes in the one study to assess 
this were low.117 The only study relating structural pathology to quality of life was vulnerable to 
selection bias, and the nature of this relationship therefore remains unclear.188 No studies identified 
within this review described the relationship between residual structural damage and ongoing rates 
of respiratory exacerbations, or mortality. As described in the literature review above, further 
investigation of the relationship between post-TB structural damage and long-term patient centred 
outcomes is required.  
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In addition, only two studies investigating the relationship between imaging and spirometry were 
identified within this review. Both were CXR studies, and whilst they suggest a correlation between 
the extent of abnormality / fibrocavitatory change with lung function, the relationship between 
imaging features such as bronchiectasis and mosaicism – which are more accurately seen on CT 
imaging – and lung function remains unclear. In the absence of these data, the ability of spirometry – 
which is a minimally invasive tool which could potentially be widely used in a decentralized fashion in 
resource poor settings – to detect and diagnose residual post-TB structural pathology remains unclear.  
 DATA FROM SSA AND HIV-INFECTED INDIVIDUALS ARE LACKING 
This review has identified a paucity of data on post-TB structural pathology from sSA and from HIV-
positive patients.  
It is biologically plausible, based on the high rates of respiratory co-exposures described in the 
literature review above, and challenges of delayed diagnosis and limited health service access seen in 
many parts of sSA, that post-TB lung damage may differ in both pattern and severity in this region 
compared to that in middle and high income settings. Collection of primary data on the nature of post-
TB lung damage in sSA is required.  
Whilst HIV infected adults have atypical or less extensive patterns of pathology seen on imaging at TB 
diagnosis,78 81 85 patients are at risk of IRIS reactions during TB treatment, and opportunistic infections 
in the context of advanced HIV, both of which may alter the evolution of lung damage over the 6-
month course of TB treatment. It cannot be assumed the extent of residual lung damage amongst HIV-
infected adults surviving to TB treatment completion will be minimal, and direct measurement of 
residual pathology in the HIV-positive population is required.  
 STUDY STRENGTHS AND LIMITATIONS 
This study was limited by the inclusion of English language articles only. This approach was taken for 
pragmatic reasons, but may have introduced important bias into our findings. In addition, whilst the 
inclusion of studies with consecutive recruitment of patients only will have minimised bias in the 
prevalence estimates presented here, it may have led us to exclude important data from other studies 
in which alternative recruitment strategies were used. The heterogeneity of patient populations, 
treatment regimens, and the timing and modality of imaging meant that it was not possible to perform 
a meta-analysis. Interpretation of findings is limited by the highly variable quality of studies identified, 
the majority of which failed to specify how the radiological abnormalities reported on imaging were 
defined, and did not use gold-standard methods of reporting, making them vulnerable to 
misclassification of outcomes. Selection bias was a common issue; many studies were unclear about 
the reference population from which participants were drawn. The cross-sectional studies imaging 
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patients sometime after treatment completion consistently struggled to locate eligible patients, and 
were limited by survival bias.  
The strengths of this review include the use of several databases with no limitation on study dates, 
and the use of reference and citation review to identify additional papers. 
3.5 CONCLUSION 
This systematic review identified a high burden of residual structural pathology amongst adults 
completing PTB treatment, with a wide range of features recorded on CT imaging including cavitation, 
fibrosis, bronchiectasis, emphysema and mosaicism, and features of ongoing inflammation. However, 
the quality of studies included in this review was limited, findings were mostly drawn from cross 
sectional data, and little information on associated morbidity was identified. A better understanding 
of the nature of this structural lung damage, its evolution over time, relationships with abnormal 
spirometry, and the associated impact on patients’ lives and livelihoods is needed to guide clinical 
management and health-service planning.  
CT imaging is able to detect a broader range of pathology than CXR, and should be the imaging 
modality of choice for research studies aiming to phenotype post-TB lung damage. Studies performing 
paired CXR / spirometry and CT imaging will be of use in determining the ability of these more 
accessible techniques to detect underlying structural pathology, for practical use in LMICs.  
Future CT imaging studies should aim to use develop standardised scoring tools, and use high quality 
reporting standards. Inclusion of measures of disease extent and pattern, in addition to just 
prevalence, are required to allow better interpretation of the implications of findings. This is 
particularly relevant for findings such as bronchiectasis which appear common and may have long-
term clinical implications. Specific attention is required for HIV-infected groups, those living in sSA, 
and those treated for MDR/RR PTB disease, for whom current data are lacking.  
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Table 7: Studies reporting prevalence of imaging patterns on CXR imaging following treatment for thoracic tuberculosis 
Timing of 
imaging Author, Year Country Study design   TB pattern 
Participant HIV 
status 
Treatment 
episode Drug sensitivity 
Number of 
participants 
 
Prevalence of pathology (%)  
Quality 
score 
On completion 
of TB Treatment 
Yu, 
1995194 Taiwan Prospective cohort Pulmonary Negative Not specified Mixed 22 Abnormal imaging: 13.6 % 3/5 
Al Hajjaj,  
2000195 Saudi Arabia Prospective cohort  Pulmonary Not specified Not specified Not specified 1080 
Abnormal imaging: 65.9%, Cavitation: 15.0%, 
Pleural thickening 6.9%, Lung destruction 52.4% 3/5 
de Valliere,  
2004171 South Africa 
Prospective cohort 
 Pulmonary Mixed Not specified MDR 33 
Abnormal imaging: 93.9 - 100%, Cavitation:  
51.5% - 69.7% 2/5 
Buyukoglan, 
2007 196 Turkey Prospective cohort  Pulmonary Negative Not specified Not specified 25 Cavitation:  28.0% 3/5 
Swaminathan, 
2007 197 India Prospective cohort Miliary Positive Not specified Not specified 31 
Abnormal imaging: 22.6%. Lung destruction: 
3.2% 3/5 
Angthong,  
2011 114 Thailand Prospective cohort Pulmonary 
Mixed - data 
disaggregated First episode Not specified 
98 HIV+ Abnormal imaging: 84.7%, Cavitation:  11.2%, Fibrosis: 70.4%, Bronchiectasis: 11.2% 4/5 
 
12 HIV- Abnormal imaging: 41.7%, Cavitation: 8.3%, Fibrosis: 25.0%, Bronchiectasis: 8.3% 
Small, 1994 198 America Retrospective cohort Pulmonary Positive Not specified Not specified 13 Abnormal imaging: 23.1% 3/5 
Menon, 2015 199 India Retrospective cohort 
Pulmonary, 
pleural, 
mediastinal 
Not specified First episode Not specified 441 
Abnormal imaging: 40.4, Cavitation: 21.4%, 
Pleural thickening: 21.2%, Fibrosis: 38.7%, 
Bronchiectasis: 4.3%, Mediastinal lesions: 23.6% 
2/5 
Kallan,  
1988 200 India Cross sectional Pulmonary Not specified Not specified Not specified 119 
Abnormal imaging: 100.0% , Cavitation: 42.0%, 
Bronchiectasis: 7.6% 1/4 
Anonymous, 
1973 175 India 
RCT–TB treatment 
regimens* Pulmonary Not specified Not specified Not specified 173 Cavitation: 49.7% 4/5 
Hamilton,  
2008 174 America 
RC –TB treatment 
regimens* Pulmonary Negative Not specified Fully sensitive 834 Cavitation:  23.3% 4/5 
Kenangalem, 
2013 176 Indonesia 
RCT–additional Vit D 
/ L-arginine† Pulmonary Mixed First episode Mixed 77 Cavitation: 18.2% 2/5 
On completion 
and at 6m 
Corlan,  
1997 115 Romania 
RCT–additional 
M.vaccae† Pulmonary Retreatment Mixed Mixed 
43 – CXR  on 
completion Cavitation: 83.7% 
3/5 
32 – CXR  at 
6 months Cavitation: 68.8% 
6–63 months 
post completion 
Singla,  
2009 178 India Cross sectional Pulmonary Negative Not specified MDR 45 Abnormal imaging: 97.8%, Cavitation: 53.3% 1/4 
14–18 years post 
completion 
Banu Rekha, 
2009 118 India Cross sectional Pulmonary Not specified First episode Not specified 198 Abnormal imaging: 85.9% 1/4 
5 years post 
completion 
Lisha,  
2012 201 India Cross sectional Pulmonary Not specified Mixed Mixed 224 Abnormal imaging: 65.6% 2/4 
0–252 months 
post completion 
Baez-saldana, 
2013 107 Mexico Cross sectional Pulmonary Mixed Not specified Not specified 127 Abnormal imaging: 96.9% 2/4 
*Data included from both arms 
†Data included from placebo arms only 
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Table 8: Studies reporting prevalence of imaging patterns on CT imaging on completion of treatment for pulmonary tuberculosis 
Author, Year Country Study design   
Participant HIV 
status 
Treatment 
episode Drug sensitivity 
Number of 
participants Prevalence of pathology (%)  
Quality 
score 
Poey,  
1997202 Martinique Prospective cohort Negative Not specified Not specified 27 
Cavitation: 7.4%, Bronchiectasis: 85.2%, Fibrosis: 92.6%, Pleural thickening: 
4.8%, Nodules: 25.9%, Consolidation: 3.7%, Ground glass pattern: 7.4%, 
Reticulation: 44.4%,  
3/5 
Long,  
1998179 Canada Prospective cohort Negative Not specified Fully sensitive 20 
Bronchiectasis: 50.0%, Fibrosis: 80.0%, Pleural thickening: 0.1%, Nodules: 55.0%, 
Consolidation: 15.0%, Emphysema/Bullae: 45.0%, Mosaicism: 70.0%, Tree in 
bud 20.0% 
3/5 
Bombarda,  
2003 203 Brazil Prospective cohort Negative Not specified Not specified 20 
Cavitation: 30.0%, Bronchiectasis: 35.0%, Fibrotic bands: 70.0%, Nodules: 55.0%, 
Consolidation: 15.0%, Mass lesions: 45%, Tree in bud: 5.0% 3/5 
Lee,  
2008204 Taiwan Prospective cohort Negative First episode Fully sensitive 52 
Cavitation: 34.6%, Bronchiectasis: 44.2%, Fibrosis: 92.3%, Pleural thickening: 
50.0%, Nodules: 55.8%, Consolidation: 19.2%, Emphysema/Bullae: 15.4%, Mass 
lesions: 7.7%, Ground glass pattern: 1.9%, Parenchymal calcification: 11.5%, 
Tree in bud: 0% 
1/5 
 
Capone 
2017205 Brazil Prospective cohort Not specified Not specified Not specified 74 
Cavitation: 16%, Bronchiectasis: 86%, Nodules: 48%, Parenchymal opacities: 
25%, Parenchymal calcifications: 47%, Architectural distortion: 91%, Tree in bud: 
5.4% 
1/5 
 
 
Table 10: Studies reporting severity scores of residual changes on CXR imaging performed following treatment for pulmonary TB 
Author Country Study design n Participant HIV status 
Treatment 
episode 
Drug 
sensitivity 
Timing of 
imaging Source of severity score Severity score description Findings 
Quality 
score  
de Valliere,  
2004 171 
South 
Africa 
Prospective 
cohort 33 Mixed Not specified MDR On completion Not specified 
CXR split into 6 zones. 
Involvement of each zone 
scored 0-3. Total score 18. 
Mean score 6.5/18 2/5 
Ralph,  
2010 206 Indonesia 
Prospective 
cohort 152 Mixed Not specified  Mixed On completion 
Ralph 2010 - diagnostic CXR 
scoring system 
% lung affected + 40 if 
cavitation seen. Total 
score 140. 
Median score 10/140, Range 
0 - 115 3/5 
Wang,  
2010 173 Taiwan 
Prospective 
cohort 98 Negative Not specified 
Not 
specified 
1 year post 
completion Not specified 
Minimal / Moderate / 
Advanced fibrosis* 
60.2% Minimal 
14.3% Moderate 
25.5% Advanced 
3/5 
Chen,  
2011 207 Taiwan 
Prospective 
cohort  51 Negative Not specified 
Not 
specified On completion 
McAdams & Erasmus 1995 - 
active TB CXR scoring 
system 
Minimal / Extensive† 31.4% Extensive  3/5 
Menon, 
2015199‡ India 
Retrospective 
cohort 441 
Not 
specified First episode 
Fully 
sensitive On completion 
1969 National TB associate 
of the USA – diagnostic CXR 
scoring system 
Minimal / Moderate / 
Moderately advanced / Far 
advanced 
55.7% Minimal 
22.8% Moderate 
15.2% Moderately advanced 
6% Advanced 
2/5 
How,  
2014 208 Malaysia 
Retrospective 
cohort 156 Mixed Mixed 
Not 
specified On completion 
1961 National TB 
association USA  -diagnostic 
CXR scoring system 209 
Minimal / Moderate / 
Advanced disease¶ 
26.2% Minimal 
60.8% Moderate 
13% Advanced 
2/5 
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Singla,  
2009 178 India Cross sectional 45 Negative Not specified MDR 
6-63m post 
completion 
1961 National TB 
association USA  -diagnostic 
CXR scoring system209 
Minimal / Moderate / 
Advanced disease¶ 
35.6% Minimal 
22.2% Moderate 
40.0% Advanced 
1/4 
Lisha,  
2012 201 India Cross sectional 224 
Not 
specified Mixed Mixed 
5 years post 
completion 
1961 National TB 
association USA  -diagnostic 
CXR scoring system 209 
Minimal / Moderate / 
Advanced disease¶  
34.3% Minimal 
13.4% Moderate 
4.5% Advanced 
2/4 
Banu Rekha, 
2009 188 India Cross sectional 198 
Not 
specified First episode 
Not 
specified 
14 - 18 years 
post completion Not specified 
CXR divided into 6 zones, 
and zones counted 
35.9% ≤2 zones 
50% >2 zones 1/4 
Godoy,  
2012 210 Brazil Cross sectional 18 Negative Retreatment MDR On completion 
Wilcox & Ferguson 1989 - 
diagnostic CXR scoring 
system 211 
Grade I - III#  
61.1% Grade I 
22.2% Grade II 
16.7% Grade III 
2/4 
Ramos, 2009 
212 Brazil 
Retrospective 
cohort 37 
Not 
specified Not specified 
Not 
specified On completion 
Wilcox & Ferguson 1989 - 
diagnostic CXR scoring 
system 211 
Grade I - III# 
 
38% - Grade I 
35% - Grade II 
27% - Grade III 
1/5 
 
Baez-saldana, 
2013 213 Mexico Cross sectional 127 Mixed Not specified 
Not 
specified 
0-252 months 
post completion 
Created by authors for 
grading post-TB CXR 
changes & validated in study 
CXR split into 4 quadrants. 
Involvement of each one 
scored 0-5. Total score 20. 
Mean score 6.46/20 
Standard deviation 4.14 2/4 
de la Mora, 
2015 187 Mexico Cross sectional 
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Not 
specified Mixed Mixed 
Post completion. 
With CAO: 2.7+/- 
4.3 yrs 
Without CAO: 
2.3 +/- 2.1 yrs 
Not specified 
Number of lung quadrants 
with fibrocavitatory 
changes. Total number of 
cavities 
With CAO: 1.8 +/-0.8 
affected quadrants, 1.4 +/- 
0.8 cavities 
Without CAO: 1.3 +/- 0.6 
affected quadrants, 0.5 +/-
0.7 cavities 
1/4 
Kenangalem, 
2013 176 Indonesia 
RCT - Vit D / L-
argenine 77 Mixed First episode Mixed On completion 
Ralph 2010 - diagnostic CXR 
scoring system 
% lung affected + 40 if 
cavitation seen 
Total score 140 
Papuans: Median score 
6/140, Range 2-15 
Non papuans: Median score 
12.5/140, Range 4-20.5 
2/5 
* Minimal- mild - lung fibrosis <50% of RUL, no change in architecture/ clouding or lung marking or vasculature. Moderate - lung fibrosis >50% of RUL, no change in architecture/ clouding or lung marking or 
vasculature / lung collapse / tortuous airways / bronchiectasis. Advanced - fibrosis of whole RUL, combined with collapse, bronchiectasis and tortuous airways 
†Minimal - slight to moderate density not containing cavitation with total extent not exceeding lung volume on one side above the chondro-sternal junction. Extensive - slight to moderate density extending more 
than total volume of one lung or equivalent in both lungs 
‡Study included paƟents treated for pulmonary, pleural or mediasƟnal TB – no disaggregated data available, so all included here 
¶Minimal - Unilateral or bilateral. Lesions of slight to moderate density with no cavitation. Involvement should not exceed space above 2nd chondrosternal junction and the spine of the 4th or body of 5th vertebra. 
Moderate - Unilateral or bilateral. Disseminated lesions of slight-moderate density may extend through total volume of 1 lung or equivalent in both lungs. Dense/confluent lesions limited to 1/3 of one lung. Total 
diameter of cavitation must be <4cm. Advanced - more extensive than moderate. 
#Grade I - minimal change in 1 zone, with no cavities. Grade II - 2-3 zones involved, or 1 zone with cavitation. Grade III - severe involvement of >3zones, with or without cavitation 
**Results stratified according to the presence of Chronic Airway Obstruction (CAO) on spirometry, as defined by a ratio of the post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity 
(FVC) ratio <0.7, and the % predicted FEV1< lower limit of normal: patients with CAO (n=24), without CAO (n=46). Mean and standard deviation for time since treatment and radiology findings given 
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4 THE BURDEN OF CHRONIC RESPIRATORY 
SYMPTOMS AND ABNORMAL SPIROMETRY 
IN URBAN MALAWI 
4.1 INTRODUCTION 
The systematic review presented in Chapter 3 has highlighted clear gaps in our understanding of the 
patterns and prevalence of post-TB lung damage in sSA. At the same time, as described in Chapter 2, 
data on the burden of CLDs in the African region are also lacking.  
In order to provide some understanding of the background prevalence of respiratory exposures and 
CLD in urban Blantyre, against which PTB disease and post-TB lung damage are experienced, we did a 
population-level survey of respiratory symptoms and spirometry in an age and gender stratified 
sample of adults living in Chilomoni district of Blantyre. The study was conducted using the 
standardised community sampling approaches, data collection tools, and centralised quality control 
procedures established by the 2005 Burden of Obstructive Lung Disease (BOLD) initiative: a multi-
country programme of work designed to measure the prevalence of airways disease in various global 
settings.28  
Study design and data collection were led by Professor Kevin Mortimer, and data analysis and write 
up completed by myself as a PhD student. Findings were published in 2016 (Meghji et al. Am J Respir 
Crit Care Med. 2016;194(1):67-76).  
4.2 METHODS  
An age (18–39 and >40 years) and sex stratified population-representative sample of 2,000 adults was 
randomly taken from an enumerated population of Chilomoni district of urban Blantyre, Malawi. 
Fieldworkers conducted home visits to assess eligibility and to seek informed consent between 
February 2013 and August 2014. Individuals were excluded if they were not permanent residents of 
the area, were pregnant, or were acutely unwell. Up to three repeat visits were conducted to locate 
initially absent residents. A target sample size of 1,200 adults completing the study, split equally 
between men and women, and those aged 18 to 39 years and 40 years or older, was chosen to allow 
stratified prevalence estimates of spirometric abnormalities with acceptable precision, in accordance 
with the BOLD protocol. 
Standardized BOLD questionnaires about respiratory symptoms and exposures were administered in 
the local language, Chichewa. Questions were asked about respiratory exposures including smoking 
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and biomass use, but no data were collected on marijuana use. Data on previous TB disease was 
collected through participant self-report only, and these reports were not verified against clinic 
registers. Pre- and post-bronchodilator spirometry was performed according to American Thoracic 
Society (ATS) standards using the ndd EasyOne Spirometer (ndd Medical Technologies; Zurich, 
Switzerland). Anthropometric measurements and a blood sample for HIV and haematology assays 
were taken. Participants were given the results of the clinical observations and spirometry 
measurements at the point of testing. HIV test results were communicated to participants who wished 
to know their results. Minimal questionnaire data were collected from patients who declined to 
participate in the full study. Quality assurance of questionnaire and spirometry data was provided by 
the central BOLD coordinating centre.  
Two reference ranges were used for age, gender and height standardization of spirometry data: 
standardization using the NHANES III reference range was used to allow comparison with other BOLD 
study sites, and comparison with a local reference range generated using the spirometry data from 
non-smoking adults with no history of respiratory disease or symptoms who were included within this 
study was used for internal comparison. Patterns of spirometric deficit were described using the 
following definitions: spirometric obstruction (FEV1/FVC ratio<0.7), moderate-severe obstruction 
(FEV1/FVC ratio<0.7 & FEV1<80% predicted), and Low FVC (FEV1/FVC ratio≥0.7 & FVC<80% predicted). 
Fixed cut offs and % predicted values were used to facilitate comparison with other BOLD studies. The 
term spirometric restriction has been avoided here, in light of the limitations described above.  
Survey weighting was used to calculate population representative prevalence estimates and develop 
regression models using the Svy package in Stata v12. Associations between spirometric abnormalities 
/ symptoms and predictor variables were examined in bivariate and multivariable logistic regression 
models. Home ownership and household water and sanitation were used as proxy markers of 
socioeconomic status (SES), and no adjustments were made for multiple tests in exploratory analyses. 
A manual forward stepwise regression technique was used to develop multivariable models, with age 
and sex included a-priori, together with variables with a p-value 0.2 on bivariate analysis.  Missing data 
were imputed using simple univariate procedures, and sensitivity analyses were used to compare 
results with complete case analyses. Ethical approval was given by the National Health Sciences 
Research Committee and the Liverpool School of Tropical Medicine Research Ethics Committee 
(Protocol 12.08). 
4.3 RESULTS 
The study flow diagram is shown in Figure 1. Of the 2000 randomly selected adults, 1469 (73.5%) were 
located by fieldworkers and 1240 (62.0%) were eligible for inclusion. Of eligible adults, 85.4% 
(1059/1240) consented to participate and completed the full questionnaire, with 70.7% (749/1059) 
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performing ATS standard spirometry (Figure 1). The 167 individuals who did not complete the full data 
questionnaire were more likely to be male (56.3% (94/167) vs. 42.1% (446/1059)) and ever-smokers 
(12.0% (20/167) vs 10.4% (110/1059)) compared to those contributing full data.  
 
Figure 1: Participant recruitment flow diagram 
 
 
 
4.3.1 PARTICIPANT CHARACTERISTICS 
Mean participant age was 41.9 years (SD 15.3), and 57.9% were female. Overall 37.4% were educated 
to primary school level only. Although 59.3% of participants were from households that owned their 
own home, only 25.1% had access to flush toilets and 46.6% had a private indoor or outdoor water 
supply (Table 1). A total of 10.4% (110/1057) were ever smokers, with exposure was more frequently 
reported by men: 9.2% of men and 0.7% of women were current smokers; 12.8% of men and 1.3% of 
women were ex-smokers. 80.9% of those who had smoked reported <10 pack-years of exposure. 
Despite this study being conducted in an urban setting, 85.2% (900/1057) of the population reported 
use of a biomass fuel (mostly charcoal) for cooking or heating water on an open fire for ≥6 months, 
and 31.9% reported the use of an open fire burning wood, dung, or crop residues for heating water. 
Farming was the reported occupation of 29.2% of participants, even in this urban setting. 
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Table 1: Characteristics of participants completing full BOLD core questionnaire, including those with and without ATS 
standard spirometry 
Variable (n) Number (%) Mean (SD) 
Age group (n=1058) 
- 18-29 
- 30-39 
- 40-49 
- 50-59 
- 60-69 
- 70+ 
 
283 
190 
253 
182 
98 
52    
 
(26.8 %) 
(18.0 %) 
(23.9 %) 
(17.2 %) 
(9.3 %) 
(4.9 %) 
Gender (n=1059) 
- Male  
- Female 
 
446 
613 
 
(42.1 %) 
(57.9 %) 
Level of education (n=1054) 
- None 
- Primary 
- Middle 
- High school or college 
 
59 
394 
391 
210 
 
(5.6 %) 
(37.4 %) 
(37.1 %) 
(19.9%) 
Years of education (n=1057) 9.29 4.35 
HIV status (n=933) 
- Negative 
- Positive 
 
707 
226  
 
(75.8 %)  
(24.2 %) 
Self reported previous TB (n=1057) 
- No 
- Yes 
 
1026 
31 
 
(97.1 %) 
(2.9 %) 
Haemoglobin (g/dL) (n=936) 13.9 (1.80) 
Eosinophil blood count >2% (n=927) 
- No 
- Yes 
 
291 
636  
 
(31.4 %) 
(68.6 %) 
BMI group (kg/m2) (n=972) 
- Underweight (BMI<18.5) 
- Normal (18.5≥BMI<25) 
- Overweight (25≥BMI<30) 
- Obese (BMI≥30 
 
77 
568 
202 
125 
 
(7.9 %) 
(58.4 %) 
(20.8 %) 
(12.9 %) 
Home ownership (n=1057) 
- Yes 
- No 
 
627 
430 
 
(59.3 %) 
(40.7 %) 
Access to private water supply (indoor OR outdoor 
tap) (n=1057) 
- Yes 
- No 
 
 
492 
565 
 
 
(46.6 %) 
(53.4 %) 
Household has flush toilet (n=1057) 
- Yes 
- No 
 
265 
792 
 
(25.1 %) 
(74.9 %) 
Smoking status (n=1057) 
- Ever 
- Never 
 
110 
947 
 
(10.4 %) 
(89.6 %) 
Pack years of smoking (n=1057) 
- 0 years 
- >0 and <10years 
- ≥10 years 
 
947 
89 
21 
 
(89.6 %) 
(8.4 %) 
(2.0 %) 
Biomass exposure* (n=1057) 
- No 
- Yes 
 
157 
900 
 
(14.8 %) 
(85.2 %) 
Working in farming >3m (n=1056) 
- No 
- Yes 
 
748 
308 
 
(70.8 %) 
(29.2 %) 
*Use of charcoal/coal/coke or burning of wood/dung/crop residue for >6 months for cooking, or burning of wood/dung/crop 
residue for heating water 
 
7.9% of the population had low BMI (<18.5 kg/m2), 20.8% were overweight (BMI 25-30 kg/m2), and 
12.9% were obese (BMI>30 kg/m2). The prevalence of self-reported previous TB within this cohort was 
2.9% (31/1058). Data on HIV status were available for 88.1% of those who completed the core 
questionnaire, of whom 24.2% were HIV-infected. Haemoglobin levels were normally distributed with 
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mean 13.9g/dL (SD 1.8) and range 6.7-21.4 g/dL. The median white cell count (WCC) was 5.0 (IQR: 4.1-
5.9); 68.6% of participants had blood eosinophil counts exceeding 2.0% of the total WCC. 
4.3.2 RESPIRATORY SYMPTOMS 
Overall, 11.8% (SE: 1.2) of participants had at least one respiratory symptom, and 5.0% (SE: 0.8) 
reported respiratory problems interfering with their daily activities.  
Cough was the most common symptom – current cough was reported by 7.5% (SE: 0.9) of participants, 
but chronic cough present on most days for >3 months/yr was reported by only 0.5% (SE: 0.2). 
Breathlessness was described by 3.6% (SE: 0.7) of participants, with 21.2% (SE: 8.5) of this group 
reporting severe functional impairment and stopping for breath after walking 100 yards on a flat 
surface (modified Medical Research Council breathlessness score = 3). Wheeze within the past year in 
the absence of an upper respiratory tract infection was reported by 1.4% (SE: 0.4) only. Sputum 
production, described as phlegm produced on most days for >3 months/yr, was the least common 
symptom, reported by only 0.2% (SE: 0.2) of all study participants (Table 2, Figure 2) 
Figure 2: Age and gender stratified prevalence of respiratory symptoms: upper panel depicts symptom prevalence among 
men; lower panel depicts symptom prevalence among women. (N=1056) 
The questions asked were as follows: Do you usually have a cough when you don’t have a cold? (n = 1,056); Do you usually 
bring up phlegm from your chest? (n = 1,056); Have you had wheezing/whistling in your chest at any point in in the past 12 
months, in the absence of a cold? (n = 1,007); Do you have shortness of breath when hurrying on the level or walking up a 
slight hill? (n = 970); and Have breathing problems interfered with your usual daily activities? (n = 1,056). 
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4.3.3 SPIROMETRY 
Three factors were statistically significantly associated with completion of ATS standard spirometry: 
lower median age [41.0 years (IQR: 28-51) vs. 44.0 years, (IQR: 31-56), p<0.001], higher mean 
haemoglobin [14.07(SD 1.80) vs. 13.62(SD 1.76), p<0.001], and a greater average number of years of 
education [9.47(SD 4.20) vs. 8.85(4.65), p=0.036]. No other statistically significant differences were 
identified at alpha = 0.05 level between groups who did and did not complete spirometry.  
Amongst the 749/1059 patients who performed ATS standard spirometry, 4.3% (SE 1.1) of men and 
4.1% (SE 1.1) of women had post-bronchodilator obstruction (FEV1/FVC <0.7). A high proportion of 
this was at least moderate in severity: 3.2% (SE 1.0) of men and 3.9% (SE 1.0) of women had an FEV1 
<80% predicted using the NHANES reference ranges, and 2.0% (SE 0.7) of men and 2.7% (SE 0.9) of 
women using local reference ranges. The prevalence of obstruction increased with age: any 
obstruction and moderate-severe obstruction were seen in 2.9% (SE 0.9) and 2.6% (SE 0.9) of 18-39 
year olds, and 9.0% (SE 1.4) and 7.0% (SE 1.2) of ≥40 year olds. The number of participants in the Low 
FVC group was higher than that with obstruction in both genders and across age-group strata (Figure 
3). 
Figure 3: Age & gender stratified prevalence estimates for abnormal spirometry, amongst those completing ATS quality 
spirometry: upper panel depicts symptom prevalence among men; lower panel depicts symptom prevalence among women 
(n=749) 
Moderate to severe airway obstruction (FEV1/FVC<0.7 and FEV1<80% predicted) and low FVC pattern (FEV1/FVC≥0.7 and 
FVC<80%), defined using NHANES III reference ranges 
 
 
84 
 
The estimated prevalence of both the obstruction and low FVC groups were higher when NHANES III 
reference ranges were used, compared to local reference ranges (Table 3). This difference was 
particularly marked for low FVC: 38.6% (SE 2.1) were included within this category using the NHANES 
reference range, compared to (9.0%, SE 1.2) using locally derived reference ranges. Airway reversibility 
was present in 4.2% (0.8) of the cohort, but only 17.3% (SE 7.7) of those with reversibility had airway 
obstruction following bronchodilator. 
4.3.4 FACTORS ASSOCIATED WITH RESPIRATORY SYMPTOMS 
Ever smoking was positively associated with both cough and sputum production in bivariate analysis, 
and in multivariable analysis the odds of usual cough were 2.37 higher in current vs. never smokers 
(95% CI 1.12-5.02) (Table 4). The odds of regular sputum expectoration were 5.94 times higher (95% 
CI 1.95-18.06) in those with previous biomass exposure compared to those without. Employment in 
farming was positively associated with all symptoms in bivariate analyses, and the odds of exertional 
breathlessness remained significantly higher (OR 6.32, 95% CI: 1.87-21.32) in those employed in 
farming for >3 months compared to non-farmers in multivariable analysis. 
Women were less likely to report cough or sputum production in bivariate analyses, and their odds of 
cough remained lower (OR 0.31, 95% CI 0.15-0.65) than men in multivariable analysis. Low BMI was 
positively associated with wheeze and sputum production in bivariate analysis, and the odds of usual 
sputum production remained 3.49 (95% CI 1.37 – 8.86) times higher in those with BMI<18.5kg/m2 
compared to normal weight in the multivariable model. No statistically significant relationships 
between symptoms and markers of SES or education persisted in multivariable models.  
One-third of those with cough were HIV-infected, and a positive association was seen between cough 
and HIV-infection in multivariate analysis (OR 1.94, 95% CI 1.10-3.44). HIV-infection was not associated 
with other respiratory symptoms. Self reported previous TB was not statistically associated with any 
symptoms. Moderate-severe obstruction, Low FVC, or reversibility, defined using NHANES III 
reference ranges were not associated with respiratory symptoms (Table 5). 
4.3.5 FACTORS ASSOCIATED WITH POST-BRONCHODILATOR 
AIRWAY OBSTRUCTION 
Participant age was the factor most clearly associated with airway obstruction in bivariate and 
multivariable analyses, increasing in a non-linear fashion with a 10.12 times higher risk of moderate 
to severe obstruction (95% CI 3.54-28.93) in those aged ≥60 years compared to 18-29 year olds. This 
finding was also seen in the sensitivity analysis restricted to complete-case data.  No association was 
seen between HIV-infection, ever smoking or biomass exposure and airway obstruction. Individuals 
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without access to private water supply had 2.44 times higher risk of moderate to severe obstruction 
in multivariable analysis (95% CI 1.01 – 5.88) (Table 6).  
4.3.6 FACTORS ASSOCIATED WITH THE LOW FVC GROUP 
BMI was strongly associated with having a reduced FVC and normal FEV1/FVC ratio, as defined using 
NHANES III reference ranges: those who were underweight had 4.09 (95% CI 2.04-8.22) times higher 
odds of falling into this category compared to those with normal weight in the multivariable model. 
Older age was negatively associated with low FVC, and those aged over 60-years had 0.53 (95% CI: 
0.29-0.96) times the odds of being in the low FVC category compared to the 18-29 year group. No 
other risk factors for a low FVC deficit were identified in the multivariable model (Table 7). 
When the low FVC group was defined using local reference ranges, no clear trend in the relationship 
between age and reduced vital capacity emerged. The odds of being in the low FVC group were higher 
if underweight (OR 2.80, 95% CI 1.19-6.55) in bivariate analysis only. In multivariable analysis, previous 
TB was associated with higher odds of of being in the Low FVC group (OR 3.01, 95% CI 1.07-8.50).  
4.4 DISCUSSION 
Data from this population based cross-sectional study of non-communicable respiratory disease 
amongst adults in urban Blantyre, Malawi, suggested a high burden of chronic respiratory symptoms 
and abnormal spirometry within community. Cough was the most commonly reported symptom, and 
the prevalence of reduced FVC was particularly marked. Large differences were observed in the 
estimated prevalence of spirometric deficits using NHANES and locally defined reference ranges. No 
relationship between symptoms and spirometry were identified, and the role of previous TB disease 
in contributing to these findings remains unclear. 
 THERE IS A HIGH BACKGROUND PREVALENCE OF CHRONIC LUNG 
PATHOLOGY IN MALAWI  
The burden of respiratory symptoms and spirometric abnormalities seen in this ‘well’ outpatient 
population sample from urban Blantyre was high, with 11.8% (SE: 1.2) reporting at least 1 respiratory 
symptom, 4.2% (SE: 0.8%) noted to have an obstructive FEV1/FVC ratio on spirometry, and the 
prevalence of a reduced FVC pattern thought to lie between 9.0% (SE: 1.2%) – 38.6% (SE: 2.1%), 
depending on the reference range used. These findings are consistent with data presented above, 
from subsequent studies completed in rural Malawi which show a prevalence of respiratory symptoms 
of 12.6 – 22.5%, and abnormal spirometry in over 40% of adults.33 39 Together, these findings suggests 
a high background prevalence of chronic respiratory abnormalities in the Malawian setting. 
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 LOW FVC IS THE DOMINANT PATTERN OF ABNORMALITY 
The high prevalence of a reduced FVC is surprising, but has subsequently been reproduced in data 
from other BOLD study sites in sSA.32 It is also of some concern, as low FVC has been shown to be 
associated with increased mortality, even in the absence of respiratory symptoms and a diagnosis of 
respiratory disease in both US and ecological studies.18 106  
Full lung function testing and imaging were not completed within this study, such that it is not possible 
to determine the true cause of the low FVC seen here, but it is perhaps unlikely that this is the result 
of true restrictive lung pathologies which are thought to be rare. It may instead be the case that low 
lung volumes in resource poor settings such as Malawi are the result of  impaired lung growth over 
the life course – early lung development is a well recognised determinant of adult lung volumes,17 and 
suboptimal in-utero conditions, low birth weight, respiratory tract infections, and nutritional 
deficiencies which can predict adult lung health are more prevalent in resource poor settings.214 215 
The negative correlation seen between spirometric restriction and age here may represent a birth 
cohort effect, whereby the incidence of restriction is decreasing over time, but would also fit with 
earlier mortality amongst those with restriction. Prospective studies – perhaps with birth cohorts – 
are required to better understand the causes of low FVC in sSA, and the prognostic and public health 
implications of this finding.   
Of note - within this data set, self-reported previous TB emerged as a strong risk factor for reduced 
FVC in multivariate analysis, and was associated with a three-fold increase in the odds of reduced FVC. 
However, this relationship was only seen when local reference ranges were used to define the low 
FVC group. The prevalence of previous TB was noted to be 2.9% only within this cohort – given the 
ongoing stigma surrounding TB disease in settings such as Blantyre,43 there may have been some 
under-reporting and this figure may underestimate the true burden of previous disease within the 
study population. However, these data do suggest that whilst post-TB lung pathology might contribute 
to the burden of low FVC seen in this setting, it is unlikely to be the dominant cause. 
 CHOICE OF REFERENCE RANGE IS IMPORTANT IN THE INTERPRETATION 
OF SPIROMETRY RESULTS 
Data analysis for this study was complicated by the large differences in spirometry classification when 
local and NHANES III references were used. This was particularly marked for the low FVC pattern where 
prevalence estimates were 9.0 vs. 36.8% with the local vs. NHANES III ranges, compared to differences 
in estimates of moderate to severe obstruction which were 2.3% vs. 3.6% only.  
As discussed in Chapter 2, the selection of a reference range is controversial, with genetic differences 
between sSA and Caucasian groups perhaps making the use of the NHANES III Caucasian range 
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inappropriate, and ubiquitous local exposures such as early childhood infections or maternal 
malnutrition limiting the ability of local reference ranges to define optimal lung function. The expected 
FVC values given by the Malawian reference range are clearly much lower than those given by the 
NHANES III range, such that more readings are considered abnormally low when the latter is used. 
This suggests that either the FVC volume is particularly vulnerable to either genetic differences, or to 
early childhood or environmental exposures which are prevalent in Malawi and drive differences in 
predicted norms between reference ranges.  
 SMOKING, BIOMASS EXPOSURE AND HIV DO NOT EMERGE AS 
PREDICTORS OF OBSTRUCTION 
It is noticeable that ever-smoking, biomass exposure, and HIV were not associated with airway 
obstruction within this cohort. This may be an issue of study power, given the surprisingly low 
prevalence of obstruction detected. However, it may also reflect a true lack of association, or limited 
/ misclassified measurement of these exposures.  
Although 10.4% of the cohort reported ever-smoking, almost 90% of these individuals had a pack year 
exposure of less than 10-years, such that the degree of exposure may have been too limited to impact 
on lung function. It should be noted that marijuana use, which may be particularly common amongst 
young men in Malawi, was not measured in this study, and may have been an additional but 
unmeasured source of respiratory damage.  
The lack of association demonstrated with biomass exposure was initially thought likely to be related 
to misclassification, with self-reported fuel use acting as a poor measure of true exposures. However, 
subsequent data from a rural BOLD study conducted in Malawi failed to demonstrate any association 
between measured particulate matter (PM2.5) and carbon monoxide (CO) levels with either FEV1 or 
FVC,33 suggesting that this may be a true finding and that exposure to these pollutants is not a key 
driver of airway obstruction in this setting. 
The lack of association between HIV and abnormal spirometry within these data contrast with findings 
from North American cohorts, which suggest an increased prevalence of airway obstruction in adults 
with HIV disease.216 It has been suggested that this is the result of chronic immune activation seen in 
the context of HIV disease,26 but in fact measures of HIV disease severity including CD4 count and viral 
load do not appear to be associated with the prevalence of abnormal spirometry,217 and delayed time 
to ART does not appear to have pulmonary consequences,218 suggesting that it may not be HIV disease 
itself which is driving airway obstruction in these groups but rather a high burden of associated 
exposures including smoking and respiratory infections.  Whilst that lack of association between HIV 
disease and both airway obstruction and restriction in this cohort may be true, a more nuanced 
exploration of the relationship with time to ART and CD4 count may be helpful in confirming this.  
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The most consistent correlate of obstruction demonstrated in these data was lack of access to a 
private water supply independently associated with greater than 2-fold higher odds of airway 
obstruction regardless of which reference range was used.  This measure is a proxy for socioeconomic 
situation of the individual, and is likely a marker of an individual’s environmental exposures and 
opportunities, both historically and at the present time. The relationship between SES and obstruction 
is consistent with the strong socioeconomic gradients seen in other resource rich settings.219 It is not 
possible to tease out the mechanism of these relationships, and it is not clear why this finding did not 
extent to the low FVC group, but these data do suggest that the poorest individuals are also the most 
vulnerable to airway obstruction in the Malawian setting.  
 COUGH IS THE MOST COMMON SYMPTOM 
Cough was the most common respiratory symptom reported, with ‘usual cough’ seen in 9.3% of men 
and 5.7% of women. The association with HIV raises the possibility that undiagnosed pulmonary 
tuberculosis may be responsible for part of this presentation.125 220-223 However although current 
cough is one of the four symptoms included within the WHO TB symptom screening algorithm, its 
positive predictive value for TB disease may be low – data from the ZAMSTAR TB prevalence survey 
conducted in South Africa and Zambia suggest that only 2.1 - 6.0% of those with current cough were 
found to have culture proven TB disease,224 suggesting that the majority of people with cough do not 
in fact have active TB disease. The association of chronic cough with ever smoking suggest that 
bronchial irritation from smoke inhalation may underlie these symptoms, and the degree to which this 
symptom represents chronic respiratory pathology rather than active infection is unclear.   
In contrast, a low prevalence of sputum production was reported within this study, by only 4.0% of 
participants. Where it was seen it was associated with biomass exposure, although HIV status and 
previous TB exposure – both thought to be causes of bronchiectasis and potential causes of productive 
lung disease in this setting – were not correlated with its presence.  
 UNDERLYING PATTERNS OF PATHOLOGY ARE UNCLEAR 
No correlations were demonstrated between respiratory symptoms and spirometry results within this 
study, and imaging was not included, such that it is challenging to identify specific types of respiratory 
pathology underlying our findings.    
However, a wide range of environmental exposures and host characteristics have been shown to be 
associated with the different respiratory symptoms and patterns of abnormal spirometry measured in 
this study: ever smoking, HIV status, involvement in farming, biomass exposure, BMI, and 
socioeconomic status have been highlighted in different multivariate models as associated with 
different outcomes. The diversity of these associations may suggest that, as one might expect within 
a large patient cohort, there are a range of pathological processes at play here. Further attempts to 
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define this spectrum of pathology, would be of help in guiding more nuanced diagnostic and 
management algorithms for respiratory disease which are specifically targeted to resource poor 
settings.  
 THE ROLE OF TB IS UNCLEAR 
Although previous TB was included as a covariate in many of the models constructed in this analysis, 
it is important to note that only self-reported disease was measured in this study – the extent to which 
this reflects true previous TB disease is unclear. TB is widely associated with HIV disease such that it is 
highly stigmatizing, and medical documentation in Malawi can be limited, such that there may have 
been some under-reporting of disease.  
In this study, no association was observed between self-reported previous TB and airway obstruction 
/ respiratory symptoms, and an association with low FVC was seen only when local reference ranges 
are used. In contrast, results from the rural BOLD study subsequently completed in Malawi, showed 
that self-reported TB disease (reported by 3.2% of the cohort) was in fact associated with both lower 
FEV1 and FVC volumes. These differences in findings may in part be explained by the limited accuracy 
of self-reported previous TB disease.  
Of note, many of the population-based studies of the relationship between previous TB and residual 
spirometric deficits described in the literature review above relied on self-reported TB disease to 
determine exposure. Under-reporting of previous disease and the resulting misclassification of 
exposure groups, will if anything, have led to underestimation of the difference in the prevalence of 
abnormal spirometry between groups, such that the increased odds of persistent abnormal 
spirometry may be even greater than estimated.  
 STRENGTHS AND LIMITATIONS 
Limitations of this study include the challenges posed by working with a mobile urban population: it 
was not possible to locate over 25% of the initial random sample, and 9.6% had permanently left the 
area between enumeration and fieldworker home visits. Few data are available on the demographics 
of these missing groups, and it is therefore difficult to determine how and to what extent this has 
biased our findings. In addition, only 71% of those who were included were able to complete adequate 
spirometry with fewer older individuals. As a result, the target sample size of 600 adults over and 600 
adults under 40-years of age with high quality spirometry was not reached, and power to detect 
significant associations in the exploratory analyses was reduced.  
Symptomatic individuals were not screened for pulmonary TB, and the proportion of abnormalities 
attributable to active TB disease, rather than background chronic lung pathology, are therefore 
unclear. In addition, the ability of this study to define the specific patterns of pathology underlying the 
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symptoms and abnormal spirometry detected is limited given the lack of imaging and measurement 
of total lung capacity, and given this was a cross sectional survey these data are unable to describe 
the impact of respiratory pathology on morbidity and mortality over time.  
Lastly, in this study a stepwise approach to variable selection was used in regression analyses. In recent 
years there has been a move away from this approach in the literature, as it is thought that this 
strategy may not adequately control for confounding, and may misrepresent the causal relationships 
underlying the relationships being investigated.225 The stepwise regression analyses used here are 
likely vulnerable to some bias, and must therefore be interpreted with some caution.  
A key strength of this study was the enumeration of the target population at the start of the study, 
followed by age and gender stratified sampling, which allowed for population-weighted prevalence 
estimates to be drawn and associations to be measured. In addition, spirometry was conducted to ATS 
standards with careful quality control, and data on multiple respiratory exposures and comorbidities 
including HIV were collected.  
4.5 CONCLUSION 
This study provides a picture of the typical burden of respiratory abnormalities amongst ‘well’ 
community-based adults in urban Blantyre, Malawi, and sets the context for the data to be presented 
in Chapter 5 below. Key findings include the presence of respiratory symptoms amongst 11.8% (SE: 
1.2), airway obstruction in 4.2% (SE: 0.8%), and dominant low-FVC pattern which was seen in 9.0% (SE: 
1.2%) – 38.6% (SE: 2.1%) according to whether local or NHANES III reference ranges were used for 
standardization. Risk factors which might have been assumed to be driving abnormal spirometry in 
this setting, including smoking, biomass exposure and HIV infection, did not emerge as predictors, 
whilst low socioeconomic situation (SES) were associated with airway obstruction, and low BMI was 
associated with the low- FVC pattern.  
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Table 2: Age and gender stratified prevalence of respiratory symptoms amongst those completing core questionnaire  
Definition of restriction Age group Male (n=446) Prevalence (SE) 
Female (n=613) 
Prevalence (SE) 
Total (n=1059) 
Prevalence (SE) 
Cough 
(Do you usually cough 
when you don't have a 
cold?) 
18-29 years  8.0 % (2.4%) 3.2% (1.4%) 5.4% (1.4%) 
30-39yrs 8.7% (2.9%) 4.1% (2.0%) 6.6% (2.8%) 
40-49yrs 15.9% (3.9%) 12.7% (2.6%) 14.4% (2.4%) 
50-59yrs 7.0% (3.0%) 17.3% (3.6%) 11.9% (2.4%) 
60-69yrs 7.3% (4.1%) 10.5% (4.1%) 8.8% (2.9%) 
≥70yrs 14.3% (6.6%) 17.4% (7.9%) 15.7% (5.1%) 
TOTAL 9.3% (2.5%) 5.7% (1.0%) 7.5% (0.9%) 
Sputum 
(Do you usually bring 
up phlegm from your 
chest?) 
18-29 years 5.6% (2.1%) 1.3% (0.9%) 3.3% (1.1%) 
30-39yrs 5.4% (2.4%) 1.0% (1.0%) 3.4% (2.4%) 
40-49yrs 8.0% (2.9%) 2.4% (1.2%) 5.3% (1.6%) 
50-59yrs 9.9% (3.5%) 6.4% (2.3%) 8.2% (2.2%) 
60-69yrs 4.9% (3.4%) 7.0% (3.4%) 5.9% (2.4%) 
≥70yrs 14.3% (6.6%) 4.3% (4.3%) 9.8% (4.2%) 
TOTAL 6.3% (2.3%) 2.8% (0.6%) 4.0% (0.7%) 
Wheeze 
(Have you had 
wheezing / whistling in 
your chest at any point 
in past 12m, in the 
absence of a cold) 
18-29 years  1.6% (1.1%) 1.3% (0.9%) 1.4% (0.7%) 
30-39yrs 0 0 0 
40-49yrs 3.4% (2.9%) 3.6% (1.5%) 3.5% (1.2%) 
50-59yrs 1.4% (1.4%) 2.7% (1.6%) 2.0% (1.0%) 
60-69yrs 7.3% (4.1%) 0 3.9% (2.2%) 
≥70yrs 0 4.3% (4.3%) 2.0% (2.0%) 
TOTAL 1.5% (0.6%) 1.3% (0.5%) 1.4% (0.4%) 
MRC dyspnoea II * 
(Do you have shortness 
of breath when 
hurrying on the level or 
walking up a slight hill?) 
18-29 years 4.0% (1.8%) 4.6% (1.7%) 4.3% (1.2%) 
30-39yrs 0 1.0% (1.0%) 0.5% (0.5%) 
40-49yrs 1.2% (1.2%) 4.1% (1.6%) 3.0% (1.0%) 
50-59yrs 1.6% (1.6%) 7.4% (2.7%) 4.3% (1.5%) 
60-69yrs 8.8% (4.9%) 6.4% (3.6%) 7.7% (3.1%) 
≥70yrs 0 7.7%(7.4%) 3.0% (2.9%) 
TOTAL 2.3% (0.9%) 3.8% (1.0%) 3.1% (0.7%) 
Any respiratory 
symptom† 
(Any of cough, sputum, 
wheeze without cold, 
exertional 
breathlessness as 
above) 
18-29 years 11.2% (2.8%) 8.4% (2.2%) 9.7% (1.8%) 
30-39yrs 12.1% (3.4%) 5.2% (2.2%) 8.9% (2.1%) 
40-49yrs 20.0% (4.3%) 18.4% (3.1%) 19.3% (2.8%) 
50-59yrs 18.5% (4.8%) 27.7% (4.5%) 22.9% (3.3%) 
60-69yrs 20.6% (6.9%) 20.4% (5.8%) 20.5% (4.5%) 
≥70yrs 21.7% (8.6%) 31.3% (11.6%) 25.7% (7.0%) 
TOTAL 13.4% (1.8%) 10.2% (1.4%) 11.8% (1.2%) 
Functional limitation 
(Have breathing 
problems interfered 
with your usual daily 
activities) 
18-29 years 5.6% (2.1%) 4.4% (1.6%) 5.0% (1.3%) 
30-39yrs 5.4% (2.4%) 1.0% (1.0%) 3.4% (1.4%) 
40-49yrs 5.7% (2.5%) 10.3% (2.4%) 7.9% (1.7%) 
50-59yrs 8.5% (3.3%) 3.6% (1.8%) 6.2% (1.9%) 
60-69yrs 4.9% (3.4%) 5.3% (3.0%) 5.1% (2.3%) 
≥70yrs 3.6% (3.5%) 13.0% (7.0%) 7.9% (3.8%) 
TOTAL 5.7% (1.2%) 4.3% (1.0%) 5.0% (0.8%) 
*Excluding 86 patients with alternative reasons for mobility impairment 
†Excluding 60 patients with alternative reasons for mobility impairment & no other respiratory symptoms 
 
  
92 
 
Table 3: Age & gender stratified prevalence estimates for abnormal spirometry, amongst those completing ATS quality 
spirometry 
Spirometric definition 
(Reference range) Age group 
Male (n=328) 
Prevalence (SE) 
Female (n=421) 
Prevalence (SE) 
Total (n=748) 
Prevalence (SE) 
Post bronchodilator 
obstruction 
 
FEV1/FVC Ratio <0.7 
18-29 years  2.0% (1.4%) 2.7% (1.6%) 2.4% (2.0%) 
30-39yrs 4.5% (2.5%) 2.9% (2.0%) 3.8% (1.7%) 
40-49yrs 0 6.7% (2.3%) 3.1% (1.1%) 
50-59yrs 12.7% (4.8%) 7.7% (3.0%) 10.9% (2.9%) 
60-69yrs 23.1% (8.3%) 15.6% (6.4%) 19.8% (5.4%) 
≥70yrs 41.2% (12.0%) 33.3% (13.6%) 37.9% (9.0%) 
TOTAL 4.3% (1.1%) 4.1% (1.1%) 4.2% (0.8%) 
Post bronchodilator 
moderate to severe 
obstruction 
 
FEV1/FVC ratio <0.7 
AND FEV1<80% 
predicted 
 
NHANES ref range 
18-29 years 2.0% (1.4%) 2.7% (1.6%) 2.4% (1.0%) 
30-39yrs 3.0% (2.1%) 2.9% (2.0%) 2.9% (1.5%) 
40-49yrs 0 5.0% (2.0%) 2.3% (0.9%) 
50-59yrs 11.8% (4.5%) 7.7% (3.0%) 9.8% (2.8%) 
60-69yrs 11.5% (6.3%) 12.5% (5.9%) 12.0% (4.4%) 
≥70yrs 29.4% (11.1%) 33.3% (13.6%) 31.0% (8.6%) 
TOTAL 3.2% (1.0%) 3.9% (1.0%) 3.6% (0.7%) 
Post bronchodilator 
moderate to severe 
obstruction 
 
FEV1/FVC ratio <0.7 
AND FEV1<80%  
predicted 
 
Locally derived ref 
range 
18-29 years 2.0% (1.4%) 2.7% (1.6%) 2.4% (1.0%) 
30-39yrs 0 0 0 
40-49yrs 0 3.4% (1.7%) 1.5% (0.8%) 
50-59yrs 7.8% (3.8%) 7.7% (3.0%) 7.8% (2.4%) 
60-69yrs 7.7% (5.2%) 6.3% (4.3%) 7.1% (3.5%) 
≥70yrs 23.5% (10.3%) 25.0% (12.5%) 24.1% (8.0%) 
TOTAL 2.0% (0.7%) 2.7% (0.9%) 2.3% (0.6%) 
Low FVC 
 
FEV1/FVC Ratio>0.7, 
AND FVC<80% 
predicted 
 
NHANES ref range 
18-29 years  49.0% (5.0%) 34.5% (4.5%) 41.7% (3.4%) 
30-39yrs 29.9% (5.6%) 36.2% (5.8%) 32.7% (4.0%) 
40-49yrs 32.8% (5.6%) 52.9% (4.6%) 42.0% (3.8%) 
50-59yrs 31.4% (6.5%) 46.2% (5.7%) 28.3% (4.4%) 
60-69yrs 38.5% (9.6%) 10.6% (8.7%) 39.4% (6.6%) 
≥70yrs 17.6% (9.3%) 8.3% (8.0%) 13.8% (6.4%) 
TOTAL 39.5% (3.1%) 37.7% (2.9%) 38.6% (2.1%) 
Low FVC 
 
FEV1/FVC Ratio>0.7, 
AND FVC<80% 
predicted 
 
Locally derived ref 
range 
 
18-29 years 13.0% (3.4%) 8.2% (2.6%) 10.6% (2.1%) 
30-39yrs 4.5% (2.5%0 4.3% (2.5%) 4.4% (1.8%) 
40-49yrs 13.4% (4.2%) 10.9% (2.9%) 12.3% (2.6%) 
50-59yrs 5.9% (3.3%) 10.3% (3.4%) 7.9% (2.4%) 
60-69yrs 15.4% (7.1%) 12.5% (5.9%( 14.1% (4.7%) 
≥70yrs 11.8% (7.8%) 0 6.9% (4.7%) 
TOTAL 10.2% (1.9%) 7.6% (1.6%) 9.0% (1.2%) 
Airway reversibility 
 
FEV1 increase ≥200ml 
AND ≥12% following 
bronchodilator 
18-29 years  4.0% (2.0%) 3.6% (1.8%) 3.8% (1.3%) 
30-39yrs 1.5% (1.5%) 2.9% (2.0%) 2.1% (1.2%) 
40-49yrs 7.4% (3.2%) 9.2% (2.6%) 8.2% (2.1%) 
50-59yrs 7.8% (3.8%) 6.5% (2.8%) 7.2% (2.4%) 
60-69yrs 3.8% (3.8%) 3.0% (3.0%) 3.5% (2.5%) 
≥70yrs 5.9% (5.7%) 16.7% (10.8%) 10.4% (5.7%) 
TOTAL 4.0% (1.2%) 4.4% (1.1%) 4.2% (0.8%) 
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Table 4: Bivariate and multivariable associations with respiratory symptoms‡ in all age groups, n=1056 
Variable 
Usual cough (n=103) Usual sputum (n=51) Exertional dyspnoea (n=35) Wheeze (n=21) 
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Odds 
Ratio 95% CI 
Age group 
- 18-29 
- 30-39 
- 40-49 
- 50-59 
- ≥60 
 
1.0 
1.24 
2.96 
2.37 
2.21 
 
- 
0.56-2.71 
1.55-5.65* 
1.20-4.70* 
1.07-4.60 
 
1.0 
0.97 
2.37 
1.82 
1.81 
 
- 
0.44-2.17 
1.19-4.71* 
0.87-3.81 
0.85-3.86 
 
1.0 
1.05 
1.68 
2.66 
2.31 
 
- 
0.36-3.00 
0.67-4.22 
1.11-6.36• 
0.93-5.76• 
 
1.0 
1.12 
1.97 
3.64 
2.32 
 
- 
0.38-3.12 
0.75-5.16 
1.43-9.26* 
0.82-6.55 
 
1.0 
0.11 
0.57 
0.98 
1.48 
 
- 
0.01-0.82• 
0.21-1.53 
0.39-2.50 
0.56-3.93 
 
1.0 
0.09 
0.28 
0.40 
0.74 
 
- 
0.01-0.80* 
0.08-1.03 
0.11-1.42 
0.18-3.00 
 
1.0 
Empty 
2.53 
1.44 
2.31 
 
- 
- 
0.75-8.58 
0.35-6.01 
0.57-9.44 
 
1.0 
Empty 
1.97 
0.99 
1.39 
 
- 
- 
0.48-8.06 
0.17-5.73 
0.24-7.93 
Gender 
- Male 
- Female 
 
1.0 
0.59 
 
- 
0.36- 0.99* 
 
1.0 
0.72 
 
- 
0.41-1.27 
 
1.0 
0.28 
 
- 
0.13-0.60• 
 
- 
0.31 
 
- 
0.15-0.65* 
 
1.0 
1.63 
 
- 
0.66-4.03 
 
1.0 
1.78 
 
- 
0.68-4.68 
 
1.0 
0.87 
 
- 
0.29-2.66 
 
1.0 
0.41 
 
- 
0.13-1.27 
Years of education 0.92 0.87 - 0.97*   0.93 0.85-1.00†   0.93 0.86-1.00†   1.05 0.93 – 1.19   
Smoking status  
- Never 
- Ever 
 
1.0 
3.03 
 
- 
1.55 – 5.92* 
 
1.0 
2.37 
 
- 
1.12-5.02* 
 
1.0 
3.71 
 
- 
1.58–8.70• 
  
 
1.0 
1.16 
 
- 
0.32 – 4.22 
  
 
- 
0.25 
 
- 
0.03-1.93† 
 
 
 
 
HIV status§ 
- Negative 
- Positive 
 
1.0 
2.12 
 
- 
1.19-3.78* 
 
1.0 
1.94 
 
- 
1.10-3.44* 
 
1.0 
1.60 
 
- 
0.76-3.37 
  
 
1.0 
0.99 
 
- 
0.32-3.02 
  
 
1.0 
0.99 
 
- 
0.32-3.04 
  
Haemoglobin (g/dL)§ 0.96 0.82 – 1.13   1.26 1.03 -1.53•   0.86 0.69-1.06†   0.770 0.60-0.99• 0.74 0.58-0.94* 
Eosinophil blood count 
>2% 
- No 
- Yes 
 
1.0 
1.25 
 
- 
0.67 – 2.34 
  
 
1.0 
1.34 
 
- 
0.57-3.17 
  
 
1.0 
0.78 
 
- 
0.30-1.99 
  
 
1.0 
1.33 
 
- 
0.33-5.31 
  
BMI (kg/m2) 
Underweight (<18.5) 
Normal (18.5-25) 
Overweight (25 - 30) 
Obese (≥30) 
 
1.17 
1.0 
0.75 
0.51 
 
0.46 – 2.97 
- 
0.38-1.48 
0.25-1.06† 
  
 
4.33 
1.0 
0.39 
1.41 
 
1.71-10.95• 
- 
0.15-1.02† 
0.46-4.31 
 
3.26 
1.0 
0.37 
1.15 
 
1.32-8.07* 
- 
0.15-0.91* 
0.31-4.30 
 
1.61 
1.0 
0.77 
1.75 
 
0.34-7.52 
- 
0.21-2.83 
0.56-5.51 
  
 
6.10 
1.0 
0.87 
3.59 
 
1.37-27.07• 
- 
0.16 -4.73 
0.61-21.00 
 
5.38 
1.0 
1.16 
5.47 
 
1.23-23.50* 
- 
0.26-5.16 
0.93-32.38 
Self reported previous 
TB 
- No 
- Yes 
 
1.0 
2.18 
 
- 
0.74-6.44† 
  
 
1.0 
1.79 
 
- 
0.38-8.33 
  
 
1.0 
2.61 
 
- 
0.55-12.47 
  
 
1.0 
Empty 
 
- 
- 
  
Does household own 
own home 
- Yes 
- No 
 
 
1.0 
0.87 
 
 
- 
0.51-1.47 
  
 
 
1.0 
0.71 
 
 
- 
0.35-1.47 
  
 
 
1.0 
0.72 
 
 
- 
0.30-1.74 
  
 
 
1.0 
0.44 
 
 
- 
0.14-1.45† 
  
Household has own 
water supply (indoor 
OR outdoor tap) 
- Yes 
- No 
 
 
 
1.0 
1.75 
 
 
 
- 
1.02-3.00• 
  
 
 
 
1.0 
1.06 
 
 
 
- 
0.52-2.19† 
  
 
 
 
1.0 
1.30 
 
 
 
- 
0.54-3.11 
  
 
 
 
1.0 
0.80 
 
 
 
- 
0.26-2.44 
  
Household has flush 
toilet  
- Yes 
- No 
 
 
1.0 
1.13 
 
 
- 
0.61-2.10 
  
 
 
1.0 
0.56 
 
 
- 
0.26-1.20† 
 
 
1.0 
0.42 
 
 
- 
0.19-0.91* 
 
 
1.0 
0.58 
 
 
- 
0.23-1.44 
  
 
 
1.0 
0.49 
 
 
- 
0.15-1.59 
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Any biomass exposure† 
- No 
- Yes 
 
1.0 
1.39 
 
- 
0.62-3.15 
  
 
1.0 
5.46 
 
- 
1.85-16.25• 
 
1.0 
7.05 
 
 
2.28-21.80* 
 
1.0 
0.60 
 
- 
0.21-1.72 
  
 
1.0 
0.51 
 
- 
0.12-2.12 
  
Farming >3m 
- No 
- Yes 
 
1.0 
2.31 
 
- 
1.35-3.94• 
  
 
1.0 
2.31 
 
- 
1.14-4.70• 
  
 
1.0 
4.30 
 
- 
1.80-10.31• 
 
1.0 
6.32 
 
- 
1.87-21.32* 
 
1.0 
2.81 
 
- 
0.92-8.52† 
  
* p<0.05  
†Use of charcoal/coal/coke or burning of wood/dung/crop residue for >6 months for cooking, or burning of wood/dung/crop residue for heating water 
‡Presence of respiratory symptoms ascertained using the following quesƟons, derived from the BOLD study core quesƟonnaire: 
Usual cough: Do you usually cough when you don’t have a cold? 
Usual sputum: Do you usually bring up phlegm from your chest, or do you usually have phlegm in your chest that is difficult to bring up, when you don’t have a cold? 
Exertional dyspnea: Are you troubled by breathlessness when hurrying on the level or walking up a slight hill? 
Wheeze: Have you had wheeze/whistling in your chest at any time in the past 12months? In the last 12 months have you had this wheeze or whistling only when you have had a cold? (exclude if yes to the latter 
question) 
§Imputation of data required for 11.9% of HIV values, and 11.8% of haemoglobin values. Imputation of all other values ≤0.1 
 
Table 5: Bivariate associations between respiratory symptoms and abnormal spirometry 
Variable Usual cough (n=103/1056) Usual sputum (n=51/1056) Exertional breathlessness (n=35/970) Wheeze without cold (n=21/1056) 
 Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI 
Airway obstruction* 
- No 
- Yes 
 
1.0 
1.11 
 
- 
0.44-2.80 
 
1.0 
1.64 
 
- 
0.60-4.51 
 
1.0 
0.98 
 
- 
0.20-4.83 
 
1.0 
2.99 
 
- 
0.73-12.33 
Spirometric restriction* 
- No 
- Yes 
 
1.0 
0.82 
 
- 
0.44-1.53 
 
1.0 
1.52 
 
- 
0.69-3.37 
 
1.0 
2.79 
 
- 
0.87-8.91 
 
1.0 
2.80 
 
- 
0.86-9.0.9 
Reversibility 
- No 
- Yes 
 
1.0 
2.28 
 
- 
0.80-6.52 
 
1.0 
1.91 
 
- 
0.40-9.08 
 
1.0 
Empty 
 
- 
- 
 
1.0 
2.52 
 
- 
0.61-10.3 
*Defined using NHANES reference range 
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Table 6: Bivariate and multivariable associations of risk factors with post bronchodilator airway obstruction, n=749 
Outcome variable Post bronchodilator airway obstruction (FEV1/FVC ratio <0.7) Post bronchodilator mod-severe airway obstruction, NHANES III  (FEV1/FVC ratio <0.7 & FEV1<80% predicted) 
 
Predictor variable 
Bivariate association Multivariable association§ Bivariate association Multivariable association 
Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI 
Age group 
- 18-29 
- 30-39 
- 40-49 
- 50-59 
- ≥60 
 
1.0 
1.61 
1.31 
5.03 
14.33 
 
- 
0.45 – 5.72 
0.42 – 4.09 
1.73 – 14.67* 
5.18 - 39.60* 
 
1.0 
1.76 
1.22 
5.16 
15.76 
 
- 
0.50 - 6.20  
0.38 - 3.89 
1.77 – 15.03* 
5.71 – 43.46* 
 
1.0 
1.25 
0.97 
4.50 
9.22 
 
- 
0.33-4.79 
0.29-3.26 
1.52-13.29 
3.24-26.27 
 
1.0 
1.38 
0.93 
4.66 
10.12 
 
- 
0.36-5.25 
0.27-3.15 
1.58-13.79* 
3.54-28.93* 
Gender 
- Male 
- Female 
 
1.0 
0.97 
 
- 
0.46 – 2.04 
 
1.0 
1.10 
 
- 
0.50-2.39 
 
1.0 
1.20 
 
- 
0.53-2.75 
 
1.0 
1.34 
 
- 
0.57-3.17 
Years of education (yrs) 0.88 0.82 – 0.94*   0.88 0.81-0.94*   
HIV status 
- Negative 
- Positive 
 
1.0 
1.32  
 
- 
0.50 – 3.44 
  
 
1.0 
0.93 
 
- 
0.30-2.89 
  
Self reported previous TB 
- No 
- Yes 
 
1.0 
1.28 
 
- 
0.28 – 5.96 
  
 
1.0 
1.54 
 
- 
0.33-7.23 
  
Haemoglobin (g/dL) 0.89 0.75-1.06†   0.89 0.73-1.09   
Eosinophil blood count >2% 
- No 
- Yes 
 
1.0 
1.92 
 
- 
0.73-5.06† 
  
 
1.0 
2.51 
 
- 
0.70-9.05† 
  
BMI (kg/m2) 
- Underweight (BMI<18.5) 
- Normal (18.5≥BMI<25) 
- Overweight (25≥BMI<30) 
- Obese (BMI≥30) 
 
2.08 
1.0 
0.86 
1.43 
 
0.64 – 6.74 
- 
0.35 - 2.13 
0.39 – 5.19 
  
 
2.36 
1.0 
0.79 
0.54 
 
0.71-7.78 
- 
0.29-2.20 
0.15-2.00 
  
Smoking status  
- Never 
- Ever 
 
1.0 
1.25 
 
- 
0.57-2.73 
  
 
1.0 
0.94 
 
- 
0.38-2.35  
  
Home ownership 
- Yes 
- No 
 
1.0 
1.08 
 
- 
0.52-2.27 
  
 
1.0 
1.10 
 
- 
0.49-2.48 
  
Access to private water supply (indoor OR outdoor tap) 
- Yes 
- No 
 
1.0 
2.29 
 
- 
1.07-4.91* 
 
1.0 
2.55 
 
- 
1.14 – 5.71* 
 
1.0 
2.23 
 
- 
0.95-5.23† 
 
1.0 
2.44 
 
- 
1.01-5.88* 
Household has flush toilet 
- Yes 
- No 
 
1.0 
1.67 
 
- 
0.61-4.53 
  
 
1.0 
1.57 
 
- 
0.52-4.78 
  
Any biomass exposure‡ 
- No 
- Yes 
 
1.0 
2.55 
 
- 
1.00-6.50† 
  
 
1.0 
2.10 
 
- 
0.81-5.47† 
  
Working in farming >3m 
- No 
- Yes 
 
1.0 
1.79 
 
- 
0.87-3.70† 
  
 
1.0 
1.62 
 
- 
0.72-3.66 
  
* p<0.05 † p<0.2 ‡Use of charcoal/coal/coke or burning of wood/dung/crop residue for >6 months for cooking, or burning of wood/dung/crop residue for heating water §Multivariable model developed using 
variables correlated at p<0.2 level in bivariate analysis, and age group & gender as a priori risk factors, with imputation for missing data. 
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Table 7: Bivariate and multivariable associations of risk factors with reduced FVC, n=749 
Outcome variable Low FVC, NHANES III (FEV1/FVC ratio >0.7 & FVC >80% predicted) Low FVC, local reference ranges (FEV1/FVC ratio >0.7 & FVC >80% predicted) 
 
Predictor variable 
Bivariate association Multivariable association§ Bivariate association Multivariable association 
Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI 
Age group 
- 18-29 
- 30-39 
- 40-49 
- 50-59 
-  ≥60 
 
1.0 
0.68 
1.02 
0.87 
0.63 
 
- 
0.43-1.07 
0.67-1.53 
0.55-1.37 
0.37-1.07 
 
1.0 
0.64 
1.00 
0.85 
0.53 
 
- 
0.40-1.02 
0.66-1.53 
0.52-1.38 
0.29-0.96* 
 
1.0 
0.39 
1.19 
0.73 
1.12 
 
- 
0.15-1.00† 
0.62-2.27 
0.34-1.59 
0.50-2.52 
 
1.0 
0.38 
1.06 
0.64 
1.08 
 
- 
0.15-0.97* 
0.55 – 2.05 
0.28 – 1.48 
0.48 – 2.41 
Gender 
- Male 
- Female 
 
1.0 
0.93 
 
- 
0.65-1.32 
 
1.0 
0.95 
 
- 
0.65-1.40 
 
1.0 
0.73 
 
- 
0.40-1.33 
 
1.0 
0.70 
 
- 
0.38-1.28 
Years of education (years) 1.00 0.96-1.05   0.96 0.91-1.02   
BMI (kg/m2) 
- Underweight (BMI<18.5) 
- Normal (18.5≥BMI<25) 
- Overweight (25≥BMI<30) 
- Obese (BMI≥30) 
 
3.91 
1.0 
1.02 
1.37 
 
1.98-7.73* 
- 
0.65-1.62 
0.77-2.44 
 
4.09 
1.0 
1.07 
1.58 
 
2.04-8.22* 
- 
0.66-1.73 
0.85-2.96 
 
2.80 
1.0 
1.20 
0.92 
 
1.19-6.55* 
- 
0.54-2.67 
0.41-2.03 
  
Haemoglobin (g/dL) 1.00 0.90-1.15   1.13 0.91 – 1.41   
Eosinophil blood count >2% 
- No 
- Yes 
 
1.0 
0.972 
 
- 
0.65 -1.46 
   
1.0 
1.05 
 
- 
0.53 – 2.07 
  
HIV status 
- Negative 
- Positive 
 
1.0 
1.29 
 
- 
0.83-1.99 
   
1.0 
1.23 
 
- 
0.60-2.49 
  
Self-reported previous TB 
- No 
- Yes 
 
1.0 
2.34 
 
- 
0.89-6.18† 
   
1.0 
2.74 
 
- 
0.94-7.96† 
 
1.0 
3.01 
 
- 
1.07 -8.50* 
Smoking status  
- Never 
- Ever 
 
1.0 
0.95 
 
- 
0.54-1.67 
   
1.0 
0.80 
 
- 
0.30 -2.14 
  
Home ownership 
- Yes 
- No 
 
1.0 
0.82 
 
- 
0.57-1.17 
   
1.0 
1.25 
 
- 
0.69-2.27 
  
Access to private water supply (indoor OR outdoor tap) 
- Yes 
- No 
 
1.0 
0.91 
 
- 
0.64-1.30 
   
1.0 
1.62 
 
- 
0.88-2.98 
  
Household has flush toilet 
- Yes 
- No 
 
1.0 
0.86 
 
- 
0.57-1.28 
   
1.0 
1.19 
 
- 
0.59-2.43 
  
Any biomass exposure‡ 
- No 
- Yes 
 
1.0 
1.00 
 
- 
0.62-1.63 
   
1.0 
1.19 
 
- 
0.51-2.79 
  
Working in farming >3m 
- No 
- Yes 
 
1.0 
0.88 
 
- 
0.58-1.32 
   
1.0 
0.98 
 
- 
0.49-1.98 
  
* p<0.05 † p<0.2 ‡Use of charcoal/coal/coke or burning of wood/dung/crop residue for >6 months for cooking, or burning of wood/dung/crop residue for heating water §Multivariable model developed using 
variables correlated at p<0.2 level in bivariate analysis, and age group & gender as a priori risk factors, with imputation for missing data.
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5 POST-TB LUNG DAMAGE IN MALAWIAN 
ADULTS: A PROSPECTIVE COHORT STUDY  
 
5.1 INTRODUCTION 
In Chapter 3 our limited understanding of the prevalence, patterns, and outcomes associated with 
post-TB lung damage was described. Despite the ongoing high incidence of TB disease in the African 
region where estimated incident rates remain 254/100,000 and 30% of new TB patients are HIV co-
infected, a surprising lack of data from sSA and HIV-infected adults was highlighted. The prospective 
cohort study of post-TB lung damage amongst HIV-infected and -uninfected adults in Malawi which is 
presented here is a direct response to this lack of data. This work was done in urban Blantyre, and 
draws on the background data on the burden of respiratory abnormalities amongst community based 
adults in this setting which was presented in Chapter 4, for comparison.  
The overarching hypothesis for this study was that a subset of both HIV-infected and -uninfected adult 
participants completing treatment for PTB in this setting have post-TB lung damage, which is clinically 
relevant, and associated with adverse outcomes. This study is presented in full in here, according to 
STROBE reporting recommendations.  
5.1.1 AIMS & OBJECTIVES 
The overall aim of this study was to determine the prevalence and pattern of post-TB lung damage 
amongst adults in urban Blantyre, Malawi, and to define the impact of this damage on patients’ lives 
and livelihoods.   
The specific objectives were: 
1. To determine the prevalence and pattern of post-TB lung damage in HIV infected and 
uninfected adults completing treatment for pulmonary tuberculosis in urban Blantyre. 
2. To determine the morbidity and mortality experienced by patients in the 12-months 
following PTB treatment completion, and their relationship to residual post-TB lung damage. 
3. To determine the ongoing costs and dissaving experienced by patients in the 12-months 
following PTB treatment completion. 
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5.2 METHODS 
5.2.1 STUDY DESIGN 
This was a prospective cohort study of adults aged ≥15 years completing treatment for pulmonary TB 
in urban Blantyre, Malawi, with a 1-year follow up period (Figure 1). Ethics approval was provided by 
the College of Medicine Research and Ethics Committee (COMREC) in Malawi (P.10/15/1813) and The 
Liverpool School of Tropical Medicine Research Ethics Committee in the UK (15.040RS).  
Figure 1: Schematic for study design 
 
 
5.2.2 STUDY SETTING 
The PTB services and local context in Blantyre and Malawi were described in the introductory chapter 
of this thesis. Within this study, data were collected at three time points: at PTB treatment completion 
(+/- 2 weeks), and 6- and 12- months (+/- 4 weeks) after treatment completion. The baseline and 12-
month study visits were performed at the local referral hospital (Queen Elizabeth Central Hospital 
(QECH)), whilst the 6-month visit was completed at the participant household. Screening and 
recruitment were completed between February 2016 – April 2017, and follow up was completed in 
April 2018.   
5.2.3 PARTICIPANTS 
 ELIGIBILITY 
Adults living in urban Blantyre were eligible for recruitment to the study within the final 2-months of 
a first treatment course for PTB disease. All those who had been defined as having PTB by the National 
Treatment Programme were eligible, including both those with and without microbiological 
confirmation of disease (Table 1). 
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TB treatment outcomes were verified at the point of PTB treatment completion. Individuals with 
treatment success (completion or cure) were included, but those who had defaulted / failed treatment 
by this time point were excluded. Individuals with treatment success who remained symptomatic with 
a positive TB symptom screen (current cough, fever, weight loss, night sweats) at PTB treatment 
completion, were asked to submit a sputum sample for smear and culture, and if positive for MTB 
were excluded. 
Table 1: inclusion and exclusion criteria 
Inclusion criteria 
 
Exclusion criteria 
Informed consent 
≥15yrs years of age 
Resident of urban Blantyre 
Pulmonary Tuberculosis, as defined by National Treatment Programme 
First episode of PTB treatment 
Treatment completion or cure 
WHO danger signs (confused or agitated, 
unable to walk unaided, respiratory distress, 
temperature >39, systolic blood pressure 
<90mmHg) 
Treatment failure / default  
 
 RECRUITMENT 
Sequential participants were recruited from 9 TB treatment centres in urban Blantyre. These were 
located at district health centres (n=6), the tertiary referral hospital QECH (n=1), and two small private 
hospitals (n=2), and were the main providers of TB services to the population. 
Potentially eligible patients were identified by TB officers in these centres and referred to the central 
study offices at QECH for formal assessment, informed consent and enrolment by trained study staff. 
Consent was taken from the guardian with assent from the adolescent for those aged <18 years, in 
accordance with local guidelines.  
Participants were recruited upstream (within the final 2 months) of treatment completion, to give 
multiple opportunities to identify eligible patients: during the continuation phase of treatment 
patients visit the TB offices monthly to collect medication, and thus each individual had 3 visits at 
which they could be identified (4-month visit, 5-month visit, end of TB treatment visit). The following 
measures were taken to maximize patient identification and referral by TB officers: 
 Monthly training for TB officers, throughout the duration of the study 
 Weekly visits to all TB offices by the study team to help TB officers to identify potentially 
eligible patients approaching the end of their TB treatment from within the NTP registers 
 Weekly visits from the TB surveillance system staff 
 Monthly feedback to TB Officers about patients attending for formal screening  
 A financial incentive, paid at a fixed rate to all TB Officers within the network on a monthly 
basis, as part of the existing Hit TB / TB programme collaboration 
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 PARTICIPANT REIMBURSEMENT 
Participants were reimbursed after each study visit to an amount deemed appropriate by the local 
community engagement teams / ethics committee, with adjustments made over the course of the 
study in line with rising costs of living. For a visit to the hospital, reimbursement was approximately 
2500MK – this is the equivalent of $3.44 (Exchange rate $1 USD: 726MK, March 2017), and compares 
to a median monthly individual income reported across the cohort of $41.32 (IQR: $11.02- 96.42) at 
the point of TB treatment completion.  
 PARTICIPANT FOLLOW-UP 
Contact was maintained with participants between study visits with a scheduled phone call at the 3-
month point. In the event of a missed study visit, home visits were conducted and the next of kin 
contacted in order to locate the participant. 
 CLINICAL MANAGEMENT 
As this was an observational study, participants were signposted to routine health services (local 
health centres, or QECH emergency department) if they became unwell over the course of the study. 
Clinical review by the study PI was only performed if the participant remained unwell with evidence 
of clinical deterioration after input from routine services. If participants were admitted to hospital 
during the follow up period, all study investigations were made available to the medical team 
responsible for the patient’s care, but direct clinical care was not provided by the study team.  
Participants with abnormal findings from investigations performed as part of this study were reviewed 
by the study PI during the course of follow-up if urgent clinical intervention was required. 
Management with locally available treatment was based on a priori guidelines which were drafted 
prior to study initiation, and included discussion with a local specialist respiratory physician (PB) as 
required. All participants were offered a routine one-to-one clinical review with a respiratory physician 
(JM, PB, JR) after their final 12-month study visit, where they received written copies of all blood 
results, spirometry results, and CT imaging, and findings were explained.  
 
5.2.4 DATA SOURCES / MEASUREMENT 
Questionnaire data were collected at each study visit, and investigations completed according to a 
pre-defined schedule summarized in Table 2 and described in detail below.  
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Table 2: Data collection schedule 
Study visit Questionnaire content Investigations 
Baseline visit - TB 
treatment 
completion 
 
(QECH) 
Demographic details Pre and post bronchodilator spirometry 
Respiratory exposures – smoking and biomass EQ5D3L utility score 
Comorbidities, including – HIV disease Clinical observations 
History of TB disease episode 6-minute walking test 
TB symptom screen Chest radiograph 
St George’s Respiratory Questionnaire Non contrast HRCT chest 
Household socioeconomic status  HIV testing 
Current and pre-TB disease income / 
employment  Blood tests – FBC +/-CD4 and plasma 
 Baseline household dissaving Sputum smear and culture (if +ve TB symptom screen) 
6-month follow-up 
 
(Participant 
household) 
TB symptom screen  Pre and post bronchodilator spirometry 
St George’s Respiratory Questionnaire EQ5D3L utility score 
Health care use and associated costs, since 
baseline Clinical observations 
 Sputum smear and culture (if +ve TB symptom screen) 
12-month follow-up 
 
(QECH) 
TB symptom screen  Pre and post bronchodilator spirometry 
St George’s Respiratory Questionnaire EQ5D3L utility score 
Health care use and associated costs, since 
baseline Clinical observations 
Household dissaving, since baseline 6-minute walking test 
Current income / employment assessment Chest radiograph 
 Blood tests – plasma, FBC +/- CD4  if symptomatic 
 Sputum smear and culture (if +ve TB symptom screen) 
HRCT: High resolution computerized tomography; EQ5D3L: EuroQol standardized quality of life assessment tool, using 3-
options for 5-dimensions of health; QECH: Queen Elizabeth Central Hospital, Blantyre, Malawi.  
 
 
QUESTIONNAIRE DATA 
 HISTORY OF TB DISEASE 
Information about the TB episode, including TB disease classification (pulmonary/extrapulmonary), 
treatment dates, baseline microbiology, and treatment outcome, were collected at the baseline study 
visit. Malawian adults carry their own inpatient and outpatient medical records in the form of a small 
booklet or ‘health passport’. Data on TB disease and treatment were verified by review of this 
document where possible, as well as the TB NTP register. Cases were discussed with the TB officers in 
the referring health centre if required.  
Patients were asked if they had received immunosuppression with steroids during TB treatment, and 
this was verified in the health passport.  
 HISTORY OF HIV DISEASE 
Participants were asked about their HIV status at the baseline study visit, and the health passport 
reviewed for a signed and dated test result or evidence of ART use. Data on the timing of diagnosis 
and ART initiation and concurrent co-trimoxazole use were collected for those known to be positive. 
Any patient who reported negative status but had not had a test within the past 1-month was retested, 
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as were those who reported positive status but had no documentation. Testing was performed by a 
trained Queen Elizabeth Central Hospital (QECH) counsellor using the Determine HIV Rapid Test 
(Alere), with confirmation of positive results with the Uni-Gold Recombigen HIV Rapid Test 
(TrinityBiotech). Participants with new positive diagnoses were referred to the ART clinic for 
assessment and treatment initiation as per Malawi test-and-treat guidelines.  
 RESPIRATORY EXPOSURES 
Data on self-reported smoking and cannabis use were collected at baseline. There are no standardized 
measures of cannabis exposure, and consumption volumes are difficult to ascertain given the weight 
per unit of purchase and consumption in Blantyre (rolled joints known as ‘mbaba’, or parcels known 
as ‘bola’) are unknown. The average number of mbaba smoked per day, and the total years of use 
were therefore recorded. 
Data on self-reported individual level biomass exposure were collected, including the dominant fuel 
used, and information on the duration of use of specific fuels for cooking / heating water within the 
household. No direct measurements of particulate or biomass fuel exposure were made.  
 CO-MORBIDITIES 
Participants were asked about existing diagnosis of cardiac disease, respiratory disease, and diabetes 
with verification in the health passport where possible.  
 QUALITY OF LIFE AND CLINICAL SYMPTOM DATA 
Participants were asked to rank their general health on a four-point Likert scale, from poor to 
excellent, as a summary measure of overall health status.   
The SGRQ was completed in full at each study visit. Permission was obtained for the development of 
a Chichewa version of the questionnaire for use in this study. Translation was performed  by an official 
translation service, and the questionnaire reviewed / corrected by the Malawian members of the 
study team prior to use. Given low literacy rates in the Malawian population, a modified approach was 
used, with questionnaires administered by study staff who read questions and answer options to study 
participants in a standardized fashion and documented patient choices. The 3-month version of the 
questionnaire was used in this study: respiratory symptom questions referred to patient experience 
over the preceding 3-month period, whilst activity and impact questions referred to the current 
situation only. Summary scores (symptom, activity, impact, and total) scaled from 0 (optimal health) 
to 100 (worst health) were generated for each questionnaire completed by weighting and combining 
answers to the SGRQ questions according to the pre-specified SGRQ algorithm.156  
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Data on the burden of individual clinical symptoms were taken from the SGRQ, including information 
on the frequency of cough, breathlessness, sputum production and wheeze, and data on the severity 
of breathlessness. 
The EQ-5D-3L was completed at each study visit with permission granted by the EuroQol group.226 
Data were collected across 5 key domains of health and function (mobility, self-care, their usual 
activities, issues of pain / discomfort, and anxiety or depression), and the EQ5D3L Visual Analogue 
Score (VAS) was completed independently by participants.  
 SOCIOECONOMIC SITUATION 
Data were collected from all participants on their educational level. Data on household assets 
(ownership of mobile phone, television, radio, landline phone, fridge, bike, motor bike, car, bank 
account) and household characteristics (electricity supply, water supply, toilet situation, main fuel) 
were collected at TB treatment completion, with verification of materials making up wall / floor / roof 
of households completed at the 6-month home visit. Participants were asked to report on food security 
within the household at each study visit.  
National and urban household wealth quintiles were calculated using the indicator tool derived from 
the Malawi Malaria Indicator Survey, 2012 (Equity Measurement Toolkit, Social Franchising Metrics 
Working Group). A newer quintile tool based on the 2015-16 Malawi DHS data was released in 2018, 
after the start of this study, but employed different household asset / characteristic data variables and 
could not therefore be used retrospectively.  Wealth quintiles were calculated at the start of the study 
and assumed to be fixed through the duration of the study. 
 HEALTH SERVICE USE  
Participants were asked about outpatient visits and admissions within the past 6-month period at both 
the 6-month and 1-year study visits. Outpatient visits to the study PI for abnormal study results were 
not included in this count.  
Data were collected on the date, indication, location, duration, cost and management of events, and 
information verified in the health passport where possible. Acute respiratory events were defined as 
“unscheduled visits to a health care provider (outpatient or inpatient) due to a respiratory complaint 
(e.g. cough, breathlessness, wheeze, sputum production, haemoptysis, chest pain)”.  
 TB RETREATMENT 
Participants were asked whether they had been initiated on TB retreatment by routine TB services, at 
both 6- and 12-month study visits, and health passports reviewed for evidence of this. Individuals who 
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were restarted on TB treatment by either routine health services, or as a result of study screening, 
remained within the study but aerosolizing investigations such as spirometry were omitted. 
 COSTS AND DISSAVING 
Data on personal and household incomes and occupations were collected for three time points: prior to 
TB illness, at the point of TB treatment completion, and 1-year following TB treatment completion. 
Information about the first two time points was collected at the baseline study visit, and data 
regarding the latter at the final study visit.  
Participants were asked to recall any dissaving (use of savings, borrowing of money, or selling of assets 
to cover illness related costs) in the 1-year period prior to TB treatment completion – which included 
the period of illness prior to diagnosis, and the duration of treatment – at the baseline study visit. They 
were then asked to report on ongoing dissaving experienced following treatment completion at both 
the 6- and 12-month visits.  
Data on the direct and indirect costs incurred by participants and guardians for each health care visit 
completed during the follow-up period were collected. All costs were reported by participants in 
Malawi Kwacha and converted into US Dollars using the exchange rate from the study mid-point 
(March 2017, $1 USD: 726MK). Income, cost, and dissaving questions were adapted from the STOP-
TB costing questionnaire.167 
CLINICAL OBSERVATIONS 
Vital signs were recorded at every study visit. Mid upper arm circumference (MUAC) and BMI were 
recorded. The presence of palatal Kaposi’s Sarcoma and peripheral oedema were documented by a 
trained research nurse.  
MEASURES OF FUNCTIONAL CAPACITY 
Participants were asked whether they had been unable to work in relation to health problems in the 
past 1-month, at both the baseline and 1-year visits. The 6-minute walk test was completed along a 
30-m course in a flat hospital corridor at baseline and 1-year visits, as per ATS guidelines,227 and the 6-
minute walking distance and post-test oxygen saturation were recorded.  
BLOOD TESTS 
All participants had a full blood count at baseline, with a CD4 count if HIV-infected. Plasma samples 
were taken at both baseline and 1-year study visits, and stored locally at -80 degrees, before being 
shipped to the National Aspergillus Centre in Manchester, UK in batches, for measurement of 
Aspergillus IgG using the Bio-Rad Platelia and Bordier Aspergillus IgG ELISA kits (performed by BW).  
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Storage and shipment were performed with the consent of participants, ethical approval, and the 
necessary Material Transfer Arrangement.  
SPUTUM SMEAR AND CULTURE 
A TB symptom screen was performed by the study team at each study visit, and a sputum sample 
requested for smear and culture from those reporting any of current cough, fever, weight loss, or night 
sweats. Cultures were run on the BACTEC Mycobacteria Growth Indicator Tube (MGIT) system (Becton 
Dickson) for a maximum of 42 days, after sputum decontamination. MGIT positive samples were 
checked with a Ziehl-Neelson (ZN) stain to confirm the presence of a mycobacterium, and ID testing 
(MPT 64 antigen detection kit, SD Bioline) used to confirm the presence of Mycobacterium tuberculosis 
(MTB), with further culturing and testing as required. Whilst the TB laboratory in Blantyre was able to 
identify the presence of non-tuberculous mycobacteria (NTM) in sputum, further speciation was not 
possible on site.   
SPIROMETRY 
Pre- and post-bronchodilator spirometry were measured at each study visit.  
All staff performing spirometry underwent a rigorous 4-day formal training course prior to the start of 
the study, with re-training at the study mid-point. Training was provided by a certified provider, and 
covered the principles underlying spirometry, ATS-standard approach to pre- and post-bronchodilator 
testing, basic data interpretation and quality control, and equipment maintenance. 
The EasyOne spirometer was used throughout, with daily calibration using a 3L-calibration syringe. 
Participants were assessed for contraindications prior to testing (Table 3) – if any were detected, 
testing was either withheld, or rescheduled with discussion with the study PI (JM) as appropriate.  
Table 3: Relative and absolute contraindications to spirometry228 
Category Factor identified 
Absolute contraindication 
 
Unstable angina 
Heart attack < 3 months 
Hospitalisation for cardiac problem < 3 months 
Chest / abdominal surgery < 3 months 
Detached retina / eye surgery <3 months 
3rd trimester pregnancy 
Relative contraindication Tachycardia with HR >100 
BP >180/110 
 
Acute illness 
On TB retreatment / under investigation for active PTB recurrence 
Each patient was asked to perform a minimum of 3 and maximum of 8 pre- and post-bronchodilator 
attempts, with the target of achieving 3 good curves for each. Where consistently poor technique / 
difficulty performing the test was observed, participants were asked to return on another occasion for 
repeat testing. Salbutamol was administered via a spacer after the pre-bronchodilator tests, using 2 x 
100mcg doses from an MDI device. A minimum of 15 minutes was allowed between administration of 
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salbutamol and repeat spirometry. Nose clips were found to function poorly in the study population, 
so participants were asked to pinch their noses during testing. Disposable spirettes were used and 
changed for each patient. Testing was performed in the seated position. Participant age (yrs), standing 
height (mm), and weight (kg) were recorded at the time of testing, to allow for standardization of 
results. Spirometry data were stored electronically using EasyWare software. 
CT IMAGING 
High resolution computerised tomography imaging (HRCT) imaging was included within the study as 
the ‘gold standard’ investigation for structural lung pathology and is therefore described prior to CXR 
imaging throughout this chapter. 
All participants were offered low dose HRCT imaging at PTB treatment completion, except for those 
with the following contraindications: absence of informed consent, positive pregnancy test / self-
reported current pregnancy, inability to travel to imaging centre. Any patient reporting a positive TB 
symptom screen (cough, weight loss, fever, night sweats, haemoptysis) at the baseline study visit was 
asked to submit sputum, and was only booked for imaging if smear negative.  
CTs were performed in batches, with 8-12 sequentially booked participants transported to the imaging 
centre every 1-4 weeks, depending on imaging capacity / study demand.  Participants were prioritised 
by time from PTB treatment completion, with the aim of minimising this time interval. For logistical 
reasons, 2 imaging centres were used: Blantyre Adventist Hospital (BAH), Blantyre (Feb - Aug 2016) 
and Kamuzu Central Hospital (KCH), Lilongwe (Nov 16- May 17). Travel to the latter required a full 
day’s round trip.  
An unenhanced low dose imaging protocol was used at both scanning locations. Scans were taken of 
supine participants in full inspiration, with coverage from apices to bases (Appendix 2, Table 1). Scans 
were reconstructed using a lung algorithm only, accepting that this would give limited diagnostic 
quality for soft tissue. Images were stored in stored in DICOM format electronic files. 
All scans were checked by the study PI (JM) within 5 days of acquisition, and participants reviewed if 
clinically indicated.  
CXR IMAGING 
Plain chest radiology was used to determine change in structural pathology over time.  
CXR images were acquired from all participants with the exception of pregnant women at baseline 
and 1-year study visits.  Digital images were taken where possible, with hard films obtained in the 
event of equipment malfunction, and selection of imaging modality was therefore independent of 
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patient characteristics. All hard copy images were ‘digitalised’ in order to allow for remote reporting. 
This was performed at the UK National Conservation Centre, in order to optimise image quality.  
Images were reviewed on a weekly basis by the study PI (JM), and participants reviewed if clinically 
indicated.  
ASCERTAINMENT OF MORTALITY 
All participants were asked to provide both their own contact details and address, and those of a next 
of kin when registered for the study. In the event of a participant missing a study visit, attempts were 
made to contact them directly in the first instance. If unsuccessful, the next of kin was contacted by 
phone / in person to determine the participant vital status. Repeated attempts at contacting both 
participants and the next of kin were made, with home visits as required.  
If a participant was found to have died, the approximate date and circumstances were ascertained, 
including whether they had been restarted on TB retreatment although formal verbal autopsies were 
not done. 
5.2.5 DATA MANAGEMENT 
Questionnaire data were collected in electronic format using Open Data Kit (ODK) software. The EQ-
5D-3L questionnaire is not validated for electronic use and was therefore completed on paper using 
the Teleform system and converted to electronic format in batches over the course of the study. 
Spirometry data were stored electronically using EasyWare software. The majority of CT and CXR 
imaging data were directly collected and stored in DICOM format electronic files, and digital versions 
of hard-copy CXR films were stored as JPEG imaging files.   
Data were anonymized on collection, with hard copies stored locally in a secure site at the Malawi 
Liverpool Wellcome Trust research centre, and electronic data stored in a secure master database held 
on the Liverpool School of Tropical Medicine server. Data were cleaned at the end of the study, and a 
final analysis-ready database saved on this central server. Consent was taken to store study data for a 
10-year period from collection. 
Quality control and processing of cleaned spirometry, CT and CXR data were required to generate 
variables for analysis. The approaches taken were informed by the issues of measurement highlighted 
in Chapter 2.  
SPIROMETRY DATA 
All spirometry tests were independently reviewed by 2 readers (JM and LZ) to identify usable curves, 
in accordance with CDC National Institute for Occupational Safety and Health (NIOSH) guidelines, and 
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the BOLD study quality control procedures.229 230 Consensus review was used in the event of any 
disagreement, and data were extracted from spirometry attempts deemed to be usable at the end of 
this process only. Full details of the methods used for quality control and consensus reading are 
described in Appendix 2.  
As explained in the literature review in Chapter 2, spirometry data were standardized for primary 
analysis using the GLI-2012 African American equations, with the aim of identifying individuals within 
the cohort who were left with abnormal lung function on completing PTB treatment, relative to their 
peers. Z-scores were used to describe the severity of impairment, and lower limit of normal (LLN) cut-
off values were used to define normal / abnormal FEV1 and FVC z-scores in order to describe patterns 
of deficit: the presence of obstruction was based on an FEV1/FVC <LLN, and those without obstruction 
were classified as having a low FVC pattern (FVC <LLN) or a normal pattern (FVC >LLN) (Table 4). No 
category of mixed disease was included in the analysis. 
Table 4: Classification of spirometry  
Category FEV1/FVC ratio FEV1* FVC 
Obstruction <LLN  
 
n/a 
 
n/a 
Low FVC ≥LLN 
 
n/a 
 
<LLN 
Normal ≥LLN  
 
n/a ≥LLN 
*FEV1 not directly included in diagnostic criteria, but implied through use of ratio 
 
In order to better understand the impact of the reference range used on data findings and 
interpretation, spirometry data from TB treatment completion were standardised using each of the 4 
reference ranges (GLI-2012, NHANES III Caucasian, NHANES III African American, Malawi), % predicted 
values calculated, and patterns compared. Age and gender stratified prevalence estimates for airway 
obstruction and low FVC were also generated using fixed FEV1/FVC ratios and % predicted values 
calculated using the NHANES III reference range, in order to allow comparison to the urban Malawi 
BOLD study results described in Chapter 4.  
As per the ATS/ERS guidelines, reversibility was defined as an increase in FEV1 of >200ml between 
pre- and post-bronchodilator readings, where this increase was >12% of baseline FEV1 value.  
CT DATA 
 CT SCORING TOOL 
As discussed in the literature review in Chapter 2, no post-TB lung damage scoring tools were 
identified in the literature, and a dedicated tool was therefore developed for use here (Table 5). The 
tool was informed by the systematic review of the existing literature on post-TB lung damage above, 
pictorial essays of chest imaging at various stages of PTB disease, and review of image scoring systems 
commonly used in other chronic respiratory diseases, including bronchiectasis, COPD, and interstitial 
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lung diseases. It was developed by the study PI and two Europe-trained consultant radiologists: a 
consultant chest radiologist with predominantly UK specialist respiratory experience (JJ), and an ID 
radiologist with more than 10-years’ experience of TB related pathology and imaging in sub-Saharan 
Africa (EJ). 
 Particular attention was paid to the selection of variables used to measure bronchiectasis and airways 
pathology. Established radiological criteria from the Fleischner guidelines were used for the majority 
of variables,191 except for the category of ‘Emphysematoid destruction’ – this is a feature described in 
the TB literature but not mentioned in the Fleischner guidelines. Joint scoring of a training set of CT 
images obtained from a previous study of patients receiving TB-retreatment in urban Blantyre was 
used to refine the scoring tool prior to use. 
Table 5: CT scoring system used for data analysis 
Initial name of variable Initial definition Scoring options 
PARENCHYMAL VARIABLES 
Scored at lobar level. Mutually exclusive variables, summing to 100% for each lobe. 
Parenchymal bands Linear opacity 1-3mm thick, up to 5cm long. 
Usually extends to visceral pleura. 
May be accompanied by anatomical distortion 
% of lobe (to nearest 5%) 
Atelectasis Reduced volume accompanied by increased 
lucency in the unaffected part of the lung. 
May be accompanied by displacement of 
fissures, bronchi, vessels. 
% of lobe (to nearest 5%) 
Consolidation Homogeneous increase in lung parenchymal 
attenuation which obscures the margins of 
vessels and airway walls. An air bronchogram 
may be present. 
% of lobe (to nearest 5%) 
Ground glass opacification Hazy increased lung opacity with preservation of 
bronchial and vascular margins 
% of lobe (to nearest 5%) 
Mosaicism Areas of reduced lung parenchymal attenuation. 
Component of the mosaic attenuation pattern, 
where a patchwork of differing lung attenuation 
is seen. 
% of lobe with darker areas (to 
nearest 5%) 
Emphysema Focal areas or regions of low attenuation usually 
without visible walls 
% of lobe (to nearest 5%) 
Emphysematoid destruction Focal area of destruction / emphysematous 
change associated with features of healing TB, 
suggesting destruction of small airways. 
% of lobe (to nearest 5%) 
Cavities / cystic airspaces Gas filled space, seen as a lucency or low-
attenuation area within a pulmonary 
consolidation, a mass, or a nodule. Consolidation 
may have resolved leaving a thin wall only. 
% of lobe (to nearest 5%) 
Normal Normal parenchyma, not affected by any of the 
pathological processes above 
% of lobe (to nearest 5%) 
BRONCHIECTASIS VARIABLES 
Scored at lobar level. Extent assessed first, with Pattern and Severity scored only if bronchiectasis seen. 
Bronchiectasis 
 
Airway lumen diameter 
greater than accompanying 
pulmonary artery outer 
diameter,  
OR 
Airways visible in the lung 
periphery,  
OR  
Lack of normal tapering 
 
Extent 
 
 
0: Absent 
1: ≤1 BP segment 
2: 2 BP segments 
3: ≥ 3 BP segments 
Pattern 
(Scored only if bronchiectasis seen and ‘extent’ 
score >0) 
1: Cystic (Ballooned' outline, with 
diameter increasing towards 
periphery) 
2: Cylindrical (Regular and straight 
outline, with abrupt termination) 
3: Varicose (Irregular bronchial 
outline, with bulbous termination) 
Severity 
 
1: Trivial (bronchial lumen is <twice 
adjacent vessel diameter) 
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Maximum degree of airway dilatation, to be 
measured by comparing diameter of airway 
lumen to diameter of adjacent vessel. 
 
(Scored only if bronchiectasis seen and ‘extent’ 
score >0) 
2: Bronchial lumen is 2-3 times 
adjacent vessel diameter 
3: Bronchial lumen is >3 times 
adjacent vessel diameter 
AIRWAY VARIABLES 
Scored at lobar level. All variables independent of each other. 
Bronchial wall thickening Thickening of bronchial walls 0: Absent 
1: Mild 
2: Moderate  
3: Severe 
Missing: Unable to assess 
Mucous plugging Mucous seen in proximal large airways 0: Absent 
1: Mild 
2: Moderate  
3: Severe  
Tree in bud Centrilobular branching pattern, resembling a 
budding tree. Most pronounced at the periphery. 
0: Absent 
1: Mild 
2: Moderate  
3: Severe 
CAVITY VARIABLES 
Scored at lobar level. Independent of parenchymal scores. Extent scored first, with size and severity scored only if cavities 
seen 
Cavity 
 
Gas filled space, seen as a 
lucency or low-attenuation 
area within a pulmonary 
consolidation, a mass, or a 
nodule. Consolidation may 
have resolved leaving a thin 
wall only. 
Mycetoma 
Extent 0: Absent 
1: 1-2 cavities 
2: 3-5 cavities 
3: >5cavities 
Maximum size Maximum diameter (mm) 
Mycetoma 
 
Discrete mass of hyphae, within a cavity. May 
have air crescent sign. May have sponge like 
pattern with areas of calcification. 
0: Absent 
1: Present 
OTHER LOBAR VARIABLES 
Scored at lobar level 
Nodules Rounded opacities, well or poorly-defined, 
>5mm, measuring up to 3cm in diameter 
0: Absent 
1: <5 nodules 
2: ≥5 nodules 
3: Miliary 
WHOLE LUNG VARIABLES 
Scored at level of hemithorax / whole lung 
Pleural effusion Accumulation of fluid within pleural space 0: Absent  
1: Present 
Pleural thickening Pleural thickening of ≥10mm 0: Absent  
1: Present 
Lymph nodes Mediastinal / hilar lymph nodes ≥10mm diameter 0: Absent 
1: Present 
DOMINANT PATHOLOGY 
Impression of reporting radiologist, after review of individual variables above 
Compatible with resolving PTB – No other pathology 
Compatible with resolving PTB, plus other diagnosis 
Resolving PTB or other diagnosis equally likely 
Not compatible with resolving PTB, other diagnosis likely 
 
 CT SCORING PROCESS 
All CT images were independently scored by two consultant radiologists (EJ and JJ). Anonymised 
images were used, with no accompanying demographic or health related information. There was no 
pre-specification of the order of image review, but images were provided to both radiologists in the 
same format and in the same order in batches, over the course of the study. Neither the maximum 
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number of images to be read in each sitting, nor the reviewing environment (eg. quality of computer 
screen) were pre-specified.   
CTs were scored on a lobar basis, with six lobes per scan - for scoring purposes the lingula was counted 
as a full lobe. Bronchial anatomy was used to define the lobes – this corresponds to fissures on the 
right, but on the left helps to differentiate upper and middle "lobes" or lingula which have no 
horizontal fissure between them. The division between the lingula and left upper lobe was drawn at 
the level of the lingular bronchus.  
Data from the first 20 independently reported scans from within this study were reviewed by the 
radiologists to consolidate training. Findings were compared, discrepancies calculated, and the data 
and images were reviewed together in person by the radiologists to confirm that comparable 
approaches were being used. Re-scoring of initial data for these first 20 scans was permitted, but no 
subsequent changes to independently reported data were made over the course of the study. 
Clarification notes generated from this review, and after analysis of the full study dataset, are 
presented in Appendix 3, Table 2.  
A live online image scoring database was created in order to facilitate efficient scoring, with safe and 
secure data storage, and a clear audit trail for any changes made to data. Image scores were entered 
directly into the database by radiologists, as images were reviewed. Default buttons for all severity 
and extent scores were set as ‘Absent’ in the database, with radiologists changing these as required. 
Parenchymal scores were left empty with radiologists entering scores at 5% intervals as required, and 
compulsory totals of 100% for each lobe. A free-text box was included for radiologists to note any 
queries or additional features.  
 MEASUREMENT OF INTER-READER RELIABILITY 
Lobar scores generated for each variable were summed across the whole lung, for each scan report 
produced by each reader, and these whole lung scores were then compared between readers. The 
following measures of inter-reader consistency were used to describe the level of discrepancy 
between original image readers: 
- Cohen’s kappa score – ordinal variables 
The kappa score accounts for the probability of agreement occurring by chance. It is generally 
accepted that values <0.40 indicate limited agreement, values 0.41-0.75 represent good 
agreement, and values >0.75 excellent agreement. A score of 1.0 indicates perfect agreement 
between readers.  
- Weighted Cohen’s kappa score – ordinal variables with multiple categories 
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A quadratic weighting was used here such that discrepancies between categories that are close 
together are less meaningful and less severely penalised that more extreme discrepancies 
between readers. Scores were calculated in Stata v13, using the wgt(w2) function. 
- Intra-class correlation coefficient – continuous variables 
Parenchymal scores were treated as continuous variables for discrepancy measurement. As the 
differences in reader reports for individual scans are of interest, rather than average reports 
across the cohort, a two-way fixed effects model measuring absolute agreement for individual 
readings was used. 
 CONSENSUS REVIEW 
Consensus reading was performed by a third independent reader (HZ - a senior specialist chest 
radiologist with 3-months experience working in sSA). This was completed at a lobar level for the most 
discrepant scans and variables. The method used to select scans, lobes and variables for review is 
described in Appendix 3. 
Reviews were performed at the end of the study, and the following training was provided to support 
this: 
- The consensus reader was provided with the imaging reporting SOP, all of the CT images which 
had been acquired, and all of the original reads performed by both of the primary radiologists 
before starting consensus reading of the required subset of scans. 
- An in-person meeting with one of the original readers (EJ) was scheduled for a detailed review of 
these data, prior to starting consensus reviews. Meeting with the second reader (JJ) was not 
possible, but scoring data from this reader were reviewed to provide a perspective of the different 
scoring approach, in order to minimise bias.  
- A discussion between the consensus reader and one of the original readers was scheduled for 
after the consensus reading of the first 10 scans, in order to resolve any early issues arising.  
For all of the scans reviewed, the consensus reader was provided with the anonymised scores 
produced by both original radiologists, to inform their own decision. They were able to either choose 
one of the original scores or generate their own response, and the score generated by this final 
consensus reviewer was considered the ‘final’ score for each variable reviewed. 
 GENERATION OF FINAL DATA SET 
Original reads and consensus reads were combined to form a single ‘final’ data value for each variable 
for each scan, using the approach detailed in Appendix 2, section 3.  
Where there was agreement between original readers for a given variable in a given lobe, the agreed-
on score was used as the final data point. Where original readers had disagreed and a consensus 
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review had been performed, the consensus score was used as the final data point. Where original 
readers had disagreed, but no consensus read was available, the approach taken depended on the 
variable over which there was discrepancy: scores from the original readers were averaged for 
continuous variables (eg. parenchymal scores), pathology was considered to be present if either or 
both original readers felt it to be so for binary scores (eg. mycetoma, pleural pathology), and random 
selection of original reads was used for nominal variables which could not be combined (eg. 
bronchiectasis pattern).  
 
 GENERATION OF FINAL VARIABLES FOR ANALYSIS 
Lobar scores were summed to generate whole-lung level scores for data analysis. This approach was 
taken for two reasons:  firstly, in order to include lobar measures, one would have to account for 
clustering across ‘repeated measures’ between lobes, because lobes within one individual are more 
likely similar than those between individuals, and secondly it is likely that the amount or severity of 
pathology across the whole lung is of greater clinical relevance than lobar pathology.  
This pragmatic approach assumes that the impact or presence of pathology in all lobes has the same 
meaning – that is, the impact of pathology in the RUL is the same as that of pathology in the LLL. Equal 
weighting of all lobes (including the lingula) implies that each lobe contributes the same volume of 
parenchyma / pathology to the overall lung, regardless of variation in their true size. 
Several new variables were derived from the data collected above. These included:  lobar presence / 
absence scores for airway pathologies, a composite variable for ‘destroyed lobes’, a composite 
variable for atelectasis and parenchymal banding, and a % score for the total amount of abnormal 
parenchyma seen across the lung both with and without mosaicism. The approach taken to generate 
these variables is detailed in Appendix 3. 
Briefly, moderate to severe airway pathology (bronchiectasis, bronchial wall thickening, tree in bud, 
mucus plugging, and airway narrowing) was considered present in a lobe if final score generated by 
averaging original reads or on consensus review was ≥2. A lobe was considered destroyed or non-
functioning if ≥90% of parenchyma was occupied by atelectasis, parenchymal banding or destroyed 
by cavities/cystic airspaces. 
CXR DATA 
 CXR SCORING TOOL 
A CXR scoring system was designed for use (Table 6), using terms and patterns similar to those which 
had been used in the CT scoring system.  
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Table 6: CXR scoring variables and definitions  
Initial name of variable Initial definition Scoring options 
PARENCHYMAL VARIABLES  
Scored at lobar level. Mutually exclusive variables, summing to 100% for each lobe. 
Parenchymal bands Linear opacity 1-3mm thick, up to 5cm long. Usually extends 
to visceral pleura.  
May be accompanied by anatomical distortion. 
% of lobe (to nearest 5%) 
Consolidation / ground 
glass 
Consolidation: Homogeneous increase in lung parenchymal 
attenuation which obscures the margins of vessels and airway 
walls. An air bronchogram may be present.  
OR 
Ground glass appearance: hazy increase in opacification with 
preservation of bronchial and vascular margins 
% of lobe (to nearest 5%) 
Cavities / cystic airspaces Gas filled space, seen as a lucency or low-attenuation area 
within a pulmonary consolidation, a mass, or a nodule. 
Consolidation may have resolved leaving a thin wall only. 
% of lobe (to nearest 5%) 
Atelectasis Reduced volume accompanied by decreased opacity in the 
unaffected part of the lung.  
Signs of volume loss should be seen, and may include: 
displaced hila / fissures / bronchi, narrowed rib spacing, 
tortuous trachea, hyper-expansion and linear vessels 
extending through other lung zones 
% of lobe (to nearest 5%) 
 
CAVITY VARIABLES 
Reported at a lobar level 
Cavity Gas filled space, seen as a lucency or low-attenuation area 
within a pulmonary consolidation, a mass, or a nodule. 
Consolidation may have resolved leaving a thin wall only. 
 
0 = Absent 
1 = 1-2 cavities 
2 = 3-5 cavities 
3 = >5cavities 
Maximum diameter of 
largest cavity, in mm 
Mycetoma Discrete mass of hyphae, within a cavity. May have air 
crescent sign. 
0 = Absent 
1 = Present 
OTHER LOBAR VARIABLES 
Nodules 
 
Rounded opacities, well or poorly-defined, ≥5mm, measuring 
up to 3cm in diameter. 
0 = Absent 
1 = <5 
2 = ≥5 
3 = Miliary 
Ring and tramline markings Prominent ring  
-shaped opacities representing thickened airways seen end-
on, or parallel lines if seen longitudinal. 
0 = Absent 
1 = Mild 
2 = Moderate  
3 = Severe (whole zone) 
WHOLE LUNG VARIABLES 
Hyper-expansion Large lung fields with flattened hemidiaphragms.  0 = Absent 
1 = Present 
Pleural thickening Visible pleural thickening ≥10mm with any distribution over 
visceral / parietal surfaces. 
0 = Absent 
1 = Present 
Pleural effusion Accumulation of fluid within the pleural space, identified by 
blunted costophrenic angle +/- visible meniscus.  
0 = Absent 
1 = Present 
Lymph nodes Prominent mediastinal or hilar lymph nodes. 0 = Absent 
1 = Present 
Dominant pathology 
Compatible with resolving PTB – No other pathology  As per the impression of 
the reader Compatible with resolving PTB, plus other diagnosis 
Resolving PTB or other diagnosis equally likely 
Not compatible with resolving PTB, other diagnosis likely 
 
 CXR SCORING PROCESS 
Formal reporting was completed in batches in order of image acquisition / digitalisation. All films were 
read independently by 2 readers – one was a respiratory physician trainee (JM), and the other was a 
consultant radiologist (EJ). Images were scored directly into a reporting database, as described above. 
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All films were checked for the correct horizontal rotation (L/R sides) before reading using the location 
of the stomach bubble, position of the airways, and the location of the aortic knuckle. Orientation was 
checked against the CT report only when there was genuine concern about dextrocardia, but no other 
comparisons were made with the CT imaging during CXR scoring. The radiologist reporting both CT 
and CXR imaging for the study (EJ) reported these image types independently, at distinct times. 
CXRs were scored on a zonal basis, with each lung field divided into 3 zones for reporting, giving a total 
of 6 zones for each film. This division was done by each reader independently for each film. The 
upper/middle zone boundary was drawn at the level of aortic knuckle, and the middle/lower zone 
boundary drawn at the bottom of the thick portion of the pulmonary artery. Where there was clear 
lobar collapse / volume loss of a single lobe, the collapsed area was scored as a single zone and the 
remainder of that hemithorax was then split into 2 further zones for scoring.  
An SOP was designed and agreed by both image readers. After the first 20 X-Rays had been 
independently read, both readers’ results were reviewed together with the original images. Imaging 
definitions were clarified, and scores revised within the primary data set if required. Paired reports for 
24 further x-rays were reviewed by both readers together again in November 2017, to ensure a 
consistent approach. This allowed for clarification of imaging definitions, but no changes were made 
to baseline scores at this stage. The notes generated during this process are shown in Appendix 4.  
 INTER-READER RELIABILITY AND CONSENSUS REVIEW 
The approach to the measurement of inter-reader reliability and selection of images for consensus 
review was similar to that described for CT imaging above. However, no third reader was required for 
consensus review of CXR images: the smaller amount of time required for X-ray reading meant that 
the 2 to original readers were able to conduct an in-person review together for discrepant scans, and 
reach agreement on final scores through discussion. The approach to selecting images and variables 
for consensus review is detailed in Appendix 4.  
 GENERATION OF FINAL DATA SET 
Final scores were generated at the zonal level using an approach similar to that taken in CT reading: 
where there was agreement between original readers, the agreed score was used as the final score; 
where there was discrepancy of original reads, but a consensus review had been conducted, the 
consensus score was used as the final score. In the absence of agreement or consensus review, the 
following approaches were taken: 
- Parenchymal scores – extent scores given by the original readers were averaged.  
- Ring and tramline scores – severity scores given by the original readers were averaged.  
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- Nodule scores - significant overlap was noted between the nodule categories of <5 and ≥5 
between readers, and on review this distinction was felt unlikely to be clinically useful. Nodule 
scores were collapsed down to give 3 categories of pathology: no nodules, non-miliary nodules 
(any number), or miliary pathology. If, even after collapsing the variable, there was no agreement 
and no consensus decision was available, data were classified as missing for this zone.  
- Mycetoma – as for nodules, mycetoma data were classified as missing in the absence of 
agreement or consensus review 
- Pleural pathology & hyper-expansion – the report provided by the more experienced reader (EJ) 
was used 
New variables for ‘absent’ parenchyma (non-functioning tissue due to atelectasis, cavities or banding), 
and ‘destroyed’ zones (where 90% of a lobe appeared absent due to the above) were generated, as 
per the CT analysis. Atelectasis and banding were also collapsed together, and where binary scores for 
the presence / absence of ring and tramline change within a zone were required, only zones with an 
average score ≥2 were counted. For ease of analysis, and because they potentially originate from 
similar inflammatory aetiologies, ground glass and consolidation were combined together in analyses.  
5.2.6 MINIMISING BIAS 
Selection bias was minimized by including a range of health centres across Blantyre within this study, 
and encouraging TB officers at these centres to identify and refer all potentially eligible PTB patients 
to the study team for review. Our aim was to achieve sequential recruitment of eligible patients. This 
was supported by regular visits to each health centre to review the NTP register and identify 
potentially eligible patients to target for referral, regular feedback to TB officers on their referral and 
recruitment numbers, and the provision of training and financial incentives for TB officers throughout 
the recruitment period. 
Financial reimbursements were provided to participants ensured that individuals from lower SES 
groups were able to participate. Flexibility around dates and times of study visits, including weekend 
reviews, allowed those who were working to attend for assessment. Results of baseline investigations 
performed at TB treatment completion were not communicated to the study team or participants 
until the end of the 1-year follow up period, unless clinically indicated, in order to avoid bias in the 
reporting and recording of outcome data over the course of the study. Recall bias in the reporting of 
health seeking and economic data was minimized by allowing a maximum of 6-months between study 
visits. Standardised approaches were used for the collection of quality of life, spirometry, and walking 
test data.  Definitions of exposures and outcomes for the analysis of cohort data were established 
prior to data analysis, where possible.   
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5.2.7 VARIABLES 
Exposure and outcome variables for use in the cohort analysis are described below.  
EXPOSURE VARIABLES 
In the absence of a validated scoring system for post-TB lung damage (PTLD), an a priori case definition 
of post-TB lung damage was established by consensus discussion prior to starting this study, in order 
to differentiate between individuals with marked residual lung damage at TB treatment completion, 
and those with mild / absent pathology (Table 7). The process through which this composite definition 
which includes both spirometry and CT measures of lung pathology was generated is detailed in 
Appendix 5.  
Table 7: A priori definition of PTLD, for use in cohort analysis 
Criteria PTLD present 
Spirometric PTLD Airway obstruction with FEV1/FVC ratio<LLN and FEV1<LLN 
OR 
Low FVC with FEV1/FVC ratio≥0.7 and FVC<LLN 
CT PTLD Moderate-severe bronchiectasis in ≥3 lobes 
OR 
Parenchymal abnormality of ≥1/3 of the lung tissue 
LLN: Lower limit of normal, as classified using GLI 2012 reference ranges 
 
In primary analyses, individuals meeting the a priori definition of either spirometric or CT defined PTLD 
were classified as ‘exposed’, and those with normal measurements / abnormalities not meeting these 
criteria were considered to be ‘unexposed’. Secondary analyses were performed using different 
definitions of PTLD as the exposure of interest, in order to determine which aspect of residual lung 
damage were the most closely related to patient outcomes. These included Spirometric PTLD, CT PTLD, 
or both CT and spirometric PTLD. The latter group – identifying those with both extensive structural 
pathology and spirometric abnormality at TB treatment completion – is likely to be the group with the 
most severe residual pathology.  
OUTCOME VARIABLES 
Five primary outcomes were recorded over the 1-year follow up period (Table 8). 
Table 8: Definition of cohort study outcomes 
Outcome variable Definition 
Quality of life Prevalence of impaired quality of life (SGRQ total score >6), 1-year post TB treatment completion 
Chronic 
respiratory 
symptoms  
Prevalence of self-reported cough OR sputum production OR breathlessness OR wheeze occurring 
at least monthly (several days/ week, or most days/week), 1-year post TB treatment completion. 
 
Acute respiratory 
exacerbation 
Presence of ≥1 unscheduled visit to a health care provider (outpatient or inpatient) due to a 
respiratory complaint (cough, breathlessness, wheeze, sputum production) within the 1-year 
period 
TB retreatment  Initiation of TB retreatment within 1-year from TB treatment completion – including those with and without microbiological evidence of disease recurrence.  
Mortality All-cause mortality within 1-year from TB treatment completion  
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Of note, these outcomes are altered from those specified in the original study protocol. The initial 
intention had been to model the SGRQ total score at 1-year as a continuous outcome, using linear 
regression techniques. However, the data collected for this parameter were extremely right skewed 
such that this approach was not feasible. The SGRQ-total score at 1-year was therefore modelled as a 
binary outcome in a logistic model: because no local normative data are available for the SGRQ, a cut 
off value of 6 was chosen, based on the mean total score quoted for a ‘normal’ individual with no 
history of respiratory disease in the SGRQ manual.156   
Similarly, the initial plan had been to model the factors predicting the presence of regular weekly, 
rather than regular monthly, respiratory symptoms at 1-year post treatment completion. In fact the 
prevalence of weekly symptoms was low (4.1% (15/368)), such that models would have been 
underpowered. Factors predicting ongoing monthly symptoms, seen in 113/368 individuals (30.7%), 
were therefore modelled instead.  
Lastly, the original data analysis plan for this study included construction of a model for incidence rates 
of respiratory exacerbations during the 1-year follow up, according to the person-time contributed by 
each participant. Within the cohort, a total of 62 participants experienced at least one unscheduled 
outpatient visit or admission for respiratory reasons (70 unscheduled respiratory outpatient visits 
across 57 individuals, and 11 unscheduled respiratory admissions across 11 individuals). This number 
was felt to be limited and logistic regression models exploring covariates associated with the presence 
/ absence of at least 1 respiratory event during the follow up period were constructed instead of using 
person-time analyses. Models included both individuals contributing full follow-up data for the 1-year 
(n=364) period, or 6-months’ data only (n=16), but because it is not possible to include person-time in 
a logistic model, these groups were not differentiated between.  
5.2.8 STUDY SIZE 
The sample size was calculated around the precision estimate for the binary PTLD variable at TB 
treatment completion. Assuming 400 participants completing baseline data collection, we anticipated 
being able to estimate a PTLD prevalence within the full patient cohort of between 10-50% with 5% 
precision and 95% confidence level (Table 9). 
Table 9: Power calculation for precision estimate at recruitment 
Confidence level Precision Prevalence Sample size 
95% 5% 10%  139 
  30%  323 
  50% 385 
A 20% loss to follow up was assumed over the 1-year study period, leaving 320 participants remaining 
at study completion. Assuming a baseline prevalence of PTLD of 30%, this would leave 96 participants 
with PTLD in the cohort at the 1-year time point. The feasibility of detecting differences in both binary 
119 
 
and continuous outcomes between groups with and without PTLD, given these numbers, was 
assessed. 
For binary outcomes: If the proportion of participants experiencing an adverse outcome (Eg. Impaired 
quality of life at 1-year, persistent chronic respiratory symptoms at 1-year, or ≥1 acute respiratory 
exacerbation over 1-year follow up) was assumed to be 30% amongst those with baseline PTLD and 
10% amongst those without PTLD, this sample size would allow us to detect a difference in proportions 
with 80% power and 5% significance.  
For continuous outcomes: A minimum of 36 individuals would be required in the smaller participant 
group (those with PTLD at baseline) would allow us to detect a difference 0.5 standard deviations 
between the means of continuous outcomes including the SGRQ total score and incidence rate of 
respiratory exacerbations in those with / without PTLD, and this sample size was therefore deemed 
sufficient. 
5.2.9 STATISTICAL METHODS 
All data analyses were performed in Stata v13.0 (Statacorp, 2013). 
DESCRIPTIVE ANALYSES OF CLINICAL DATA 
 PARTICIPANT CHARACTERISTICS 
Study numbers and follow up were outlined using a consort diagram. Baseline characteristics of the 
cohort were then described.  
 CLINICAL AND RESPIRATORY PARAMETERS 
Data on the clinical symptoms, quality of life, clinical measurements, blood results, 6MWT results, 
spirometry findings, and imaging data at each of the study visits were reported in turn, with population 
level change over time described for each. Where possible, data were stratified by baseline TB 
microbiology or HIV status. Groups were compared using the Chi2/Fisher’s exact tests (categorical 
variables), Wilcoxon rank-sum tests (non-parametric continuous variables), or t-tests (continuous 
variables with normal distribution). 
Spirometry findings were compared across reference ranges, and the age and gender stratified 
prevalence of obstruction and low FVC were calculated using the NHANES III Caucasian reference 
range for comparison with data from the Malawi BOLD study described in Chapter 4.  
Sensitivity analyses were performed to determine whether time to imaging and the CT scanner used 
were correlated with CT imaging findings, and whether patterns of CXR change over time varied 
amongst those who received digital imaging at both baseline and 1-year. 
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 HETEROGENEITY OVER TIME 
Individual level heterogeneity in the direction and magnitude of change over time were described, 
across parameters 
 PATTERNS OF PATHOLOGY 
Participant characteristics, quality of life and symptom scores, and CT imaging findings were compared 
between participants according to their pattern of spirometry at TB treatment completion in order to 
determine whether structural pathology and clinical presentation varied between groups. 
Comparisons were made between those with normal and abnormal spirometry, and between those 
with obstruction and low FVC patterns only. 
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DESCRIPTIVE ANALYSIS OF PARTICIPANT OUTCOME DATA 
Patterns of health service use, and the incidence of TB retreatment and all-cause mortality were 
described. 
FACTORS PREDICTING SPIROMETRIC DEFICITS 
Exploratory regression analyses were conducted to identify factors predicting residual spirometric 
deficits at TB treatment completion and 1-year post treatment completion, and factors associated 
with change over time between these two time points. Models were constructed with inclusion of a 
pre-specified set of predictors with no reduction strategy (Table 10). 
Table 10: Variables to be included in multivariate models of spirometry, for each time point 
Parameter 
Time point  
TB treatment completion Change over time 1-year post treatment completion 
Spirometry 
outcomes 
 
 
Linear regression: 
- Absolute FEV1 (ml) 
- Absolute FVC (ml) 
- FEV1/FVC ratio (%)  
 
Logistic regression: 
- Obstructive deficit 
- Low FVC deficit 
Linear regression: 
- Change in absolute FEV1 (ml) 
- Change in absolute FVC (ml) 
 
Linear regression: 
- Absolute FEV1 (ml) 
- Absolute FVC (ml) 
- FEV1/FVC ratio (%)  
 
Logistic regression: 
- Obstructive deficit 
- Low FVC deficit 
Covariates 
included to 
standardize 
spirometry 
Age 
Gender 
Height 
 
Age 
Gender 
Height 
 
Age 
Gender 
Height 
  
Covariates 
included for 
investigation 
HIV and CD4 count  
Baseline TB microbiology 
BMI at TB treatment 
completion 
Ever smoking 
Socioeconomic status  
Food instability 
Illness duration prior to 
treatment 
HIV and CD4 count  
Baseline TB microbiology 
BMI at TB treatment completion 
Ever smoking 
Socioeconomic status  
Food instability 
 
HIV and CD4 count  
Baseline TB microbiology 
BMI at TB treatment completion 
Ever smoking 
Socioeconomic status  
Food instability 
Illness duration prior to 
treatment 
 
Baseline spirometry - FEV1, FVC, 
ratio, or pattern of deficit 
 
Baseline CT pathology - 
parenchymal abnormality or 
bronchiectasis 
 
Events over 1-year follow up: 
acute respiratory exacerbation, 
TB retreatment   
 OUTCOMES 
Both linear regression models for absolute FEV1 and FVC volumes (ml) and FEV1/FVC ratio (%), and 
logistic regression models for the presence/absence of Obstructive and Low FVC patterns of 
spirometric deficits were built. Age, gender and height were included in all models to ‘standardise’ for 
these well-known determinants of lung volumes.  
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 COVARIATES 
The selection of participant characteristics to include in the models as covariates was hypothesis 
driven. 
- HIV status and CD4 count were combined into a single variable, in order to allow both parameters 
to be included within a combined model for HIV infected and uninfected participants.  
- Baseline TB microbiology was included as a binary variable, with participants defined as having 
positive microbiology if they were sputum smear, culture, or GeneXPert positive at diagnosis. 
- BMI at TB treatment completion was included as a marker of overall wellbeing, nutritional status, 
and muscle bulk at the end of treatment. Haemoglobin at treatment completion was included as 
a marker of general wellbeing, and a potential predictor of breathlessness.  
- Ever-smoking was included, but strong co-linearity with cannabis exposure meant that it was not 
possible to include the latter also. The quality of self-reported individual level biomass exposure 
obtained within the study was felt to be unreliable and therefore not included.  
- A binary variable for urban socioeconomic quintile was included to reflect limited wealth and 
associated exposures. Food insecurity was present if participants reported difficulty getting food 
within the past month sometimes or often, and included as a measure of acute poverty.  
- Illness duration prior to treatment was included as a binary variable due to the likely limited 
accuracy and low resolution of this variable. It was thought more likely to determine baseline 
spirometry, rather than change over time, and was therefore not included in models of the latter.  
In order to determine the extent to which the severity of lung pathology at TB treatment completion 
determines spirometry 1-year later, the following measures of baseline pathology were included in 
models of 1-year spirometry: 
- Spirometry at TB treatment completion: co-linearity between FEV1, FVC and FEV1/FVC ratio meant 
that all three parameters could not be included together in each model, and only the measure 
related to the parameter being modelled was therefore ‘controlled for’ (e.g. in a model for FEV1 
at 1-year, the FEV1 at treatment completion was controlled for) 
- CT pathology at TB treatment completion: the parameters of CT PTLD included within the a priori 
definition of disease (≥3 lobes with mod-severe bronchiectasis, ≥1/3 abnormal parenchyma) were 
included as simple measures of extensive baseline lung pathology 
Variables for ongoing respiratory exacerbations over the course of the 1-year period and recurrent TB 
disease were also included, as potential drivers of ongoing decline.  
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 MODEL BUILDING APPROACH 
The need for an interaction term between HIV and TB was investigated. Linear regression assumptions 
including the normality of residuals, homoscedasticity of and co-linearity between predictors, and the 
linearity of relationships between continuous predictor variables and the spirometric outcomes were 
investigated to ensure that models were appropriate. Primary data for outliers were reviewed, and 
data points excluded if errors suspected. 
All individuals with BOLD valid spirometry data at TB treatment completion were included in the 
models for spirometry at TB treatment completion (n=330). However, only those who had had 
completed BOLD standard spirometry at both treatment completion and the 1-year time points, and 
had been imaged with CT scanning at baseline were including in models for change over time, and 
spirometry at 1-year (n=290). Participants with missing HIV status (n=2) and SES (n=33) were excluded 
from analyses.  
Logistic regression models constructed for patterns of spirometric deficits included participants with 
either Obstruction vs. ‘normal’ spirometry, or Low FVC vs ‘normal’ spirometry at each time point.  
RELATIONSHIPS BETWEEN PTLD AND PATIENT-CENTRED OUTCOMES 
Multivariate regression models were built to determine the relationship between post-TB lung 
damage at TB treatment completion, and ongoing morbidity/mortality in the subsequent 1-year follow 
up period (Table 11). Exposure and outcome variables have been described above.  
Table 11: Variables to be included in multivariate models of patient-centred outcomes 
Parameter Exposure of interest Outcomes of interest Potential confounders 
Variables  Primary analysis: 
- Either spirometric OR CT 
PTLD at TB treatment 
completion 
 
Secondary analysis: 
- Spirometric PTLD  
- CT PTLD 
- Both spirometric and CT 
PTLD 
 
 
Quality of life at 1yr 
Chronic respiratory symptoms at 1 yr 
Acute respiratory exacerbations over1 
yr 
TB retreatment over 1yr 
All-cause mortality over 1yr 
 
Age 
Gender 
HIV and CD4 count (collapsed 
variable) 
Baseline TB microbiology 
BMI at TB treatment completion 
Hb at TB treatment completion 
Ever smoking 
Socioeconomic status  
Food instability 
Spirometric PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN) / Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) using 
GLI-2012 reference equations 
CT PTLD: Moderate-severe bronchiectasis in ≥3 lobes / parenchymal abnormality of ≥1/3 of the lung tissue, excluding 
mosaicism 
 MODEL BUILDING APPROACH 
Models were built in a stepwise process using pre-specified sets of predictors with no reduction 
strategy. A minimum number of potentially confounding patient and clinical characteristics were first 
included, followed by inclusion of the PTLD exposure parameter of interest.  
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The selection of participant characteristics to include in the models as covariates was hypothesis 
driven, and similar to that listed above. Because these models were aimed at identifying the 
relationship between PTLD at treatment completion and ongoing outcomes, no information on the 
duration of illness prior to treatment completion was included. 
All outcomes investigated here were binary, and logistic models were therefore used. The need for an 
interaction term between HIV and TB was investigated within each model, but no other interaction 
terms were tested.  
 MISSING DATA 
Baseline socioeconomic status was missing in 33 individuals who failed to complete the 6-month visit 
and therefore did not have their household data (floor, wall, and ceiling materials) completed. A high 
proportion of these participants missed this visit because they were unwell / died, and excluding their 
data was thought likely to bias model results. Data for the housing materials were therefore imputed 
for these individuals, and SES quintiles calculated. All models were constructed using this imputed 
data set. Two participants with missing HIV status were excluded from the analysis. No other data 
were found to be missing.    
Only individuals who had both valid spirometry and CT data at TB treatment completion were included 
in the analysis. 
 EXPLORATORY ANALYSES – SPECIFIC IMAGING / SPIROMETRY 
PARAMETERS 
Additional models were constructed to examine the relationship between specific CT and spirometry 
features of interest, rather than the a priori PTLD definition, and patient outcomes controlling for 
confounders. These models were exploratory, and generated in response to data findings rather than 
specified in the data analysis plan. The exposures of interest are listed below: 
- Bronchiectasis 
Models were constructed including bronchiectasis as an exposure in three different ways: using 
the number of lobes affected by moderate – severe bronchiectasis as a continuous predictor, 
using the presence of bronchiectasis affecting ≥3 lobes as a binary predictor, and using the whole 
lung bronchiectasis severity score as a continuous predictor.   
- Destroyed lobes 
The presence of ≥1 destroyed lobe with ≥90% parenchyma non-functioning due to atelectasis, 
parenchymal banding, or cavities / cystic airspaces was explored as a potential predictor of 
outcome.  
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- Potentially inflammatory pathology 
Exploratory models for the relationship between nodules seen on CT at treatment completion, 
the extent of ground glass and consolidation as a continuous variable, and the presence of ground 
glass or consolidation covering at least half of a lobe on baseline CT as a binary variable, and the 
outcomes of TB retreatment and death were constructed.  
- Spirometry 
Exploratory models were constructed using Obstruction and Low FVC patterns as distinct 
exposures of interest. Exploratory models were also constructed to investigate the relationship 
between FEV1 and FVC z-scores as continuous predictors of outcome.  
 DESCRIPTIVE ANALYSIS OF HEALTH ECONOMIC DATA 
Direct and indirect costs incurred by participants over the 1-year follow-up period were described, 
together with data on dissaving, in order to describe the financial impact of PTB disease beyond the 
end of TB treatment.  
5.3 RESULTS 
5.3.1 PARTICIPANTS 
Between 10th February 2016 and 27th April 2017, 450 individuals were referred by TB Officers for 
screening of whom 405 met eligibility criteria by the time of TB treatment completion and were 
included in the study (Figure 2). The 1-year follow-up of enrolled subjects was completed on 30th April 
2018.  
A total of 364/405 (89.9%) of participants completed all study visits and contributed outcome data for 
the full 1-year follow up period. A further 16/405 (3.9%) of participants contributed 6-months data 
only, including those who completed the first half of the study (n=12), and those who contributed data 
for the latter half (n=4). 25/405 (6.2%) participants completed the baseline study visit only and did not 
contribute any further data.  Amongst the 37/405 (9.1%) participants lost to follow up over the course 
of the study, 59.5% (22/37) were alive but relocated away from Blantyre, 29.7% (11/37) died, and 8.1% 
(3/37) withdrew. Contact was lost with only 1 participant. Limited data were available for the 45 
participants initially referred for recruitment, but who did not formally enter the study at TB treatment 
completion (n=45). No statistically significant differences were observed in median age (35yrs (IQR 28-
41) vs. 33yrs (IQR 28-41) years, p=0.865), or gender (67.9% vs. 60.0% male, p=0.284). 
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Figure 2: Flow diagram for study 
 
 
5.3.2 PARTICIPANT CHARACTERISTICS 
A total of 77.3% (313/405) of participants had had microbiologically confirmed disease at diagnosis. 
Of these, 68.1% (213/313) were diagnosed based on a positive sputum smear result and 31.9% 
(100/313) were diagnosed using XPert MTB-RIF testing (Table 12). No smear status was documented 
for the latter group, and 32.0% (78/244) of these individuals were HIV co-infected.  
Of the 91 participants in the cohort who had been started on TB treatment in the absence of 
microbiological confirmation, 58.2% (54/91) had been documented in the TB register as having 
radiological evidence of disease on CXR at treatment initiation.  
Table 12: Baseline TB diagnostics by HIV status 
Microbiological status Total HIV negative HIV positive p-value 
Microbiologically confirmed (n=313) 
- Smear positive, not specified 
- Scanty smear positive 
- Smear 1+ 
- Smear 2+ 
- Smear 3+ 
- Xpert MTB-RIF 
 
4 (1.3%) 
28 (9.0%) 
39 (12.5%) 
53 (16.9%) 
89 (28.4%) 
100 (31.9%) 
 
2 (1.4%) 
13 (9.4%) 
21 (15.1%) 
30 (21.6%) 
52 (37.4%) 
21 (15.9%) 
 
2 (1.4%) 
15 (8.7%) 
18 (10.4%) 
23 (13.3%) 
37 (21.4%) 
78 (45.1%) 
 
<0.001*** 
No microbiological confirmation (n=91) 
- Radiological diagnosis 
- Clinical diagnosis 
 
54 (58.2%) 
38 (41.8%) 
 
10 (50.0%) 
10 (50.0%) 
 
43 (60.6%) 
28 (39.4%) 
 
0.446 
*p<.05, **p<.01, ***p<.001 
The characteristics of the 405 participants completing baseline data collection are shown in Table 13, 
stratified by these baseline microbiology results.  
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Table 13: Participant characteristics, stratified by baseline TB microbiology 
Characteristic Total (n=405) 
Micro –ve 
(n=92) 
Micro +ve 
(n=313) p-value 
Demographics 
Age (yrs) 35 (28 – 41) 37.5 (32.5 – 43) 34 (28 - 39) <0.001*** 
Age group 
- 15-19yrs 
- 20-29yrs 
- 30-39yrs 
- 40-49yrs 
- 50-59yrs 
- 60yrs+ 
 
17 (4.2%) 
95 (23.5%) 
180 (44.4%) 
86 (21.2%) 
17 (4.2%) 
10 (2.5%) 
 
1 (1.1%) 
16 (17.4%) 
38 (41.3%) 
28 (30.4%) 
4 (4.4%) 
5 (5.4%) 
 
16 (5.15) 
79 (25.2%) 
142 (45.3%) 
58 (18.5%) 
13 (4.2%) 
5 (1.6%) 
 
0.017* 
Sex 
- Male 
- Female 
 
275 (67.9%) 
130 (32.1%) 
 
59 (64.1%) 
33 (35.9%) 
 
216 (69.0%) 
97 (31.0%) 
 
0.378 
TB variables from diagnosis 
Self-reported duration of illness prior to 
treatment initiation (weeks) 8.7 (4.3 – 13.0) 13.0 (4.3 – 26.1) 8.7 (4.3 – 13.0) 0.027* 
Location at diagnosis 
- Outpatient 
- Inpatient 
 
346 (85.4%) 
59 (14.6%) 
 
71 (77.2%) 
21 (22.8%) 
 
275 (87.9%) 
38 (12.1%) 
 
0.011* 
Steroid use during treatment 
- No 
- Yes 
- Unknown 
 
360 (88.9%) 
22 (5.4%) 
23 (5.7%) 
 
79 (85.9%) 
6 (6.5%) 
7 (7.6%) 
 
281 (89.8%) 
16 (5.1%) 
16 (5.1%) 
 
0.559 
HIV variables 
HIV status 
- Negative 
- Positive 
- Unknown 
 
159 (39.3%) 
244 (60.3%) 
2 (0.5%) 
 
20 (21.7%) 
71 (77.2%) 
1 (1.1%) 
 
139 (44.4%) 
173 (55.3%) 
1 (0.3%) 
 
<0.001*** 
ART use (n=244) 
- No 
- Yes 
 
20 (8.2%) 
224 (91.8%) 
 
9 (12.7%) 
62 (87.3%) 
 
11 (6.4%) 
162 (93.6%) 
 
0.102 
Co-trimoxazole use (n=234) 
- No 
- Yes 
 
23 (9.8%) 
211 (90.2%) 
 
11 (16.2%) 
57 (83.8%) 
 
12 (7.2%) 
154 (92.8%) 
 
0.037* 
Duration on ART (months) (n=221) 6.6 (5.5 – 24.6) 7.4 (6.1 – 25.6) 6.1 (5.5 – 24.0) 0.068 
CD4 if HIV-positive (cells/µL) (n=242) 229 (127 – 397) 206 (130 – 386) 233 (120 – 403) 0.514 
Respiratory exposures 
Ever smoking 
- Never 
- Ever 
 
285 (70.4%) 
120 (29.6%) 
 
77 (83.7%) 
15 (16.3%) 
 
208 (66.5%) 
105 (33.6%) 
 
0.001*** 
Pack years, amongst smokers (n=120) 2.7 (0.7 – 6.0) 3.0 (0.5 – 7.2) 2.6 (0.7 – 6.0) 0.407 
Ever smoked cannabis (n=362) 
- Never 
- Ever 
 
308 (85.1%) 
54 (13.3%) 
 
77 (92.8%) 
6 (7.2%) 
 
231 (82.8%) 
48 (17.2%) 
 
0.025* 
Cannabis exposure (Joints per day*years 
smoked) (n=54) 5.5 (2.0 – 15.0) 7.5 (3.0 – 14.0) 5.5 (2.0 – 15.5) 0.730 
Main fuel 
- Electricity 
- Charcoal 
- Wood 
 
21 (5.2%) 
338 (83.5%) 
46 (11.4%) 
 
8 (8.7%) 
74 (80.4%) 
10 (10.9%) 
 
13 (4.2%) 
264 (84.4%) 
36 (11.5%) 
 
0.225 
Existing diagnoses 
Chronic respiratory disease 9 (2.2%) 2 (2.2%) 7 (2.2%) 1.000 
Cardiac disease 1 (0.3%) 1 (1.1%) 0 (0.0%) 0.227 
Diabetes 6 (1.5%) 0 (0.0%) 6 (1.9%) 0.344 
*p<.05, **p<.01, ***p<.001 
 DEMOGRAPHICS 
The median age within the cohort was 35yrs (IQR 28-41). The overall proportion of males was 67.9% 
(275/405), and 4/130 of the female participants were pregnant at the time of TB treatment 
completion.  
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 HISTORY OF TB DISEASE 
Participants were unwell with symptoms include cough, weight loss or fever for a median of 8.7 weeks 
(IQR 4.4 – 13.0 weeks) before TB treatment initiation. Those who were microbiologically negative at 
diagnosis had a longer illness duration than those with microbiological confirmation of disease (13.0 
wks (IQR 4.3-26.1) vs. 8.7 wks (IQR 4.3-13.0), p=0.027). A total of 14.4% of the cohort had been 
admitted to QECH at the time of TB-diagnosis, including a higher proportion of HIV positives compared 
to HIV negatives (17.2% (42/244) vs. 10.1% (16/159), p=0.046). Only 5.4% (22/385) of the cohort had 
clearly documented use of steroids over the course of treatment. 
 HISTORY OF HIV DISEASE 
HIV-status was verified in 403 study participants, with 2 participants declining testing. A total of 60.3% 
(244/405) of the cohort confirmed to be HIV-infected at TB treatment completion. The highest HIV-
prevalence was seen in the 30-39-year (66.7%, 120/180) and 40-49-year (80.0%, 68/85) age groups 
(Figure 3).  
Figure 3: HIV prevalence by age group, at TB treatment completion (n=403) 
 
Amongst those who were HIV infected, 91.8% (224/244) were receiving ART and 86.5% (211/244) 
were taking co-trimoxazole. The date of ART treatment initiation was available for 221 participants, 
amongst whom median time on treatment was 6.6 months (IQR 5.5 – 24.6). That is, of the HIV positive 
participants within the cohort who were receiving ART, 40.3% (89/221) had started treatment 
after/together with TB treatment initiation, 25.8% (57/221) had started treatment within the 6-
months prior to TB diagnosis, and 33.9% (75/221) had started prior to this. CD4 cell counts were also 
available for 242/244 HIV-infected participants at TB treatment completion: median cell count was 
228 cells/µL (IQR 127-397), and 42% (102/242) of HIV-infected participants had a CD4 count which 
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remained below 200 cells/µL. The nadir CD4 count, documented within 1-month of HIV diagnosis, was 
available for only 61 participants with a median of 156 cells/µL (IQR: 79 – 246). 
 CIGARETTE SMOKING 
29.6% (120/405) of the cohort were ever-smokers, with median exposure of 2.6 pack-years (IQR: 0.7 
- 6.0) (Table 4). There was a strong gender gradient with 43.3% (119/275) of men and only 0.8% (1/130) 
of women reporting ever-smoking. The median number of cigarettes smoked per day was 4.5/day 
(IQR: 2.0 – 9.0/day), the median duration of smoking was 10yrs (IQR 5 – 16yrs). The median age of 
starting smoking was 21 years (IQR 18 – 25.5yrs), with no significant trend observed in the prevalence 
of ever smoking across the age groups.  Only 7/120 (5.8%) of ever-smokers confirmed that they were 
still smoking. The majority of ever-smokers used manufactured rather than hand rolled cigarettes 
(90%, 108/120) with 5% (6/120) using both.  
Ever smoking was more common amongst those with microbiologically confirmed PTB disease (33.6% 
(105/313) vs. 16.2% (15/92), p=0.001). This relationship persisted even when examined amongst men 
only. No difference in any measures of smoking exposure (pack-years, duration, cigarettes/day, age of 
onset) was observed between the two groups. Smoking was more common amongst the HIV-negative 
participants compared to the HIV positives (35.2% vs. 25.4%, p=0.034). However, this relationship 
appeared to be confounded by gender -  no difference was seen in the prevalence of ever smoking 
amongst HIV negative compared to positive women (0% vs. 1.2%, p-value 0.473), and whilst the 
prevalence of smoking remained higher amongst HIV negative compared to positive men (48.7% vs. 
38.6%), the p-value for this relationship was no longer significant (p=0.096). A strong socioeconomic 
gradient was observed in smoking exposure – the prevalence of ever-smoking was 34.6% (70/202) in 
the poorest 3 quintiles, compared to 22.4% (38/170) in the richest 2 quintiles (p=0.009).  
 CANNABIS USE 
Data on cannabis use was collected in 362/405 (89.4%) participants– the missing data was a result of 
the late addition of this variable to the data collection tool, rather than refusal to answer. Like smoking, 
cannabis use was seen mainly by men with ever use in 21.6% (53/245) of men and 0.9% (1/117) of 
women. The mean age of starting cannabis use was 19.5 years (IQR: 18-23yrs). The mean duration of 
use was 5 years (IQR: 2-8 years), and the median number of joints smoked per day was 1 (IQR:1 – 1). 
Cannabis use was lowest in the poorest socioeconomic quintile (5.3%, 1/19) but no trend was 
observed in the frequency of reported cannabis use across the other quintiles. 
Ever use of cannabis was positively correlated with positive TB microbiology at diagnosis: ever use was 
seen in 88.9% (48/279) of those with positive microbiology vs. 11.1% (6/83) in those without 
(p=0.025). More cannabis use was seen amongst HIV-negative participants (25.4%, 35/138) compared 
to HIV-positive participants (8.6%, 19/222) in univariate analysis (p-value <0.001). Tobacco smoking 
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and cannabis smoking were strongly correlated: 39.8% (41/103) of ever smokers reported ever use of 
cannabis compared to 5.0% (13/259) of never smokers (p<0.0001)  
 BIOMASS EXPOSURE 
The majority of individuals used charcoal (83.5%, 338/405) or wood (11.4%, 46/405) as their main fuel. 
All participants who said that their main fuel was electricity and 51.9% (210/405) of participants overall 
used multiple fuels. Although efforts were made to determine the duration and pattern of biomass 
exposure at an individual level, the quality of the final data collected were poor with conflation of 
individual and household level exposures which it was not possible to remedy through cleaning. These 
data were considered to provide inaccurate measures of exposure and are therefore not included 
here.  
 CARDIORESPIRATORY CO-MORBIDITIES 
42.7% (173/405) of individuals had a previous respiratory diagnosis, other than TB. The majority of 
previous respiratory illness episodes were due to infections with (32.8%, 133/405) of participants 
having had a previous pneumonia, or 7.2% (29/405) an upper/lower respiratory tract infection. Only 
9/405 (2.2%) of participants had been given any formal diagnosis of a chronic lung disease by the time 
of TB treatment completion: 4 had been diagnosed with bronchitis, and 5 with asthma. Only 5/405 
(1.2%) of participants were on regular respiratory medications: 1 was using oral salbutamol, 3 inhaled 
salbutamol, and 3 were on oral theophylines. 1 participant had a history of cardiovascular disease 
(cardiomegaly), and 1.5% (6/405) of participants had a history of diabetes.  
 SOCIOECONOMIC SITUATION 
Full data required to calculate the SES quintile were available for 91.9% (372/405) of participants; the 
remaining participants missed their 6-month home visit and therefore did not have their household 
wall / floor / roofing materials recorded. When the national wealth quintile score was used, 88.2% of 
participants for whom full data were available fell in to the wealthiest quintile for Malawi with no 
participants falling into the poorest group. Data were distributed more widely when the urban quintile 
tool was used but still relatively few participants were in the poorest (5.9%) quintile with the majority 
falling in the middle ranges (Table 14). 
SES appeared lower in those with microbiologically proven disease compared to those without: 90.9% 
(20/22) of the poorest quintile had microbiologically proven disease, compared to 66.1% (37/56) of 
the wealthiest cohort (p= 0.005). Stratification by HIV status reduces the strength of this association, 
with Chi2 p-values falling to 0.074 and 0.077 in the separate HIV negative and positive groups.  
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Table 14: Socioeconomic situation of study participants at TB treatment completion, stratified by baseline microbiology 
(n=405)  
Characteristic Total (n=405) 
Micro –ve 
(n=92) 
Micro +ve 
(n=313) p-value 
Urban SES quintile (n=372) 
- Poorest 
- 2nd poorest 
- Middle 
- 2nd most wealthy 
- Most wealthy 
 
22 (5.9%) 
85 (22.8%) 
95 (25.5%) 
114 (30.6%) 
56 (15.1%) 
 
2 (2.4%) 
14 (16.5%) 
15 (17.6%) 
35 (41.2%) 
19 (22.4%) 
 
20 (7.0%) 
71 (24.7%) 
80 (27.9%) 
79 (27.5%) 
37 (12.9%) 
 
0.005** 
Years formal education 10 (7 – 12) 10 (8 – 12) 10(7 – 12) 0.106 
Maximum education level 
- No school 
- Primary 
- Secondary 
- Higher 
 
14 (3.5%) 
140 (34.6%) 
207 (51.1%) 
44 (10.9%) 
 
3 (3.3%) 
27 (29.4%) 
48 (52.2%) 
14 (15.2%) 
 
11 (3.5%) 
113 (36.1%) 
159 (50.8%) 
30 (9.6%) 
 
0.383 
Difficulty getting food for 
household 
- Never 
- Sometimes  
- Often 
 
277 (68.4%) 
92 (22.7%) 
36 (8.9%) 
 
73 (79.4%) 
14 (15.2%) 
5 (5.4%) 
 
204 (65.2%) 
78 (24.9%) 
31 (9.9%) 
 
0.036* 
*p<.05, **p<.01, ***p<.001 
 EDUCATION 
The distribution of the number of years of formal education received was left skewed with a median 
of 10 years (IQR: 7 – 12 yrs), and 38% (154/405) had either no education or primary school education 
only. Wealth quintile was positively correlated with educational standards, as would be expected: the 
majority of participants in the poorest quintile received no/primary education only (77.3%, 17/22) and 
none went on to higher education, whilst amongst the richest all participants had attended school, 
with the majority receiving either secondary or higher education (87.5%, 49/56).  
 FOOD SECURITY 
Within the cohort 14.3% (58/405) of participants reported that adults in the household had skipped 
meals so that children could eat within the past fortnight, and when asked whether difficulty getting 
food for the household had been experienced within the past 1-month, 22.7% (92/405) said this was 
the case sometimes, and 8.9% (36/405) said that this was often the case. Difficulties were 
concentrated in the lower socioeconomic quintiles, with 49.5% (100/202) of participants in the lowest 
three SES groups experiencing challenges sometimes/often, compared to 12.4% (21/170) of those in 
the higher quintiles. Difficulty accessing food was seasonal with the greatest proportion of individuals 
experiencing difficulty highest amongst the summer months / rainy season. 
5.3.3 CLINICAL AND RESPIRATORY PARAMETERS OVER 1-YEAR 
In this section of the results, population level data are presented for quality of life and symptom 
assessments, clinical observations, measures of functional capacity, blood results, spirometry, and the 
CT and CXR imaging in turn. Data from baseline, 6-month and 12-month visits are presented together 
for each set of variables. The heterogeneity observed in change over time between individuals is 
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described across multiple parameters, and the relationship between symptom, imaging, and patterns 
of spirometry at TB treatment completion are then described.  
QUALITY OF LIFE DATA 
 GENERAL HEALTH 
When asked to rank their health on a Likert scale from poor to excellent, 28.4% (115/405) reported 
ongoing poor / fair health at TB treatment completion. This proportion fell to 6.0% (22/368) at the 1-
year follow up point, and trends were similar in both HIV-infected and HIV-negative participants 
(Figure 4).  
Figure 4: Self-reported general health at each study visit, stratified by HIV status (Baseline n=405, 6-months n=376, 12-months 
n=368)  
  
A similar proportion of individuals (28.2% (114/405)) were still missing work due to poor health at TB 
treatment completion, but this figure fell to 10.0% (37/368) by 1-year later. There was strong 
agreement between self-reported health related absence from work, and self-reported general 
health: combining data from all study visits, all of those with poor health had experienced time off 
work in the last month in relation to this (100% (4/4)), whilst only 6.5% (3/46) of the group with 
‘excellent’ self-reported health had taken time off work for health reasons in the past 1-month. 
 SGRQ RESULTS 
Data for all of the SGRQ summary scores were right skewed with the majority of participants having 
low values. Wide distributions were observed for each summary score at each time point, confirming 
significant heterogeneity across the cohort (Table 15): at TB treatment completion, the median SGRQ 
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total score was 8.7 (IQR 1.2 – 23.7) but scores ranged from 0 – 53.6/100. Amongst the sub scores, 
Symptom and Activity scores were higher than Impact scores throughout. 
Table 15: Population median (IQR) and [Full range] of the SGRQ summary scores for each study visit 
 Baseline 
(n=403) 
6-month 
(n=376) 
1-year 
(n=368) 
Symptom score 11.6 (3.0 – 26.0) [0 – 67.8] 
3.0 (0 – 15.4) 
[0 – 70.0] 
3.0 (0 – 15.4) 
[0 – 63.0] 
Activity score 11.2 (0 – 35.5) [0 – 73.7] 
0 (0 – 11.9) 
[0 – 86.5] 
0 (0 – 6.2) 
[0 – 93.9] 
Impact score 5.6 (0 – 15.5) [0 – 50.0] 
0 (0 – 6.5) 
[0 – 69.8] 
0 (0 – 3.7) 
[0 – 73.6] 
Total score 8.7 (1.2 – 23.7) [0 – 56.7] 
0.4 (0 – 10.8) 
[0 – 74.9] 
0.4 (0 – 7.0) 
[0 – 75.6] 
There was a general trend towards improvement – particularly over the first 6 months following 
treatment completion. By 1-year post TB treatment completion, the median total SGRQ score was 
0.40 (IQR: 0 – 7.0), with a total range from 0 – 76 points. There we no statistically significant differences 
in total SGRQ total scores between HIV infected / negative groups at any of the study visits, and the 
trend to improvement was similar in both groups (Figure 5).  
 
Figure 5: Box plots of SGRQ total and sub scores (symptom, activity, impact) across the three study visits, stratified by HIV 
status 
 
 
A high proportion of individuals scored ‘0’ for both sub and total SGRQ scores at each study visit, 
raising some concerns about the validity of the SGRQ data. However, when SGRQ scores were 
stratified by the Likert-score self-reported categories of health, these ‘zero’ values belong largely to 
those reporting good or excellent health (Figure 6).  
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Figure 6: SGRQ Total scores across all study visits (n=1147), stratified by self-reported general health at that time 
 
 
 EQ5D3L RESULTS 
23.6% (95/403) of individuals had challenges in mobility at the baseline visit and 11.7% (43/366) at the 
1-year visit using the EQ5D3L questionnaire. Pain, which was not assessed in the SGRQ, was reported 
by 18.5% (74/400) / 15.3% (56/366) of individuals at baseline / 1-year. In keeping with the SGRQ data 
the parameter of health least affected was the ability to self-care – very few individuals had any 
problems with this at any of the study visits. Also, in keeping was a trend to improvement across study 
visits, with the percentage of participants reporting problems in any of these dimensions decreasing 
in the first 6-months in particular (Figure 7). The EQ5D3L results from the anxiety/depression score 
are difficult to interpret: this symptom appears common across all study visits within the dataset, with 
less resolution over time, but there was some concern from amongst the study team that these 
concepts – even after translation and previous validation of this tool in the local language, Chichewa 
– were difficult for study participants to grasp, and as such confidence in the accuracy of this measure 
is limited.  
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Figure 7: EQ5D3L results, across serial study visits 
  
A negative correlation was observed between the EQ5D3L Visual Analogue Score (VAS) and the SGRQ 
total score (Pearson’s correlation coefficient: -0.44, p<0.001) (Figure 13). VAS scores were clustered 
around the 10-unit intervals corresponding to the layout of the VAS scale on the scoring sheet, which 
highlights these intervals (Figure 8).  
Figure 8: Scatter diagram illustrating the relationship between the SGRQ Total score and the EQ5D3L visual analogue score 
(VAS), with data combined across study visits (n=1144), accompanied by a visual representation of the VAS score on the 
scoring sheet 
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CLINICAL SYMPTOM DATA 
At TB treatment completion 60.7% (246/405) of participants continued to experience at least 1 
respiratory symptom for at least a few days each month, and 7.7% (31/405) reported symptoms on 
several or most days each week. Although the burden of monthly and weekly symptoms was slightly 
lower amongst HIV positives vs. negatives, the difference was not statistically significant (monthly: 
58.2 vs. 64.8%, p=0.186 / weekly: 5.7% vs. 10.7%, p=0.068).  
The prevalence of symptoms decreased over time such that 30.7% (113/368) had monthly and 4.1% 
(15/368) weekly symptoms by the 1-year follow up point. The most common regular symptom was 
shortness of breath, which was experienced monthly or weekly in 39.8% and 4.2% of participants at 
baseline, and 23.4% and 2.7% of participants at the 1-year point. Wheeze was the least common 
symptom throughout. Self-reported sputum production was infrequent, and was experienced 
monthly by 12.8% (47/368) and weekly by 0.8% (3/368) of the cohort by the 1-year time point (Figure 
9). 
Figure 9: Self-reported frequency of respiratory symptoms, at each study visit 
 
Breathlessness when sitting still, washing, walking inside the house, or performing activities of 
personal care was rare at all study visits. Few participants were breathless when walking outside on 
the flat (1.2% (5/403) at baseline / 2.7% (10/368) at 1-year), but a higher proportion of participants 
needed to walk slower than peers or stop for rest when walking at their own pace at all study visits 
(26.8% (108/403) at baseline / 17.4% (64/368) at 1-year). Breathlessness when going up hills was 
reported by 43.7% (176/403) at baseline and 22.6% (83/368) at 1-year (Figure 10).  
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Figure 10: Proportion of participants experiencing breathlessness, or need to stop/slow down with various activities, at each 
study visit 
 
  
 
The psychological impact scores were the lowest out of the three SGRQ subgroup scores. At TB 
treatment completion 14.4% (58/403) were ashamed of their chest issues and 26.6% (107/403) felt 
that their chest issues were a nuisance. A trend to improvement was seen over time such that by 1-
year, 9.8% (36/368) felt ashamed, and the same number found their chest to be a nuisance by this 
time point. 15.2% (61/403) felt frail at TB treatment completion, falling to 5.2% (19/368) by 1-year 
(Figure 11). The majority of individuals retained a sense of hope that things would improve, 
throughout the study period. 
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Figure 11: Proportion of participants experiencing psychosocial issues related to ongoing respiratory problems.  
 
 
At the time of TB treatment completion, 40.0% (162/405) of study participants had chest symptoms 
that interfered with their work / preventing them from working, and 12.2% (45/368) of participants 
reported symptoms at the 1-year time point.  
Over half of the cohort (50.4% (205/405)) felt that their usual activities were limited at TB treatment 
completion, but this proportion fell to 19.8% (73/368) by 1-year. Specific challenges raised by 
participants on open questioning included: difficulty farming (19.4% (78/403 at TB treatment 
completion / 4.1% (15/368) at 1-year), and difficulty lifting heavy items (18.4% (74/403) at TB 
treatment completion / 7.1% (26/368) at 1-year). 
CLINICAL OBSERVATIONS 
 VITAL SIGNS 
Heart rate was normally distributed across the population with mean values of 79 beats per minute 
(SD: 15.4) / 78bpm (SD:14.2) and 77bpm (SD: 13.8) at each of the study visits. The prevalence of 
tachycardia (heart rate >100 beats per minute) declined over the 1-year period from 8.9% (36/405) at 
TB treatment completion to 3.5% (13/368) at the 1-year follow up (p=0.002).  
Tachypnoea (respiratory rate >20 breaths per minute) was seen in only 21.8% (88/404) of individuals 
at baseline, but was observed in 28.2% (106/376) at 6-months, and 46.7% (172/368) at the 1-year 
study visit (p<0.001). Oxygen saturations were normally distributed with mean values at sequential 
139 
 
study visits of 97.8% (SD: 1.6%), 97.8% (SD: 1.5%), and 97.4% (SD: 2.2%). Only 1.5% (6/405) individuals 
at TB treatment completion and 0.8% (3/368) at the 1-year visit had saturations which were ≤92% at 
rest.   
 BMI AND MUAC 
BMI at TB diagnosis had been recorded within routine clinical services for 88.6% (359/405) 
participants, with a median value of 18.6 kg/m2 (IQR: 16.7 – 20.3 kg/m2). BMI was lower in those with 
microbiologically proven PTB disease, compared to those with negative microbiology (18.4 vs. 19.6 
kg/m2, p=0.016) at this time (Table 16).  
BMI at TB treatment completion was measured in the full study cohort, with a median value of 20.5 
kg/m2 (IQR: 19.0-22.3 kg/m2). At this point, 17.5% (71/405) of participants were underweight with BMI 
<18.5 kg/m2, and 6.4% (30/405) were overweight or obese with BMI ≥25.0 kg/m2. Lower BMI values 
were seen amongst those reporting difficulties procuring food often compared to those with no 
difficulties (19.4 kg/m2 vs. 20.8 kg/m2, p=0.003). No relationship was observed between baseline 
microbiology and BMI at TB treatment completion. 
Table 16: BMI and MUAC measurements at TB treatment completion, stratified by baseline microbiology 
Characteristic Total (n=405) 
Micro –ve 
(n=92) 
Micro +ve 
(n=313) p-value 
BMI recorded at TB diagnosis (kg/m2)  
(n=359) 18.6 (16.8-20.3) 19.6 (16.7 – 21.4) 18.4 (16.8 – 20.1) 0.016* 
BMI (kg/m2) 20.5 (19.0 – 22.3) 20.9 (18.9 – 22.7) 20.4 (19.0 – 22.1) 0.067 
BMI categories  
- Underweight (<18.5 kg/m2) 
- Normal (18.5 – 24.9 kg/m2) 
- Overweight (25 – 29.9 kg/m2) 
- Obese (≥30 kg/m2) 
 
71 (17.5%) 
304 (75.1%) 
25 (6.2%) 
5 (1.2%) 
 
16 (17.4%) 
63 (68.5%) 
12 (13.0%) 
1 (1.1%) 
 
55 (17.6%) 
241 (77.0%) 
13 (4.2%) 
4 (1.3%) 
 
0.026 
Mid-upper arm circumference (MUAC) (cm) 24.6 (23.3 – 26.4) 25.1 (23.3 – 27.2) 24.6 (23.3 – 26.3) 0.335 
*p<.05, **p<.01, ***p<.001 
A general trend to improvement in BMI was observed over the 1-year follow up period, with an 
average increase of 0.7kg/m2. No difference in BMI was noted between HIV positive and negative 
individuals at TB diagnosis but BMI recordings for HIV-positive participants were higher than those for 
HIV-negative participants at all subsequent study visits (p<0.05 for all visits) (Figure 12). This 
relationship persisted with stratification for gender (not shown).  
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Figure 12: BMI measurements at TB diagnosis and at each study visit from TB treatment completion, stratified by HIV status 
  
 
Median MUAC at TB treatment completion was 24.6cm (IQR: 23.3 – 26.4). A strongly positive linear 
correlation was observed between MUAC and BMI measurements across study visits, with a Pearson 
correlation coefficient of 0.79, and a 0.86 kg/m2 (95% CI: 0.79 - 0.92) increase in BMI for every 1cm 
increase in MUAC.  
 FOCUSED CLINICAL EXAMINATION  
Pitting pedal oedema to the level of the ankles or shins was found in 1.7% (7/405) of participants at 
TB treatment completion, and 0.8% (3/368) participants with mild oedema of their ankles were 
observed at the 1-year study visit. Palatal Kaposi’s Sarcoma was observed in 2.0% (8/405) participants 
at TB treatment completion, and 0.3% (1/368) of participants at the 1-year study visit.  
MEASURES OF FUNCTIONAL CAPACITY 
The full six-minute walk test was completed by 97.3% (395/405) and 96.5% (355/368) participants at 
TB treatment completion and at the 1-year visit, respectively. Data for the distance walked were 
normally distributed. A mean distance of 568m (SD: 79.7m) and 611.2m (SD: 71.0m) was walked at TB 
treatment completion and at the 1-year study visit, respectively (p<0.001). The mean improvement 
observed over the 1-year period was 41.3m (SD:62.6m). The proportion of individuals with saturations 
≤92% at the end of the walk were 3.8% (15/395) and 2.8% (10/355) at these two time points.  Women 
walked shorter distances than men at both study visits (p<0.001 for both). No statistically significant 
differences in distance were identified by HIV status, after stratifying for gender (Figure 13). 
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Figure 13: 6-minute walking distance at baseline and 1-year study visits, according to gender and HIV status.  
 
 
The maximum heart rate reached during the 6MWT was positively correlated with the 6MWD 
achieved (Spearman’s r=0.221, p<0.001) across all study data (Figure 14), confirming that the distance 
walked increases as cardiovascular effort increased. At TB treatment completion the median % 
maximum heart rate was 53.6% (IQR 45.1-62.0%), and at the 1-year visit this was 57.0% (IQR 50.0 – 
65.1%), in keeping with a higher level of exercise intensity at the 1-year time point.  
Figure 14: Correlation between exercise intensity and 6-minute walking distance achieved, across both study visits (1 data 
point per patient visit, with up to 2 measures per patient)  
 
There was no clear correlation between walking distance and BMI after controlling for gender. 
However, a strong positive correlation was observed between Haemoglobin and walking distance: 
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after controlling for gender, a 1-unit increase in haemoglobin was associated with a 6.7m longer 
walking distance (95% CI: 3.2 – 10.2, p<0.001).  
Across both baseline and 1-year study visits, the distance walked was lower in those who had reported 
the need to stop or slow down when walking on the flat (569m vs. 598m, p<0.001), and those who 
reported breathlessness walking up hills (570m vs. 601m, p<0.001) compared to those who did not 
report these limitations. Weak negative correlations were observed between the 6MWD and the 
various SGRQ summary scores (-0.19 to -0.22, all p<0.001). 
5.3.4 BLOOD TESTS 
The mean haemoglobin (Hb) within the cohort was 13.7 g/dL (IQR: 12.3 – 15.1), and values were lower 
in HIV-infected participants (median 13.0 vs. 14.6 g/dL, p<0.001). Platelet and neutrophil levels were 
higher in the HIV-positive group, but lymphocyte counts were lower (1.8 vs. 1.9 x109 cells/L). There 
was no significant difference in the eosinophil counts between the groups (Table 17). Preliminary 
Aspergillus serology assays found that 2/404 samples were positive using the Bio-Rad assay (cut off 
10AU/ml), and 3/404 samples were positive using the Bordier assay at TB treatment completion.  
Table 17: Blood results at TB treatment completion 
Parameter HIV negative (n=159) HIV positive (n=244) P-value for comparison 
Haemoglobin (g/dL)  14.6 (13.3 – 15.6) 13.1 (11.7 – 14.5) <0.001*** 
Platelets (109/L) 234 (175 – 307) 277 (216 – 338) <0.001*** 
White cell count (109/L) 4.4 (3.6 – 5.1) 4.0 (3.3 – 5.0) 0.044* 
Neutrophil count (109/L) 1.8 (1.3 – 2.4) 1.9 (1.4 – 2.6) 0.010* 
Lymphocyte count (109/L) 1.9 (1.5 – 2.4) 1.8 (1.3 – 2.2) 0.004** 
Eosinophil count (109/L) 0.1 (0.1 – 0.3) 0.1 (0.1 – 0.3) 0.399 
*p<.05, **p<.01, ***p<.001 
5.3.5 SPIROMETRY 
Spirometry was attempted by 98.8% (399/405) / 96.9% (364/376) / 96.2% (354/368) at each of the 
three study visits. Post-bronchodilator spirometry data of sufficient quality (2 usable curves with 
repeatability for both FEV1 and FVC) were available for 90.1% (365/405) of participants at baseline, 
90.7% (341/376) of participants at the 6-month visit, and 91.3% (336/368) of participants completing 
the 12-month visit. 75.3% (305/405) of the cohort contributed BOLD valid readings at both TB 
treatment completion, and the 1-year follow up period. Participant characteristics were similar, except 
for a slightly higher proportion of males amongst those with valid data at both time points (70.5%vs. 
60.0%, p=0.051) (Table 18). 
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Table 18: Comparison of patient characteristics, for those with / without BOLD valid post-bronchodilator FEV1 and FVC 
readings at both TB treatment completion and the 1-year time point 
 BOLD valid 
spirometry missing 
from one time point 
(n=100) 
BOLD valid 
spirometry 
complete at TB Rx 
completion and 1-
year (n=305) 
p-value  
Age (median, IQR) 33 (28 – 38) 35 (29 – 41) 0.094 
Male gender (n, %) 60 (60.0%) 215 (70.5%) 0.051 
HIV infected (n, %) (n=403) 55 (55.6%) 189 (62.2%) 0.242 
Microbiological evidence of PTB at diagnosis (n, %) 76 (76.0%) 237 (77.7%) 0.724 
BMI at TB treatment completion (kg/m2) (median, IQR) 20.8 (19.1 – 22.6) 20.4 (18.9 – 22.2) 0.280 
Total abnormal parenchyma (0-600) (median, IQR) 125 (30 – 248) 145 (60 – 233) 0.357 
Presence of any moderate-severe bronchiectasis (n, %) 31/85 (36.5%) 139/300 (46.3%) 0.106 
SGRQ total score (median, IQR) 12.5 (1.2 – 26.6) 7.9 (1.1 – 22.9) 0.146 
Regular monthly respiratory symptoms (n, %) 63 (63.0%) 183 (60.0%) 0.594 
The mean z-scores for the FEV1 readings, FVC readings, and FEV1/FVC ratios were negative at all study 
visits, confirming that the volumes measured were lower than the age, gender and height 
standardised expected values provided by the GLI-2012 black reference ranges at all three study visits 
(Table 19). The parameter with the lowest z-scores was the FEV1 volume which was, on average 1.06 
standard deviations (SD 0.69) below the expected mean FEV1 value at the point of TB treatment 
completion and remained on average 0.88 standard deviations lower (SD:1.19) than expected by the 
1-year follow up point. Both the FEV1 and FVC increased over the course of the study, with a larger 
mean increase in the FVC compared to the FEV1 (0.20 (SD:0.55) vs. 0.33 (SD: 0.55) z-scores). Changes 
in the FEV1 and FVC z-scores were statistically significant (t test p-values: 0.043 / <0.001), but the 
change in the FEV1/FVC ratio was not.  
Table 19: Average spirometry readings for each study visit, reported as absolute values and z-scores after standardization with 
the GLI-2012 Black reference ranges, with average difference measured between baseline and 1-year 
Variable  
TB treatment 
completion (mean, 
sd) (n=365)  
6 months  
(mean, sd) (n=341) 
12 months  
(mean, sd) (n=336) 
Average change, over 1-year 
follow up (mean, sd) (n=305) 
Absolute 
value  
Z-
score 
Absolute 
value 
Z-
score 
Absolute 
value  Z-score 
Absolute 
difference  
Z-
score 
p-value 
for 
difference 
in z-scores 
FEV1 (L) 2.57 (0.69) 
-1.06 
(1.26) 2.63 (0.68) 
-0.90 
(1.25) 2.63 (0.67) 
-0.88 
(1.19) 
0.07 
(0.24) 
0.20 
(0.55) 0.043* 
FVC (L) 3.18 (0.78) -0.91 (1.23) 3.29 (0.78) 
-0.66 
(1.19) 3.31 (0.76) 
-0.61 
(1.09) 
0.15 
(0.27) 
0.33 
(0.55) <0.001*** 
FEV1/FVC  
(%) 80.87(8.92) 
-0.38 
(1.26) 79.85(9.30) 
-0.51 
(1.28) 79.54(9.55) 
-
0.54(1.29) 
-1.37 
(4.26) 
-0.17 
(0.66) 0.086 
*p<.05, **p<.01, ***p<.001 
Population distributions of both the FEV1 and FVC z-scores were lower in the HIV-negative compared 
to HIV-infected groups throughout all study visits (mean FEV1 -1.27 vs -0.94, p= 0.015; mean FVC -1.08 
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vs -0.80, p= 0.037) (Figure 15). The whiskers of these box plots are very wide for each group at each 
time point, reflecting the heterogeneity of ‘standardised’ z-scores between individuals.  
Figure 15: Box plots of FEV1, FVC, and FEV1/FVC ratio z-scores, stratified by HIV status, over time 
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PATTERNS OF SPIROMETRIC DEFICIT 
Abnormal spirometry at TB treatment completion was seen in 34.2% (125/365) of participants: 20% 
(73/365) and 14.2% (52/365) had a low FVC and obstructive pattern, respectively. In keeping with the 
changes in the distribution of z-scores presented above, the proportion of participants in the low FVC 
group decreased to 12.8% (43/336) by 1-year, whilst the proportion of participants classified as having 
airway obstruction rose to 17.9% (60/336) (Table 20). 
Table 20: Proportion of participants with abnormal spirometry at each of the study visits, classified using the 5th centile lower 
limit of normal (LLN) cut offs calculated using the GLI-2012 reference ranges. 
Pattern TB treatment 
completion(n=365) 
6 months 
(n=341) 
12 months 
(n=336) 
Obstruction 52 (14.2%) 61 (17.9%) 60 (17.9%) 
Low FVC 73 (20.0%) 45 (13.2%) 43 (12.8%) 
Normal 240 (65.8%) 235 (68.9%) 233 (69.4%) 
The proportion of participants with abnormal spirometry was higher amongst HIV-negatives 
compared to HIV-positives at all time points. However, the pattern of change over time with falling 
numbers in the low-FVC group and rising numbers classified as having obstruction was similar in both 
groups (Figure 16). 
Figure 16: Proportion of participants falling into each category of spirometric deficit, at each study visit, stratified by HIV 
status 
 
At an individual level, the majority of participants remained in the same category over the course of 
the study (Table 21). Recovery from an abnormal to normal pattern was more common amongst those 
originally in the low FVC group (31.7%, 19/60) compared to the obstructed group (16.3%, 7/43) at TB 
treatment completion. Amongst the 18 individuals found to have ‘new’ obstruction over the course of 
the study, only 50% (9/18) had experienced a true decline in their FEV1 z-score over this period. The 
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other half had experienced an improvement in both FEV1 and FVC but with a disproportionate rise in 
the latter and a corresponding fall in their FEV1/FVC ratio.   
Table 21: Relationship between spirometry pattern at TB treatment completion, and that measured at 1-year, in participants 
for whom BOLD valid readings were available for both study visits (n=305). Boxes highlighted in grey imply no change in 
classification over the 1-year follow up period. 
Spirometry at TB 
treatment completion 
Spirometry 1-year post treatment completion 
Obstruction Low FVC Normal TOTAL 
Obstruction 36 (83.7%) 0 7 (16.3%) 43 (100%) 
Low FVC 3 (5.0%) 38 (63.3%) 19 (31.7%) 60 (100%) 
Normal 15 (7.4%) 3 (1.5%) 184 (91.1%) 202 (100%) 
TOTAL 54 (17.7%) 41 (13.4%) 210 (68.9%) 305 (100%) 
REVERSIBILITY 
Amongst those with airway obstruction at TB treatment completion (FEV1/FVC ratio<LLN), the 
prevalence of reversibility was 5.8% (3/52) at TB treatment completion, 1.6% (1/61) at 6-months, and 
8.3% (5/60) at the 1-year follow-up point.  
COMPARISON BETWEEN REFERENCE RANGES 
The GLI-2012, NHANES III African American, and Malawian reference ranges lead to broadly similar 
data distributions with similar mean FEV1 values of 85.2 – 86.0% predicted, and FVC values of 86.7 – 
89.1% predicted. However, due to larger predicted lung volumes, standardisation using the NHANES 
III Caucasian ranges produces a lower mean FEV1 of 72.8% predicted and FVC of 73.8% predicted 
(Figure 17). The difference in the mean % predicted scores derived from the GLI-2012 and NHANES III 
Caucasian reference ranges is statistically significant for both the FEV1 (mean 85.2% vs. 72.8%, 
p<0.001) and FVC (mean 88.2% vs.73.8%, p<0.001).  
Figure 17: Distribution of % predicted values of FEV1 and FVC at TB treatment completed, calculated using different reference 
ranges. 
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When participants are classified according to their pattern of deficit using LLN cut-off values, the GLI-
2012, NHANES African, and Malawi reference ranges produce similar results, but a higher proportion 
of participants are allocated to the Low FVC group when the NHANES III Caucasian reference range is 
used (NHANES Caucasian: 66.9%, 244/365 vs. GLI-2012: 20.0% (73/365)) (Figure 18).  
Figure 18: Prevalence of spirometric patterns at TB treatment completion, defined using LLN cut offs from different reference 
ranges 
 
When % predicted cut offs are used to define the severity of FEV1 impairment, a larger proportion of 
individuals are classified as having ‘severe’ airflow obstruction with FEV1<50% predicted if the NHANES 
III Caucasian reference range is used. Of note - no participants were classified as having ‘Very Severe’ 
airflow obstruction using any of the reference ranges (Table 22).  
Table 22: Severity classification amongst the 35 participants with a fixed FEV1/FVC ratio<0.7 at TB treatment completion 
Severity classification GLI-2012 NHANES III African American Malawi 
NHANES III 
Caucasian 
FEV1≥80% 10 (28.6%) 10 (28.6%) 9 (25.7%) 5 (14.3%) 
50%≤ FEV1 <80% 19 (54.3%) 19 (54.3%) 19 (54.3%) 17 (48.6%) 
30%≤ FEV1 <50% 6 (17.1%) 6 (17.1%) 7 (20.0%) 13 (37.1%) 
FEV1<30% 0 0 0 0 
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COMPARISON WITH LOCAL BOLD DATA 
Age stratified spirometry findings from TB treatment and 1-year time point are shown in Table 23, 
standardized by NHANES III Caucasian reference ranges, and are compared with data from the 2013-
14 urban Blantyre BOLD study.  
Table 23: Comparison of the age- stratified prevalence estimates of moderate-severe airway obstruction and spirometric 
restriction, within this study cohort and the survey weighted prevalence estimates from the 2013-2014 BOLD study in urban 
Blantyre.  
Age group 
(n at 
baseline / 
1-year) 
Mod-severe obstruction 
FEV/FVC<0.7 and FEV1<80% predicted 
Low FVC 
FEV1/FVC>=0.7 and FVC<80% predicted 
Post-TB data set 
TB Rx completion 
% (SE) 
Post-TB data 
set 
1-year f’up 
% (SE) 
BOLD data 
set 
% (SE) 
Post-TB data 
set 
TB Rx 
completion 
% (SE) 
Post-TB data 
set 
1-year f’up 
% (SE) 
BOLD data 
set 
% (SE) 
15-19yrs 
(n=17/13) 11.8% (7.8%) 15.4% (10.0%) - 82.4% (9.2%) 61.5% (13.5%) - 
20-29yrs 
(n=83/77) 4.8% (2.4%) 6.5% (2.8%) 2.4% (1.0%) 71.1% (5.0%) 64.9% (5.4%) 32.7% (4.0%) 
30-39yrs 
(n=160/147) 7.5% (2.1%) 8.8% (2.3%) 2.9% (1.5%) 64.4% (3.8%) 55.8% (4.1%) 42.0% (3.8%) 
40-49yrs 
(n=79/75) 11.4% (3.6%) 16.0% (4.2%) 2.3% (0.9%) 62.0% (5.5%) 41.3% (5.7%) 28.3% (4.4%) 
50-59yrs 
(n=17/15) 11.8% (7.8%) 13.3% (8.8%) 9.8% (2.8%) 17.6% (9.2%) 6.7% (6.4%) 39.4% (6.6%) 
60+yrs 
(n=9/9) 11.1% (10.5%) 33.3% (15.7%) 12.0% (4.4%) 33.3% (15.7%) 33.3% (15.7%) 13.8% (6.4%) 
The prevalence of obstructive and low FVC patterns was higher at TB treatment completion and 1-
year later in the majority of age strata within this post-TB cohort, compared to that seen in the BOLD 
community sample. The low FVC pattern appears to be more common than obstructive spirometry in 
most age strata, within both the BOLD community sample, and this cohort of post-TB participants.  
5.3.6 CT IMAGING 
HRCT imaging findings are presented before CXR findings as this test is the ‘gold standard’ for the 
diagnosis of structural pathology and was performed at TB treatment completion only.  
CT IMAGING LOCATION  
A total of 385 CT scans were completed, including 148 (38.4%) at the Blantyre Adventist Hospital (BAH) 
in Blantyre, and 237(61.6%) at Kamuzu Central Hospital (KCH) in Lilongwe. Time to CT scanning is 
shown in Table 24 – over three quarters of the imaging was completed within 2-months of TB 
treatment completion.  
Random review of CT radiation doses administered to participants at both locations showed that 
exposures were within normal range and below UK safety thresholds. 
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Table 24: Time to CT imaging, weeks (n=385) 
Time from baseline visit to CT imaging Number (%) 
≤4 weeks 186 (48.3%) 
4-8 weeks 113 (29.4%) 
8-12 weeks 29 (7.5%) 
12-16 weeks 33 (8.6%) 
>16 weeks 24 (6.2%) 
 
MISSING CT DATA 
CT imaging was missed for 20 participants (Table 25). The category of ‘Physical comorbidity’ includes 
one elderly participant and another alcohol dependent participant, neither of whom were fit for the 
return journey to Lilongwe for imaging during the period when the more remote KCH facility was being 
used. The category of ‘Machine error’ includes one participant who was scanned but images lost, 
together with 2 participants who were not scanned as the CT machine was broken at the time they 
attended for imaging, and they declined / were unable to re-attend on other dates.  
Table 25: Reasons for missing CT data (n=20) 
Reason for absence of CT scan Number 
Pregnant 3 
Unable to travel to imaging facility – comorbidities 2 
Unable to travel to imaging facility – participant location 4 
Study team unable to contact participant 2 
Did not attend, despite booking 1 
Booking error – missed bookings 5 
Machine error  3 
Total 20 
 
There were no significant differences in demographic and clinical characteristics of participants who 
missed vs completed imaging (Table 26).  
Table 26: Comparison of participant characteristics, for those who missed CT imaging 
Characteristic Scan completed (N=385) Scan missed (n=20) p-value 
Age (median, IQR) 34 (28-40) 36 (28-42) 0.715 
Male gender (n,%) 262 (68.0%) 13 (65.0%) 0.776 
HIV infected (n, %) (n=403) 235 (61.4%) 9 (45.0%) 0.145 
CD4 cell count (g/dL) (median, IQR)  226 (122-392) 375 (182-484) 0.308 
Microbiological evidence of PTB at diagnosis (n, %) 299 (77.7%) 14 (70.0%) 0.425 
BMI at TB treatment completion (kg/m2) 20.5 (18.9 - 22.3) 20.9 (19.8 - 23.1) 0.149 
FEV1 z-score (median, IQR) -1.04 (-1.96 - -0.14) -1.33 (-1.72 - 0.27) 0.780 
FVC z-score (median, IQR) -0.84 (-1.6 -  - 0.15) -1.03 (-1.65 - 0.38) 0.662 
FEV1/FVC z-score (median, IQR) -0.30 (-1.08 – 0.38) -0.09 (-1.21 - 0.41) 0.808 
SGRQ total score (median, IQR) 8.9 (1.2-23.6) 5.9 (1.4 - 26.7) 0.755 
Regular monthly respiratory symptoms (n, %) 234 (60.8%) 12 (60.0%) 0.945 
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CT INTER-READER AGREEMENT 
A total of 239/385 (62.1%) of scans were selected for consensus review of at least 1 variable in ≥1 
lobe.  Levels of inter-reader agreement, and the number of lobes for which there were clean reads 
(with either identical scores from original readers, or a score confirmed by consensus review) varied 
widely between variables (Table 27). 
Table 27: Inter-reader agreement measures, for variables reported in the original CT scoring system 
Pathology Variable Measure of inter-reader 
consistency for whole-lung 
variable 
ICC (95% CI) OR 
Kappa (SE)* 
Number of lobes for which clean reads 
available (RUL/RML/RLL – LUL/Lingula/LLL) 
 
n (%) of scans with all lobes having clean 
reads 
Parenchymal variables 
Atelectasis Whole lung score  
(0-600) 
ICC: 0.81 (0.77-0.84) R lobes: 308 / 330 / 334 
L lobes: 308 / 321 / 332 
Clean reads all lobes: 177/385 (46.0%) 
Cavities / cystic air spaces Whole lung score  
(0-600) 
ICC: 0.81  (0.77-0.84) R: 344 / 378 / 370 
L: 349 / 380 / 375 
Clean reads all lobes: 301/385 (78.2%) 
Normal parenchyma Whole lung score  
(0-600) 
ICC: 0.80  (0.76 – 0.83) R:183 / 161 / 172 
L: 196 / 208 /186 
Clean reads all lobes: 73/385(19.0%) 
Mosaicism Whole lung score  
(0-600) 
ICC: 0.55 (0.48-0.62) R: 236 / 242/232 
L: 234 / 259 / 226 
Clean reads all lobes:105/385 (27.3%) 
Emphysema Whole lung score  
(0-600) 
ICC: 0.50 (0.42 – 0.57) R: 335 / 372/ 364 
L: 339 / 375 / 363 
Clean reads all lobes:291/385 (75.6%) 
Ground glass Whole lung score  
(0-600) 
ICC: 0.49 (0.41 – 0.57) R: 353 / 367 / 366 
L: 362/366 / 360 
Clean reads all lobes: 292/385 (75.8%) 
Consolidation Whole lung score  
(0-600) 
ICC: 0.43 (0.34 – 0.51) R 311 / 346 / 338 
L: 301 / 338 / 342 
Clean reads all lobes: 194/385 (50.4%) 
Parenchymal banding Whole lung score  
(0-600) 
ICC: 0.43 (0.35 -0.51) R: 221/204/232 
L: 231 / 244/ 238 
Clean reads all lobes: 86/385 (22.3%)  
Emphysematous 
destruction 
Whole lung score  
(0-600) 
ICC: 0.27 (0.18 – 0.36) R: 379 / 380 / 378 
L: 374 / 384 / 371 
Clean reads all lobes: 346/385 (89.9%) 
Airway variables 
Bronchiectasis Total extent score (0-18) Weighted kappa : 0.72 
(0.05) 
R: 296 / 340/ 324 
L: 297 / 337 / 321 
Clean reads all lobes: 195/385 (50.7%) 
Total severity score (0-18) Weighted kappa: 0.66 
(0.05) 
R: 281 / 315 / 299 
L: 266 / 307 / 292 
Clean reads all lobes: 133/385 (34.6%) 
Lobar bronchiectasis pattern, 
if mod-severe bronchiectasis 
seen 
N/a R:  41/78 (52.6%); 7/15 (46.7%); 16/35 
(45.7%) 
L: 42/80 (52.5%); 29/39 (74.4%); 25/39 
(64.1%) 
Airway plugging Total severity score (0-18) Weighted kappa: 0.51 
(0.05) 
R: 284 / 328 / 302 
L: 280 / 313 / 313 
Clean reads all lobes: 153/385 (39.7%) 
Tree in bud Total severity score (0-18) Weighted kappa: 0.45 
(0.04) 
R: 217 / 247 / 226 
L: 219 / 248 / 225 
Clean reads all lobes: 67/385 (17.4%) 
Bronchial wall thickening Total severity score (0-18) Weighted kappa: 0.42 
(0.05) 
R: 193 / 248 / 228  
L: 198 / 226 / 205 
Clean reads all lobes: 73/385 (19.0%) 
Airway narrowing Total extent score (0-18) Weighted kappa: 0.17 
(0.03) 
R: 378 / 383 / 377 
L: 367 / 383 /381 
Clean reads all lobes: 349/385 (90.7%) 
Other variables 
Cavities Total extent score (0-18) Weighted kappa: 0.65 
(0.04) 
R: 359 / 383 / 372 
L: 362 / 380 / 371 
Clean reads all lobes: 327/385 (84.9%) 
Mycetoma presence / 
absence, if cavities seen 
Kappa: 0.49 (0.05) R: 98/100 (98.0%); 16/16 (100%); 32/32 
(100%) 
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L: 103/105 (98.1%); 25/26 (96.2%); 44/44 
(100%) 
Nodules Total pattern score (0-18) Weighted kappa: 0.65 
(0.05) 
R: 267 / 320 / 304 
L: 274 / 315/ 291 
Clean reads all lobes: 115/385 (29.9%) 
Pleural pathology Presence / absence Kappa: 0.60 (0.05) 368/385 (95.6%) 
Lymphadenopathy Presence / absence Kappa: 0.17 (0.05) 339/385 (88.1%) 
*ICC - intra-class correlation coefficient. Weighted kappa scores calculated using quadratic wgt(w2) function in Stata v13. 
 
 PARENCHYMAL VARIABLES 
The greatest level of agreement was seen for atelectasis, cavity / cystic airspace, and normal 
parenchymal scores at the whole lung level (ICC ≥0.8). Agreement on the amount of mosaicism, 
emphysema, ground glass change, consolidation, and parenchymal banding was reasonable (ICC 0.43 
– 0.55). The variable ‘emphysematoid destruction’ had a very low ICC of 0.27 (95% CI: 0.18-0.36). 
Some systematic differences in the reporting approaches of the two original readers were noted in 
analysis. For example, reader 1 allocated higher scores for parenchymal banding whilst reader 2 
allocated higher scores for consolidation. This likely reflects differences in interpretation, but it is not 
possible to way in which this differential allocation of scores has happened, and therefore no variables 
were collapsed or adjusted to compensate for this.    
 AIRWAY VARIABLES 
Weighted Kappa scores were high for the whole lung airway dilatation severity and extent scores (0.72 
and 0.66), and reasonable for airway plugging and tree in bud severity scores (0.45 – 0.51). The number 
of individual lobes in which absolute agreement was achieved for these variables was, however, low 
throughout.  
The kappa score was only 0.17 for the whole lung airway narrowing score – this variable was therefore 
not consensus reviewed and was not used in further analyses. 
A ‘clean’ report on the pattern of bronchiectasis was achieved for 55.9% (160/286) of lobes with 
moderate – severe bronchiectasis. Discrepant reporting of cystic bronchiectasis – the pattern with 
greatest prognostic significance – was common, but no systematic over / under reporting by either 
reader was observed.  
At least one reader felt that it was not possible to score bronchial wall thickness in at least 1 lobe in 
58/385 (15.1%) of scans, and whole lung bronchial wall thickening severity scores were therefore not 
available for these scans. The majority of participants who had missing data for this variable were HIV 
negative (54.4%, 31/57). The total amount of abnormal parenchyma seen in these scans was more 
extensive than that in scans where bronchial wall thickening was fully reported (parenchymal score of 
277.5/600 vs. 112.5/600, p<0.001), and they were more likely to contain at least one extensively 
damaged or ‘destroyed’ lobe (46.5% vs 2.7%, p<0.001). This is consistent with the observation that 
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where there is extensive surrounding parenchymal pathology, it is often not possible to interpret the 
thickness of the bronchial wall itself. 
 OTHER VARIABLES 
Levels of agreement for cavity, nodule, and pleural scores were reasonable, with kappa values ranging 
from 0.49 – 0.65.  The level of agreement for the presence / absence of mediastinal lymphadenopathy 
– which is usually identified using CT imaging with contrast – was extremely low (Kappa 0.17). This 
variable was not consensus reviewed and was not used in further analysis.  
CT RESULTS 
There was a high prevalence of residual pathology seen on CT imaging at the point of TB treatment 
completion: only 13/385 participants (3.4%) had completely normal parenchyma, and only 3.4% 
(13/385) of the cohort had completely normal airways.  
The median abnormal parenchymal score was 137.5/600 (IQR: 55.0 – 235.0) suggesting that on 
average, participants had the equivalent of 1.4 lobes of abnormal tissue on their imaging. Atelectasis 
and banding, and mosaicism were the dominant patterns seen. 9.3% (36/385) of the cohort had at 
least one lobe in which ≥90% of parenchyma was non-functioning and had been replaced by banding, 
atelectasis, or cavities / cystic airspaces (Table 28).  
A total of 44.2% (170/385) of the cohort had moderate to severe airway dilatation, or bronchiectasis, 
in at least 1 lobe, and 7.5% (29/385) of participants had bronchiectasis affecting ≥3 lobes. 
Data from the ‘final’ dataset are presented here, stratified by HIV status. No data are presented for 
airway narrowing and lymphadenopathy as these had very poor inter-reader agreement and were 
therefore felt to be inaccurate measures and not consensus reviewed. Data for emphysematoid 
destruction are presented – this had low levels of inter-reader agreement, but was consensus 
reviewed, and continues to contribute to the overall abnormal parenchyma scores, but it must be 
interpreted with caution.  
 
Table 28: CT imaging final score results, by HIV status (both CT and HIV status available for n=383 individuals) 
Pathology  All scans (n=385) 
Median (IQR) 
[Full range] 
HIV non-reactive 
(n=148), Median (IQR) 
HIV reactive (n=235), 
Median (IQR) 
p-value 
Parenchymal pathology scores, whole lung level† 
Atelectasis and banding score (0-600)~ 45.0 (17.5 – 85.0) 
[0.0 – 320.0] 
55.0 (35.0 – 105.0) 
[0.0 – 320.0] 
35.0 (15.0 – 70.0) 
[0.0 – 260.0] 
<0.001*** 
Cavities / cystic air spaces score (0-600) 0.0 (0.0 – 10.0) 
[0.0 – 280.0] 
5.0 (0.0 – 16.3) 
[0.0 – 280.0] 
0.0 (0.0 – 5.0) 
[0.0 – 165.0] 
<0.001*** 
Mosaicism score (0-600) 32.5 (5.0 – 85.0) 
[0.0 – 325.0] 
40.0 (12.5 – 91.3) 
[0.0 – 252.5] 
27.5 (2.5 – 75.0) 
[0.0 – 325.0] 
0.024* 
Emphysema score (0-600) 0.0 (0.0 – 5.0) 
[0.0 – 430.0] 
0.0 (0.0 – 2.5) 
[0.0 – 385.0] 
0.0 (0.0 – 5.0) 
[0.0 – 430.0] 
0.016* 
Ground glass score (0-600) 0.0 (0.0- 5.0) 
[0.0 – 270.0] 
0.0 (0.0 – 5.0) 
[0.0 – 165.0] 
0.0 (0.0 – 5.0) 
[0.0 – 270.0] 
0.276 
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Consolidation score (0-600) 5.0 (0.0 – 12.5) 
[0.0 – 110.0] 
5.0 (0.0 – 12.5) 
[0.0 – 110.0] 
5.0 (0.0 – 12.5) 
[0.0 – 75.0] 
0.128 
Emphysematous destruction score (0-600) 0.0 (0.0 – 2.5) 
[0.0 – 165.0] 
0.0 (0.0 – 5.0) 
[0.0 – 120.0] 
0.0 (0.0 – 2.5) 
[0.0 – 165.0] 
0.119 
Total normal parenchyma score (0-600) 463.5 (3650 – 545.0) 
[0.0 – 600.0] 
420.0 (353.8 – 518.8) 
[0.0 – 600.0] 
490 .0 (372.5 – 560.0) 
[25.0 – 600.0] 
<0.001*** 
Total abnormal parenchyma score (0-600)# 137.5 (55.0 – 235.0) 
[0.0 – 600.0] 
180.0 (81.3 – 246.3) 
[0.0 – 600.0] 
110.0 (40.0 – 227.5) 
[0.0 – 575.0] 
<0.001*** 
Total abnormal parenchyma score, 
excluding mosaicism (0-600) 
72.5 (30.0 – 150.0) 
[0.0 – 600.0] 
93.8 (47.5 – 180.0) 
[0.0 – 600.0] 
60.0 (22.5 – 130.0) 
[0.0 – 540] 
<0.001*** 
Number of ‘destroyed’ lobes$ 
0 
1 
2 
3 
 
349 (90.7%) 
27 (7.0%) 
6 (1.6%) 
3 (0.8%) 
 
126 (85.1%) 
15 (10.1%) 
4 (2.7%) 
3 (2.0%) 
 
222 (94.5%) 
11 (4.7%) 
2(0.9%) 
0 (0%) 
 
0.009** 
Airway scores, whole lung level 
Bronchiectasis extent score (0-18) 2.5 (0.5 – 4.5) 
[0.0 – 15.5] 
3.0 (2.0 – 5.5) 
[0.0 – 15.5] 
1.5 (0.0 – 4.0) 
[0.0 – 13.5] 
<0.001*** 
Bronchiectasis severity score (0-18) 2.5 (0.5 – 5.0) 
[0.0 – 15.5] 
3.5 (1.5 – 6.0) 
[0.0 – 15.5] 
2.0 (0.0 – 4.0) 
[0.0 – 14.5] 
<0.001*** 
Number of lobes with moderate - severe 
bronchiectasis^ 
0 
1 
2 
3 
4 
5 
6 
 
 
215 (55.8%) 
101 (26.2%) 
40 (10.4%) 
17 (4.4%) 
8 (2.1%) 
2 (0.5%) 
2 (0.5%) 
 
 
65 (43.9%) 
47 (31.8%) 
24 (16.2%) 
8 (5.4%) 
3 (2.0%) 
0 (0.0%) 
1 (0.7%) 
 
 
149 (63.4%) 
54 (23.0%) 
15 (6.4%) 
9 (3.8%) 
5 (2.1%) 
2 (0.9%) 
1 (0.4%) 
 
 
0.004** 
Any moderate-severe cystic bronchiectasis 
^^ 
No 
Yes 
 
336 (87.3%) 
49 (12.7%) 
 
120 (81.1%) 
28 (18.9%) 
 
215 (91.5%) 
20 (8.5%) 
 
 
0.003** 
Bronchial wall thickening severity score (0-
18)@(n=327) 
3.0 (1.5 – 5.5) 
[0.0 – 14.5] 
3.0 (1.5 – 5.5) 
[0.0 – 13.5] 
3.0 (1.0 – 6.0) 
[0.0 – 14.5] 
0.388 
Tree in bud severity score (0-18) 3.5 (1.5 – 6.0) 
[0.0 – 17.0] 
4.5 (2.5 – 6.5) 
[0.0 – 14.5] 
3.0 (1.0 – 6.0) 
[0.0 – 17.0] 
<0.001*** 
Airway plugging severity score (0-18) 1.0 (0.0 – 2.0) 
[0.0 – 12.0] 
1.0 (0.5 – 2.5) 
[0.0 – 9.0] 
1.0 (0.0 – 2.0) 
[0.0 – 12.0] 
0.020* 
Other variables, whole lung level 
Presence of mycetoma 
No 
Yes 
 
380 (98.7%) 
5 (1.3%) 
 
144 (97.3%) 
4 (2.7%) 
 
234 (99.6%) 
1 (0.4%) 
 
0.003** 
Presence of any nodules  
No 
Yes 
Unclear 
 
 
64 (16.6%) 
228 (59.2%) 
93 (24.2%) 
 
30 (20.3%) 
88 (59.5%) 
30 (20.3%) 
 
33(14.0%) 
139 (59.2%) 
63 (26.8%) 
 
 
0.154 
Presence of miliary nodules 
No 
Yes 
 
381 (98.9%) 
4 (1.0%) 
 
148 (100.0%) 
0 (0.0%) 
 
231 (98.3%) 
4 (1.7%) 
 
0.111 
Presence of pleural pathology (effusions or 
thickening) 
No 
Yes 
 
 
354 (92.0% 
31 (8.1%) 
 
 
136 (91.9%) 
12 (8.1%) 
 
 
216 (91.9%) 
19 (8.1%) 
 
 
0.994 
*p<.05, **p<.01, ***p<.001 
†Parenchymal score off 100 is equivalent to one lung lobe. Total possible score across the lung, including all 6 lobes, is 600.  
~Atelectasis and banding reported separately, but data presented together due to conflation in reporting 
#Sum of scores for all parenchymal pathologies, including atelectasis, parenchymal banding, cavities/cystic airspaces, 
mosaicism, emphysema, ground glass opacification, consolidation, and emphysematoid destruction 
$Destroyed lobe is one in which ≥90% of parenchyma is occupied by banding, atelectasis, or cavities / cystic airspaces 
^Bronchiectasis classified as present if average severity score between two readers, or consensus score, was ≥2, so on average 
bronchial lumen considered to be 2-3 times adjacent vessel diameter in these lobes 
^^Present if moderate to severe bronchiectasis seen in at least 1 lobe, and pattern here deemed to be cystic based on initial 
agreement between readers or consensus review of scans, or random selection of initial reader reports where disagreement 
seen but absence of consensus review 
@Absent for scans where unable to report wall thickness in at least 1 lobe, therefore likely biased towards milder pathology 
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 PARENCHYMAL PATHOLOGY 
There was a large degree of heterogeneity in the extent of each pattern of pathology, within the 
cohort: all data were right skewed with most participants having small volumes of pathology, but wide 
distributions were seen for both HIV infected and uninfected groups, and a subset of individuals were 
observed to have extensive ongoing abnormality with each pattern (Figure 19). The most extensive 
pathologies observed in both groups were atelectasis and banding, followed by mosaicism. 
Statistically lower amounts of atelectasis and banding, cavities and cystic airspaces, and mosaicism 
were noted in HIV infected adults, compared to HIV uninfected adults (median: 55.0 vs. 35.0, p<0.001 
/ 5.0 vs. 0.0, p<0.001 / 40.0 vs. 27.5, p<0.001). However, this pattern was reversed for emphysema, 
where the IQR of the extent of pathology was marginally but statistically higher for the HIV-infected 
group. No differences were seen in the extent of ground glass opacification and consolidation between 
HIV infected / uninfected groups.  
Figure 19: Box plots of the total extent of patterns of parenchymal pathology, stratified by HIV status, seen on CT imaging at 
TB treatment completion 
 
 
Focal residual destruction of an individual lung lobe was common (Figure 20), with a higher prevalence 
in HIV negatives compared to HIV positives (15% (22/148) vs. 5.6% (13/235)). A total of 3/385 (0.8%) 
of participants, all of whom were HIV negative, completed TB treatment with 3 lobes or the equivalent 
of a hemithorax being destroyed.  
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Figure 20: Paired X-rays and CT slices from participants with at least one destroyed lung lobe  
 
 
 AIRWAYS PATHOLOGY ON CT 
A wide range of severities of airway dilatation, airway plugging, and tree in bud were observed (Figure 
21). The median bronchiectasis severity score was higher in HIV negative compared to HIV positive 
individuals (3.5 vs. 2.0/18, p<0.001), and the proportion of participants with moderate to severe 
airway dilatation documented in at least 1-lobe was also higher amongst the HIV-negative group 
(56.1%(83/148) vs. (36.6% (86/235), p=0.004). 
Figure 21: Box plots of airway pathology severity scores, seen on CT imaging at TB treatment completion, stratified by HIV 
status 
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Amongst the scans in which it was reported, no difference in the bronchial wall thickening severity 
scores were observed between HIV infected and uninfected groups. However, as noted above the 
majority of participants who had missing data for this variable were HIV negative, and also had more 
severe parenchymal pathology, such that these data could be biased. A close relationship was 
observed between bronchial dilatation and bronchial wall thickening on images (Figure 22). 
Figure 22: Axial slices from CT images of participants with bronchiectasis and bronchial wall thickening  
 
Cystic bronchiectasis was seen in 12.7% (49/385) participants at TB treatment completion, and was 
more common in HIV negative compared to HIV positive individuals, although these data need to be 
interpreted with some caution, given the limitations of measurement and discrepancies in the 
reporting of pattern outlined above.  
 OTHER PATHOLOGIES  
59.2% (228/385) had nodules confirmed by both readers / reported by the consensus scorer at TB 
treatment completion, but no difference in prevalence was seen between those with and without HIV 
infection.  
A miliary pattern of pathology was seen in 4 individuals. One was restarted on TB treatment during 
the 1-year follow up interval, with respiratory symptoms and signs consistent with disseminated TB 
disease and an ongoing positive Xpert MTB test. None of the other three individuals were restarted 
on treatment – all were followed up for the full 1-year period and remained alive, suggesting that 
these imaging findings may not infact have been related to active TB disease.   
Residual pleural pathology – thickening or effusion – was seen in 8.1% (31/385) of participants only. 
This was rarer than anticipated, particularly as this pathology was defined as present if either reader 
reported it as such. No difference was seen by HIV status.  
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Mycetoma were rare, and their presence agreed on in only 1.3% (5/385) participants. Interestingly, 
none of these participants had positive or borderline positive immunology on aspergillus serology 
assays.   
RELATIONSHIPS BETWEEN CT VARIABLES 
A heat map showing the relationships between key airway and parenchymal pathologies, represented 
by pairwise Pearson correlation coefficients between variables reported at the whole lung level, is 
shown below (Figure 23).  
Figure 23: Heat map of Pearson correlation coefficients between CT pathologies reported at the whole lung level. All 
highlighted variables have statistical significance with p-value<0.05, and are positive in value. (n=385). 
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 RELATIONSHIPS BETWEEN PARENCHYMAL VARIABLES 
The extent of atelectasis and banding was highly correlated with other parenchymal pathologies 
including the extent of consolidation (Pearson’s correlation coefficient R:0.427, p<0.001). The extent 
of cavities or cystic airways was also weakly associated with both the amount of atelectasis and 
banding (R: 0.299, p<0.001), and consolidation (R: 0.182, p<0.001).  
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Ground glass opacification and mosaicism were the most independent patterns, with few correlations 
with other parenchymal parameters. Mosaicism and emphysema – two pathologies which can be 
associated with airway obstruction on spirometry – did not appear to be correlated with each other, 
suggesting that they did not tend to occur together.  
 RELATIONSHIPS BETWEEN AIRWAY VARIABLES 
Bronchiectasis extent and severity scores were very strongly correlated with each other (Pearson’s R: 
0.929, p<0.001) suggesting that participants with more BP segments affected also had a greater 
degree of airway dilatation. The severity score only was therefore used in further analyses. 
The severity scores for all four patterns of airway pathology (airway dilatation, bronchial wall 
thickening, airway plugging, and tree-in-bud change) were correlated with each other: Pearson’s R 
values ranged from 0.377 – 0.448, and all were significant at p<0.001 (Figure 24).   
Figure 24: Scatter plots of relationships between whole lung severity scores for airway pathologies (n=385 /n=327 for 
bronchial wall thickening graphs) 
 
 
 RELATIONSHIPS BETWEEN PARENCHYMAL AND AIRWAY VARIABLES 
The strongest correlations seen between airway and parenchymal variables were observed between 
the bronchiectasis severity score, and the extent of atelectasis/ banding (Pearson’s R: 0.657, p<0.001), 
and cavities/cystic airspaces (R: 0.504, p<0.001). These relationships remained present when data 
were examined at a lobar level (Figure 25), suggesting that these patterns occur together in the lung.  
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Figure 25: Heat map showing associations between airway severity and parenchymal extent scores reported on CT imaging, at 
the lobar level within scans. All highlighted variables have p-value<0.05, and are positive in value. Legend as above. (n=385 / 
327 for bronchial wall thickening variables) 
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 RELATIONSHIPS WITH NODULES AND PLEURAL PATHOLOGY 
The odds of having nodules reported were higher in individuals with more extensive atelectasis and 
banding (OR 1.01 for a 1-unit increase in parenchymal score, p=0.001), consolidation (OR 1.05, 
p=0.001), and mosaicism (OR 1.01, p-0.008). A consistently positive relationship was observed 
between the presence of nodules and the severity scores of all four patterns of airway pathology (OR 
1.14 – 1.31, with p-values from <0.001 to 0.026). 
Pleural pathology was positively associated with atelectasis/banding (OR 1.01, p<0.001), and cavities 
and cystic airspaces (OR 1.01, p=0.002). Amongst the airway pathologies was positively correlated with 
the airway dilatation severity score only (OR 1.11, p=0.035). The odds of having pleural pathology were 
over 8-fold higher amongst those with mycetoma (OR 8.07, 95% CI: 1.30 - 50.2), but mycetoma were 
rare within this cohort: amongst the 5 participants with this finding, only 2 were seen to have 
concurrent pleural thickening.  In these two participants, the areas of pleural thickening are extremely 
near to the location of the mycetoma – whilst this might suggest invasive fungal disease, aspergillus 
serology was negative in both individuals.   
CT SENSITIVITY ANALYSES 
 TIME TO SCANNING 
No significant differences in participant characteristics including age, gender, HIV status, baseline TB 
microbiology or BMI at treatment completion were observed between those imaged within 1-month 
of treatment completion (n=186) vs. those imaged after this time (n=199). Ground glass opacification 
was more extensive in those who were imaged later with a wider IQR observed (0-5.0 vs. 0-2.5/600, 
p=0.012) but no other differences in parenchymal or airway parameters were identified  
 SCANNING LOCATION 
Participant characteristics and imaging features were compared between participants scanned in each 
of the two CT-imaging locations (Table 29). Those imaged in Blantyre waited longer to be imaged. A 
slightly higher proportion of participants with microbiologically proven disease was seen amongst 
those travelling to Lilongwe (81.9% vs. 71.0%, p=0.012), but groups were otherwise similar.  
Comparisons of imaging results suggests small but statistically larger amount of emphysema observed 
on the Lilongwe scans, but more extensive ground glass change, and higher bronchial wall thickening 
and airway plugging scores on the Blantyre scans.  
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Table 29: Comparison of participant and imaging features between those imaged locally in Blantyre, and those imaged in 
Lilongwe (n=385) 
Characteristic Blantyre (n=148) 
Median (IQR) / N 
(%) 
Lilongwe (n=237) 
Median (IQR) / N 
(%) 
p-value 
Participant characteristics 
Age (median, IQR) 36 (28-41) 34 (29-40) 0.488 
Male gender (n,%) 96 (64.9%) 166 (70.0%) 0.289 
HIV infected (n, %) (n=383) 86 (58.5%) 149 (63.1%) 0.365 
Microbiological evidence of PTB at diagnosis (n, %) 105 (71.0%) 194 (81.9%) 0.012* 
BMI at TB treatment completion (kg/m2) 20.5 (18.7 – 22.3) 20.5 (19.0 – 22.2) 0.890 
Time to imaging (weeks) 6.5 (4.0-12.7) 3.6 (1.7-5.1) <0.001*** 
Imaging features with statistically significant differences between groups 
Emphysema 0 (0-1.3) 0 (0-5.0) <0.001*** 
Ground glass opacification 0 (0-5.0) 0 (0-2.5) 0.010* 
Bronchial wall thickness severity 3.5 (1.5 – 6.0) 3 (1.0-5.5) 0.022* 
Airway plugging severity 1.5 (0.5 – 3.0) 0.5 (0-2.0) <0.001*** 
*p<.05, **p<.01, ***p<.001 
 
5.3.7 CXR IMAGING 
CXR IMAGING TYPE 
403/405 individuals were imaged at TB treatment completion, and 361/368 at 1-year. Amongst the 
359 participants imaged at both study visits, 26.2% (94/359) received digital imaging at both time 
points (Table 30).  
Table 30: Imaging type by study visit 
Baseline study visit 1-year study visit Total 
Digital image Hard image No imaging 
Digital image 94 145 35 274 (67.7%) 
Hard image 120 0 9 129 (31.9%) 
No imaging 2 0 0 2 (0.5%) 
Total 216 (53.3%) 145 (35.8%) 44 (10.9%) 405 (100.0%) 
MISSING CXR DATA 
On average, those who did not receive CXR imaging at both time points (n=46) had a higher SGRQ total 
score (15.9 vs. 8.1, p=0.035) and a non-significantly higher prevalence of monthly symptoms (73.9% 
vs. 59.1%, p=0.052) compared to those who were imaged at both time points (n=359) (Table 31).  
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Table 31: Comparison of participant characteristics, for those with / without CXR imaging available at both TB treatment 
completion and the 1-year time point 
 CXR missing from at 
least 1 time point 
(n=46) 
CXR available for 
both time points 
(n=359) 
p-value  
Age (median, IQR) 34.5 (27.0 – 41.0) 35.0  (29.0 – 40.0) 0.686 
Male gender (n, %) 29 (63.0%) 246 (68.5%) 0.454 
HIV infected (n, %) (n=403) 25 (55.6%) 219 (61.2%) 0.467 
Microbiological evidence of PTB at diagnosis (n, %) 34 (73.9%) 279 (77.7%) 0.562 
BMI at TB treatment completion (kg/m2) (median, IQR) 20.7 (19.4 – 22.3) 20.5 (18.8 – 22.3) 0.475 
FEV1 z-score at TB treatment completion (median, IQR) -0.92 (-1.69 - -0.10) -1.07 (-1.96 - -0.13) 0.581 
FVC z-score at TB treatment completion (median, IQR) -0.82 (-1.63 – 0.02) -0.87 (-1.61 - -0.18) 0.429 
SGRQ total score (median, IQR) 15.9 (5.1 – 26.1) 8.1 (0.9 – 23.2) 0.035* 
Regular monthly respiratory symptoms (n, %) 34 (73.9%) 212 (59.1%) 0.052 
*p<.05, **p<.01, ***p<.001 
 
CXR INTER-READER AGREEMENT 
203/403 (50.4%) of the baseline and 218/361 (60.4%) of the 1-year images were selected for 
consensus review of at least 1 variable in ≥1 zone. Levels of agreement between the two readers are 
presented below. Data are presented separately for the images collected at baseline and 1-year, and 
the number of zones / images for which there was a ‘clean read’ available after consensus review are 
shown (Table 32). The range of ICC and Kappa values for the variables reported are similar to those 
observed in the CT data reporting described above.  
Table 32: Individual reader and consensus data for the whole-lung variables scored on CXR at TB treatment completion, and 
the 1-year time point 
Pathology Variable 
Baseline CXR (n=403) 1-year CXR (n=361) 
Inter-reader 
consistency, 
whole-lung 
variable 
 
ICC# (95% CI) 
/ 
Kappa^ (SE) 
# Zones for which clean reads 
available  
(Right upper/ middle/lower – 
Left upper/middle/lower) 
 
% of scans with all lobes 
having clean reads 
Inter-reader 
consistency, 
whole-lung 
variable 
 
ICC# (95% CI) 
/ 
Kappa^ (SE) 
# zones for which clean reads 
available  
(Right upper/ middle/lower – 
Left upper/middle/lower) 
 
% of scans with all lobes 
having clean reads 
Parenchymal 
banding 
Whole lung 
score  
(0-600) 
ICC: 0.40  
(0.31-0.48) 
R: 384/391/384 
L: 380/386/372 
Clean reads all lobes:  
302 (74.9%) 
ICC: 0.38  
(029 – 0.47) 
R: 340/348/344 
L: 338/350/343 
Clean reads all lobes: 
277(76.7%) 
Consolidation / 
ground glass 
Whole lung 
score  
(0-600) 
ICC: 0.73 
(0.68-0.77) 
R: 325/328/341 
L: 339/332/353 
Clean reads all lobes:  
183 (45.4%) 
ICC: 0.52  
(0.44 - 0.59) 
R: 309/331/323 
L: 313/332/325 
Clean reads all lobes:  
203 (56.2%) 
Cavities / cystic air 
spaces 
Whole lung 
score  
(0-600) 
ICC: 0.89  
(0.87-0.91) 
R: 379/393/398 
L: 383/390/400 
Clean reads all lobes:  
340 (84.4%) 
ICC: 0.70  
(0.74 – 0.75) 
R: 317/344/353 
L: 331/347/358 
Clean reads all lobes:  
264 (73.1%) 
Atelectasis Whole lung 
score  
(0-600) 
ICC: 0.76  
(0.71-0.79) 
R: 359/395/394 
L: 376/396/394 
Clean reads all lobes:  
315 (78.2%) 
ICC: 0.68  
(0.62 – 0.73) 
R: 319/350/353 
L: 318/354/353 
Clean reads all lobes:  
257 (71.2%) 
Normal Whole lung 
score  
(0-600) 
ICC: 0.89  
(0.87-0.91) 
R: 307/317/326 
L: 319/320/331 
Clean reads all lobes:  
154 (38.2%) 
ICC: 0.82  
(0.79 – 0.85) 
R: 290/307/309 
L: 289/311/308 
Clean reads all lobes:  
154 (42.7%) 
Ring and tramlines Total 
severity 
score (0-18) 
Weighted 
kappa:  
0.61 (0.05) 
R: 336/324/339 
L: 329/314/362 
Clean reads all lobes:  
211 (52.4%) 
Weighted 
kappa:  
0.59 (0.05) 
R: 304/302/318 
L: 306/310/338 
Clean reads all lobes:  
199 (55.1%) 
Nodules Total 
pattern 
score (0-18) 
Weighted 
kappa:  
0.53 (0.05) 
R: 396/400/399 
L: 397/394/401 
Clean reads all lobes:  
Weighted 
kappa:  
0.64 (0.05) 
R: 356/353/358 
L: 358/359/360 
Clean reads all lobes:  
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387 (96.0%) 348 (96.4%) 
Mycetoma Presence / 
absence 
N/a* 401/403 (99.8%) N/a* 361/361 (100.0%) 
Pleural pathology Presence / 
absence 
Kappa:  
0.52 (0.05) 
355/403 (88.1%) Kappa:  
0.42 (0.05) 
309/361 (85.6%) 
Lymphadenopathy Presence / 
absence 
Kappa:  
0.25 (0.05) 
392/403 (97.3%) Kappa:  
0.01 (0.04) 
352/361 (97.5%) 
Hyper expansion Presence / 
absence 
Kappa:  
0.07 (0.02) 
343/403 (84.9%) Kappa:  
0.15 (0.04) 
317/361 (87.8%) 
*Not possible to calculate kappa scores here, as pathology too rare. #ICC - intra-class correlation coefficient. ^Weighted kappa 
scores calculated using quadratic wgt(w2) function in Stata v13. 
CXR RESULTS  
Results from the final dataset are presented for individuals completing CXR imaging at both baseline 
and 1-year time points (n=359) in Table 33.  
Table 33: CXR imaging results at baseline and 1-year (n=359) 
Pathology  Baseline visit, Median 
(IQR) [Full range] 
1-year, Median (IQR) 
[Full range] 
p-value  
Parenchymal pathology scores, whole lung level~ 
Total abnormal parenchymal scores (0-600) 18 (3 – 55) 
[0 – 310] 
13 (0 – 43) 
[0 – 425] 
0.023* 
Cavities / cystic air spaces score (0-600) 0 (0 – 2.5) 
[0 – 293] 
0 (0 – 5) 
[0 – 215] 
0.007** 
Atelectasis / banding score (0-600) 0 (0 – 20) 
[0 – 185] 
5 (0-20) 
[0 – 240] 
0.564 
Consolidation / ground glass score (0-600) 10 (0 – 25) 
[0 – 195] 
3 (0 – 13) 
[0 – 195] 
<0.001*** 
Presence of ≥1 ‘destroyed’ zone (n, %)# 10 (2.8%) 16 (4.5%) 0.231 
Bronchiectasis, whole lung level 
Ring and tramline severity score (0-18) 1 (0 – 3) 
[0 – 14] 
1 (0 – 3) 
[0 – 15] 
0.260 
Number of zones with mod-severe ring and 
tramline change^ 
0 
1 
2 
3 
4 
5 
6 
 
 
251 (69.9%) 
77 (21.5%) 
22 (6.1%) 
7 (2.0%) 
0 (0.0%) 
1 (0.3%) 
1 (0.3%) 
 
 
258 (71.9%) 
73 (20.3%) 
15 (4.2%) 
8 (2.2%) 
2 (0.6%) 
3 (0.8%) 
0 (0.0%) 
 
 
0.470 
Other scores, whole lung level 
Nodules 
Absent 
Present 
Unclear 
 
286 (79.7%) 
66 (18.4%) 
7 (2.0%) 
 
273 (76.0%) 
80 (22.3%) 
6 (1.7%) 
 
0.423 
Mycetoma 
Absent 
Present 
Unclear 
 
357 (99.4%) 
1 (0.3%) 
1 (0.3%) 
 
358 (99.7%) 
1 (0.3%) 
0 (0.0%) 
 
0.606 
Pleural pathology (effusions or thickening) 
Absent 
Present 
 
352 (87.3%) 
51 (12.7%) 
 
303 (83.9%) 
58 (16.1%) 
 
0.178 
Hyper-expansion 
Absent 
Present 
 
341 (84.6%) 
62 (15.4%) 
 
317 (87.8%) 
44 (12.2%) 
 
0.202 
*p<.05, **p<.01, ***p<.001 
~Parenchymal score off 100 is equivalent to one lung zone. Total possible score across the lung, including all 6 zones, is 600.  
#Destroyed lobe is one in which ≥90% of parenchyma is occupied by banding, atelectasis, or cavities / cystic airspaces 
^Present if final ring and tramline score is ≥2 for the zone 
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 PARENCHYMAL PATHOLOGY  
On average, an improvement was seen in the extent of parenchymal pathology reported on CXR over 
1-year with a decrease in the median amount of abnormal parenchyma seen (18 points (IQR: 3-55) vs 
13 points (IQR: 0-43), p=0.023). Improvement was particularly marked for consolidation and ground 
glass change: these patterns were relatively sparse on CXR imaging, but were more extensive at TB 
treatment completion compared to 1-year (10 points (IQR: 0 - 25) vs 3 points (IQR: 0 - 13), p<0.001) 
(Figure 26). 
Figure 26: Population level data for the extent of parenchymal pathologies seen on CXR, at baseline and 1-year (n=359) 
 
 
CT imaging findings suggested that at TB treatment completion, 9.3% (36/385) of scans had at least 1 
lobe essentially ‘destroyed’ by atelectasis, cavities / cystic airspaces, and banding. Chest x-ray imaging 
was less sensitive to this finding: only 2.8% of CXR films were found to have at least 1 destroyed lobe 
at the same time point. At 1-year, 4.5% (16/359) of CXR images were found to have at least 1 destroyed 
lobe.   
 RING AND TRAMLINES  
Ring and tramline change was also seen less frequently on CXR than bronchiectasis was seen on CT 
imaging: 29.5% (119/403) of participants had moderate-severe ring and tramline change in at least 
one zone on CXR at TB treatment completion, compared to 44.2% (170/385) with moderate to severe 
bronchiectasis in at least one lobe in on CT imaging. However, correlation between the overall severity 
scores for ring and tramline on CXR and bronchiectasis on CT imaging was reasonable (Pearson 
correlation coefficient 0.627, p<0.001). 
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At the population level, no significant change was observed in average ring and tramline severity 
scores between baseline and 1-year: median severity scores remained 1 with IQR 0 -3 at both time 
points. At the end of the 1-year follow up period, 28.0% (101/361) of individuals have moderate-severe 
ring and tramline pathology seen in at least 1 lobe.  
 OTHER PATHOLOGIES  
The proportion of participants with non-miliary nodules remained similar from baseline (18.4% 
(66/403)) to 1-year (22.3% (80/359)).  
Mycetoma were seen on CXR for only one individual at the 12-month time point. This participant had 
not had confirmed mycetoma on CT imaging at baseline.   
Pleural pathology was seen in 12.7% (51/403) of baseline and 16.1% (58/361) of repeat CXRs. Both 
values were higher than that seen on CT imaging at the point of treatment completion, where the 
prevalence was 8.1% (31/385) only.  
Hyper-expansion was noted in 15.4% (62/403) of baseline CXRs, and 12.2% (44/361) of 1-year CXRs. 
The difference in prevalence at these time points was not statistically significant. No correlation was 
identified between the presence of hyper-expansion on CXR at TB treatment completion, and the 
extent of CT based features of airway disease including mosaicism, emphysema, or bronchiectasis 
severity (data not shown). 
COMPARISON OF CXR AND CT IMAGING RESULTS 
The prevalence of pathology was higher on CT imaging: only 3.4% (13/385) individuals had completely 
normal parenchyma on baseline CT compared to 24.3% (98/403) on baseline CXR. On average, the 
extent of pathology detected was also greater on CT where the median amount of abnormal pathology 
was 138 points (IQR: 55-235) including mosaicism / 73 points (IQR: 30-150) excluding mosaicism, 
compared to just 18 points (IQR: 2.5 – 55) on CXR imaging.  
However, the broad patterns and relative severities of pathology seen were similar between 
modalities. The extent of parenchymal pathologies, and the total ring and tramline / bronchiectasis 
severity scores were correlated between modalities (Figure 27). Atelectasis and banding were 
amongst the most widespread pathologies reported using both modalities, and CT and CXR extent 
scores were strongly correlated for this variable (Pearson’s R 0.658, p<0.001). Cavities/cystic airspaces 
much less extensive using both modalities, but readings were also strongly correlated (Pearson’s R 
0.842, p<0.001). The weakest correlation was seen for ground glass change and opacification 
(Pearson’s R 0.369, p<0.001), which was reported more extensively on CT imaging. Ring and tramline 
scores on CXR, and airway dilatation or bronchiectasis severity scores on CT were well correlated, with 
Pearson’s R of 0.627, p<0.001.  
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Figure 27: Correlation between CT imaging and CXR findings, for the extent of parenchymal and airway pathology.  
 
 
SENSITIVITY ANALYSIS 
The patterns of pathology and change over time observed amongst those who received digital imaging 
at both time points (n=94) were similar to those seen in the broader cohort (Table 34).  
Table 34: CXR imaging results at baseline and 1-year for those imaged with digital CXR at both time points (n=94) 
Pathology  Baseline visit  
Median (IQR) 
[Full range] 
1-year 
Median (IQR) 
[Full range] 
p-value  
Parenchymal pathology scores, whole lung level* 
Total abnormal parenchyma (0-600) 16 (0 – 48)  
[0 – 300] 
11 (3 – 43) 
[0 – 245] 
0.899 
Cavities / cystic air spaces score (0-600) 0 (0 – 3) 
[0 – 293] 
0 (0-8) 
[0 – 150] 
0.107 
Atelectasis / banding score (0-600) 3 (0 – 15) 
[0 – 150] 
5 (0 – 20) 
[0 – 110] 
0.793 
Consolidation / ground glass score (0-600) 5 (0 – 23) 
[0 – 125] 
3 (0 – 10) 
[1 – 75] 
0.104 
Presence of ≥1 ‘destroyed’ zone (n, %) 3 (3.2%) 4 (4.3%) 0.700 
Bronchiectasis, whole lung level 
Ring and tramline severity score (0-18) 2 (0 – 3.5) 
[0 – 10.5] 
1 (0 – 2.5) 
[0 – 11] 
0.289 
Number of zones with mod-severe ring and 
tramline change^ 
0 
1 
2 
3 
4 
 
 
58 (61.7%) 
24 (25.5%) 
8 (8.5%) 
4 (4.3%) 
0 (0.0) 
 
 
65 (69.2%) 
20 (21.3%) 
3 (3.2%) 
4 (4.3%) 
2 (2.1%) 
 
 
0.284 
Other scores, whole lung level 
Nodules 
Absent 
 
80 (85.1%) 
 
77 (81.9%) 
 
0.832 
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Present 
Unclear 
13 (13.8%) 
1 (1.1%) 
16 (17.0%) 
1 (1.1%) 
Mycetoma 
Absent 
Present 
Unclear 
 
93 (98.9%) 
0 (0.0) 
1 (1.11%) 
 
93 (98.9%) 
1 (1.1%) 
0 (0.0) 
 
0.398 
Pleural pathology (effusions or thickening) 
Absent 
Present 
 
85 (90.4%) 
9 (9.6%) 
 
78 (83.0%) 
16 (17.0%) 
 
0.133 
Hyper-expansion 
Absent 
Present 
 
83 (88.3%) 
11 (11.7%) 
 
84 (89.4%) 
10 (10.6%) 
 
0.817 
*Parenchymal score off 100 is equivalent to one lung zone. Total possible score across the lung, including all 6 zones, is 600.  
#Destroyed lobe is one in which ≥90% of parenchyma is occupied by banding, atelectasis, or cavities / cystic airspaces 
^Present if final ring and tramline score is ≥2 for the zone 
 
 
5.3.8 INDIVIDUAL LEVEL HETEROGENEITY IN CHANGE OVER 
TIME, ACROSS PARAMETERS 
As shown above, trends to improvement were demonstrated across the majority of the clinical and 
respiratory parameters measured over the 1-year time period. However, heterogeneity was observed 
at the individual level across many of these parameters, with subgroups of individuals showing no 
change, improvement, and deterioration over the 1-year follow up period (Table 35), and variation in 
the magnitude of change observed within these groups.  
Table 35: Individual level heterogeneity observed within key clinical and respiratory parameters, over the 1-year follow up 
period 
Parameter 
Proportion of participants with each pattern of change observed over 1-
year 
Size of change 
amongst those 
deteriorating 
Median (IQR) Improvement No change Deterioration 
Quality of life and 
symptoms     
General health, Likert 
score 31.3% (115/368) 62.2% (229/368) 6.5% (24/368) N/a 
SGRQ total score 68.3% (250/366) 12.0% (44/366) 19.7% (72/366) 6.8 points (3.0 – 19.1) 
Presence of monthly 
respiratory symptoms 
Resolution of 
symptoms – 36.1% 
(133/368) 
No change in 
symptoms – 56.6% 
(207/368) 
New monthly 
symptoms – 7.6% 
(28/368) 
N/a 
Functional capacity     
6MWD (m) 77.0% (268/348) 0.3% (1/368) 22.7% (79/348) -34m (-54 - - 10) 
Clinical observations     
BMI 70.1% (258/368) 1.4% (5/368) 28.5% (105/368) -0.6kg/m2 (0.3 - -1.2) 
Spirometry data     
FEV1 z-score 66.2% (202/305) 0 33.8% (103/305) -0.2 z-scores (-0.1 - -0.5) 
FVC z-score 75.1% (229/305) 0 24.9% (76/305) -0.2 z-scores (-0.1 - -0.4) 
CXR data     
Total abnormal 
parenchyma score 50.4% (181/359) 21.2% (76/359) 28.4% (102/359) 
12.5 points (5.0 – 
22.5) 
Ring and tramline 
score 37.6% (135/359) 30.4% (109/359) 32.0% (115/359) 1.5 points (0.5 – 2.0) 
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 PARTICIPANTS EXPERIENCING DETERIORATION 
Between 19.7 – 33.8% percent of participants experienced any deterioration in at least one of the key 
clinical and respiratory parameters over the 1-year follow up period. The magnitude of this 
deterioration was often marked. The overlap between groups experiencing decline in each of these 
parameters has yet to be explored. 
 PARTICIPANTS EXPERIENCING IMPROVEMENT 
A ‘catch up’ phenomenon was observed amongst those experiencing improvement whereby those 
with the greatest deficit at TB treatment completion showed the largest amount recovery over time. 
This pattern was seen for multiple parameters including the SGRQ scores, the 6-minute walking 
distance, and spirometry parameters (Figure 28).  
Figure 28: Graph to show the relationship between baseline levels of impairment, and change observed over 1-year period for 
the SGRQ total score, 6-minute walking distance, FEV1 and FVC z-scores 
Histograms: Magnitude of change observed over the 1-year period  
Scatter plot: Mean baseline observation, for the group represented by each bar  
 
 
 
Despite this ‘catch up’ phenomenon, recovery was incomplete: on average, participants with the worst 
parameters at TB treatment completion still had the worst parameters at 1-year. This pattern was 
again observed amongst multiple parameters including quality of life scores, 6-minute walking 
distances and CXR parameters when participants were stratified into quintiles based on their baseline 
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scores (Figure 29), as well as spirometry parameters when participants were stratified by LLN cut-offs 
at baseline (Figure 30). 
Figure 29: Average scores at each study visit for participants stratified into quintiles by baseline scores for SGRQ total score, 6-
minute walking distance, and CXR parameters. 
 
 
 
 
Figure 30: Mean FEV1 and FVC z-scores at each of the three study visits, according to whether volumes measured at TB 
treatment completion were above or below the lower-limit of normal cut off calculated using the GLI-2012 reference range.  
 
 
It must be noted that in these exploratory analyses, individuals have been classified as showing 
improvement or decline if any positive or negative change was observed in repeated measures. In 
fact, some of the variation observed here may be related to test-retest variability in the measures 
used, rather than true change in clinical status. Further analyses are required to identify individuals 
improving or deteriorating by a magnitude greater than the minimal clinically important difference 
(MCID) for each parameter. 
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5.3.9 RELATIONSHIP BETWEEN SYMPTOMS, CT IMAGING AND 
SPIROMETRY AT TB TREATMENT COMPLETION 
Comparing participants with any abnormal spirometry (including both obstructive and low-FVC 
groups) to those with normal spirometry at TB treatment completion, those with abnormal spirometry 
were more likely to be HIV negative (50.4% vs. 33.2%, p=0.001), to have lower BMI (19.9 vs. 20.6, 
p=0.002), and to have lower socioeconomic situations (67.6% vs. 48.9%, p=0.001). The majority of 
patterns of structural pathology seen on CT imaging were more extensive in those with abnormal vs. 
normal spirometry, except for the extent of ground glass and emphysema where no difference was 
observed. Summary SGRQ scores were all higher in those with abnormal spirometry (SGRQ total score 
18.6 vs. 6.1, p=0.001), and regular breathlessness experienced at least monthly was more common in 
this group (56.8% vs. 37.9%, p=0.001) (Table 36). 
However, when groups with obstruction and low FVC only were compared, few differences were 
observed. Individuals with obstruction were older (36.5 vs. 32 yrs, p=0.014) and a higher proportion 
come from the lowest SES quintiles (78.7% vs. 59.4%, p=0.031), but the only statistically significant 
differences in CT pathology were a larger amount of atelectasis and banding in those in the low FVC 
group (median score 64/600 vs. 78/600, p=0.026), and a higher extent of bronchial wall thickening in 
the obstruction group (median score 6.8/18 vs 3.5/18, p<0.001). No differences in the SGRQ scores or 
the burden of specific symptoms were observed.  
Table 36: Characteristics of participants with obstruction, low FVC, or normal spirometry at TB treatment completion, with p-
values presented for comparisons between any normal and any abnormal patterns (n=365), and the obstruction and low FVC 
groups only (n=125) 
Parameter 
Spirometry pattern, at TB treatment completion p-value for comparison 
Obstruction 
(n=52) 
Low FVC 
(n=73) 
Normal 
(n=240) 
Normal vs. 
abnormal 
Obstruction 
vs. Low FVC 
Participant characteristics  
Age 36.5 (18 – 41.5) 32 (26 – 37) 36 (30 – 41.5) 0.028* 0.014* 
Male gender 35 (67.3%) 47 (64.4%) 170 (70.8%) 0.305 0.734 
Positive HIV status 25 (48.1%) 37 (50.7%) 159 (66.8%) 0.001** 0.774 
CD4 count (cells / uL) 242 (171 – 398) 300 (196 – 499) 210 (106 – 376) 0.005** 0.528 
Positive baseline TB microbiology  41 (78.9%) 62 (84.9%) 180 (75.0%) 0.108 0.379 
BMI (kg/m2) at TB Rx end 20.5 (18.5 – 22.2) 19.8 (18.6 – 21.0) 20.6 (19.3 – 22.3) 0.002** 0.438 
Ever smoker 19 (36.5%) 20 (27.4%) 72 30.0%) 0.813 0.277 
Poorest 3 SES quintiles 37 (78.7%) 38 (59.4%) 110 (48.0%) 0.001** 0.031* 
Imaging at TB treatment completion  
Total abnormal parenchyma (0-
600) 260 (188 – 340) 228 (173 – 295) 90 (40 – 175) <0.001*** 0.227 
Atelectasis / banding score (0-
600) 64 (35 – 103) 78 (45 – 158) 35 (15 – 63) <0.001*** 0.026* 
Cavities / cystic airspaces (0-600) 10 (0 – 20) 8 (0 – 30) 0 (0 – 5) <0.001*** 0.618 
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Mosaicism score (0-600) 60 (8 – 155) 50 (18 – 118) 23 (5 – 65) <0.001*** 0.738 
Emphysema score (0-600) 0 (0 – 10) 0 (0 – 3) 0 (0 – 5) 0.411 0.083 
Ground glass score (0-600 0 (0 – 10) 0 (0 – 5) 0 (0 – 5) 0.367 0.823 
Consolidation score (0-600) 8 (3 – 25) 8 (3 – 18) 4 (0 – 10) <0.001*** 0.803 
Presence of ≥1 destroyed lobe 5 (9.6%) 14 (19.2%) 15 (5.4%) 0.002** 0.142 
Bronchiectasis severity score (0-
18) 4 (2 – 6) 4.5 (2 – 6.5) 2 (0 – 3.5) <0.001*** 0.842 
Bronchial wall thickening severity 
scores (0-18) (n=306) 6.8 (4.5 – 9.5) 3.5 (1.5 – 6.0) 2.5 (1.0 – 4.5) <0.001*** <0.001*** 
Tree in bud severity score (0-18) 5.3 (2.5 – 9.0) 5.0 (2.5 – 7.0) 3.0 (1.0 – 5.5) <0.001*** 0.475 
Airway plugging severity score (0-
18) 2.0 (0.5 – 4.0) 1.5 (0.5 – 2.5) 0.5 (0 – 2.0) <0.001*** 0.097 
Clinical parameters at TB treatment completion  
SGRQ Activity score (0-100) 23.3 (0 – 53.2) 24.1 (0 – 41.4) 5.8 (0 – 30.4) <0.001*** 0.409 
SGRQ Symptom (0-100) 19.4 (3.0 – 34.7) 21.8 (3.0 – 28.5) 11.6 (3.0 – 24.0) <0.001*** 0.479 
SGRQ Impact score (0-100) 11.2 (1.6 – 26.9) 8.2 (1.6 – 20.8) 5.1 (0 – 11.5) <0.001*** 0.358 
SGRQ Total score (0-100) 19.5 (3.0 – 34.2) 18.5 (2.1 – 25.2) 6.1 (0.8 – 19.9) <0.001*** 0.330 
Cough ≥ monthly 24 (46.2%) 28 (38.4%) 82 (34.2%) 0.162 0.383 
Breathlessness ≥ monthly 30 (57.7%) 41 (56.2%) 91 (37.9%) 0.001** 0.865 
Sputum production ≥ monthly 19 (36.5%) 18 (24.7%) 61 (25.4%) 0.392 0.151 
6-minute walk distance (m) 554 (489 – 642) 569 (509 – 611) 579 (525 – 627) 0.086 0.973 
*p<.05, **p<.01, ***p<.001 
 
 
5.3.10 PARTICIPANT OUTCOME DATA 
Some of the outcomes to be included in the cohort analyses draw on the data already presented, 
including those relating to persistent symptoms and quality of life scores. However, in this section data 
on the incidence of ongoing respiratory events, TB retreatment and mortality will be given.  
HEALTH SERVICE USE 
Three types of health seeking episode were seen during the 1-year follow up of this cohort: planned 
outpatient appointments (n=264, across 168 individuals), unscheduled outpatient visits (n=173, across 
130 individuals), and inpatient admissions (n=11, in 11 individuals).  
A total of 437 all-cause outpatient appointments were identified across 254 participants, and 27 all-
cause inpatient admissions were observed across 24 individuals (Table 37). Amongst the outpatient 
visits recorded, 60.4% (264/437) were pre-booked, and 39.6% (173/437) were unscheduled. Of all 
participants contributing follow up data to the study, 44.2% (168/380) individuals had at least 1 
booked outpatient visit within the year, and 34.2% (130/380) had at least 1 unscheduled outpatient 
visit.  
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Table 37: Number of unscheduled outpatient visits and Inpatient admissions per person, presented across the whole study 
population (n=380), as well as separately for those contributing 1-year (n=364) or 6-month (n=16) of follow up data. 
Number 
of events 
All participants contributing 
follow up data (n=380) Full 1-year follow up (n=364) 6-month follow-up (n=16) 
Any cause Respiratory cause Any cause 
Respiratory 
cause Any cause 
Respiratory 
cause 
Outpatient visits 
0 126 (33.2%) 323 (85.0%) 118 (32.4%) 311 (85.4%) 8 (50.0%) 12 (75.0%) 
1 135 (35.5) 47 (12.4%) 129 (35.4%) 43 (11.8%) 6 (37.5%) 4 (25.0%) 
2 76 (20.0%) 7 (1.8%) 75 (20.6%) 7 (1.9%) 1 (6.3%) 0 
3 27 (7.1%) 3 (0.8%) 27 (7.4%) 3 (0.8%) 0 0 
4 12 (3.2%) 0 11 (3.0%) 0 1 (6.3%) 0 
5 3 (0.8%) 0 3 (0.8%) 0 0 0 
6 1 (0.3%) 0 1 (0.3%) 0 0 0 
Inpatient admissions 
0 356 (93.7%) 353 (97.0%) 341 (93.6%) 15 (93.8%) 11 (91.7%) 16 (100%) 
1 22 (5.8%) 11 (3.0%) 21 (5.8%) 1 (6.3%) 1 (8.3%) 0 
2 1 (0.3%) 0 1 (0.3%) 0 0 0 
3 1 (0.3%) 0 1 (0.3%) 0 0 0 
 
 RESPIRATORY EPISODES 
16.3% (62/380) of individuals had at least one scheduled or unscheduled health-seeking episode 
related to respiratory symptoms during follow-up. A higher incidence was seen amongst those 
contributing 6-month vs. 1-year of follow up data (25.0% (4/16) vs. 15.9% (58/364)), but this difference 
was not statistically significant.  
Of the 62 individuals, the majority (77.4%, 28/62) had one episode, with only 14 individuals 
experiencing between 2-4 events. The median time to the first respiratory outpatient visit was 152 
days (IQR: 116-191 days, n=57), and median time to the first respiratory admission was 225 days (IQR: 
188 – 276 days, n=11). 
 OUTPATIENT EVENTS 
Booked visits were more commonly seen in HIV infected individuals: 66.4% (154/232) of HIV positives 
had at least one pre-booked outpatient appointment during follow-up, of which the majority were to 
the ART / HIV clinic (92.0%, 230/250), compared to only 9.6% (14/146) of HIV negatives.  Across both 
groups, only 3.6% (9/264) of scheduled outpatient visits were to the chest clinic. 
40.5% (70/173) of the unscheduled outpatient visits were for respiratory reasons and classified as 
acute respiratory exacerbations. Approximately half were due to increased cough (55.7%, 39/70), and 
a third related to increased breathlessness (34.3%, 24/70), with other reasons including chest pain, 
sputum production, and wheeze. These 70 respiratory visits were shared across 58 participants, with 
the majority (65.5%, 38/58) experiencing one visit only. The majority of unplanned respiratory 
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outpatient visits were to the primary health centre or public hospital (85.7%, 60/70), with only 2 visits 
to the local pharmacy or grocer. Antibiotics were prescribed in 80% of unscheduled respiratory visits. 
The most commonly used antibiotics were amoxicillin (21/56, 55.4%) and co-trimoxazole (14/56, 
25.0%), but ciprofloxacin, erythromycin, ceftriaxone or various combinations were also used. More 
HIV-negative individuals experienced unscheduled outpatient visits compared to HIV-infected 
participants (40.4% vs. 30.2%, p=0.041). 
 ADMISSIONS 
40.7% (11/27) of inpatient admissions during follow up were for respiratory reasons including 
increased breathlessness and increased cough. Six of the respiratory admissions occurred amongst 
five individuals who were started on TB retreatment during the follow up period.  
The majority of respiratory admissions were at public hospitals (90.9%, 10/11), and in 72.7% (8/11) of 
cases the individual was accompanied by a guardian. Antibiotics were known to have been received 
in 54.6% (6/11) of cases, and included co-amoxiclav, co-trimoxazole, ceftriaxone, multiple antibiotics 
or in 2 cases unknown medications. Median admission duration was 20 nights (IQR: 4-59), but this 
long duration was driven by participants admitted for TB treatment, who at the time of this study were 
required to receive inpatient treatment with intramuscular streptomycin for the first 2-months of the 
retreatment regimen. Amongst those admitted but not restarted on TB retreatment, the median 
duration of admission was 6.5 days (IQR: 3-10 days).  
 TB SYMPTOMS AND RETREATMENT 
18.9% (71/376) of participants had a positive TB symptom screen at the 6-month visit, and 10.6% 
(39/368) at the 1-year visit. Current cough was the most common TB symptom identified: this was 
reported by 18.1% (68/376) of individuals at the 6-month time point, and 9.5% (35/368) at the 1-year 
visit. Sputum was obtained at 100/110 of the symptom positive study visits, amongst which 4% (4/100) 
were found to have MTB confirmed disease on culture. Drug sensitivities were not available. Three 
further individuals had an NTM isolated on a primary culture but repeat samples were negative, 
suggesting that these were contaminants only. Of the 92 individuals with a positive symptom screen, 
11 were started on retreatment during study follow-up. Amongst the 81 symptomatic participants 
who were not started on TB retreatment, only 1 died over the study duration.  
In total, 3.7% (15/405) of study participants started TB retreatment during study follow-up. The 
median time from TB treatment completion to retreatment was 204 days (total range: 57-318 days, 
n=13). Overall, evidence with either smear or culture positivity was available for 46.7% (7/15) of 
individuals started on retreatment (Table 38). A total of 4 individuals were started on retreatment due 
to persistently positive Xpert MTB results, and the time to diagnosis from the initial TB treatment 
completion for these individuals were 76 days, 115 days, 180 days, and 259 days. Sputum cultures are 
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not available for any of these individuals, but all had experienced associated clinical features which 
could be suggestive of active disease.  
Table 38: The basis of diagnosis of recurrent TB disease, according to the system within which diagnosed (n=15) 
Basis of TB diagnosis Malawi NTP (n=11) 
Research study  
(n=4) Total (n=15) 
Smear positive 4 0 4 (26.7%) 
Smear positive / Culture negative 0 1 1 (6.7%) 
Spear negative / Culture positive 0 2 2 (13.3%) 
Xpert positive 3 1 4 (26.7%) 
Radiological diagnosis 3 0 3 (20.0%) 
Unknown 1 0 1 (6.7%) 
 
Mortality amongst those starting retreatment was high: one third died during the course of follow-up 
(5/15), but only two had completed their 8-month TB retreatment regimens by the time of the final 
study visit and so final outcomes for the majority of cases are unknown.  
 MORTALITY  
11 participants died during the 1-year follow up period: 7 passed away within the first 6-months of 
follow up, and 4 thereafter. Amongst those who died, 5/11 (45.5%) had been started on TB 
retreatment (Table 39). 
Table 39: Adverse outcomes (death and TB retreatment) during the 1-year follow up period (n=405) 
TB retreatment 
Death 
No Yes 
No 384 (94.8%) 6 (1.5%) 
Yes 10 (2.5%) 5 (1.2%) 
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5.3.11 FACTORS ASSOCIATED WITH ABNORMAL SPIROMETRY  
Exploratory analyses of the factors predicting spirometry results at TB treatment completion and 1-
year, and those predicting change over time, are shown below. These include linear models for 
individual spirometry parameters (absolute FEV1, absolute FVC, and FEV1/FVC ratio), and logistic 
models for patterns of deficit (obstruction vs. normal spirometry, low FVC vs. normal spirometry) at 
the various time points. 
A reduced set of models are presented for each spirometry measure, across each of the three time 
points, in the main text. Detailed tables with models grouped by the time point of interest (spirometry 
at TB treatment completion, change over time, spirometry at 1-year) rather than by parameter are 
given in Appendix 5. 
MODEL CONSTRUCTION  
During construction of the linear models for factors predicting the change in spirometry 
measurements over time, 4 outliers were identified. Manual review of spirometry traces for these 
individuals showed that although both baseline and 1-year traces had been independently quality 
controlled and felt to include usable data, when these readings were compared, they appeared 
inconsistent, suggesting that either the baseline or 1-year readings were incorrect. These 4 data points 
were therefore excluded from all models.  
The additional inclusion of a quadratic ‘height2’ variable was considered across the models but was 
found to have limited effect on the variable co-efficients whilst improving R2 values only very slightly, 
and as such was not incorporated in final models. In addition, an inconsistent signal of interaction 
between HIV and TB was identified across the models, but as this was seen in a minority of models 
only was not included in final models either.  
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LINEAR REGRESSION: ABSOLUTE FEV1 AT TREATMENT COMPLETION AND 1-YEAR, AND CHANGE OVER TIME  
Table 40: Linear regression models for absolute FEV1 volume at TB treatment completion (n=330), change in volume over 1-year follow-up (n=290), and absolute volume at 1-year (n=290) 
 TB treatment completion (n=330) Change over 1 year (n=290) 1-year post TB treatment completion (n=290) 
 Multivariate model R2 0.455 
Participant characteristics 
R2: 0.114 
Full multivariate model 
R2:0.232 
Basic multivariate model 
R2: 0.513 
+ Baseline spirometry 
R2: 0.924 
+ Baseline imaging 
R2: 0.580 
Full multivariate model 
R2: 0.926 
Age (yrs) -12.6  (-18.6 – -6.7)*** -4.1 (-6.6 – -1.7)** -5.6 (-8.0 – -3.2)*** -15.5 (-21.4 – -9.6)*** -5.7 (-8.1 – -3.3)*** -14.4 (-19.9 – -8.8)*** -5.6 (-8.0 – -3.2)*** 
Male gender 401.1 (231.2 – 571.0)*** 72.1 (-3.1 – 144.0) 131.2 (60.2 – 202.2)*** 468.2 (196.2 – 640.3)*** 125.4 (55.1 – 195.7)** 506.9 (345.9 – 667.9)*** 130.8 (59.5 – 202.0)*** 
Height (m) 37.9 (28.8 – 47.0)*** 1.4 (-2.5 – 5.3) 6.1 (2.0 – 10.2)** 39.2 (29.9 – 48.4)*** 6.4 (2.4 – 10.4)** 38.7 (30.0 – 47.3)*** 6.1 (2.0 – 10.2)** 
HIV positive at TBRx end 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
47.8 (-85.0 – 180.6) 
189.9 (40.4 – 339.4)* 
 
103.1 (47.2 – 159.0)**  
68.6 (5.8 – 131.5)* 
 
105.9 (52.7 – 159.1)*** 
86.4 (25.4 – 147.4)** 
 
127.1 (-7.0 – 261.3) 
243.7 (93.1 – 394.3)** 
 
107.1 (54.0 – 160.1)** 
92.5 (32.4– 152.6)** 
 
141.6 (15.8 – 267.3)* 
212.2 (71.5 – 353.0)** 
 
105.3 (51.8 – 158.8)*** 
86.0 (24.0 – 147.2)** 
Positive baseline TB 
microbiology 
22.1  
(-117.2 – 161.5) -42.9 (-101.2 – 15.4) -33.4 (-88.2 – 21.5) -12.7 (-152.0 – 126.6) -38.6 (-93.7 – 16.6) -12.2 (-142.1 – 117.7) -33.6 (-88.7 – 21.4) 
BMI at TB treatment 
completion (kg/m2) 
38.6  
(18.3 – 58.8)*** -4.2 (-13.2 – 4.8) 0.21 (-8.5 – 8.9) 33.9 (12.4 – 55.3)** 0.9 (-7.7 – 9.6) 18.6 (-1.9 – 39.1) 0.2 (-8.5 – 8.9) 
Illness duration ≥1-month 
prior to TB treatment 
-116.1  
(-231/8 – 0.3)*   -123.8 (-241.3 – -6.20)* -9.4 (-56.3 – 37.5) -80.8 (-191.3 – 29.6) -5.6 (-52.5 – 41.3) 
Ever smoking -87.3  (-226.6 – 52.1) 24.7 (-33.4 – 82.7) 10.5 (44.6 – 65.6) -64.5 (-203.2 – 74.1) 12.7 (-42.3– 67.8) -35.6 (-202.6 – 40.1) 10.5 (-44.7 – 65.7) 
Poorest 3x SES quintiles -99.2 (-226.4 – 28.0) 16.4 (-37.7 – 70.5) -2.3 (-53.8 – 49.2) -103.2 (-232.8 – 26.4) 1.2 (-50.4 – 52.7) -81.2 (-202.6 – 40.1) -2.8 (-54.6 – 49.0) 
Intermittent food insecurity -10.3 (-139.8 – 119.2) 17.3 (-37.4 – 72.0) 16.9 (-34.6 – 68.4) 11.3 (-119.5 – 142.0) 16.2 (-35.6– 67.9) 24.4 (-97.7 – 146.5) 17.2 (-34.4 – 68.8) 
FEV1 (ml) at TBRx completion   -0.14 (-0.18 – -0.09)***  0.87 (0.82 – 0.91)***  0.86 (0.82 – 0.91)*** 
≥1/3 abnormal parenchyma   12.2 (-58.0 – 82.5)   -406.0  (-563.3 – -248.8)*** 12.5 (-57.9 – 82.9) 
≥3 lobes with mod-severe 
bronchiectasis   -42.3 (-131.0 – 46.3)   
-243.1  
(-452.0 – -34.3)* -41.7 (-130.6 – 47.3) 
Any OPD / IP respiratory 
visits   -41.1 (-109.2 – 27.0)  
  
-40.8 (-109.1 – 27.5) 
TB retreatment   -165.4 (-366.0 – 35.2)  
  
-165.1 (-366.1 – 35.9) 
*p<.05, **p<.01, ***p<.001 
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LINEAR REGRESSION: ABSOLUTE FVC AT TREATMENT COMPLETION AND 1-YEAR, AND CHANGE OVER TIME  
Table 41: Linear regression models for absolute FVC volume at TB treatment completion (n=330), change in volume over 1-year follow-up (n=290), and absolute volume at 1-year (n=290) 
 TB treatment completion (n=330) Change over 1 year (n=290) 1-year post TB treatment completion (n=290) 
 Multivariate model R2 0.505 
Participant characteristics 
R2: 0.139 
Full multivariate model 
R2:0.291 
Basic multivariate model 
R2: 0.576 
+ Baseline spirometry 
R2: 0.929 
+ Baseline imaging 
R2:0.628 
Full multivariate model 
R2: 0.932 
Age (yrs) -5.3  (-11.7 – 1.2) -3.0 (-5.8 – -0.3)* -3.4 (-6.0 - -0.8)** -7.2 (-13.4 – -0.9)* -3.7 (-6.3 – -1.1)** -6.0 (-11.9 – -0.12)* -3.4 (-6.0 – -0.9)** 
Male gender 480.9  (296.2 – 665.6)*** 98.5 (18.5 – 178.5)* 174.2 (97.3 – 251.1)*** 526.3 (344.4 – 708.2)*** 165.7 (88.8 – 242.7)*** 567.5 (395.7 – 739.2)*** 175.5 (98.3 – 252.7)*** 
Height (cm) 47.2  (37.3 – 57.2)*** 1.3 (-3.0 – 5.6) 8.2 (3.6 – 12.8)** 50.4 (40.6 – 60.2)*** 8.8 (4.2– 13.4)*** 49.7 (40.5 – 58.9)*** 8.1 (3.5 – 12.8)** 
HIV positive at TBRx end 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
26.5 (-117.8 – 170.8) 
170.5 (8.0 – 333.0)* 
 
126.3 (64.1 – 188.6)*** 
102.9 (32.9 – 172.9)** 
 
123.2 (65.5 – 180.9)*** 
115.7 (49.6 – 181.8)** 
 
117.4 (-24.5 – 259.2) 
272.1 (112.9 – 431.4)** 
 
126.8 (68.7 – 184.9)*** 
130.5 (64.8 – 196.1)*** 
 
136.0 (1.84 – 270.1)* 
241.1 (91.0 – 391.2)** 
 
124.5 (66.5 – 182.6)*** 
116.6 (50.3 – 182.8)** 
Positive baseline TB 
microbiology 
17.0  
(-134..5 – 168.5) -9.5 (-74.3 – 55.4) 4.1 (-55.5 – 63.7) 28.7 (-118.6 – 176.1) -2.9 (-63.3 – 57.5) 30.0 (-108.6 – 168.5) 4.7 (-55.1 – 64.4) 
BMI at TB treatment 
completion (kg/m2) 
51.5  
(29..5 – 73.5)*** -12.3 (-22.3 – -2.4)* -5.2 (-14.7 – 4.4) 38.5 (15.8 – 61.1)** -4.4 (-14.0 – 5.1) 23.0 (1.17 – 44.9)* -5.1 (-14.7 – 4.4) 
Illness duration ≥1-month 
prior to TB treatment 
-72.6  
(-198.5 – 53.2)   -70.0 (-194.3 – 54.3) 6.6 (-44.5 – 57.7) -26.0 (-143.8 – 91.8) 12.7 (-38.0 – 63.4) 
Ever smoking -23.1  (-174.6 – 128.4) 24.9 (-39.7 – 89.5) 14.0 (-45.7 – 73.8) 2.7 (-143.9 – 149.4) 21.3 (-38.8 – 81.4) 28.0 (-110.6 – 166.6) 13.9 (-45.9 – 73.7) 
Poorest 3x SES quintiles -12.9  (-151.2 – 125.4) 16.8 (-43.4 – 77.0) 3.0 (-52.7 – 58.7) -15.7 (-152.8 – 121.3) 13.4 (-42.8 – 69.6) 2.9 (-126.5 – 132.4) 4.1 (-51.8 – 60.1) 
Intermittent food insecurity 36.8  (-104.0 – 177.6) 25.7 (-35.2 – 86.6) 35.6 (-20.3 – 91.6) 80.5 (-57.7 – 218.8) 33.3 (-23.5 – 90.0) 95.5 (-34.7 – 255.8) 35.0 (-21.1 – 91.1) 
FVC (ml) at TB treatment 
completion   -0.16 (-0.21 – -0.11)***  0.85 (0.80 – 0.89)***  0.84 (0.79 – 0.89)*** 
≥1/3 abnormal parenchyma   40.6 (-35.0 – 116.1)   -368.0 (-535.7 – -200.2)*** 39.7 (-36.1 – 115.4) 
≥3 lobes with mod-severe 
bronchiectasis   -92.8 (-189.0 – 3.4)   -309.1 (-531.9 - -86.3)** -94.4 (-191.0 – 2.1) 
Any OPD / IP respiratory visits   -79.9 (-153.8 – -6.0)*  
  
-80.6 (-154.7 – -6.5)* 
TB retreatment   -114.4 (-332.0 – 103.2)  
  
-114.8 (-332.8 – 103.1) 
*p<.05, **p<.01, ***p<.001 
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LINEAR REGRESSION: FEV1/FVC RATIO AT TREATMENT COMPLETION AND 1-YEAR 
 
Table 42: Linear regression models for FEV1/FVC ratio (%) at TB treatment completion (n=330) and 1-year later (n=290) 
 
 
TB treatment completion 
(n=330) 1-year post TB treatment completion (n=290) 
 
Multivariate 
Model 
R20.165 
Basic multivariate model 
R2: 0.204 
+ Baseline spirometry 
R2: 0.841 
+ Baseline imaging 
R2:0.216 
Full multivariate model 
R2: 0.843 
Age (yrs) -0.3 (-0.4 – -0.2)*** -0.3 (-0.4 – -0.2)*** -0.1 (-0.1 – -0.0)** -0.3 (-0.4 – -0.2)*** -0.1 (-0.1 – -0.0)*** 
Male gender -0.1 (-2.9 – 2.7) 1.2 (-1.9 – 4.2) 0.1 (-1.3 – 1.4) 1.3 (-1.7 – 4.4) -0.0 (-1.4 – 1.4) 
Height (m) -0.0 (-0.2 – 0.1) -0.0 (-0.2 – 0.1) 0.0 (-0.1 – 0.1) -0.0 (-0.2 – 0.12) -0.0 (-0.1 – 0.1) 
HIV positive at TB treatment completion 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
1.2 (-1.0 – 3.3) 
2.1 (-0.4 – 4.5) 
 
1.3 (-1.1 – 3.6) 
1.4 (1.3 – 4.0) 
 
0.2 (-0.9 – 1.2) 
0.0 (-1.2 – 1.2) 
 
1.3 (-1.1 – 3.6) 
1.2 (-1.5 – 3.8) 
 
-0.1 (-0.9 – 1.2) 
-0.2 (-1.1 – 1.4) 
Positive baseline TB microbiology 0.1 (-2.1 – 2.4) -1.3 (-3.8 – 1.1) -1.1 (-2.2 – -0.0)* -1.3 (-3.8 – 1.1) -1.2 (-2.3 – -0.0)* 
BMI at TB treatment completion (kg/m2) -0.0 (-0.4 – 0.3) 0.2 (-0.2 – 0.5) 0.2 (0.0 – 0.4)* 0.1 (-0.2 – 0.5) 0.2 (0.0 – 0.4)* 
Illness duration ≥1-month prior to TB treatment -2.1 (-4.0 – -0.2)* -2.1 (-4.2 – -0.1)* -0.3 (-1.2 – 0.7) -1.9 (-4.0 – 0.2) -0.3 (-1.2 – 0.7) 
Ever smoking -1.5 (-3.8 – 0.8) -1.2 (-3.7 – 1.3) 0.1 (-1.0 – 1.2) -1.0 (-3.4 – 1.5) 0.2 (-0.9 – 1.3) 
Poorest 3x SES quintiles -2.8 (-4.9 – -0.7)** -3.0 (-5.3 – -0.7)* -0.3 (-1.4 – 0.7) -2.8 (-5.1 – -0.5)* -0.2 (-1.3 – 0.8) 
Intermittent food insecurity -1.1 (-3.2 – 1.0) -1.4 (-3.7 – 0.9) -0.2 (-1.2 – 0.9) -1.4 (-3.7 – 0.9) -0.2 (-1.2 – 0.9) 
FEV1/FVC ratio (%) at treatment completion   0.91 (0.86 – 0.96)***  0.91 (0.86 – 0.97)*** 
≥1/3 abnormal parenchyma    -3.0 (-6.0 – -0.0) -0.3 (-1.7 – 1.1) 
≥3 lobes with mod-severe bronchiectasis    -0.2 (-4.1 – 3.8) 0.9 (-0.8 – 2.7) 
Any OPD / IP respiratory visits   
  
0.6 (-0.8 – 2.0) 
TB retreatment   
  
-2.7 (-6.8 – 1.4) 
*p<.05, **p<.01, ***p<.001 
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LOGISTIC REGRESSION: OBSTRUCTION VS. NORMAL SPIROMETRY AT TREATMENT COMPLETION AND 1-YEAR 
Table 43: Logistic regression models for airway obstruction (FEV1/FVC <LLN) vs. normal spirometry at TB treatment completion (n=267) and 1-year later (n=250) 
 
 TB treatment completion (n=267) 1-year post TB treatment completion (n=250) 
Age (yrs) 1.01 (0.98 – 1.05) 1.02 (0.98 – 1.05) 1.02 (0.98 – 1.08) 
Gender 
- Female 
- Male 
 
1.0 
0.84 (0.30 – 2.38) 
 
1.0 
0.84 (0.30 – 2.31) 
 
1.0 
1.35 (0.31 – 5.96) 
Height (cm) 1.01 (0.95 – 1.07) 0.99 (0.93 – 1.04) 0.95 (0.87 – 1.03) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.50 (0.22 – 1.10) 
0.30 (0.11 – 0.80)* 
 
1.0 
0.53 (0.24 – 1.18) 
0.58 (0.93 – 1.04) 
 
1.0 
0.9 (0.32 – 3.50) 
1.5 (0.38 – 5.71) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
0.72 (0.29 – 1.78) 
 
1.0 
1.44 (0.57 – 3.64) 
 
1.0 
3.36 (0.83 – 13.56) 
BMI at TB treatment completion (kg/m2) 0.91 (0.79 – 1.05) 0.91 (0.78 – 1.05) 1.00 (0.81 – 1.24) 
Illness duration prior to TB treatment 
- <1-month 
- ≥1-month 
 
1.0 
1.79 (0.86 – 3.74) 
 
1.0 
1.60 (0.78 – 3.26) 
 
1.0 
1.54 (0.54 – 4.39) 
Ever smoking 
- Never 
- Ever 
 
1.0 
1.03 (0.45 – 2.36) 
 
1.0 
1.30 (0.59 – 2.89) 
 
1.0 
1.63 (0.52 – 5.10) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
3.08 (1.31 – 7.23)* 
 
1.0 
1.79 (0.80 – 3.98) 
 
1.0 
0.74 (0.23 – 2.36) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
1.91 (0.91 – 4.01) 
 
1.0 
1.95 (0.95 – 4.03) 
 
1.0 
1.59 (0.53 – 4.70) 
Baseline spirometry pattern 
- Normal 
- Obstruction 
- Low FVC 
  
 
1.0 
117.91 (31.26 – 444.73)*** 
2.92 (0.64 – 13.40) 
Parenchyma, except mosaicism 
- <1/3 abnormal 
- ≥1/3 abnormal 
  
 
1.0 
1.38 (0.36 – 5.26) 
Mod-severe bronchiectasis 
- <3 lobes 
- ≥3 lobes 
  
 
1.0 
2.58 (0.41 – 16.20) 
Any OPD / IP respiratory visits 
- No 
- Yes 
  
 
1.0 
0.33 (0.07 – 1.67) 
*p<.05, **p<.01, ***p<.001 
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LOGISTIC REGRESSION: LOW FVC VS. NORMAL SPIROMETRY AT TREATMENT COMPLETION AND 1-YEAR 
Table 44: Logistic regression models for low FVC pattern (FEV1/FVC ≥LLN and FVC<LLN) vs. normal spirometry at TB treatment completion (n=283) and 1-year later (n=242) 
 
 TB treatment completion (n=283) 1-year post TB treatment completion (n=242) 
Age (yrs) 0.96 (0.92 – 0.99)* 0.96 (0.91 – 1.01) 1.00 (0.93 – 1.08) 
Gender 
- Female 
- Male 
 
1,0 
0.99 (0.41 – 2.37) 
 
1.0 
0.41 (0.14 – 1.20) 
0.06 (0.01 – 0.50)* 
Height (cm) 0.99 (0.94 – 1.04) 1.02 (0.95 – 1.08) 1.12 (0.98 – 1.28) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.82 (0.44 – 1.75) 
0.42 (0.17 – 1.07) 
 
1.0 
0.61 (0.27 – 1.41) 
0.34 (0.10 – 1.16) 
 
1.0 
0.16 (0.04 – 0.70)* 
0.21 (0.03 – 1.59) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
1.11  (0.50 – 2.46) 
 
1.0 
1.30 (0.50 – 3.39) 
 
1.0 
1.82 (0.35 – 9.46) 
BMI at TB treatment completion (kg/m2) 0.89 (0.79 – 1.01) 0.87 (0.75 – 1.02) 0.96 (0.77 – 1.20) 
Illness duration prior to TB treatment 
- <1-month 
- ≥1-month 
 
1.0 
1.28 (0.68 – 2.39) 
 
1.0 
1.40 (0.64 – 3.08) 
 
1.0 
0.43 (0.11 – 1.67) 
Ever smoking 
- Never 
- Ever 
 
1.0 
0.86 (0.40– 1.86) 
 
1.0 
1.04 (0.40 – 2.70) 
 
1.0 
1.25 (0.24 – 6.45) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
1.31 (0.65 – 2.63) 
 
1.0 
1.19 (0.51 – 2.78) 
 
1.0 
0. 67 (0.14 – 3.09) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
1.65 (0.83 – 3.26) 
 
1.0 
2.03 (0.88 – 4.65) 
 
1.0 
1.48 (0.35 – 6.30) 
Baseline spirometry pattern 
- Normal 
- Obstruction 
- Low FVC 
  
 
1.0 
Empty^ 
216.98 (37.87 – 1243.21)*** 
Parenchyma, except mosaicism 
- <1/3 abnormal 
- ≥1/3 abnormal 
  1.0 1.53  (0.31 – 7.62) 
Mod-severe bronchiectasis 
- <3 lobes 
- ≥3 lobes 
  
 
1.0 
15.37 (1.19 –199.01)* 
Any OPD / IP respiratory visits 
- No 
- Yes 
  
 
1.0 
0.94 (0.16 – 5.39) 
TB retreatment 
- No 
- Yes 
  
 
1.0 
1.31 (0.00 – 512.60) 
*p<.05, **p<.01, ***p<.0001
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MODEL FINDINGS 
 HIV AND TB MICROBIOLOGY AT BASELINE 
HIV-infected participants had preserved spirometry at TB treatment completion and 1-year later, 
compared to HIV negatives: controlling for other participant characteristics, the absolute FEV1 volume 
in HIV positives with CD4 counts <200cells/uL was was 190ml (95% CI: 40 - 339ml) larger at baseline 
and 244 ml (95% CI: 93 - 394ml) larger at 1-year compared to HIV negative adults, and absolute FVC 
volume was 171ml (95% CI: 8 - 333ml) larger at baseline and 272ml (95% CI: 113 - 431ml) larger at 1-
year. Because the magnitude of the associations with absolute FEV1 and FVC volumes are broadly 
similar HIV status was not independently associated with the FEV1/FVC ratio. HIV status was not 
associated with airway obstruction or low FVC patterns of deficit in the logistic models.  
HIV-infected participants also showed a greater recovery in their lung volumes over the follow-up 
period. This pattern was consistent across both CD4 groups: on average, controlling for other 
participant characteristics, the increment in FEV1 was 69-103ml larger and in FVC was 103-126ml 
larger in HIV positives compared to negatives.  
In the majority of models, baseline TB microbiology was not a significant predictor of spirometry 
outcomes in either univariate or multivariate analyses controlling for HIV.  
 BMI 
Participants with higher BMI values at TB treatment completion had better lung volumes at both this 
time point and 1-year later: controlling for characteristics including food security, SES and HIV, a 
1.0kg/m2 higher BMI at treatment completion was associated with FEV1 volumes which were 39ml / 
34ml higher at baseline and 1-year, and FVC volumes which were 52ml / 39ml higher.  
 SOCIOECONOMIC STATUS AND DELAYS TO TREATMENT 
Neither socioeconomic quintile nor food insecurity were independently associated with absolute FEV1 
or FVC volumes at baseline or 1-year in multivariate models. However, low SES was an independent 
predictor of the FEV1/FVC ratio: on average participants from lower socioeconomic quintiles had ratios 
which were 2.8% lower (95% CI: 0.7-4.9% lower) at TB treatment completion, and 3.0% lower (95% CI: 
0.7-5.3% lower) 1-year later. That is, whilst the individual negative relationships between SES and 
individual FEV1 or FVC measures were not statistically significant, the differential association with the 
FEV1 and FVC parameters was sufficient to alter the ratio and act as a risk factor for increasing airway 
obstruction.  
Illness duration prior to treatment was negatively correlated with both the FEV1 and FEV1/FVC ratio: 
on average, and controlling for other participant characteristics, those who had been unwell for ≥1-
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month had FEV1 volumes which were 116ml lower (95% CI: 0.3 – 239ml) at baseline and 124ml lower 
(95% CI: 6 – 241ml) at 1-year, and FEV1/FVC ratios which were 2.1% (95% CI: 0.1 – 4.2%) lower at both 
time points, compared to those with <1-month to treatment. The relationship between illness 
duration and FVC was not statistically significant at either time point.  
 SMOKING 
Ever smoking was not correlated with lung function measures at either TB treatment completion, or 
1-year later in multivariate analyses. It was also not correlated with change in lung function over time.  
 BASELINE PATHOLOGY AS A PREDICTOR OF SPIROMETRY AT 1-YEAR 
Spirometry at TB treatment completion was the strongest predictor of spirometry at 1-year – this 
pattern was seen in both linear models of absolute FEV1 and FVC volumes, and logistic models for 
patterns of deficit. Controlling for participant characteristics, a 100ml larger baseline FEV1 volume was 
associated with an 87ml larger (95% CI: 82-91ml) FEV1 at 1-year, and a 100ml larger baseline FVC 
volume was associated with an 85ml larger (95% 80-89ml) FVC at 1yr. In the linear models for both 
FEV1 and FVC at 1-year, the addition of baseline spirometry to predictive models including participant 
characteristics increased the model R2 values from 0.51 to 0.92 for FEV1, and 0.58 to 0.93 for FVC, 
suggesting that spirometry at TB treatment completion explains much of the heterogeneity in the 
volumes at 1-year.    
The extent of structural damage on CT at TB treatment completion was an alternative predictor of 
spirometry at 1-year: controlling for participant characteristics, the presence of parenchymal 
pathology affecting ≥1/3 of the lung at TB treatment completion was associated with FEV1 and FVC 
volumes which were on average 406ml (95% CI: 249 – 563ml) and 368ml (95% CI: 200 – 536ml) lower 
at 1-year, and the presence of bronchiectasis affecting ≥3-lobes at TB treatment completion was 
associated with FEV1 and FVC volumes which were on average 243ml (95% CI: 34 – 452ml)and 309ml 
(95% CI: 86 – 532ml) lower at 1-year.  
If both measures of baseline spirometry and baseline CT pathology were included together in models 
for 1-year spirometry outcomes, the relationships between imaging and outcome were no longer 
significant. This suggests that the effect of baseline imaging on 1-year spirometry is mediated through 
its effect on baseline spirometry. The same is true for BMI, SES and illness duration whose relationship 
with spirometry at 1-year becomes no longer statistically significant when baseline spirometry is 
controlled for, suggesting that their association with 1-year lung function is mediated by their impact 
on spirometry at TB treatment completion. 
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 BASELINE LUNG FUNCTION AND IMAGING AS PREDICTORS OF CHANGE 
OVER TIME 
The R2 values for the models describing change in FEV1 and FVC over time were very poor, ranging 
from 0.114 – 0.291. The ability of these models to predict the trajectory of change over this 1-year 
interval is limited, in comparison to the predictive capacity of the models constructed for static 
spirometry findings at TB treatment completion or 1-year. However, within these models spirometry 
at TB treatment completion emerged as a strong predictor of change over time. The ‘catch up’ 
phenomenon described in univariate analysis of the primary data above was observed again within 
multivariate models: on average those with 100ml lower baseline FEV1 volumes had an increase in 
FEV1 volume which was 14ml (95% CI: 9 – 18ml) larger over 1-year, and those with 100ml lower 
baseline FVC volumes had an average increase which was 16ml (95% CI: 11-21ml) larger (Figure 31).  
Figure 31: Observed and predicted values for change in FEV1 and FVC (ml) over the 1-year follow up period, plotted by 
baseline spirometry measures at TB treatment completion. Predicted values derived from models controlling for participant 
characteristics and baseline imaging / lung function, with 95% Confidence intervals. 
  
 
 
The same pattern of greater recovery amongst those with the more extensive parenchymal pathology 
at TB treatment completion was seen with imaging: in models controlling for participant 
characteristics, those with ≥1/3 abnormal parenchyma at TB treatment completion had a larger 
increase in FEV1 (72ml, 95% CI: 2 – 142ml) and FVC (110ml, 95% CI: 31 – 188ml) over the follow up 
period, compared to those without such marked damage at baseline. Again, when both spirometry 
and imaging at treatment completion were included together and ‘controlled for’ in models of change 
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over time, the relationship between imaging and change ceased to be statistically significant. No 
association between extensive bronchiectasis (moderate to severe pathology affecting ≥3 lobes) and 
change in either FEV1 or FVC were seen in any of the models, including those in which bronchiectasis 
was the only imaging parameter of interest (not shown). 
 IMPORTANCE OF ONGOING RESPIRATORY INFECTIONS 
Controlling for participant characteristics +/- baseline lung pathology, the presence of ≥1 respiratory 
exacerbation and restarting TB treatment were negatively correlated with change in both FEV1 and 
FVC over time and their final values at 1-year. However, this relationship was statistically significant 
for FVC only: controlling for participant characteristics and spirometry / imaging at TB treatment 
completion, individuals experiencing ≥1 respiratory exacerbation had an 80ml greater loss in FVC (95% 
CI: 6 – 154ml) and final FVC volumes which were on average 81ml smaller (95% CI: 6.5 – 155ml) at 1-
year, compared to those without any exacerbations. However, the wide confidence intervals around 
these estimates must be noted.  
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5.3.12 RELATIONSHIP BETWEEN PTLD AND OUTCOMES 
In this section the relationship between PTLD defined using the a-priori criteria outlined above, and 
adverse patient outcomes are described, using multivariate models controlling for participant 
characteristics.  
Findings of exploratory analysis investigating the relationship between specific imaging / spirometry 
parameters at TB treatment completion and outcomes are also presented.  
MODEL CONSTRUCTION 
 A PRIORI PTLD  
The prevalence of PTLD defined by spirometry criteria at TB treatment completion was 29.6% 
(108/365), including 73 individuals with Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) and 35 individuals 
with moderate airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN).  
The prevalence of CT based PTLD was 19.0% (73/385), including 29 individuals with moderate-severe 
bronchiectasis in ≥3 lobes, and 64 individuals with parenchymal abnormality of ≥1/3 of the lung tissue, 
excluding mosaicism, with an overlap between features seen in 20 individuals.  
A total of 142 individuals had either CT or spirometry defined PTLD giving a prevalence of 35.1%, whilst 
39/405 individuals had both CT and spirometry based PTLD giving a prevalence of 9.6% (Table 45). 
Table 45: Relationship between the a priori PTLD groups defined by CT and spirometry findings 
CT defined PTLD 
Spirometry defined PTLD 
TOTAL 
Absent Present Missing 
Absent 219 64 29 312 
Present 27 39 7 73 
Missing 11 5 4 20 
TOTAL 257 108 40 405 
Spirometry defined PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN), OR Low FVC (FEV1/FVC ratio≥0.7 and 
FVC<LLN) 
CT defined PTLD: Moderate-severe bronchiectasis in ≥3 lobes, OR Parenchymal abnormality of ≥1/3 of the lung tissue 
 Dark green: Both CT and spirometry defined PTLD; Light green: Either CT or spirometry defined PTLD 
 
 A TOTAL OF 349/405 STUDY PARTICIPANTS HAD BOTH VALID CT DATA 
AND VALID SPIROMETRY DATA AVAILABLE FROM TB TREATMENT 
COMPLETION. HIV-STATUS WAS MISSING FOR 2 OF THESE PATIENTS, 
SUCH THAT DATA FROM 347 PARTICIPANTS WAS AVAILABLE FOR 
INCLUSION IN THE MODELS OF PARTICIPANT OUTCOMES CONSTRUCTED 
HERE. OUTCOME EVENTS 
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The most common outcomes observed were the presence of impaired quality of life (37.2%, 137/368) 
and regular respiratory symptoms (30.7%, 113/368) at 1-year. Amongst those contributing either 1-
year (n=364) or 6-months (n=16) of follow-up data, 16.3% (62/380) had ≥1 respiratory exacerbation 
and 3.9% (15/380) were restarted on TB treatment – these numbers were too low to perform a person-
time analysis. 2.7% (11/404) of the cohort died during follow up (Table 46). 
 
Table 46: Prevalence of adverse outcomes and description of data included in models  
Outcome 
variable 
Definition Prevalence in 
total study 
population* 
N(%) 
Outcome data 
included  in logistic 
models^ 
N (%) 
Quality of life Prevalence of impaired quality of life (SGRQ total score >6), 1-year 
post TB treatment completion 
137/368 
(37.2%) 
85/325 
Chronic 
respiratory 
symptoms  
Prevalence of self-reported cough OR sputum production OR 
breathlessness OR wheeze occurring at least monthly (several 
days/ week, or most days/week), 1-year post TB treatment 
completion. 
113/368 
(30.7%) 
102/325  
Acute 
respiratory 
exacerbation 
Presence of ≥1 unscheduled visit to a health care provider 
(outpatient or inpatient) due to a respiratory complaint (cough, 
breathlessness, wheeze, sputum production) within the 1-year 
period 
62/380 
(16.3%) 
56/335 
TB retreatment  Initiation of TB retreatment within 1-year from TB treatment 
completion – including those with and without microbiological 
evidence of disease recurrence.  
15/380 (3.9%) 13/347 
Mortality All-cause mortality within 1-year from TB treatment completion 11/404 (2.7%) 8/347  
^Denominators for parameters measured at 1-year (Quality of life & Chronic respiratory symptoms) include participants 
completing the 1-year study visit (n=368);Denominator for parameters measured over time (Acute respiratory exacerbations 
& TB retreatment) include both those completing full 1-year follow-up (n=364) and those contributing 6-months of follow-up 
data (n=16); Denominator for mortality includes the full cohort, except 1-participant who was lost to follow up and whose 
vital status was not ascertained (n=404) 
^Final models include only those with valid CT data, spirometry data, and HIV-status at TB treatment completion (maximum 
n=347), as well as those meeting conditions in previous column.  
 
MODEL FINDINGS 
Results for the multivariate models constructed to explore the relationship between PTLD and these 
outcomes, controlling for participant characteristics, are presented in Tables 47 – 51. Table 52 is a 
summary table that lists the correlation coefficients of the PTLD parameters included in the 
multivariate models constructed for each of the outcomes for comparison, together with specific 
imaging / spirometry variables included as predictors of outcome in exploratory models.  
 PARTICIPANT CHARACTERISTICS PREDICTING ADVERSE OUTCOMES 
HIV infection was associated with decreased odds of adverse respiratory outcomes at 1-year, 
regardless of CD4 count: controlling for other participant characteristics, HIV positive individuals were 
less likely to have an elevated SGRQ-total score at 1-year (CD4≥200: OR 0.28 (95% CI 0.15-0.55) / 
CD4<200: OR 0.36 (95% CI: 0.17-0.75)), less likely to have chronic respiratory symptoms at 1-year 
(CD4≥200: OR 0.31 (95% CI 0.17-0.58) / CD4<200: OR 0.36 (95% CI: 0.18-0.73)), and less likely to have 
experienced an acute respiratory episode by 1-year (CD4≥200: OR 0.40 (95% CI 0.19-0.82) / CD4<200: 
OR 0.29 (95% CI: 0.12-0.70)), compared to HIV negatives. No association was demonstrated between 
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HIV status and TB retreatment. Although HIV infection with CD4 count<200 cells/uL was associated 
with increased odds of death in the year following treatment completion in univariate analysis, this 
was not significant in multivariate models.  
Higher levels of haemoglobin at TB treatment completion were associated with reduced odds of 
having an elevated SGRQ-total score (OR 0.79, 95% CI: 0.67-0.94) or chronic respiratory symptoms at 
1-year (OR 0.82, 95% CI:0.70 – 0.97), as well as decreased odds of all-cause mortality over this year 
(OR 0.63, 95% CI 0.41 – 0.97).  
No other participant characteristics were identified as clear predictors of adverse outcomes across the 
models, including demographic factors, socioeconomic status, and ever-smoking. 
 PTLD AND PERSISTENT RESPIRATORY SYMPTOMS 
Controlling for participant characteristics, the presence of respiratory symptoms occurring on a weekly 
or monthly basis 1-year after TB treatment completion was the outcome most widely associated with 
different measures of post-TB lung damage. In the primary analysis, the odds of persistent symptoms 
were 1.74 times higher in those who had had either spirometry or CT defined PTLD (95% CI:1.03 – 
2.95) at treatment completion. In the secondary analysis, the odds of persistent symptoms were 3.65 
times higher (95% CI: 1.62 – 8.22) in who met the criteria for both CT and spirometry defined PTLD at 
treatment completion.  
In the exploratory analysis, moderate to severe bronchiectasis in ≥3 lobes was independently 
associated with ongoing symptoms at 1-year (OR 2.88, 95% CI: 1.16 – 7.10). The presence of moderate 
obstruction on spirometry at treatment completion was predictive of ongoing symptoms (OR 2.53, 
95% CI: 1.15 – 5.59), and higher FEV1 z-scores and FEV1/FVC ratios at TB treatment completion were 
associated with decreased odds of persistent symptoms. Although FVC z-scores were associated with 
a reduction in symptoms, the OR for this relationship was not statistically significant.  
 PTLD AND IMPAIRED QUALITY OF LIFE 
In primary analysis, controlling for participant characteristics, the relationship between PTLD defined 
by either CT or spirometry criteria, and the presence of an increased SGRQ score at 1-year was not 
statistically significant (OR 1.54, 95% CI: 0.99 – 2.69). However, on secondary analysis, the odds of 
having a reduced quality of life at 1-year were 3.57 times higher in those who had had both extensive 
CT and spirometry abnormalities at TB treatment completion (95% CI: 1.55 – 8.25).  
In the exploratory analysis conducted for this outcome, the imaging parameter which best predicted 
an impaired quality of life at 1-year was the presence of extensive parenchymal pathology of ≥1/3 
parenchyma (OR2.19, 95% CI: 1.11 – 4.31) at treatment completion. Spirometry classified according 
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to the pattern of deficit was not independently associated with the outcome, but higher FEV1 z-scores, 
FVC z-scores and FEV1/FVC ratios were all protective against impaired quality of life. 
 PTLD AND ACUTE RESPIRATORY EVENTS / TB RETREATMENT / ALL-CAUSE 
MORTALITY  
Controlling for participant characteristics, no associations were observed between any measures of 
PTLD at TB treatment completion, and the occurrence of an acute respiratory event (n=56) or all-cause 
mortality (n=8) within the 1-year follow up period for the participants with full data who were included 
in the models (n=335/n=347). This was the case for both the broad PTLD groups specified a-priori, and 
parameters included in the exploratory analyses.  
None of the a-priori PTLD definitions were associated with the initiation of TB retreatment during 
follow up, but an increase in FEV1 z-score at treatment completion was associated with a reduction in 
the odds of TB retreatment during follow up of 43% (OR: 0.57, 95% CI: 0.34-0.96).  
The potentially inflammatory pathologies (ground glass change, consolidation, nodules) were not 
associated with either TB retreatment or death during follow up. The presence of a destroyed lung 
lobe was not correlated with any of the outcomes measured.  
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PRESENCE OF REDUCED QUALITY OF LIFE AT 1-YEAR 
Table 47: Logistic regression models for elevated (>6) vs. normal (≤6) SGRQ total score, at 1-year post TB treatment completion. OR (95% CI) presented. (n=325) 
 
 Univariate analysis Participant characteristics +  Spiro PTLD + CT PTLD + Either PTLD^ 
+ Both PTLD$ 
(n=238) 
Age (yrs) 1.01 (0.99 – 1.04) 1.01 (0.99 – 1.04) 1.02 (0.99 – 1.04) 1.01 (0.99 – 1.04) 1.01 (0.99 – 1.04) 1.01 (0.97 – 1.04) 
Gender 
- Female 
- Male 
 
1.0 
0.75 (0.45 – 1.28) 
 
1.0 
0.93 (0.44 – 1.97) 
 
1.0 
0.96 (0.45 – 2.04) 
 
1.0 
0.89 (0.42 – 1.90) 
 
1.0 
0.94 (0.44 – 2.00) 
 
1.0 
0.87 (0.35 – 2.14) 
HIV status  
- Negative 
- Positive, CD4≥200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.42 (0.24 – 0.76)** 
0.62 (0.33 – 1.15) 
 
1.0 
0.28 (0.15 – 0.55)*** 
0.36 (0.17 – 0.75)** 
 
1.0 
0.30 (0.15 – 0.58)*** 
0.39 (0.19 – 0.83)* 
 
1.0 
0.28 (0.14 – 0.54)*** 
0.37 (0.18 – 0.78)** 
 
1.0 
0.29 (0.15 – 0.57)*** 
0.40 (0.19 – 0.84)* 
 
1.0 
0.27 (0.12 – 0.60)** 
0.32 (0.14 – 0.715)** 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
0.88 (0.49 – 1.58) 
 
1.0 
0.77 (0.40 – 1.47) 
 
1.0 
0.78 (0.41 – 1.50) 
 
1.0 
0.78 (0.41 – 1.51) 
 
1.0 
0.77 (0.40 – 1.47) 
 
1.0 
0.61 (0.28 – 1.30) 
BMI at TB treatment  end (kg/m2) 0.99 (0.91 – 1.09) 1.02 (0.93 – 1.13) 1.04 (0.94 – 1.14) 1.04 (0.95 – 1.15) 1.04 (0.94 – 1.14) 1.07 (0.95- 1.21) 
Hb at TB treatment  end(g/dL) 0.86 (0.75 – 0.97)* 0.79 (0.67 – 0.94)** 0.80 (0.66 – 0.94)** 0.79 (0.66 – 0.94)* 0.79 (0.66 – 0.94)** 0.80 (0.65 – 0.97)* 
Ever smoking 
- Never 
- Ever 
 
1.0 
1.11 (0.65 – 1.89) 
 
1.0 
1.22 (0.64 – 2.33) 
 
1.0 
1.27 (0.66 – 2.44) 
 
1.0 
1.18 (0.61 – 2.27) 
 
1.0 
1.24 (0.65 – 2.37) 
 
1.0 
1.50 (0.68 – 3.29) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
1.10 (0.66 – 1.81) 
 
1.0 
1.01 (0.56 – 182) 
 
1.0 
0.96 (0.53 – 1.74) 
 
1.0 
0.97 (0.53 – 1.76) 
 
1.0  
0.96 (0.53 – 1.74) 
 
1.0 
0.78 (0.37 – 1.61) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
1.15 (0.68 – 1.93) 
 
1.0 
1.16 (0.63 – 2.11) 
 
1.0 
1.09 (0.60 – 2.01) 
 
1.0 
1.13 (0.61 – 2.08) 
 
1.0 
1.11 (0.61 – 2.04) 
 
1.0 
1.39 (0.65 – 2.96) 
Spirometric PTLD# 
- No 
- Yes 
 
1.0 
1.78 (1.06 – 3.01)* 
 
 
 
1.0 
1.76 (0.99 – 3.13) 
   
CT PTLD# 
- No 
- Yes 
 
1.0 
1.85 (1.03 – 3.34)* 
  
 
1.0 
2.07 (1.09 – 3.96)* 
  
Either spiro or CT PTLD^ 
- No 
- Yes 
 
1.0 
1.57 (0.95 – 2.60) 
   1.0 1.54 (0.88 – 2.69)  
Both spiro and CT PTLD$ 
- No 
- Yes 
 
1.0 
3.03 (1.46 – 6.31)** 
    
 
1.0 
3.57 (1.55 – 8.25)** 
*p<.05, **p<.01, ***p<.001 
#Spirometric PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN) / Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) using GLI-2012 reference equations; CT PTLD: Moderate-severe bronchiectasis in ≥3 lobes / 
parenchymal abnormality of ≥1/3 of the lung tissue, excluding mosaicism 
^Participants with either Spirometric and CT PTLD (n=121) at baseline compared to those with neither (n=198) at baseline 
$Participants with both Spirometric and CT PTLD (n=36) at baseline compared to those with neither (n=198) at baseline  
  
190 
 
PRESENCE OF CHRONIC RESPIRATORY SYMPTOMS AT 1-YEAR 
Table 48: Logistic regression models for chronic respiratory symptoms at 1-year, OR (95% CI) presented. (n=325). 
Chronic respiratory symptoms defined as the presence of self-reported cough OR sputum production OR breathlessness OR wheeze occurring at least monthly (several days/ week, or most days/week) 
 
 Univariate analysis Participant characteristics +  Spiro PTLD + CT PTLD + Either PTLD^ 
+ Both PTLD$ 
(n=238) 
Age (yrs) 0.99 (0.97 – 1.02) 1.00 (0.97 – 1.02) 1.00 (0.97 – 1.02) 0.99 (0.97- 1.02) 0.99 (0.97 – 1.02) 0.97 (0.94 – 1.01) 
Gender 
- Female 
- Male 
 
1.0 
0.61 (0.37 – 1.00) 
 
1.0 
0.85 (0.42 – 1.71) 
 
1.0 
0.87 (0.43 – 1.77) 
 
1.0 
0.82 (0.40 – 1.66) 
 
1.0 
0.86 (0.42 – 1.73) 
 
1.0 
0.92 (0.40 – 2.16) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.46 (0.26 – 0.79)** 
0.53 (0.29 – 0.98)* 
 
1.0 
0.31 (0.17 – 0.58)*** 
0.36 (0.18 – 0.73)** 
 
1.0 
0.33 (0.17 – 0.61)*** 
0.40 (0.20 – 0.82)* 
 
1.0 
0.30 (0.16 – 0.56)*** 
0.37 (0.18 – 0.76)** 
 
1.0 
0.32 (0.17 – 0.59)*** 
0.40 (0.20 – 0.83)* 
 
1.0 
0.37 (0.17 – 0.78)** 
0.41 (0.18 – 0.92)* 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
0.80 (0.46 – 1.40) 
 
1.0 
0.66 (0.36 – 1.22) 
 
1.0 
0.67 (0.36 – 1.24) 
 
1.0 
0.67 (0.36 – 1.25) 
 
1.0 
0.66 (0.36 – 1.22) 
 
1.0 
0.52 (0.25 – 1.08) 
BMI at TB Rx end (kg/m2) 1.01 (0.93 – 1.10) 1.04 (0.95 – 1.14) 1.07 (0.97 – 1.17) 1.07 (0.97 – 1.17) 1.07 (0.97 – 1.17) 1.06 (0.94 – 1.19) 
Haemoglobin at TBRx end (g/dL) 0.88 (0.78 – 1.00) 0.82 (0.70 – 0.97)* 0.82 (0.70 – 0.97)* 0.82 (0.69 – 0.97)* 0.82 (0.69 – 0.97) 0.85 (0.70 – 1.02) 
Ever smoking 
- Never 
- Ever 
 
1.0 
0.83 (0.49 – 1.39) 
 
1.0 
0.93 (0.50 – 1.73) 
 
1.0 
0.98 (0.52 – 1.84) 
 
1.0 
0.89 (0.47 – 1.66) 
 
1.0 
0.94 (0.50 – 1.75) 
 
1.0 
1.20 (0.57 – 2.54) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
1.25 (0.78 – 2.02) 
 
1.0 
1.39 (0.80 – 2.42) 
 
1.0 
1.32 (0.75 – 2.31) 
 
1.0 
1.3 (0.77– 2.37) 
 
1.0 
1.32 (0.75 – 2.30) 
 
1.0 
1.18 (0.60 – 2.32) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
1.08 (0.66 – 1.76) 
 
1.0 
1.00 (0.57 – 1.77) 
 
1.0 
0.93 (0.52 – 1.66) 
 
1.0 
0.98 (0.55 – 1.75) 
 
1.0 
0.96 (0.54 – 1.70) 
 
1.0 
1.01 (0.49 – 2.06) 
Spirometric PTLD# 
- No 
- Yes 
 
1.0 
2.19 (1.33 – 3.61)** 
 
 
1.0 
2.11 (1.22– 3.65)* 
   
CT PTLD# 
- No 
- Yes 
 
1.0 
1.72 (0.97 – 3.04) 
  
 
1.0 
2.03 (1.09 – 3.80)* 
  
Spiro or CT PTLD^ 
- No 
- Yes 
 
1.0 
1.75 (1.09 – 2.83)* 
   
 
1.0 
1.74 (1.03 – 2.95) 
 
Spiro and CT PTLD$ 
- No 
- Yes 
 
1.0 
3.43 (1.66 – 7.09)** 
    
 
1.0 
3.65 (1.62 – 8.22)** 
*p<.05, **p<.01, ***p<.001 
#Spirometric PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN) / Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) using GLI-2012 reference equations 
#CT PTLD: Moderate-severe bronchiectasis in ≥3 lobes / parenchymal abnormality of ≥1/3 of the lung tissue, excluding mosaicism 
^Participants with either Spirometric and CT PTLD (n=121) at baseline compared to those with neither (n=198) at baseline   
$Participants with both Spirometric and CT PTLD (n=36) at baseline compared to those with neither (n=198) at baseline  
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≥1 ACUTE RESPIRATORY EPISODE OVER 1-YEAR 
Table 49: Logistic regression models for the presence / absence of ≥1 acute respiratory episode in the 1-year follow period amongst those contributing 6-12m follow up person time (n=335). OR (95% CI) presented.  
 
 Univariate analysis Participant characteristics +  Spiro PTLD + CT PTLD + Either PTLD^ 
+ Both PTLD$ 
(n=247) 
Age (yrs) 1.01 (0.99 – 1.04) 1.02 (0.99 – 1.05) 1.03 (1.00 – 1.06) 1.02 (0.99 – 1.05) 1.02 (0.99 – 1.05) 1.01 (0.97- 1.05) 
Gender 
- Female 
- Male 
 
1.0 
0.78 (0.42 – 1.42) 
 
1.0 
1.13 (0.49 – 2.58) 
 
1.0 
1.16 (0.50 – 2.68) 
 
1.0 
1.10 (0.48 – 2.53) 
 
1.0 
1.14 (0.49 – 2.64) 
 
1.0 
1.72 (0.61 – 4.81) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.51 (0.26 – 1.00)* 
0.50 (0.23 – 1.06) 
 
1.0 
0.40 (0.19 – 0.82)* 
0.29 (0.12 – 0.70)** 
 
1.0 
0.41 (0.20 – 0.86) 
0.32 (0.13 – 0.77) 
 
1.0 
0.39 (0.19 – 0.81)* 
0.30 (0.12 – 0.71)** 
 
1.0 
0.41 (0.20 – 0.85)* 
0.33 (0.13 – 0.80)* 
 
1.0 
0.50 (0.20 – 1.26) 
0.37 (0.14 – 1.02) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
1.05 (0.52 – 2.11) 
 
1.0 
1.17 (0.55 – 2.51) 
 
1.0 
1.20 (0.56 – 2.56) 
 
1.0 
1.19 (0.56 – 2.54) 
 
1.0 
1.17 (0.55 – 2.50) 
 
1.0 
1.03 (0.43 – 2.49) 
BMI at TB treatment end (kg/m2) 0.98 (0.89 – 1.09) 0.99 (0.89 – 1.11) 1.01 (0.90 – 1.13) 1.01 (0.90 – 1.13) 1.01 (0.91 – 1.13) 0.99 (0.86 -1.15) 
Hb at TB treatment end (g/dL) 0.90 (0.78 – 1.04) 0.84 (0.70 – 1.01) 0.84 (0.70 – 1.01) 0.83 (0.69 – 1.00) 0.83 (0.69 – 1.00) 0.79 (0.63 – 0.98) 
Ever smoking 
- Never 
- Ever 
 
1.0 
0.61 (0.31 – 1.22) 
 
1.0 
0.58 (0.26 – 1.26) 
 
1.0 
0.59 (0.27 – 1.31) 
 
1.0  
0.56 (0.25 – 1.24) 
 
1.0 
0.58 (0.26 – 1.28) 
 
1.0  
0.60 (0.23 – 1.56) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
0.77 (0.43 – 1.36) 
 
1.0 
0.73 (0.38 – 1.43) 
 
1.0 
0.69 (0.35 – 1.36) 
 
1.0 
0.72 (0.37 – 1.41) 
 
1.0 
0.69 (0.35 – 1.35) 
 
1.0 
0.76 (0.33 – 1.73) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
0.92 (0.50 – 1.69) 
 
1.0 
1.00 (0.49 – 2.02) 
 
1.0 
0.94 (0.46 – 1.92) 
 
1.0 
0.98 (0.48 – 2.00) 
 
1.0 
0.94 (0.46 – 1.91) 
 
1.0 
0.65 (0.25 – 1.71) 
Spirometric PTLD# 
- No 
- Yes 
 
1.0 
1.76 (0.97 – 3.20) 
 
 
1.0 
1.73 (0.90 – 3.34) 
   
CT PTLD# 
- No 
- Yes 
 
1.0 
1.38 (0.69 – 2.77) 
  1.0 1.53 (0.72 – 3.24)   
Either spiro or CT PTLD^ 
- No 
- Yes 
 
1.0 
1.75 (0.98 – 3.12) 
   
 
1.0 
1.74 (0.92 – 3.31) 
 
Both spiro and CT PTLD$ 
- No 
- Yes 
 
1.0 
1.79 (0.75 – 4.31) 
    
 
1.0 
1.96 (0.74 – 5.18) 
*p<.05, **p<.01, ***p<.001 
#Spirometric PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN) / Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) using GLI-2012 reference equations 
#CT PTLD: Moderate-severe bronchiectasis in ≥3 lobes / parenchymal abnormality of ≥1/3 of the lung tissue, excluding mosaicism 
^Participants with either Spirometric and CT PTLD (n=121) at baseline compared to those with neither (n=198) at baseline  $Participants with both Spirometric and CT PTLD (n=36) at baseline compared to those with 
neither (n=198) at baseline  
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INITIATION OF TB RETREATMENT DURING 1-YEAR 
Table 50: Logistic regression models for TB retreatment (n=13) within the year follow-up (n=347). OR (95% CI) presented. 
 
 Univariate analysis Participant characteristics +  Spiro PTLD + CT PTLD + Either PTLD 
+ Both PTLD 
(n=256) 
Age (yrs) 1.00 (0.95 – 1.06) 0.98 (0.92 – 1.05) 0.99 (0.92 – 1.05) 0.98 (0.92 – 1.05) 0.98 (0.91 – 1.05) 0.96 (0.87 – 1.06) 
Gender 
- Female 
- Male 
 
1.0 
1.53 (0.41 – 5.67) 
 
1.0 
3.40 (0.58 – 19.71) 
 
1.0 
3.73 (0.62 – 22.43) 
 
1.0 
3.44 (0.58 – 20.54) 
 
1.0 
3.75 (0.61 – 22.97) 
 
1.0 
18.77  (1.36 – 259.01)* 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.64 (0.15 – 2.74) 
1.49 (0.42 – 5.30) 
 
1.0 
0.64 (0.13 – 3.08) 
0.95 (0.20 – 4.58) 
 
1.0 
0.69 (0.14 – 3.33) 
1.09 (0.22 – 5.43) 
 
1.0 
0.62 (0.13 – 2.99) 
0.96 (0.20 – 4.63) 
 
1.0 
0.69 (0.14 – 3.32) 
1.14 (0.22 – 5.84) 
 
1.0 
0.25 (0.03 – 2.12) 
0.24 (0.03 – 2.13) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
1.57 (0.34 – 7.22) 
 
1.0 
1.99 (0.38 – 10.46) 
 
1.0 
2.07 (0.40 – 10.78) 
 
1.0 
1.99 (0.38 – 10.34) 
 
1.0 
2.02 (0.39 – 10.48) 
 
1.0 
4.85 (0.42 – 55.68) 
BMI at TB treatment completion 
(kg/m2) 0.77 (0.59 – 1.00) 0.84 (0.63 – 1.10) 0.86 (0.65 – 1.14) 0.86 (0.65 – 1.13) 0.86 (0.65 – 1.14) 0.75 (0.50 – 1.12) 
Haemoglobin at TB treatment 
completion (g/dL) 0.75 (0.58 –  0.96) 0.68 (0.50 – 0.92) 0.67 (0.49 – 0.92) 0.66 (0.48 – 0.91)* 0.67 (0.48 – 0.92) 0.54 (0.34 – 0.86)** 
Ever smoking 
- Never 
- Ever 
 
1.0 
1.04 (0.31 – 3.46) 
 
1.0 
0.85 (0.22 – 3.34) 
 
1.0 
0.88 (0.22 – 3.47) 
 
1.0 
0.83 (0.21 – 3.31) 
 
1.0 
0.86 (0.22 – 3.39) 
 
1.0 
0.26 (0.04 – 1.80) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
1.11 (0.34 – 3.56) 
 
1.0 
1.20 (0.30 – 4.80) 
 
1.0 
1.14 (0.29 – 4.55) 
 
1.0 
1.16 (0.29 – 3.31) 
 
1.0 
1.14 (0.28 – 4.54) 
 
1.0 
0.74 (0.12 – 4.69) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
0.91 (0.27 – 3.00) 
 
1.0 
0.75 (0.17 – 3.18) 
 
1.0 
0.66 (0.15 – 2.91) 
 
1.0 
0.71 (0.16 – 3.06) 
 
1.0 
0.66 (0.15 – 2.92) 
 
1.0 
1.61 (0.24 – 10.74) 
Spirometric PTLD# 
- No 
- Yes 
 
1.0 
2.09 (0.69 – 6.39) 
 
 
1.0 
2.08 (0.58 – 7.40) 
   
CT PTLD# 
- No 
- Yes 
 
1.0 
1.95 (0.58 – 6.54) 
  
 
1.0 
1.78 (0.48 – 6.60) 
  
Either spiro or CT PTLD^ 
- No 
- Yes 
 
1.0 
2.00 (0.66 – 6.09) 
   
 
1.0 
2.09 (0.59 – 7.34) 
 
Both spiro and CT PTLD$ 
- No 
- Yes 
 
1.0 
2.93 (0.70 – 12.25) 
    
 
1.0 
1.84 (0.36 – 9.50) 
*p<.05, **p<.01, ***p<.001 
#Spirometric PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN) / Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) using GLI-2012 reference equations 
#CT PTLD: Moderate-severe bronchiectasis in ≥3 lobes / parenchymal abnormality of ≥1/3 of the lung tissue, excluding mosaicism 
^ Participants with either Spirometric and CT PTLD (n=121) at baseline compared to those with neither (n=198) at baseline   
$Participants with both Spirometric and CT PTLD (n=36) at baseline compared to those with neither (n=198) at baseline  
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ALL-CAUSE MORTALITY DURING 1-YEAR 
Table 51: Logistic regression models for death (n=8) within the year follow-up (n=347), OR (95% CI) presented.  
 
 Univariate analysis Participant characteristics +  Spiro PTLD + CT PTLD + Either PTLD 
+ Both PTLD 
(n=256) 
Age (yrs) 1.04 (0.99 – 1.11) 1.02 (0.94 – 1.11) 1.02 (0.94 – 1.11) 1.02 (0.94 – 1.11) 1.02 (0.94 – 1.11) 1.05 
Gender 
- Female 
- Male 
1.0 
1.36 (0.27 – 6.87) 
1.0 
1.26 (0.13 – 12.64) 
 
1.0 
1.24 (0.12 – 12.58) 
1.0 
1.28 (0.13 – 12.55) 
1.0 
1.21 (0.12 – 12.05) 
 
1.0 
0.64 (0.05- 8.51) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
1.08 (0.07 – 17.49) 
9.32 (1.10 – 78.76)* 
 
1.0 
0.75 (0.04 – 13.29) 
3.73 (0.34 – 41.05) 
 
1.0 
0.74 (0.04 – 13.19) 
3.64 (0.32 – 41.17) 
 
1.0 
0.82 (0.05 – 14.80) 
3.88 (0.34 – 43.88) 
 
1.0 
0.72 (0.04 – 12.74) 
3.36 (0.30 – 38.08) 
1.0 
0.54 (0.03 – 10.46) 
1.99 (0.16 – 25.00) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
0.27 (0.07 – 1.10) 
 
1.0 
0.37 (0.07 – 1.91) 
 
1.0 
0.37 (0.07 – 1.91) 
 
1.0 
0.38 (0.07 – 2.04) 
 
1.0 
0.38 (0.07 – 1.99) 
 
1.0 
0.61 (0.09 – 4.11) 
BMI at TB treatment completion (kg/m2) 0.69 (0.49 – 0.98)* 0.73 (0.49 – 1.07) 0.72 (0.49 – 1.08) 0.71 (0.47 – 1.07) 0.72 (0.48 – 1.07)  0.56 (0.32 – 0.97) 
Haemoglobin at TB treatment 
completion (g/dL) 0.57 (0.41 – 0.80)** 0.63 (0.41 – 0.97)* 0.63 (0.41 – 0.97) 0.64 (0.41 – 0.98)* 0.63 (0.41 – 0.98) 0.71 (0.41 – 1.23) 
Ever smoking 
- Never 
- Ever 
 
1.0  
0.77 (0.15 – 3.90) 
 
1.0 
1.00 (0.14 – 6.91) 
 
1.0 
0.99 (0.14 – 6.90) 
 
1.0 
0.94 (0.13 – 6.59) 
1.0 
0.96 (0.14 – 6.73) 
1.0 
0.39 (0.03 – 4.74) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
0.61 (0.13 – 2.77) 
 
1.0 
0.86 (0.15 – 4.95) 
 
1.0 
0.89 (0.14 – 5.61) 
1.0 
0.96 (0.15 – 5.95) 
1.0 
0.98 (0.15 – 6.29) 
1.0  
0.53 (0.06 – 4.81) 
Food insecurity 
- Never 
- Sometimes / often 
 
n/a 
no deaths amongst those 
missing meals 
     
Spirometric PTLD# 
- No 
- Yes 
 
1.0 
0.79 (0.16 – 3.96) 
 
 
1.0 
0.88 (0.12 – 6.43) 
   
CT PTLD# 
- No 
- Yes 
 
1.0 
0.60 (0.07 – 4.98) 
  
 
1.0 
0.49 (0.05 – 5.14) 
  
Either spiro or CT PTLD^ 
- No 
- Yes 
 
1.0 
0.55 (0.11 – 2.76) 
   1.0 0.63 (0.09 – 4.33)  
Both spiro and CT PTLD$ 
- No 
- Yes 
 
1.0 
0.93 (0.11 – 7.91) 
    1.0 0.46 (0.04 – 5.58) 
*p<.05, **p<.01, ***p<.001 
#Spirometric PTLD: Airway obstruction (FEV1/FVC ratio<LLN and FEV1<LLN) / Low FVC (FEV1/FVC ratio≥0.7 and FVC<LLN) using GLI-2012 reference equations 
#CT PTLD: Moderate-severe bronchiectasis in ≥3 lobes / parenchymal abnormality of ≥1/3 of the lung tissue, excluding mosaicism 
^Participants with either Spirometric and CT PTLD (n=121) at baseline compared to those with neither (n=198) at baseline   
$Participants with both Spirometric and CT PTLD (n=36) at baseline compared to those with neither (n=198) at baseline  
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SUMMARY TABLE FOR ALL MODELS: PTLD CORRELATION COEFFICIENTS ONLY 
Table 52: Correlation coefficients from multivariate models for each outcome, including ORs for PTLD parameters controlling for participant characteristics 
Category of exposure PTLD measure SGRQ ≥6
# 
(n=85/325) 
Chronic respiratory 
symptoms# 
(n=102/325) 
≥1 acute respiratory event in 
1-year^ 
(n=56/335) 
TB retreatment§ 
(n=13/347) 
Death§ 
(n=8/347) 
Composite PTLD exposures, 
at TB treatment completion 
 
*Primary analysis 
Spiro PTLD 1.76 (0.99 – 3.13) 2.11 (1.22 – 3.65)** 1.73 (0.90 – 3.34) 2.08 (0.58 – 7.40) 0.88 (0.12 – 6.43) 
CT PTLD 2.07 (1.09 – 3.96)* 2.03 (1.09 – 3.80)* 1.53 (0.72 – 3.24) 1.78 (0.48 – 6.60) 0.49 (0.05 – 5.14) 
Either Spiro OR CT PTLD 1.54 (0.99 – 2.69) 1.74 (1.03 – 2.95)* 1.74 (0.92-3.31) 2.09 (0.59 – 7.34) 0.63 (0.09 – 4.33) 
Both Spiro and CT PTLD 3.57 (1.55 – 8.25)** n=238 
3.65 (1.62 – 8.22)** 
n=238 
1.96 (0.74 – 5.18) 
n=247 
1.84 (0.36 – 9.50) 
n=256 
0.46 (0.04 – 5.58) 
n=256 
Imaging parameters, at TB 
treatment completion Total extent of abnormal parenchyma (0-600) 1.00 (1.00 – 1.00) 1.00 (1.00 -1.00) 1.00 (1.00 -1.00) 1.00 (1.00 -1.00) 0.98 (0.99 – 1.00) 
>1/3 Abnormal parenchyma  2.19 (1.11 – 4.31)* 1.82 (0.94 – 3.54) 1.46 (0.66 – 3.25) 2.21 (0.59 – 8.30) 0.61 (0.06 – 6.49) 
Number of lobes containing moderate–severe 
bronchiectasis (0-6) 1.21 (0.96 – 1.53) 1.19 (0.94 – 1.49) 1.06 (0.80 – 1.39) 1.40 (0.91 – 2.14) 0.80 (0.36 – 1.77) 
Mod-severe bronchiectasis in ≥3 lobes 2.37 (0.94 – 6.00) 2.88 (1.16 – 7.10)* 1.65 (0.58 – 4.72) 3.49 (0.75 – 16.18) 1.40 (0.11 – 18.66) 
Whole lung bronchiectasis severity score (0-
18) 1.07 (0.98 – 1.17) 1.04 (0.95 – 1.13) 0.97 (0.87 – 1.08) 1.09 (0.92 – 1.28) 0.92 (0.70 – 1.20) 
≥1 destroyed lobe 0.63 (0.24 – 1.64) 0.62 (0.25 – 1.55) 0.58 (0.18 – 1.81) 1.88 (0.36 – 9.78) No deaths amongst those with >=1 lobe destroyed 
Total extent of ground glass and consolidation 
(0-600)    1.00 (0.99 – 1.02) 0.99 (0.97 – 1.02) 
Ground glass and consolidation affecting ≥half 
a lobe    2.23 (0.50 – 9.89) 0.48 (0.04 – 5.87) 
Nodules confirmed by 2 original readers / 
consensus reader    4.45 (0.89 – 22.2) 0.62 (0.12 – 3.20) 
Spirometric parameters, at 
TB treatment completion Moderate obstruction 1.82 (0.80 – 4.11) 2.53 (1.15 – 5.59)* 1.31 (0.50 – 3.41) 1.61 (0.30 – 8.60) 1.00 (0.09 – 11.48) 
Low FVC 1.43 (0.75 – 2.73) 1.49 (0.80 – 2.75) 1.69 (0.82 – 3.47) 1.79 (0.46 – 6.99) 0.84 (0.08 – 9.38) 
FEV1 z-score 0.68 (0.54 – 0.86)** 0.73 (0.58 – 0.90)** 0.79 (0.61 – 1.02) 0.57 (0.34 – 0.96)* 0.88 (0.42 – 1.85) 
FVC z-score 0.76 (0.61 – 0.96)* 0.83 (0.67 – 1.03) 0.83 (0.63 – 1.07) 0.66 (0.41 – 1.08) 1.13 (0.54 – 2.39) 
FEV1/FVC ratio 0.96 (0.93 – 0.99)** 0.96 (0.93 – 0.99)** 0.98 (0.95 – 1.02) 0.97 (0.91 – 1.03) 0.97 (0.89 – 1.05) 
*p<.05, **p<.01, ***p<.001 
#Participants with CT and valid spirometry at baseline, who completed 1-year study visit, with symptom and QoL data available (n=325) 
^Participants with CT and valid spirometry at baseline, who contributing any duration of follow up data – 6m or 12m (n=335) 
§Participants with CT and valid spirometry at baseline (n=347) 
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5.3.13 HEALTH ECONOMIC DATA 
This chapter has thus far focused on the burden of clinical and respiratory morbidity following PTB 
disease. In this section data on the economic impact of PTB disease will be reviewed.  
ECONOMIC SITUATION AT TB TREATMENT COMPLETION 
 
Table 53: Socioeconomic situation of study participants at TB treatment completion, stratified by baseline microbiology 
(n=405)  
Characteristic Total (n=405) 
Micro –ve 
(n=92) 
Micro +ve 
(n=313) p-value 
Occupation 
- Unemployed 
- Student 
- Self employed / business person 
- Employed – Gov / NGO / private 
- Other 
 
148 (36.5%) 
33 (8.2%) 
109 (26.9%) 
109 (26.9%) 
6 (1.5%) 
 
33 (35.9%) 
5 (5.4%) 
28 (30.4%) 
24 (26.1%) 
2 (2.2%) 
 
115 (36.7%) 
28 (9.0%) 
81 (25.9%) 
85 (27.2%) 
4 (1.3%) 
 
0.695 
Monthly individual income (USD)*  
(n=402) 41.32 (11.02 – 96.42) 55.20 (16.53 – 110.19) 41.32 (11.02 – 96.42) 0.337 
Monthly household income 
(USD)*(n=285) 85.40 (44.08 – 192.84) 104.68 (42.70 – 192.84) 82.64 (44.08 – 192.84) 0.856 
Dissaving incurred during treatment 
- No 
- Yes 
 
107 (26.4%) 
298 (73.6%) 
 
27 (29.4%) 
65 (70.7%) 
 
80 (25.6%) 
233 (74.4%) 
0.469 
Amount of dissaving incurred ($ USD)* 
(n=283) 59.23 (20.66 – 137.74) 68.87 (39.60 – 137.74) 53.03 (19.29 – 137.74) 0.032* 
*p<.05, **p<.01, ***p<.001 
 
 INCOME AND OCCUPATION 
Median monthly individual income across the cohort was the equivalent of $41.32 per week (IQR: 
$11.02 – 96.42) at TB treatment completion, and just over half (54.6% (221/405)) the participants 
were the highest earner in their household. Only 285 individuals were able to report their household 
income at the point of TB treatment completion – reporting was gender biased with 75.6% of men 
(208/275) and only 59.2% (77/130) aware of this figure. Where current household income was given, 
the median figure was $85.40 per month (IQR: $44.08 – 192.84) (Table 53).  
Over one third of participants were unemployed (36.5% (148/405)) at the point of TB treatment 
completion. Of note, even participants who were reported as unemployed within our study reported 
some income – this was mainly derived from intermittent piecework or money given to them from 
family or community members. The median income amongst the unemployed at treatment 
completion was $11.02 per month (IQR: 0 – 38.57).  
 DISSAVING 
Almost three quarters of the cohort (73.6% (298/405)) had experienced some dissaving between the 
onset of TB illness to the point of TB Treatment completion, with a median value of $59.23 (20.66 – 
137.74). This money had been obtained from the use of household savings in 44.7% (181/405), 
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borrowing money in 43.7% (177/405), and selling household property to cover illness related costs in 
32.6% (132/405). Household items, mobile phones, and means of transport were the most common 
items sold. The median amount of dissaving across the whole cohort was $27.55 (IQR: $0 – 97.38). 
There was a strong socioeconomic gradient to this dissaving: amongst the poorest quintile 90.2% 
(20/22) experienced dissaving with a median amount of $33.06 (IQR: $13.77 – 99.17), compared to 
the richest quintile where dissaving was experienced by 50% only but at a higher amount of $165.29 
($93.66 – 419.42). An indication of the impact of dissaving on family wellbeing is that 17.0% (69/405) 
reported that at least one child in the family had had either dropped out of school or had their 
schooling interrupted over the last year due to the participant’s illness. The gender distribution 
amongst the first child pulled out was approximately equal (46.4% female / 53.6% male), and the mean 
age was 12.9yrs (SD 4.6yrs).  
COSTS INCURRED DURING 1-YEAR FOLLOW-UP 
 DIRECT COSTS 
The majority of both outpatient visits (95.0%, 415/437) and inpatient admissions (88.9%, 24/27) 
occurred within the public sector, where care is free at the point of delivery. Nevertheless, direct costs 
were incurred by participants in 63.3%, 68.8%, and 100% of the planned outpatient, unscheduled 
outpatient, and inpatient events respectively (Table 54). 
Table 54: Median direct costs incurred (US $) for each type of study visit* 
Cost description 
Planned OPD visits (n=264) Unscheduled OPD visits (n=173) Inpatient admissions (n=27) 
Incurred 
(n, %) 
Amount, if 
cost incurred 
($USD) 
(median, IQR) 
Incurred 
(n, %) 
Amount, if cost 
incurred ($USD) 
(median, IQR) 
Incurred 
(n, %) 
Amount, if cost 
incurred 
($USD) 
(median, IQR) 
Clinic fees 2 (0.8%) 0.34  (0.28 – 0.41) 13 (7.5%) 
0.69 
(0.34 – 2.75) 3 (11.1%) 
9.64  
(6.89 -43.33) 
Medication  3 (1.1%) 2.07  (0.62 – 4.41) 18 (10.4%) 
2.41  
(1.03 – 2.89) 2 (7.4%) 
41.32  
(27.55 – 55.10) 
Travel  141 (53.4%) 0.83 (0.69 – 1.10) 103 (59.5%) 
0.96  
(0.69 – 1.65) 26 (96.3%) 
7.85  
6.89 – 11.71 
Accommodation 0 n/a 0 n/a 2 (7.4%) 35.47  (8.95 – 61.98) 
Food  40 (15.2%) 0.38 (0.28 – 0.69) 54 (31.2%) 
0.65  
(0.34 – 0.69) 27 (100%) 
9.23  
(5.23 – 15.15) 
Airtime  82 (31.1%) 0.21  (0.14 – 0.28) 57 (33.0%) 
0.28  
(0.14 – 0.28) 23 (85.2%) 
1.03 
(0.55 – 1.79) 
Any direct costs 167 (63.3%) 0.96 (0.55 – 1.38) 119 (68.8%) 
1.38  
(0.83 – 2.75) 27 (100%) 
19.56  
(13.57 – 55.79) 
*Costs reported in Malawi Kwacha and converted into US Dollars using the exchange rate from the study mid point (March 
2017, $1 USD: 726MK) 
Costs per visit were on average limited for outpatient visits: when these were incurred, median values 
were between $0.96 – $1.38 USD. Inpatient admissions were much more expensive with median cost 
$19.56 (IQR: $13.57 – 55.79). Median expenses were $17.22 (IQR: 12.67 – 19.97) in non-retreatment 
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admissions, and $54.55 (IQR: 33.75 – 72.73) in retreatment related stays.  If direct health care costs 
incurred over the 1-year period were calculated at an individual level, rather than on a per-visit basis, 
on average individuals who contributed a full year of follow-up data (n=364) had costs of $0.21 (IQR: 
0 - $1.72) over the course of follow-up. 
 INDIRECT COSTS 
The median amount of time taken for any outpatient appointment was 3 hours (IQR: 2-4hrs). 
Participants were asked whether they had lost any income time – that is, time when they would have 
been working – as a result of the visit, and the answer was positive for just 56.4% (149/264) outpatient 
episodes. Where any income time was lost, the amount of time lost was minimal (median 1 hour (IQR: 
0 – 1 hrs) (Table 55).  
Table 55: Indirect costs incurred by participants and guardians at each type of health seeking episode, with average amount 
spent when cost was incurred 
Variable Planned OPD visit (n=264) 
Unscheduled OPD 
visits (n=173) 
Inpatient admissions 
(n=27) 
Time taken for visit (median, IQR) 3 hours (2-3) 3 hours (2-4) 4 nights (2-19) 
Any loss of income time reported (n, %) 149 (56.4%) 83 (48.0%) 8 (29.6%) 
Self-reported income hours lost, if yes 1 hour (1-2) 2 hours (1-2) 74.5 hours (28-664)  
Attendance by guardian 4 (1.5%) 32 (18.5%) 24 (88.9%) 
Reported loss of income time by guardian (n, %) 0 (0%) 2 (6.3%) 1 (4.1%) 
Reported income hours lost by guardian, if yes 0 hours 2 hours (2-2) 4 hours (4-4) 
 
Although the average duration of admissions experienced during follow up was 4 nights (IQR: 2-19 
nights), under a third of participants reported missing income time during the admission period.  This 
difference may be related to gender: 63% (276/437) outpatient episodes were amongst men, but 67% 
(18/27) of admissions were seen in women, and women were less likely to report loss of income time 
compared to men (11% vs. 67%). The male dominance of outpatient visits may explain the higher 
prevalence of income time lost here.  
Our data show that a guardian accompanied the unwell participant for only 4/264 planned and 32/173 
unscheduled outpatient visits, and that loss of income time for guardians was rare and limited during 
these episodes. Although a higher proportion of admissions were accompanied by a guardian (24/27), 
again only 1 reported a loss of income during this time.  
Per person, amongst participants contributing full follow up data within this study (n=364), income 
time was lost in relation to ongoing health seeking by 44.2% (161/364), and the median amount of 
time lost for each of these individuals was 2 hours (IQR: 1 – 3). Income time was lost by guardians to 
3/364 of these individuals, and the median amount of time lost by guardians in these cases was 2 
hours (IQR 2- 4). 
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FINANCIAL IMPACT OF TB DISEASE 
 INCOME AND EMPLOYMENT 
A general decline was observed across all income and employment variables from the period prior to 
TB related illness to the point of TB treatment completion, with a gradual but incomplete recovery 
over the subsequent year (Table 56).  
Table 56: Self-reported occupation and income prior to TB related illness, after treatment, and 1-year after this 
Variable Prior to PTB disease (n=405)~ 
TB treatment 
completion (n=405)# 
1-year post 
treatment 
completion (n=368)# 
p-value 
Occupation (n, %) 
- Unemployed 
- Student 
- Self-employed 
- Employed – Gov / NGO / 
Private 
- Other 
 
76 (18.8%) 
35 (8.6%) 
133 (32.8%) 
154 (38.0%) 
7 (1.7%) 
 
148 (36.5%) 
33 (8.2%) 
109 (26.9%) 
109 (26.9%) 
6 (1.5%) 
 
110 (29.9%) 
24 (6.5%) 
95 (25.8%) 
117 (31.8%) 
22 (6.0%) 
 
<0.001*** 
Monthly individual income 
(USD)^  
55.10 (20.39 – 
132.23) 41.32 (11.02- 96.42) 43.53 (0.0 – 104.68) 0.002** 
Monthly household income 
(USD)^§ 
126.72 (66.12 – 
231.41) 
n=283 
85.40 (44.08 – 
192.84) 
n=285 
93.66 (49.59 – 
154.27) 
n=267 
<0.001*** 
Individual as primary earner in 
household (n, %) 
 
231 (57.0%) 
 
221 (54.6%) 223 (60.6%) 0.237 
*p<.05, **p<.01, ***p<.001 
~Data collected at baseline study visit at TB treatment completion, with participants asked to recall situation prior to illness  
#Data collected contemporaneously at study visits at TB treatment completion / 1-year later 
^Income data collected in Malawi Kwacha, but standardized using exchange rate at study midpoint ($1 USD: 726MK, March 
2017) 
§Household income data available for 76.7% (633/825) of data points collected amongst men, and 51.8% (202/390) of data 
points collected amongst women, due to limited participant recall 
 
The proportion of individuals who were unemployed increased from 18.8% prior to illness to 36.5% at 
the point of TB treatment completion. Although both the number and proportion of individuals who 
were unemployed did subsequently decline in the 1-year period following TB treatment, still almost 
1/3rd of participants remained unemployed at the end of follow-up. Many individuals categorized as 
‘unemployed’ were however working in the informal sector with some income from piece work, or 
from money provided to them by friends and family, but the median individual income in individuals 
reporting unemployment at any of the data collection time points was $0 (IQR $0 - 38.02) per month.  
Self-reported individual and household incomes followed the same pattern: median individual 
earnings fell from $55.10 pre illness to $41.32 at treatment completion and rose to $43.53 one year 
later; median household income fell from $126.72 prior to the start of the TB illness episode to $85.40 
at TB treatment completion, before recovering to $93.66 one year later. For both individual and 
household income, recovery was incomplete and even at 1-year earnings were not back to baseline. 
The proportion of participants who were the primary earner in the household remained broadly 
similar across this period.  
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 DISSAVING 
In the year prior to TB treatment completion, almost ¾ of the cohort had experienced some dissaving 
(72.6%, 298/405). Amongst these participants, dissaving generated a median of $59 (IQR: $21 – 138) 
(Table 57), which on average equated to 66% (IQR: 30 – 172%) of the monthly income for the 
household at TB treatment completion for this group, amongst those for whom household income 
was known (n=221). The proportion of individuals experiencing dissaving due to illness was lower in 
the year following TB treatment (50.5%, 186/368). Amongst these individuals, the median total 
amount generated was $41 (IQR: $21 – 94), or 72% (IQR: 27 – 161%) of the monthly household income 
at TB treatment completion amongst those for whom household income was known (n=143).  
The most common form of dissaving in the year prior to TB treatment completion was the use of 
savings in 44.7% (181/405) of participants. The proportion of individuals still able or choosing to use 
this method of dissaving in the year after treatment completion fell to 4.6% (17/368). In contrast, 
borrowing money was common throughout the 2-year period, with no significant change in the 
proportion of individuals using this approach in the first and second year (43.7% vs. 39.7%, p=0.257). 
Friends and family were common sources of funds, but the black market was also frequently used: 
10.7% of those borrowing money prior to TB treatment completion and 17.1% of those borrowing 
money thereafter used this source. 32.6% of individuals sold assets to generate funds in the year prior 
to TB treatment completion and 23.6% of participants in the subsequent year. Household goods and 
phones were the most common items sold, but the sale of potentially income generating assets 
including land, livestock, and means of transport were also observed.   
Dissaving was more common in poorer wealth quintiles: it was seen in 90.9% (20/22) of the poorest 
vs. 50.0% (28/56) of the least poor quintile in the year prior to treatment completion, and 59.1% 
(13/22) of the poorest vs. 21.8% (12/56) of the least poor quintile in the year following treatment 
completion. Use of savings was the most common form of dissaving in the highest socioeconomic 
quintile, and was still being used by 9.1% in the year following TB treatment completion, whilst no 
individuals in the poorest two quartiles used savings to release funds by this second year.  The average 
absolute amounts of money released by dissaving were similar between quintiles, ranging from $33.75 
– 50.96, with no clear gradient observed. However, when standardized by monthly household income 
reported at TB treatment completion, the poorest households are seen to experience a 
proportionately larger amount of dissaving (85.9% vs. 29.5% of monthly household income in the 
poorest vs. least poor quintiles). 
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Table 57: Dissaving incurred over the 1-year PTB disease and treatment period (n=405), and the subsequent 1-year of 
recovery (n=368), with values presented averaged across the whole cohort, and averaged amongst those who incurred 
dissaving. 
 Variable 1-year preceding TB 
treatment completion 
(n=405) 
  
1-year following TB 
treatment completion  
(n=368) 
P-value  
Overall dissaving 
Any dissaving incurred (n,%) 298 (72.6%) 186 (50.5%) <0.001*** 
Dissaving incurred, across full cohort (USD) 
(Median, IQR) $27.55 (0 – 97.38) $3.44 (0 – 41.32) <0.001*** 
Dissaving incurred, amongst those incurring 
dissaving only (Median, IQR) 
$59.23 (20.66-137.74) 
n=283 
$41.32 (20.66 – 93.66) 
n=183 0.040* 
Use of savings 
Any use of savings (n, %) 181 (44.7%) 17 (4.6%) <0.001*** 
Amount used, across cohort (USD) (Median, 
IQR) $0 (0-45.04) $0 (0-0) <0.001*** 
Amount used, amongst those using savings  
(USD) (Median, IQR) 
$68.87 (27.55 – 137.74) 
n=169 
$118.46 (34.44 – 210.06) 
n=16 0.209 
Borrowing of 
money 
Any borrowing of money (n, %) 177 (43.70%) 146 (39.67%) 0.257 
Amount borrowed, across cohort (USD) 
(Median, IQR) $0 (0-14.46) $ 0 (0-20.66) 0.832 
Amount borrowed, amongst those 
borrowing money (USD) (Median, IQR) 
$20.66 (9.64 – 41.32) 
n=172 
$26.86 (13.77 – 51.65) 
n=144 0.010* 
From family (n,%) 52/177 (29.4%) 65/146 (44.5%) 0.005** 
From friends (n,%) 111/177 (62.7%) 113/146 (77.4%) 0.004** 
From black market (n,%) 19/177 (10.7%) 25/146 (17.1%) 0.096 
From co-operative (n,%) 12/177 (6.8%) 6/146 (4.1%) 0.298 
From employer (n,%) 12/177 (6.8%) 2 (1.4%) 0.017* 
From bank (n,%) 3/177 (1.7%) 0/146 0.114 
From other source (n,%) 1/177 (0.6%) 0 0.370 
Selling of assets Any assets sold (n,%) 132 (32.6%) 87 (23.6%) 0.006** 
Amount generated, across cohort (USD) 
(Median, IQR) $0 (0-10.67) $0 (0-0) 0.018* 
Amount generated amongst those who sold 
assets (USD) (Median, IQR) 
$27.55 (11.02 – 61.98) 
n=131 
$46.49 (13.77 – 89.53) 
n=86 0.059 
Sale of household item (n,%) 104/132 (78.8%) 65/87 (74.7%) 0.482 
Sale of mobile phone (n,%) 27/132 (20.5%) 19/87 (21.8%) 0.806 
Sale of means of transport (n,%) 10/132 (7.6%) 10/87 (11.5%) 0.325 
Sale of land (n,%) 5/132 (3.8%) 0 0.066 
Sale of livestock (n,%) 5/132 (3.8%) 10/87 (11.5%) 0.027* 
Sale of farm produce (n,%) 3/132 (2.3%) 1/87 (1.2%) 0.544 
School dropout Any children in household dropped out / 
interrupted schooling to assist family (n,%) 69 (17.0%) 35 (9.5%) 0.002** 
*p<.05, **p<.01, ***p<.001 
 INTERRUPTION OF EDUCATION 
A high proportion of individuals needed to pull children out of school / interrupt their education to 
assist the household due to their illness in the year following TB treatment completion. This was 
reported by 17% (69/405) of study participants during the period of TB illness and treatment but 
continued to be reported by 9.5% (35/368) of participants in the year after treatment completion.  
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5.4 DISCUSSION 
The key findings from this prospective study of residual lung damage amongst HIV-positive and 
negative individuals completing treatment for PTB in urban Blantyre include a substantial burden of 
persistent lung pathology following PTB treatment in both groups, with marked variation in the 
pattern and severity of damage, and a lower burden but similar pattern of disease amongst HIV-
infected adults. A general trend to recovery was observed across multiple clinical and respiratory 
parameters, but this recovery was incomplete such that pathology persists at 1-year, and 
heterogeneity in the direction and magnitude of change was observed between individuals. The 
presence of residual lung damage at TB treatment completion was found to be positively correlated 
with impaired quality of life and ongoing chronic respiratory symptoms 1-year later. There are no 
dedicated health services available to address these problems in Malawi. Lastly, these data 
demonstrate that even at TB treatment completion, adults remain physically and economically 
vulnerable, and continue to experience health-related costs and dissaving..  
 A HIGH BURDEN OF RESIDUAL LUNG PATHOLOGY IS SEEN AT TB 
TREATMENT COMPLETION  
This study found a high burden of residual lung pathology at TB treatment completion across multiple 
respiratory parameters.  
CHRONIC RESPIRATORY SYMPTOMS AT TB TREATMENT COMPLETION 
At TB treatment completion 60.7% (246/405) of participants experienced ≥1 respiratory symptom for 
at least a few days each month, and 7.7% (31/405) had symptoms on several/most days each week. 
Although the 3-month SGRQ questionnaire used to collect these data asked about symptoms over the 
preceding 3-months, such that these data may reflect the symptom burden within the latter portion 
of the TB treatment period, the presence of symptoms was correlated with the presence of abnormal 
spirometry at treatment completion, suggesting that what was reported is consistent with true 
residual pathology.  
The most common regular symptom was shortness of breath, which was experienced regularly on a 
monthly basis by 39.8% and on a weekly basis by 4.2% of participants at treatment completion. 26.8% 
(108/403) needed to walk slower than peers or stop for rest when walking at their own pace, which 
may be equivalent to MRC III dyspnoea score. This finding is consistent with previous studies which 
have found a high burden of breathlessness amongst post-TB cohorts, with increased breathlessness 
seen in those with more extensive imaging pathology or spirometric deficits.107 110  
Cough and sputum were the next most common symptoms after breathlessness, experienced on a 
regular monthly basis in 36.0% (146/405) / 25.9% (105/405) of individuals and a weekly basis in 2.7% 
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(11/405) / 2.0% (8/405) of individuals. This may have implications for stigma within this population: 
previous work from this setting has suggested that cough, HIV and TB disease are often conflated in 
public opinion in Malawi and all are classed as severe illnesses,43 with joint public health screening 
activities emphasizing cough as a ‘sign’ of underlying HIV and TB disease compounding this belief. Both 
HIV and TB remain highly stigmatizing in many sSA settings, and this may explain the high proportion 
of individuals who felt ashamed of their cough/breathing at treatment completion (14.4% (58/403)). 
No studies of patient experiences of stigma following TB disease or stigma experienced in relation to 
ongoing symptoms were identified in the literature, but further qualitative work is required to explore 
this phenomenon.  
A low prevalence of wheeze was seen at each study visit. Although a correlation with airway 
obstruction was demonstrated, the concept of ‘wheeze’ was noted to be difficult to explain to study 
participants, and the caution must be used when interpreting data for this construct. However, if true, 
this would suggest that this is a poor ‘screening’ test for airway obstruction being present in only 13% 
of those with this spirometric deficit.  
Difficulties farming were raised by 19.4% (78/403) and challenges with lifting heavy items by 18.4% 
(74/403) of individuals at TB treatment completion. It is likely that this level of impairment is related 
to general physical deconditioning as well as respiratory impairment, but it is of concern in this setting. 
Although Blantyre is an urban environment, a large proportion of the population here are involved in 
manual work, either for running the household, income generation, or the farming of subsistence 
crops. In addition, it is a hilly city, with poor infrastructure and limited public transport access deep 
into settlement areas. As such, the potential for a given level of respiratory pathology, reduced general 
health, or symptom such as breathlessness to significantly effect participants’ lives is significant.  
QUALITY OF LIFE AT TB TREATMENT COMPLETION 
Median SGRQ total scores were 8.7 with a wide IQR (1.2- 23.7). No normative data were available from 
this setting for comparison, but existing data from COPD cohorts in resource rich settings suggest that 
a score >6 is abnormal, and over half of the cohort had a score above this level at this time point 
(54.8%, 221/403).156 These data are supported by a previous study of SGRQ scores amongst a US based 
cohort of post-TB patients which demonstrated a negative correlation between spirometric indices 
and quality of life scores. 120The symptom and activity sub scores were highest throughout, suggesting 
that these parameters were of greatest concern to participants.  Although the impact score was the 
lowest, still 14.4% (58/403) felt ashamed of their cough/breathing, over a quarter felt that their chest 
problem was a nuisance (26.6%, 107/403), and 15.1% (61/403) felt that they had become frail or an 
invalid.  Clearly then, PTB disease and its respiratory sequelae are important for patients’ quality of 
life at TB treatment completion.  
203 
 
This was the first study to use the SGRQ within a post-TB population in the African setting. Good 
correlations observed between SGRQ scores and other measures of quality of life within this cohort 
(EQ5D3L VAS score and Likert self-reported health scores) are reassuring and suggest that this is likely 
a valid measure. However, a few areas of concern with its use were identified: a high proportion of 
the cohort had total / sub-scores of 0 at each study visit, which is relatively unusual – previous studies 
based in European settings have suggested that even amongst ‘well’ individuals, median SGRQ scores 
are usually higher than 0,231 with the mean total score in healthy individuals with no history of 
respiratory disease quoted at 6 (IQR: 5-7) in the original SGRQ manual.156 These studies have often 
included individuals who are older than those in this cohort, which may explain some of the difference. 
However, there may also some cultural differences in the way the questions are interpreted/ 
answered between cultures, with previous North American studies showing differences in 
questionnaire responses between white US born, foreign-born, and non-white participants in the 
same setting, which may reflect some cultural bias.120 In addition, during the conduct of this study 
some of the questions included within the SGRQ – particularly those relating to sports and the use of 
stairs – were observed to be confusing for study participants and perhaps inappropriate for a poor 
Malawian setting. Locally relevant activities such as farming and manual work were not addressed at 
all, and symptoms such as ‘chest pain’ which are commonly reported manifestations of respiratory 
pathology within the Malawian setting were not enquired about. Whilst the SGRQ is likely a valid 
measure of quality of life in this context, if it is continued to be used here, some adjustments in either 
the questions included, or the weighting algorithm used to calculate scores may be required. Simpler 
alternatives such as a simple general health Likert score or the MRC dyspnoea may provide viable 
alternatives.  
SPIROMETRY FINDINGS AT TB TREATMENT COMPLETION 
When standardized using the GLI-2012 African American reference ranges, z-scores for all measured 
respiratory parameters were negative at TB treatment completion (FEV1 -1.06 (SD: 1.26), FVC -0.91 
(SD: 1.23), FEV1/FVC ratio -0.38 (SD: 1.26), suggesting that on average, all of these parameters were 
lower than expected given the age, height and gender of study participants. 34.2% of participants were 
classified as having abnormal spirometry at treatment completion – low FVC pattern was the dominant 
pattern seen in 20% of the cohort, with 14.2% observed to have an obstructive pattern. The broad 
similarity in data distributions between reference ranges confirms that these negative values are 
unlikely to be a function of reference range alone, and in fact underestimates the degree of 
abnormality which would likely have been seen had the NHANES III Caucasian reference ranges been 
used. Comparison with age stratified data from the community based BOLD study completed in urban 
Blantyre in 2013-14 shows that the prevalence of both of these patterns of abnormality in the post-
TB group is likely higher than that seen in the general population.  
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These are the first data from a post-TB population in the sSA region, outside of South Africa, but 
support finding from previous studies which have suggested that PTB disease is associated with 
increased odds of both airway obstruction and spirometric restriction, with more recent BOLD data 
suggesting that those with a self-reported history of PTB disease have lower FEV1/FVC ratios and FVC 
values.13-15 104  
The high burden of spirometric deficits within this generally young and active group is likely to have 
long-term implications for respiratory and non-respiratory morbidity, and mortality. Exploratory 
analyses completed within this post-TB cohort show that higher FEV1, FVC and FEV1/FVC ratio z-scores 
at TB treatment completion are protective against ongoing symptoms and impaired quality of life at 
1-year. However, previous studies of broader populations from resource rich settings have shown 
associations between reduced FEV1, FVC and FEV1/FVC ratios and adverse long-term outcomes 
including increased dyspnoea232, but also increased health care use / respiratory exacerbations, and 
mortality.134 135 137-139 Detrimental associations between impaired lung function and non-respiratory 
outcomes including cardiac and metabolic disorders, evidence of increased systemic inflammation, 
and a higher incidence of premature death have also been demonstrated.233 It is plausible that 
reduced ‘peak’ lung function in early adulthood occurring as a result of PTB disease in resource poor 
settings such as Malawi could give rise to similar adverse outcomes in this setting over time, and 
further investigation of these outcomes in the post-TB population are required. 
CT IMAGING FINDINGS AT TB TREATMENT COMPLETION 
This high burden of spirometry deficits was matched by a significant burden of structural abnormality 
on HRCT imaging. Only 1.3% (5/385) of participants imaged with CT had both completely normal lung 
tissue and completely normal airways at TB treatment completion. The median extent of abnormal 
parenchyma seen was the equivalent of almost 1.4 lobes, 44.2% of individuals had moderate to severe 
bronchiectasis (airway dilatation ≥2 times diameter of adjacent vessel) in at least one lobe, and 9.3% 
of individuals were left with at least one non-functioning lobe (≥90% of tissue occupied by atelectasis 
and banding, or cavities and cystic airspaces).  
The high prevalence of bronchiectasis seen here is consistent with estimates from previous studies in 
the Americas / Taiwan where bronchiectasis was reported in 35 - 86% of post-TB cases,179 202-205 and is 
of some concern. Data from cohorts of bronchiectasis patients in resource rich settings suggest that 
extensive disease is associated with adverse outcomes over 6m-14 year follow up periods including 
accelerated FEV1 decline, recurrent exacerbations, hospital admissions, and all-cause mortality.135 150 
152-155 Thus far, within this cohort study, the presence of moderate-severe bronchiectasis in ≥3 lobes 
has been shown to be associated with the presence of chronic respiratory symptoms at 1-year as might 
be expected, but no other outcomes. Further follow up of post-TB study participants with this 
pathology is required.   
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Of note, at both the whole lung and lobar level in this cohort, severe airway dilatation was associated 
with more extensive atelectasis / banding, cavities / cystic airspaces, and consolidation. This suggests 
that bronchiectasis is generally not an isolated phenomenon in the post-TB context – rather, it is 
associated with a broader pattern of lung damage and destruction as described above, and may in 
part be ‘traction’ bronchiectasis, secondary to the architectural destruction. It may be the case that it 
is the combined effect of this destruction and distortion, rather than factors related to bronchiectasis 
alone, that drives outcomes in this patient group. In addition, post-TB bronchiectasis appears to be 
fairly focal with the majority of people with bronchiectasis experiencing this in 1-2 lung lobes only 
(82.9%, 141/170). Studies of outcomes amongst Western cohorts have often used the presence of 
bronchiectasis affecting ≥3 lobes as an imaging marker of disease severity – although the same 
approach was used in the analyses presented here,135 154 further exploration of the extent of disease 
which is clinically important in this context may be warranted. No data on the distribution and nature 
of bronchiectasis are available from previous CT-based studies for comparison. 
A second finding of interest within the imaging data was the high burden of potential signs of ongoing 
inflammatory pathology at TB treatment completion: all individuals included within this study had 
received 6-months of treatment and deemed to have ‘treatment success’, but residual consolidation 
was seen in 69.4%(267/385) of the cohort, ground glass opacification in 36.6% (141/385), and nodules 
confirmed by both readers in 228/365 (59.2%). Serial CXR imaging showed that the majority of 
individuals experienced a decline in the extent of consolidation and ground glass over the course of 
the year (54.0%, 194/359), confirming that many of these abnormalities were inflammatory and 
reversible in nature. As described in the introduction, PET-CT studies in Cape Town have previously 
demonstrated ongoing increased metabolic activity in focal lesions in 72% of a cohort of HIV-negative 
adults completing TB treatment,102  but that it was unclear whether these lesions represented 
persistent live mycobacterial presence or an indolent host immune response perhaps to dead 
organisms. The lack of association observed between any of these patterns of inflammation and either 
TB retreatment or death within the 1-year follow up within data from this cohort suggests that the 
latter may be more likely, but further follow up is required to confirm this, and exploration of the 
reason for such a prolonged persistent host immune response amongst a subgroup of those 
completing TB treatment is required.  
In addition to the large total volumes of pathology across the whole lung, clustering of pathology 
within a single extensively damaged lobe was a pattern commonly seen, and 9.4% (36/385) of the 
cohort had at least one lobe with ≥90% of tissue non-functional due to atelectasis / banding or cavities 
/ cystic airspaces. No other CT studies reporting the prevalence of this pathology at the point of TB 
treatment completion191 have been identified – the absence of a definition for this pattern of 
pathology from the widely used Fleischner guidelines for CT reporting may explain reluctance to report 
this feature, and a consensus definition may be required for further work. Of note, previous studies of 
patients with extensive TB-destroyed lung identified some years after TB treatment have documented 
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a high burden of pulmonary hypertension, infection, respiratory failure and mortality.109 119 234 The 
outcome data presented here do not support this – within the 1-year of follow up, the presence of at 
least 1 destroyed lobe was not associated with any of the adverse outcomes measured. This may be a 
result of the limited follow up duration within this study, but confidence intervals for the odds ratios 
estimated within all of the models constructed were very wide, and it may be that focal lung damage 
of this nature is a benign finding. Further follow up data and perhaps some comparison between those 
with collapsed vs. destroyed lobes may be warranted to better understand this.  
The prevalence and extent of mosaicism observed within this study was a surprising finding: the 
median extent of pathology was 32.5 points, but the IQR was 5 – 85, and the full range of scores 
spanned 0 – 325 points with the upper level representing the equivalent of over three lobes of 
decreased attenuation tissue. Mosaicism is defined in the Fleischner guidelines as ‘a patchwork of 
regions of differing attenuation’ but it is important to note that a degree of parenchymal 
heterogeneity can be seen in normal individuals, with up to 20% showing mild mosaicism on 
inspiratory scans. No absolute cut-offs for a ‘normal’ amount of mosaicism has been defined. It is also 
important to note that this is often an extremely subtle feature - although the ICC values for this 
variable were reasonable between readers (0.55 (95% CI: 0.48-0.62)) verbal feedback described 
reporting of this feature to be subjective and challenging, such that results must be interpreted with 
caution.  Nevertheless, these data fit with findings from the only previous CT study to report this 
feature which identified mosaicism amongst 70% of patients completing TB treatment (n=20) in 
Canada in 1998.179  
As described in Chapter 3, high amounts of lung attenuation can be caused by obstruction of the small 
airways, with gas trapping distal to the point of obstruction +/-  shunting and decreased perfusion 
through vessels in these areas, or may reflect pulmonary hypertension with regional differences in 
lung perfusion and hence a ‘patchy’ density seen on imaging.192 The pulmonary artery diameter was 
not routinely measured by radiologists in this data set, but clinical features of cor-pulmonale with 
pedal oedema were seen in 1.5% (6/385) of imaged patients only, suggesting that few are likely to 
have had extremely high right sided pressures. In addition, the amount of mosaicism seen was 
positively correlated with the severity of airway pathology at both a whole lung and lobar level on 
analysis, perhaps pointing to an airways cause of disease. One context in which both large airway 
pathology (bronchiectasis) and small airway damage (mosaicism) have been seen together in low 
resource sSA settings is in adolescents with vertically acquired HIV, where an ‘obliterative 
bronchiolitis’ picture has been observed.27 However, there is no evidence to support a HIV-mediated 
cause of mosaicism in this cohort, as the extent of low attenuation tissue actually higher in the HIV-
negative group (40.0 vs. 27.5 points, p=0.024). Nevertheless, it is possible that mosaicism – which was 
far more commonly reported and more extensive than emphysema – is the pathology underlying 
airway obstruction within this cohort. Further investigation of this finding with echocardiography and 
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perhaps expiratory CT imaging which is more sensitive / specific for pathological mosaicism may be 
warranted.  
Finally, it is worth noting that only 1.3% (5/385) of participants had mycetoma seen. Together with 
the very low prevalence of positive aspergillus serology (<1%, 3-4/404) at this time point, these data 
suggests a low burden of Aspergillus fumigatus disease in this population at TB treatment completion. 
Further follow up is required to determine whether this changes over time, and given the absence of 
positive A. fumigatus serology amongst several patients with imaging suggestive of fungal disease, 
investigation of the burden of other Aspergillus species may be worthwhile.  
 
 HIV-INFECTED INDIVIDUALS HAVE A LOWER BURDEN OF DISEASE, BUT 
PATTERNS OF PATHOLOGY ARE SIMILAR 
This is the first large study in the sSA region to present disaggregated data on the prevalence and 
pattern of post-TB Lung damage according to HIV status.  
HIV-positive status at TB treatment completion was associated with less extensive pathology at TB 
treatment completion. In univariate analysis of spirometry data, mean z-scores for both FEV1 and FVC 
were lower amongst HIV-uninfected compared to HIV-infected individuals (FEV1 -1.27 vs -0.94, p= 
0.015; FVC -1.08 vs -0.80, p= 0.037) at TB treatment completion. The same pattern was seen in 
multivariate models for factors predicting abnormal spirometry where controlling for other participant 
characteristics HIV-infected adults with CD4 counts <200cells/uL had FEV1 and FVC volumes which 
were statistically larger than HIV-negative individuals by 189.9mls (40.4 – 339.4) and 170.5mls (8.0 – 
333.0) at TB treatment completion. On CT imaging HIV negative individuals had more extensive 
parenchymal abnormality (total abnormal parenchyma score 180/600 (IQR:  81-246) vs. 110/600 (IQR: 
40 – 228), p<0.001) and statistically more severe airway dilatation, tree in bud, and airway plugging.  
Much has been published about the suppressed immune response in the context of HIV infection 
‘protecting’ against lung destruction and cavitation in response to active TB disease.83 The data from 
this study support this notion, and suggest that this protective effect during active disease translates 
into less extensive respiratory pathology at TB treatment completion. However, whilst the extent of 
pathology is on average reduced in HIV-infected individuals, the patterns of damage seen appear 
broadly similar, and abnormalities are still present with extensive pathology observed amongst some 
HIV-infected individuals. In addition, given ongoing moves to ‘test and treat’ approaches to ART 
initiation, it may be that we see convergence between the pathology seen in HIV positives and 
negatives. This is not a group that can be discounted, as it has been in the literature on post-TB lung 
damage to date. Instead, further investigation of the effect of ART duration and IRIS during TB 
treatment are required to better understand the relationship between HIV and post-TB lung damage.  
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Despite the protective effect of HIV co-infection against ‘objective’ respiratory damage on spirometry 
and imaging, it is of interest that no difference in SGRQ scores or 6-minute walking distance were 
observed between HIV positive and negative groups at TB treatment completion. Although both of 
these tests are designed to be respiratory assessments, they are not specific and are also affected by 
general physical health and conditioning – it may be that the less severe respiratory pathology seen 
amongst HIV-positives is ‘cancelled out’ by a generally increased level of physical morbidity in this 
group amongst whom the median CD4 count was 229 cells/uL (95% CI: 127 – 397), such that scores 
appear similar.  
Interestingly, controlling for HIV status, baseline TB microbiology was not consistently associated with 
any of the spirometry parameters measured at TB treatment completion. This suggest that the 
respiratory pathology seen in participants with / without positive TB microbiology at diagnosis are 
similar and supports the hypothesis that a high proportion of those with microbiologically negative 
PTB diagnosis did in fact have TB disease, and were likely exposed to the same respiratory insult as 
the rest of the study population.  
 PATTERNS OF PATHOLOGY AT TB TREATMENT COMPLETION ARE 
HETEROGENEOUS 
Although a high average burden of respiratory pathology was observed within this cohort, the wide 
degree of heterogeneity seen between individuals was marked. This was evident across all continuous 
respiratory parameters measured, including spirometry, imaging, clinical observations such as BMI, 
quality of life and 6-minute walk distance, and is reflected in the long tails seen on the population 
distributions plotted above.  
The wide distributions seen across respiratory parameters illustrates how diverse the respiratory 
response to TB as a respiratory insult can be, and is a call for more work into the host, mycobacterial, 
and environmental factors driving the nature and duration of the host immune response in PTB 
disease.89 It is only through understanding this that we may be able to identify modifiable factors 
which could help us shift patients from more extreme to milder patterns of lung damage in response 
to TB disease.  
Importantly, these findings also support the hypothesis that although some degree of residual post-
TB pathology is widespread there are a minority of patients who are left with extensive pathology: 
only 29.6% (108/365) of participants met the a-priori criteria for PTLD with either extensive CT or 
spirometry abnormalities, and 9.6% (39/405) had severe abnormalities of both imaging and 
spirometry. These are perhaps one group of patients in whom we should be concerned about adverse 
outcomes. 
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 RECOVERY IS SEEN, BUT THIS IS INCOMPLETE AND HETEROGENEOUS 
A consistent trend to recovery was seen at a population level in the 1-year period following TB 
treatment completion. Spirometry data show that the average FEV1 rose from -1.06 to -0.88 z-scores 
at 1-year, and average FVC rose from -0.91 to -0.61 z-scores at 1-year. CXR data show an average 
reduction in the total extent of abnormal parenchyma, which fell from a median score of 18 (IQR:3-
55) at treatment completion to 13 (IQR: 0-43) 1-year later (p=0.023). Six-minute walk distances 
increased by 41.3m on average, which is greater than the proposed minimum clinically important 
distance of 30m.161 The same pattern was also seen in clinical parameters such as BMI, and quality of 
life scores, with the biggest improvements seen within the first 6-months after treatment completion.  
In the literature review at the start of this thesis, the paucity of longitudinal data on the evolution of 
post-TB lung damage was highlighted, and only two previous modelling studies of change in 
spirometry over time were identified. Both of these studies suggested an initial population level 
decline with nadir lung function at 12-18 months post treatment completion112 235. This pattern is 
different to what has been observed here, where average lung function at a population level has 
improved over time. This difference can be explained by our use of real longitudinal data in 
comparison to modelling based on cross sectional data but may also be related to the way in which 
spirometry outcomes were measured. As noted in the results above, we observed an increase in the 
proportion of participants defined as having obstruction over the course of the study which rose from 
14.2% (52/365) at TB treatment completion, to 17.9% (60/336) at the 1-year time point. In fact, this 
was driven in part by a disproportionate increase in both FEV1 and FVC, rather than any true 
deterioration in lung volumes. This finding supports the use of absolute volumes or z-scores when 
interpreting changes over in time in spirometry, rather than patterns of deficit alone. 
However, just as significant heterogeneity was observed in the extent and pattern of pathology at TB 
treatment completion, so marked variation in the direction and rate of change in pathology over time 
was seen. A ‘catch up’ phenomenon was observed across multiple parameters, whereby those with 
the most extensive / severe pathology at TB treatment completion experienced the biggest 
improvement over the 1-year follow up period. This pattern was consistently seen in descriptive 
analyses of quality of life, walking distance, BMI, imaging, and spirometry data. It was also observed 
in the multivariate models of spirometry outcomes where, controlling for participant characteristics, 
individuals with the most impaired FEV1 and FVC values at TB treatment completion experienced larger 
improvement in FEV1 and FVC in the following year. It is possible that this simply reflects ‘regression 
to the mean’ alone. However, given the magnitude of change observed it could be a reassuring sign 
that there is an ongoing period of recovery which takes place following the completion of TB 
treatment, with those who were the most unwell showing the greatest capacity for improvement.  
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This ‘catch up’ pattern was however incomplete, such that participants with the most extensive 
deficits at TB treatment completion still had the most extensive deficits 1-year later. Again, this was 
seen consistently across parameters in descriptive analyses. It was also observed in the multivariate 
models of spirometry outcomes at 1-year: poor baseline FEV1 and FVC volumes at TB treatment 
completion were associated with poor FEV1 and FVC volumes at 1-year, a reduced ratio at baseline 
was a predictor of a reduced ratio at 1-year, and those classified as having an obstructive or low FVC 
pattern at baseline had markedly increased odds of being classified in the same group at the end of 
follow-up.  
Also of note is that whilst the majority of individuals did experience some recovery over the 1-year 
follow up, a sub-group of participants experienced deterioration over this period: depending on the 
parameter used to measure respiratory pathology or general health, between 19.7 – 41.5% of the 
cohort experience some deterioration over the 1-year follow up period. Whilst further analyses are 
required to determine the proportion of patients experiencing declines that are greater than the MCID 
for each parameter, this does suggest a subgroup of individuals who are at risk of ongoing 
deterioration instead of recovery.  
The implications of these findings are twofold. Firstly, despite the trend to improvement at a 
population level, a significant burden of pathology and impairment remains at 1-year. At this time 
point, 30.7% (113/368) of individuals continued to report regular respiratory symptoms on a monthly 
basis, and 4.1% (15/368) had weekly symptoms. Almost 1 in 5 participants (19.8% (73/368)) 
experienced ongoing limitations in their usual activities, whilst 12.2% felt that their chest symptoms 
were continuing to interfere with their work. Deficits in spirometry persisted: mean FEV1, FVC and 
FEV1/FVC ratio z-score values remained negative at -0.88 (SD: 1.19), -0.61 (SD: 1.09) and -0.54 (1.29), 
and 12.8% (43/336) of the cohort were defined as having a low FVC deficit whilst 17.9% (60/336) were 
defined as having obstruction. Despite some recovery in the year following TB treatment completion, 
evidence of respiratory pathology and its sequelae persisted.  
Secondly, these findings suggest that further work is required to understand which individuals are at 
greatest risk of long-term respiratory abnormalities. This group is likely to include those with the most 
severe pathology at TB treatment completion as despite recovery and ‘catch up’ these individuals are 
likely to continue to have severe long-term damage, but also the subgroup of participants who 
experience deterioration over time, regardless of their starting point. Future studies using individual 
level, multi-level analyses, may be useful to understand the characteristics and determinants of these 
groups, as they are likely to be the focus for any interventions aiming to improve long-term outcomes.  
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 POST-TB LUNG DAMAGE IS ASSOCIATED WITH CHRONIC RESPIRATORY 
SYMPTOMS AND REDUCED QUALITY OF LIFE AT 1-YEAR 
The multivariate models constructed here demonstrate that the presence of residual lung damage at 
TB treatment completion, whether it is measured using spirometry or on imaging, is an important 
predictor of both a lower quality of life and the presence of chronic respiratory symptoms at 1-year 
following treatment completion. The increase in odds of each of these outcomes is over three-fold 
higher amongst those with both extensive lung pathology on imaging (moderate to severe 
bronchiectasis in ≥3 lobes, or the equivalent of ≥1/3rd  abnormal parenchyma), and abnormal 
spirometry (reduced FVC or moderate airway obstruction), compared to those with neither of these 
features. In exploratory analysis both individual spirometry parameters and markers of structural 
pathology have also been shown to be determinants of ongoing symptom burden and quality of life. 
These data clearly show that having residual post-TB lung pathology is meaningful for participants’ 
experience of life following PTB disease. 
However, within this cohort study no association between imaging or spirometry defined PTLD and 
‘harder’ outcomes such as having an acute respiratory event, the initiation of TB retreatment, or all-
cause mortality was found, regardless of how PTLD was quantified. It may indeed be the case that 
these associations do not exist – that is, the severity and pattern of lung pathology sustained during 
PTB disease and treatment may not be a key predictor of these adverse outcomes. This would run 
counter to studies conducted in comparable chronic respiratory diseases in resource rich settings in 
which severe damage is associated with ongoing morbidity and mortality, but may well be the case in 
a context where there are so many other potentially more significant influences on health – including 
HIV disease, poverty, environmental exposures and non-respiratory diseases – compared to chronic 
lung damage. However, it is equally possible that these associations are there, but that out study was 
underpowered to detect them. The follow-up duration used in this study was limited, and the number 
of events detected for these outcomes were low. Studies investigating patient outcomes associated 
with conditions such as bronchiectasis in resource rich settings have shown differences in important 
outcomes such as hospitalisation and mortality but have required 2-14 years of follow-up to identify 
these relationships. Further follow up of this cohort is required, in order to determine this.  
Whilst we have found no evidence to suggest that acute respiratory events are predicted by the extent 
of post-TB lung damage seen at TB treatment completion, these data do suggest that acute respiratory 
events may drive deterioration in spirometry over time.  Controlling for participant characteristics and 
the severity of lung pathology at baseline, the presence of ≥1 respiratory exacerbation in the 1-year 
of study follow up was associated with a greater loss in FVC over the 1-year period, and smaller FVC 
volumes at the end of this period by 81ml (95% CI: 6.5 – 155ml). However, this finding was only 
observed with relation to the FVC, and confidence intervals for the magnitude of change in volume 
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are wide. Further follow up may help to better define a causal relationship between ongoing infective 
exacerbations and lung function deterioration. 
Another factor which may have limited the ability to detect relationships between post-TB lung 
damage and outcomes may be the use of simplistic definitions of PLTD, which failed to capture the 
actual pathology or ‘phenotype’ of damage that individuals are exposed to following TB disease. In 
this thesis, attempts were made to determine whether distinct patterns of symptoms and structural 
pathology were seen in those with airway obstruction or low FVC spirometry patterns at TB treatment 
completion. In fact, whilst both groups were more breathless, had higher SGRQ scores, and had more 
extensive imaging pathology than those with normal spirometry, few differences were observed 
between groups. This analysis suggests that patterns of spirometry deficit are a poor way of defining 
phenotypes of post-TB lung damage, as the overlap between groups is large. More complex analyses 
using machine learning techniques or principal components analyses will be required to identify 
phenotypes empirically, from the data itself, if clusters of patients are to be identified. Relationships 
between these phenotypes and outcomes must then be investigated.  
 THERE IS AN UNMET NEED FOR HEALTH CARE POST TB 
These data demonstrate both delays to TB diagnosis and treatment, as well as limited access to 
ongoing health services after treatment completion. 
DELAYS TO DIAGOSIS 
Delays to diagnosis and treatment are a well-known challenge in the TB treatment cascade – these are 
particularly marked amongst those who are smear negative, and frequently reflect health system 
delays and diagnostic challenges.62 However, the novel finding from this study is that a longer duration 
of illness prior to treatment was associated with worse lung function by the time of treatment 
completion: on average the 60% of participants (243/405) who had been unwell for ≥1-month by the 
time of treatment initiation had FEV1 volumes which were over 100ml lower at TB treatment 
completion and at 1-year, and more obstructive FEV1/FVC ratios at both time points, compared to 
those with more rapid treatment. This is perhaps unsurprising as delays likely allow more time for lung 
damage to progress before mycobacterial killing occurs and implies that earlier treatment of PTB 
disease may reduce the severity of residual damage.    
To date, active case finding / TB screening programs aimed at early diagnosis and treatment have been 
focused largely on the public health impacts of reduced transmission and decreasing mortality.222 
However, these interventions may also have the potential to reduce residual post-TB lung pathology 
amongst survivors and including measures of post-TB lung pathology within impact studies and cost-
benefit analyses for these interventions may be warranted.  
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ONGOING ACCESS TO HEALTH SERVICES 
During the course of PTB treatment individuals in Malawi are required to visit health centres on a 
monthly basis to obtain TB medications, but at the point of TB treatment completion patients are 
discharged from TB services with no routine respiratory follow-up in place. Findings from this study 
show that after discharge, 16% of this cohort had at least one unscheduled health service consultation 
for a respiratory symptom during the following year, and respiratory complaints made up 
approximately 40% of unscheduled outpatient and inpatient visits completed by the cohort during the 
year. In addition, despite the high burden of respiratory symptoms described above, only 2.2% of the 
cohort had a diagnosis of a chronic respiratory condition other than TB by the point of TB treatment 
completion. These findings suggest an unmet need for respiratory diagnosis and perhaps ongoing 
management in this cohort.  
When thinking about management of chronic disease in a setting such as Malawi, the relative cost and 
benefit to both the health service and the individual patient must be considered. Provision of ongoing 
respiratory input to HIV-infected individuals may be easier to institute, given that 66.4% of individuals 
within this cohort continued to have planned access to health services in the year following TB 
treatment completion, largely within existing ART services. However, models of integrated care for 
HIV and non-communicable diseases (NCDs) have previously been piloted within Malawi, and whilst 
found to be feasible, constraints around increasing clinic workloads and integration of new services 
within a vertical / dedicated HIV service were marked.236 Provision of ongoing care for HIV-negative 
individuals may be more complex – only 9.6% were booked for scheduled follow up, and few of these 
appointments were with medical / respiratory services, suggesting limited opportunities to integrate 
follow up within existing appointments for this patient group.  
The provision of routine ongoing follow up for either group is, therefore, likely to be complex and 
costly for both patients and health services. A proven association between post-TB lung damage and 
‘hard’ adverse outcomes such as recurrent infections, lung function decline, and mortality, may be 
required to justify this investment, and careful thought should be given to a package of interventions 
which might alter these outcomes. Screening approaches to identify those at highest risk of adverse 
outcomes, who would benefit the most from ongoing medical input, must also be developed.  
MANAGEMENT OF RESPIRATORY EXACERBATIONS 
Antibiotics were prescribed for 80% of respiratory-related outpatient visits identified in this study, and 
whilst the majority of these were appropriate for respiratory infections, a diverse range of drugs were 
used, durations of use varied, and it is unclear whether or not they were actually needed. Even in 
resource rich settings the development of clear management guidelines for infective exacerbations in 
conditions such as bronchiectasis have been hampered by the paucity of data on exacerbation 
definitions, aetiology, and antibiotic efficacy.92 Further work to understand the nature of 
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exacerbations experienced by this cohort, the decision making processes currently used for antibiotic 
prescription in different health services, and the microbiology of recurrent infections in this setting 
may help to guide the management of exacerbations in those who have recently completed PTB 
treatment in this context.  
Potential challenges in screening for recurrent PTB disease amongst this cohort have also been 
highlighted by these data. Many TB case finding programmes use symptom questionnaires as the first 
line of screening for active TB disease, however 23% of this cohort were found to have a positive WHO 
TB symptom screen at some point during the 1-year follow up, and this was frequently the result of 
ongoing cough. Only 1/81 symptomatic patients not started on TB retreatment died during follow up, 
suggesting that few of these individuals had active TB disease, and perhaps these ongoing symptoms 
were related to post-TB lung damage. The specificity of the TB symptom screen for PTB disease in this 
group may therefore be somewhat reduced. Use of the XPert MTB/RIF assay for screening within this 
population is also complex. The duration for which GXP stays positive in response to the presence of 
non-viable mycobacteria after an initial episode of disease remains unclear, but the estimated false 
positive rate at 6-months following treatment completion is 9%.237 Clear guidelines for the  use and 
interpretation  of PCR testing amongst a post-TB population may be required to minimize false positive 
results related to such practices. Finally, this cohort has a high burden of underlying lung pathology 
visible on CXR, and the use of CXR screening for identification of those with disease is likely to be 
challenging. Given the complexity surrounding the use of symptom, molecular, and imaging screening 
in this post-TB group, guidelines for TB screening specifically in this population may be of some value.  
 POST-TB LUNG DAMAGE IS EXPERIENCED ON A BACKGROUND OF 
PHYSICAL AND ECONOMIC VULNERABILITY 
Adults within this cohort had a high burden of concurrent respiratory exposures and had ongoing 
markers of poor health even at TB treatment completion. Not only had they experienced a significant 
economic insult during PTB disease and treatment, but economic recovery during the 1-year follow up 
period was limited with ongoing costs and dissaving incurred. This is a worrying background against 
which post-TB lung damage is experienced. 
CONCURRENT RESPIRATORY EXPOSURES 
The total prevalence of ever-smoking within this cohort was 29.6%, compared to an ever-smoking 
prevalence of 10.4% seen within the population based BOLD survey data presented in Chapter 4. This 
difference may be explained by confounding by factors such as male gender, which is associated with 
both PTB disease and smoking: in keeping with global estimates the ratio of men to women was 2.11 
within this study, and the prevalence of smoking amongst men was 43.3% (119/275) within this 
cohort, compared to 0.8% (1/130) amongst women. However, as discussed in Chapter 1, it is also 
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possible that the high prevalence of ever-smoking is related to its role as a risk factor for PTB disease 
itself.16 Although common, ever-smoking was not a significant predictor of spirometry at TB treatment 
completion or at 1-year, or the rate of change over time in multivariate analyses, perhaps in relation 
to the current low level of pack-year exposure observed within the cohort. Although this suggests that 
spirometry outcomes are likely similar for ever and non-smokers, this finding must be interpreted with 
caution – there are strong epidemiological and clinical data that increasing exposure to tobacco smoke 
is associated with COPD and increasing rates of lung function loss, and data on longer term outcomes 
amongst smokers is therefore required.  
An additional concern is the high prevalence of cannabis use in the cohort, with over 1/5th of men 
reporting exposure (21.6% ever-use, 53/245). The risk posed by this remains unclear – chronic 
marijuana use has been associated with chronic bronchitis, bullous airways disease, and increasing 
FVC measurements in previous studies, but not with COPD or lung cancer.238 The strong correlation 
between smoking and cannabis use within this cohort limited our ability to explore their differential 
effects of these exposures, but it is possible that this was an unmeasured driver of spirometry 
outcomes within this setting, and one whose widespread use may be relevant for the general health 
of this population.   
Lastly, the prevalence of biomass exposure is likely high within this cohort. Despite being in an urban 
setting, charcoal was the dominant fuel used for cooking / heating water by the majority of individuals 
recruited (83.5%, 338/405). Challenges in data collection meant that we have limited information on 
self-reported duration / severity of exposure, but previous data from urban Blantyre have suggested 
that average exposure to CO and PM2.5 in this setting exceeds the WHO Air Quality Guidelines,20 such 
that this is likely a further exposure of concern.  
ONGOING MARKERS OF POOR HEALTH  
Although recruitment for this study took place after a 6-month period of TB treatment, the general 
health of the cohort was noted to be poor. As expected, 60.3% (244/405) were HIV infected, and 
although the majority were receiving ART treatment by treatment completion median CD4 count 
across the cohort remained just 229 (IQR: 127 – 397) at the point of TB treatment completion. This is 
likely a function of the low nadir counts experienced prior to ART initiation, the expected long time-
lag to CD4 increment,239 and the additional hit experienced from TB disease itself.  It suggests that at 
TB treatment completion and when on ART, HIV positive individuals remain vulnerable with often 
profound immunocompromise.  
The high proportion of patients with a markedly low BMI at this point is also striking - 17.5% (71/405) 
of patients were underweight with BMI<18.5kg/m2, compared with a population prevalence of 7.9% 
within the general population included in the BOLD urban Blantyre study.34 This measure likely reflects 
many insults including malnutrition, and suggests ongoing vulnerability within the group. In addition, 
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BMI was positively correlated with both FEV1 and FVC at TB treatment completion. This effect was 
independent of both SES and acute food insecurity, suggesting that it is not simply a proxy for wealth 
/ poverty. It was also independent of HIV / the degree of immunosuppression and therefore not simply 
a reflection of HIV-related co-morbidity. The nature of the relationship between BMI and spirometry 
at these time points is unclear: this may be a causal relationship whereby patients with reduced BMI 
at TB treatment completion have reduced respiratory muscle bulk/strength and hence impaired 
spirometry, there may be confounding by PTB disease severity whereby advanced disease is 
independently associated with both BMI and lung destruction, or there may be reverse causation 
whereby a reduced BMI is a result of increased respiratory metabolism experienced by patients with 
advanced lung damage. Further understanding of factors determining BMI in this cohort, and the 
relationship between BMI and lung function with further measurement of respiratory muscle function 
and true lung volumes may help us to understand this relationship and understand whether 
interventions to improve this modifiable variable may impact the extent of respiratory impairment 
and patient outcomes following PTB disease.  
Given these findings the normal haemoglobin levels observed in the cohort at treatment completion 
were somewhat surprising. This may reflect a selection bias – anaemia is usually common amongst 
patients with active TB disease, particularly in the context of HIV co-infection, but is associated with 
increased mortality during treatment,240 and the relatively preserved levels amongst this population 
may reflect a survival bias.241  
ECONOMIC VULNERABILITY 
TB disease has marked economic consequences for adults in this setting. By the point of TB treatment 
completion, the proportion of unemployed participants had increased to over 1/3, individual and 
household incomes had declined, and almost ¾ of patients had experienced dissaving with borrowing 
of money, selling of household items, or using up of savings to meet health care costs over the course 
of TB disease. Although dissaving was more common amongst poorer individuals, 50% (28/56) of those 
in the highest SES quintile also experienced dissaving over this period, highlighting the magnitude of 
TB related costs even when services are ostensibly provided ‘free of charge’ by the state, and the fact 
that even relatively wealthy individuals in settings such as Blantyre have limited financial reserve. 
These data are in keeping with previous literature describing high patient costs during TB illness, with 
approximately 60% of costs related to loss of income, and 40% related to direct and indirect medical 
costs.129  
However, a novel finding from this study is that the financial impact of PTB disease persists, even after 
TB treatment completion. Incomplete recovery of income and employment was clearly seen: 1-year 
post treatment completion a higher proportion of individuals remain unemployed compared to pre-
disease (29.9% vs. 18.8%), and median participant incomes had not returned to their pre-disease levels 
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(median income $43.53 at 1-year vs. $55.10 pre-disease). The proportion of study participants who 
were the main earner within their household remained the same throughout the study period, 
perhaps reflecting an inability of earning to be transferred to another household member, and 
accounting for the lack of recovery in household income. Dissaving was also ongoing: in the year 
following TB treatment completion, half of the cohort experienced dissaving releasing a median of 
$41.32 (IQR: $20.66 – 93.66) through borrowing money, ongoing sales of household assets, and the 
use of savings. Perhaps most concerningly, whilst during TB illness and treatment 17% (39/405) of 
study participants pulled children out of school / interrupted their education to assist the household 
as a result of their illness, this remained the case for 9.5% (35/368) of study participants in the year 
following treatment completion. Self-reported direct and indirect costs related to health seeking were 
in fact low across the cohort, with the exception of participants started on TB retreatment, but it is 
likely that our data underestimated the ‘cost’ of time lost for informal or household work.  
These are the first data to show an ongoing economic impact of TB disease, following TB treatment 
completion. The incomplete recovery in income and employment observed here may be a result of 
difficulty regaining employment once lost in a setting such as Malawi due to high local unemployment 
rates, and the stigmatizing nature of TB disease / HIV disease. The sale of income generating household 
assets during the illness period, which within this cohort included means of transport, land, and 
livestock, may limit capacity to earn. Lastly, the physiological data presented above clearly shows that 
significant morbidity persists at TB treatment completion, with limited BMIs, ongoing advanced 
immunosuppression, a high symptom burden, and residual respiratory pathology. The extent to which 
these parameters impair patients’ ability to return to work after treatment completion is unclear. 
Further exploration of these factors is required if we are to optimize the recovery of these largely 
young, economically active patients and their households following PTB disease treatment in order to 
meet the WHO End TB strategy objective of mitigating the financial cost of TB disease. Some focus on 
the physical and economic rehabilitation of TB patients following treatment completion may be 
required to achieve this end.  
Finally, data from this study show that poverty at TB treatment completion is an independent 
predictor of airway obstruction at this time point: controlling for other characteristics, those in the 
lowest 3 urban wealth quintiles had FEV1/FVC ratios which were on average 2.8% (95% CI: 0.7 – 4.9%) 
lower than those in the highest quintiles within this cohort. The mechanism underlying this association 
is unclear. It may be that the association between poverty and airway obstruction seen in this cohort 
is completely independent of TB disease: analysis of data from general community populations in 12 
BOLD study sites showed a positive correlation between increasing wealth and the FEV1/FVC ratio both 
within and between sites, independent of age, sex and smoking,38 and local BOLD study data from 
urban Malawi have demonstrated a positive correlation between the lack of a private water supply – 
used as an SES proxy – and an obstructive FEV1/FVC ratio which is independent of previous TB disease. 
However, it may also be the case that SES at TB treatment completion is in part a product of the 
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financial effect of TB disease, such that those who experience the greatest financial hit during disease 
also sustain more significant lung damage. Whatever the mechanism, and whether this finding is 
related to or independent of  the severity of PTB disease experienced, it is of concern: tuberculosis is 
in itself is a disease of poverty and social exclusion,45 and the finding that even amongst those who 
have PTB disease and within a relatively poor population, it is those who are particularly poor who are 
at increased risk of airway obstruction, is worrying and further supports the need to address the 
socioeconomic determinants of poor health within this group.  
 STUDY STRENGTHS 
This is the first large prospective study of post-TB lung damage in the sSA setting to date. Within this 
study residual post-TB pathology was measured along multiple respiratory parameters including 
symptoms, quality of life scores, and spirometry and imaging, to provide a comprehensive description 
of residual disease. The availability of CT imaging is limited in many resource poor settings, and its 
inclusion within this study is therefore of particular value.   
 Questionnaire data were collected electronically, with few missing or incorrect entries. Rigorous 
methods of quality control were employed for spirometry, CXR, and CT data, with dual reporting and 
consensus review for each. High quality valid spirometry data were available for >90% of participants 
at each study visit. CT imaging was available for 95% of participants, and the reporting tool used for 
interpretation used clearly defined Fleischner terms where possible.  
This study included the collection of prospective data, such that it is possible to track change over 
time. Although it was completed within an urban setting with a highly mobile population, loss to follow 
up was under 10%. Both HIV positive and negative adults were included, and disaggregated data are 
presented for each group. The unselected pragmatic recruitment approach taken means that findings 
can be generalized to a wide spectrum of adults completing PTB in settings such as Malawi.  
A strong emphasis was placed on communicating study results back to participants – each individual 
was seen by a respiratory physician at the end of the 1-year follow up, and written copies of all test 
reports were given to participants and their implications explained. Collective feedback meetings were 
also held at the end of the study to communicate research findings to participants.  
Multiple patient outcomes were measured within this study, such that the relationship between post-
TB lung damage and many relevant outcomes can be assessed from this single cohort. Lastly, the 
cohort that was established as part of this study is ongoing, and offers unique opportunities to obtain 
further longitudinal data on patient outcomes and progression of respiratory pathology.  
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 STUDY LIMITATIONS 
Firstly, whilst our aim was to recruit a representative sample of those completing PTB treatment in 
urban Blantyre, relatively few individuals within the cohort were drawn from the lowest urban wealth 
quintile. This may reflect a selection bias – the fact that patients were asked to pay for transport to 
the central tertiary hospital themselves for recruitment, before being reimbursed, may have made it 
challenging for the poorest individuals to attend. However, as study participants were recruited from 
the point of TB treatment completion rather than diagnosis, this finding may reflect higher mortality 
rates amongst those with lower SES such that they are genuinely under-represented by the point of 
treatment completion.  
Secondly, this study does not include any measure of pre-TB lung damage. As such, it is not possible 
to know whether the pathology identified at TB treatment completion is the result of PTB disease only 
or related to previous respiratory disease. Whilst the ability to determine causality is certainly limited 
within this study, the intention of this study was to take a pragmatic approach to describing the burden 
of lung damage seen in this population at the point of treatment completion, and the outcomes 
related to this. This is the information of greatest use for health service planning, regardless of cause. 
As noted above, the follow-up duration of this study was constrained to 1-year by the duration of this 
PhD, which was likely too short. This resulted in models being underpowered to detect a relationship 
between residual lung damage and key long-term outcomes, including acute exacerbations, TB 
retreatment, and mortality, and also meant that the outcome measures used in the multivariate 
models constructed were altered from those specified in the original protocol. All revised definitions 
were however established before the revised models were constructed, thus limiting bias. Further 
analyses of exacerbation rates using person-time approaches are required, and must incorporate the 
longer-term data on patient outcomes which will be available from ongoing follow up of the cohort in 
the coming 2-3 years.  No control group was included within this study. The aim of this study was to 
perform an internal comparison of patient outcomes amongst those with and without severe residual 
lung damage after PTB treatment completion, and a non-TB control group was not required to this 
end. However, the availability of community symptom and spirometry data from the BOLD study 
completed very recently in urban Blantyre has allowed for comparison with background rates of 
pathology.  
Challenges were experienced in the various measures of post-TB lung damage used in this study. 
Firstly, no pre-existing validated definitions or severity scores for PTLD were identified on literature 
review, and an a priori definition was used in cohort analyses. This definition was not validated and 
may have limited the power of our analyses. Further exploratory approaches may be required to refine 
this definition. Measurement of lung function in this study was limited to spirometry, with no lung 
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volumes recorded, and as a result the true pathology underlying the low-FVC pattern in particular is 
difficult to determine.   
Lastly, several challenges were faced with CT and CXR imaging. Logistical challenges meant that 
different CT scanners and CXR modalities were used through the course of the study, and whilst 
sensitivity analyses suggest that the impact of this was likely minimal, this may have influenced 
findings. No validated reporting tool was available for post-TB lung damage, and one was designed for 
use in this study – this included several assumptions, including equal weighting of all CT lobes and CXR 
zones, which may have influenced our results. Manual reading of CT and CXR data resulted in high 
levels of inter-reader variability, with pragmatic decisions made for consensus review and generation 
of ‘final’ scores – machine reading to provide ‘objective’ measures of pathology may provide a more 
valid approach.  
Across all parameters, interpretations of patterns of change over time were based on 2-3 time points 
for each individual only. The observed trends to improvement observed may be a result of regression 
to the mean, expected test-retest variation, or participant learning on repeated testing, but the 
presence of a subgroup of individuals who deteriorated over time is perhaps reassuring against this. 
Longitudinal data with multiple ongoing measurements is required to determine if these patterns 
persist, and further analyses using MCID values to classify changes seen over time may help to 
determine the clinical relevance of observed patterns.   
Although this study was intended to be observational, it is likely that participants received a higher 
level of support and care than would have been received within routine services, as a result of regular 
6-monthly contact with the study team. Efforts were made to signpost individuals to routine services, 
rather than providing treatment through the study itself, but the fact that individuals received regular 
testing and review will likely have improved their outcomes.  
Finally, this thesis includes multiple exploratory analyses, with no corrections used for multiple 
comparisons. It is possible that some of the relationships identified are the result of chance alone. 
Several of the models constructed are vulnerable to over-fitting, with more than 1 variable included 
per 10 outcome ‘events’, such that the parameter estimates are vulnerable to bias.242  This is a single 
site study, and duplication of this study in diverse sSA settings, with larger total populations and more 
outcome events would help to reinforce findings and increase confidence in results.  
5.5 CONCLUSION  
To my knowledge, this study is the first to comprehensively describe the residual lung damage that 
persists following PTB disease along multiple parameters, together with associated outcomes, in HIV 
positive and negative adults in sSA.  
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We found a considerable burden of residual lung damage at TB treatment completion: 60.7% of 
individuals continued to experience regular respiratory symptoms on a weekly or monthly basis, 34% 
of participants were left with abnormal patterns of spirometry, and the majority had abnormal 
imaging with a median of 1.4 lobes of abnormal parenchyma, and moderate-severe bronchiectasis 
seen in 44%. A trend to recovery was observed over the 1-year follow up period across multiple 
parameters, but this was on average incomplete, such that the burden of pathology remained high at 
1-year following TB treatment completion.  
We found that whilst HIV-infection is protective against post-TB lung damage, the burden of pathology 
amongst people living with HIV is substantial and cannot be ignored – 58% of HIV infected adults had 
ongoing monthly respiratory symptoms at treatment completion, 28% had abnormal spirometry, and 
the median amount of abnormal parenchyma in this group was still 1.1 lobes-worth. Whilst severity 
of disease was reduced in this group, patterns of post-TB pathology remain similar to those those 
without HIV. This is further reason to prioritise the investigation of post-TB lung damage in sSA, where 
the burden of HIV-TB co-infection remains high. 
Severe post-TB lung damage at TB treatment completion was associated with adverse outcomes 1-
year later: the odds of both regular monthly respiratory symptoms and an impaired quality of life at 
1-year were three-fold higher amongst those with both extensive structural damage and abnormal 
airway physiology at treatment completion. However, despite this finding, and the high burden of 
pathology observed within the cohort, only 2.2% of participants had been recognized as having a 
chronic lung disease requiring further medical input by the point of TB treatment completion. This is 
particularly concerning given the high rates of concurrent respiratory exposures seen in this cohort – 
1/3 were ever smokers, over 1/5 of men reported previous cannabis use, and 84% used biomass fuels 
for cooking or heating water – further compounding their risk of adverse respiratory events. There is 
clearly an unmet need for respiratory services for this patient group, in this setting.  
Perhaps as might be expected, rates of ongoing health service use were high with 16% of participants 
having at least 1 unscheduled health service visit for deteriorating respiratory symptoms in the 1-year 
follow up period. However, no relationship was found between the extent of post-TB lung damage 
and the incidence of an exacerbation, perhaps due to limited study follow up and power. Ongoing 
longitudinal follow up is required to better determine the relationship between residual post-TB lung 
damage and the rate of respiratory exacerbations.  
Finally, this study has found that adults treated for PTB in this suffer a large economic hit from TB 
disease, and continue to experience dissaving with a limited recovery in employment and income even 
after treatment completion. Perhaps as a result 9.5% of the cohort took children out of school to help 
in the home during in the 1-year follow up period. This is clearly of concern for the long-term wellbeing 
of the household, and means that participants may be particularly vulnerable to the impact of physical 
morbidity experienced following PTB disease.  
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6 CONCLUSION 
This thesis has focused on post-TB lung damage – the residual lung pathology that persists after 
successful treatment for pulmonary TB disease. There are two global health agendas which make this 
a timely contribution: firstly, the increasing recognition of NCDs including chronic lung disease as an 
important cause of morbidity and mortality in resource poor settings,243 and secondly, the recognition 
that integrated, patient centred approaches are needed for TB care if we are to mitigate the long-term 
impact of disease on patients and their households. These agendas have been enshrined in the 2017 
Sustainable Development Goals, and the 2015 End TB strategy.64 244 This PhD sits very much at the 
intersection between these agendas. Perhaps the key message of this work is that given the high 
burden of TB sequelae such as post-TB lung damage, the NCD and TB agendas should be thought of as 
very much interlinked. In tuberculosis, as well as many other diseases relevant to LMICs, the 
boundaries between ‘infectious’ and ‘non-infectious’ disease are increasingly blurred and approaches 
to clinical care, research, and policy would likely benefit from being re-designed to reflect this.   
 POST-TB LUNG DAMAGE IS COMMON AND IMPORTANT 
In the literature and systematic reviews completed during this PhD we found few studies of post-TB 
lung damage in the sSA context, and HIV positive individuals specifically. This maybe explained by a 
focus on improving diagnosis and reducing mortality in these groups to date – it is indeed true that TB 
case fatality rates remain unacceptably high in many LMICs. However, TB related mortality is gradually 
falling, and global treatment success rates are currently 83%, such that the long term well being of 
survivors also needs to be prioritized.  
The cohort study presented in Chapter 5 of this PhD was a prospective study of post-TB sequelae in 
sSA which focused specifically on the long-term wellbeing of TB survivors. This study showed that the 
respiratory and economic wellbeing of many individuals remains limited long after successful 
completion of PTB treatment. A considerable burden of residual lung pathology was seen amongst HIV 
positive and negative groups at PTB treatment completion, with ongoing respiratory symptoms in 
60%, abnormal spirometry in 34%, bronchiectasis in 44% and at least 1 destroyed lobe in 10% of adults, 
and extensive pathology at treatment completion was associated with increased odds of poor quality 
of life and ongoing symptoms even 1-year later. Incomplete recovery of income and employment was 
widespread, and ongoing dissaving in relation to poor health continued in half the cohort in the year 
after treatment completion. Although current TB services discharge patients as ‘cured’ at the end of 
standard short-course treatment, with no ongoing follow-up, the findings of this study suggest that 
for many, physical impairment and economic vulnerability persist.   
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 IMPLICATIONS FOR FUTURE RESEARCH   
The high burden of post-TB lung damage reported in this cohort study is of concern. Further work is 
required to understand how it might be prevented, and once present, how it might be managed.  
However, if this research field is to grow in a collaborative and cohesive way, consensus is first required 
in the terminology used to describe post-TB lung pathology, and standardized measures of disease 
severity and patient outcomes must be agreed. In the absence of clear definitions, researchers 
working in this field will find it difficult to compare findings across sites in order to generate cohesive 
guidelines for further research or clinical management. Data from the cohort study presented here 
may provide some basis for these definitions, but this needs to be a joint effort drawing together all 
those with an interest in this area.  Once terminology has been agreed, I would suggest that there are 
several areas of research which should be prioritised: understanding the heterogeneity of post-TB lung 
pathology, measuring associated physical and economic outcomes over a longer follow up duration, 
and designing interventions to improve these outcomes.  
Much heterogeneity has been observed in the patterns of residual pathology amongst those 
completing treatment for PTB disease, and the evolution of this pathology over time. This wide 
spectrum is likely a product of host, pathogen, and environmental exposures, and it is only by 
understanding these factors that we we will be able to design upstream interventions to minimize 
severe forms of TB related lung damage, and reduce rates of decline in lung function over time. Further 
analysis of cohort data from this PhD may be of some use here: data driven phenotyping of patterns 
of post-TB damage may allow us to define categories of participants amongst whom exposures can be 
compared, and individual level analyses using mixed effects models may allow us to understand the 
reasons for the diverse trajectories of improvement / decline seen between individuals.  
Data from CLD cohorts in resource rich settings suggest that pathology of the nature seen in this 
context is likely to be associated with adverse outcomes including respiratory exacerbations and 
mortality. However, the cohort study presented here was likely underpowered to detect these 
associations. Prolonged follow-up of post-TB patients with outcomes measured over at least 2-5 years 
will be required in order for us to ascertain the range of physical and economic outcomes which post-
TB lung damage is associated with in settings such as Malawi.  
If an association with ‘hard’ adverse outcomes such as exacerbations and mortality is seen, 
intervention studies will be needed to determine whether these outcomes can be significantly 
improved. Individuals at high risk of adverse outcomes will need to be defined, and screening tools 
which can be used to identify these individuals in resource poor settings developed. Potential 
interventions to improve outcomes may include patient education, chest physiotherapy, appropriate 
antibiotic use during infective exacerbations, and appropriate TB screening approaches in the event 
of worsening symptoms. Strong links between TB and medical services will be required to deliver 
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these. These interventions could perhaps be trialled as a ‘package of care’ in high risk groups in 
different locations.  
Finally, in addition to studies focused specifically on post-TB lung damage, I would also argue that 
studies targeted at improving TB health systems, diagnostics and treatment regimens should broaden 
their focus from microbiological and mortality outcomes, to include measurement of morbidity aswell. 
Long-term quality of life amongst survivors of TB disease is important, and the impact of novel 
interventions along the TB treatment cascade in improving this may be significant and should be 
‘costed’ into their assessment. 
 IMPLICATIONS FOR CLINICAL PRACTICE AND PUBLIC HEALTH POLICY 
At present, the major message for communication to health care providers in sSA is increased 
awareness of post-TB lung damage. Whilst most individuals completing TB treatment are well with 
only minor respiratory deficits at TB treatment completion, there are a subset with severe residual 
lung pathology. For this group, the end of TB treatment is not the end of their illness, and ongoing 
support may be required. TB officers should be advised to encourage patients who have marked 
breathlessness and cough at TB treatment completion to present early to health care providers for 
review, in the event of a deterioration of their symptoms, and general advice on avoiding smoking and 
cannabis use should be provided. Where patients do present with chronic or worsening respiratory 
symptoms after a previous episode of PTB, post-TB lung damage should be considered within the 
differential diagnosis. Caution in the isolated use of the XPert MTB/Rif test for diagnosis of TB disease 
recurrence soon after TB treatment completion should be encouraged.   
It is perhaps too early to advocate for changes in health systems to support individuals with post-TB 
lung damage – we do not yet know whether these individuals are truly at risk of ‘hard’ adverse 
outcomes such as exacerbations and mortality, and we do not yet know whether available 
interventions would mitigate these outcomes. Ongoing clinical follow-up of these individuals is likely 
to be costly for both patients and providers, and cost-benefit for all parties must be considered 
carefully once outcome and intervention data are available.  
 SUMMARY 
This thesis marks the start of an area of research, rather than its completion. Clearly there is much to 
be done before we will be able to make clinical and public health recommendations for the 
management of post-TB lung damage in LMICs. However, the high burden of disease identified within 
this thesis requires that this work be actively pursued. It is hoped that in time, this will contribute to 
both mitigating the impact of non-communicable lung diseases, and providing integrated care for 
vulnerable PTB patients in resource poor settings such that they are able to live healthy and productive 
lives in the long-term.  
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7 APPENDICES 
7.1 APPENDIX 1: CT IMAGING PROTOCOL 
Low dose high resolution CT imaging was performed as per the protocol below. CT data (scout images, 
axial images, dose data) were saved to disk immediately after the imaging, with one disc per patient. 
Each disc was labelled with the patient initials, study ID, and date. Due to limited storage capacity at 
the scan sites, all raw data were deleted from the scanners following completion of the session. Images 
were anonymised and saved as DICOM files onto an external hard drive and the institutional server. 
Hard copies of imaging CDs were stored in a secure location within the research institution.  
 
Figure 1: CT chest imaging protocol 
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7.2 APPENDIX 2: SPIROMETRY QUALITY CONTROL 
All pre- and post- spirometry attempts recorded for each patient were reviewed by 2 readers (JM & 
LZ) independently, and graded for errors according to the CDC National Institute for Occupational 
Safety & Health (NIOSH) guidelines, and the BOLD study quality control procedures (Table 1).229 230 
Tests were reviewed in chronological order in batches of 100 through the duration of the study, with 
feedback provided to technicians as required. 
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Table 1: Grading criteria for individual spirometry trials, with source of guidelines listed 
Reason for rejection of 
spirometry curve 
 
Abbreviation 
for error 
Definition of error Reference/ source 
High PEFT p (PEFT) PEFT ≥150msecs 
 
BOLD QC requirements, which 
relaxed the ndd cut off of 120ms 
High BEV b (BEV) BEV ≥150ml  
AND 
BEV ≥5% of FVC 
 
ATS criteria, NIOSH, BOLD QC 
requirements state that for a 
curve to be included BEV must be 
<5% or <150ml, whichever is 
greater. 
Non-maximal effort e (effort) Marked lack of peak, indicating weak 
blast 
OR 
Markedly reduced peak compared to 
other curves, indicating poor filling of 
lungs at start of test 
BOLD QC requirements 
ATS criteria 
NIOSH guidelines 
Early termination of 
expiration 
t 
(termination) 
Insufficient expiratory phase on volume-
time curve – duration of expiration for < 
6 secs OR failure to reach plateau of ≥1 
sec  
OR 
Sharp early drop to 0 on flow-volume 
curve 
BOLD QC requirements 
ATS criteria 
NIOSH guidelines 
Extra breath x (extra) Visible extra breath on flow-volume and 
or the volume-time curves 
BOLD QC requirements 
NIOSH guidelines 
Glottis closure that 
influences 
measurement 
g (glottis) Abrupt flat line on volume-time curve, 
with sharp drop to 0 on flow-volume 
curve 
 
BOLD QC requirements 
ATS criteria 
NIOSH guidelines 
Leak l (leak) Descent of volume-time curve, after 
peak is reached, with ‘back-track’ of 
flow-volume curve at the end of 
expiration 
BOLD QC requirements 
ATS criteria 
NIOSH guidelines 
Obstructed 
mouthpiece 
o 
(obstruction) 
Artefact in the flow-volume and volume-
time curves, felt to be significant enough 
to affect measurement 
BOLD QC requirements 
ATS criteria 
NIOSH guidelines 
Cough that affects 
measurement  
c (cough) Cough within 1st second which is likely to 
alter FEV1, or a later cough which causes 
early termination.  
BOLD QC requirements 
ATS criteria 
NIOSH guidelines 
Zero flow error z (zero) Continuous rise of volume-time curve, 
with no plateau, and long tail on flow-
volume curve, which is felt related to 
error rather than obstructive 
impairment 
BOLD QC requirements 
NIOSH guidelines 
PEFT: Peak expiratory flow time; BEV: Back extrapolated volume 
BOLD: Burden of Obstructive Lung Disease Study; ATS: American Thoracic Society; NIOSH: National Institute for Occupational 
Safety & Health, Centres for Disease Control & Prevention; QC: Quality Control. 
 
Curves where both readers had identified errors were excluded from analysis. In the event of 
discrepancy between readers, grading was resolved by consensus discussion.  
7.2.1 MANUAL REVIEW 
Despite the scoring process above, the selected curves for several patients were noted to have 
prolonged forced expiratory times (FET), possibly related to zero-flow errors with inaccurate zeroing 
of the spirometer prior to testing. In order to ensure that curves with zero flow errors were not 
included in the analysis, the 5% of spirometry readings with the longest FET times on the ‘best test’ at 
any one study visit were manually reviewed. Traces obtained for the patient at this study visit were 
compared with those obtained from the patient at previous / later study visits to identify 
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abnormalities. Spirometry tests felt to have zero flow errors, as evidenced by a linear trend on the 
volume-time curve, an inconsistent high FVC, and the long FET, were re-classified as not-valid and 
were not used.  
In addition, spirometry readings with the 1% highest and lowest post-bronchodilator maximal FEV1 
and FVC values were manually reviewed, and readings compared across study visits to ensure 
consistency and accuracy. Curves which were clearly inconsistent with other data for a given patient 
and in whom there was suspicion of an error in study ID or test performance, were classified as not-
valid and were not used. 
7.2.2 DATA EXTRACTION FROM USABLE TRACES 
The following data were extracted separately for pre- and post-bronchodilator spirometry attempts 
from usable curves only: maximum and next-best FEV1 maximum and next-best FVC values, FEV1/FVC 
ratio. Neither PEF or MEF25-75 readings were recorded: PEF is effort dependent, and variation in an 
individual over course of a day can be up to 20%; Mid expiratory flows are highly dependent on posture 
and positioning, and because flow measurements are taken at a fixed % but different absolute 
volumes of the FVC, there is limited ability to compare values between people or over time if the FVC 
changes.  
Repeatability was assessed for usable pre- and post-bronchodilator spirometry attempts for each 
participant at each study visit by calculating the difference between the maximum and next-best FEV1 
and FVC values. BOLD quality control guidelines require a maximum difference of ≤200ml between 
the best and next best measurements in order to deem the data valid, whilst the ATS criteria are 
stricter and require a difference of ≤150ml. For this analysis, data meeting the more relaxed BOLD 
quality control guidelines were included. Only those spirometry recordings where both post-
bronchodilator FEV and FVC readings were repeatable by BOLD standards were used in the analysis.  
This means that data was used for a given patient at a given study visit only if 2 usable curves with no 
errors were available, and if the differences between both the best/next-best FEV1 and FVC readings 
across these curves were <200ml. Patients with either no usable post-bronchodilator curves, or with 
usable curves which did not meet these repeatability criteria, were defined as having ‘missing’ data 
for this test. 
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7.3 APPENDIX 3: CT METHODOLOGY DEVELOPMENT 
7.3.1 CT SCORING SYSTEM 
The CT scoring system used is described in Table 2. Notes generated by the scoring radiologists during 
the interim / final data reviews are included, and were used to guide data analysis and interpretation. 
Table 2: Final CT scoring system used for data analysis, including notes of clarification / concern generated during the course 
of the study, which may influence how data are interpreted, or inform the design of future studies 
Initial name of 
variable 
Initial definition Scoring options Notes 
Generated after r/v 
of 20 images 
Notes – generated during & 
after review of full dataset 
PARENCHYMAL VARIABLES  
Scored at lobar level. Mutually exclusive variables, summing to 100% for each lobe. 
Parenchymal 
bands 
Linear opacity 1-3mm 
thick, up to 5cm long. 
Usually extends to 
visceral pleura.  
May be accompanied 
by anatomical 
distortion 
% of lobe (to 
nearest 5%) 
Interlobular septal 
thickening to be 
scored as 
parenchymal bands 
if few, and likely 
resolving 
inflammation. If 
extensive or likely 
related to fluid or 
other cause, to 
document in free 
text.  
 
Atelectasis Reduced volume 
accompanied by 
increased lucency in 
the unaffected part of 
the lung.  
May be accompanied 
by displacement of 
fissures, bronchi, 
vessels. 
% of lobe (to 
nearest 5%) 
To be estimated as 
the proportion of 
the normal lobe 
which has been 
lost.  
 
Eg. One collapsed 
lung segment in the 
upper lobe would 
be 35% atelectasis 
in the lobe.  
Where lobes are completely 
collapsed, the collapsed 
parenchymal tissue remains 
and occupies space. The 
approach to scoring this 
collapsed tissue was not 
discussed in the initial scoring 
system.  
 
Completely collapsed lobes 
were variably scored as having 
either 100% atelectasis, or a 
high % of atelectasis + a limited 
% of consolidation. 
Consolidation Homogeneous increase 
in lung parenchymal 
attenuation which 
obscures the margins 
of vessels and airway 
walls. An air 
bronchogram may be 
present.  
 
% of lobe (to 
nearest 5%) 
Thickened wall of a 
cavitated area and 
surrounding 
consolidation to be 
included in 
consolidation % 
score.  
Classical TB rosettes 
to be included 
under 
consolidation, 
rather than as tree 
in bud or nodules 
No category of ‘other’ was 
included in the % parenchymal 
score either. Where 
indeterminate interstitial 
change was seen, this was 
classified under consolidation.  
As such, % consolidation is a 
broad category that included 
any type of opacity which did 
not meet criteria for GGO, 
nodules, or parenchymal 
banding, so covers both large 
areas of dense opacity, as well 
as areas with indeterminate 
interstitial change.  
Ground glass 
opacification 
Hazy increased lung 
opacity with 
preservation of 
bronchial and vascular 
margins 
% of lobe (to 
nearest 5%) 
  
Mosaicism Areas of reduced lung 
parenchymal 
attenuation. 
Component of the 
mosaic attenuation 
% of lobe with 
darker areas (to 
nearest 5%) 
In absence of any 
other signs of 
airways disease, 
and in presence of 
pulsation / 
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pattern, where a 
patchwork of differing 
lung attenuation is 
seen. 
 
breathing artefact, 
changes should not 
be scored as 
mosaicism.  
 
Unless 
unequivocally 
visible, do not score 
Emphysema Focal areas or regions 
of low attenuation 
usually without visible 
walls 
% of lobe (to 
nearest 5%) 
Appearances 
consistent with 
‘classical 
emphysema’ 
 
Emphysematoid 
destruction 
Focal area of 
destruction / 
emphysematous 
change associated with 
features of healing TB, 
suggesting destruction 
of small airways. 
% of lobe (to 
nearest 5%) 
Clear association of 
emphysematous 
change (areas of 
decreased lung 
attenuation) with 
signs of TB healing. 
 
Cavities / cystic 
airspaces 
Gas filled space, seen 
as a lucency or low-
attenuation area within 
a pulmonary 
consolidation, a mass, 
or a nodule. 
Consolidation may 
have resolved leaving a 
thin wall only. 
% of lobe (to 
nearest 5%) 
Parenchyma 
destroyed by cystic 
airspaces 
connected to a 
dilated bronchus 
will be scored as a 
cavity, in this 
section of the 
scoring tool 
Combining ‘absent’ 
parenchyma due to either 
cystic bronchiectasis or true 
cavitation within this % 
parenchymal category was a 
pragmatic decision, and 
reflects the reality that these 
pathologies can be very hard to 
differentiate on imaging, 
particularly where a cavity has 
ruptured through into an 
airway 
 
However, this approach means 
that the scoring system cannot 
differentiate between these 
two pathologies, even when 
the difference was relatively 
clear. This means that it is not 
possible to differentiate 
between negative outcomes 
associated with the % of tissue 
destroyed by cystic 
bronchiectasis, and the % 
destroyed by cavitation.   
 
Finally, it means that this 
category is likely mislabelled 
and should be referred to as 
‘absent’ parenchyma, rather 
than parenchyma destroyed by 
cavities.  
Normal Normal parenchyma, 
not affected by any of 
the pathological 
processes above 
% of lobe (to 
nearest 5%) 
 Areas of parenchyma with 
normal airspaces but 
interspersed discrete nodules 
or tree in bud were classified as 
‘normal’ here.   
BRONCHIECTASIS VARIABLES 
Scored at lobar level. Extent assessed first, with Pattern and Severity scored only if bronchiectasis seen. 
Bronchiectasis 
 
Airway lumen 
diameter 
greater than 
accompanying 
pulmonary 
Extent 
 
 
0: Absent 
1: ≤1 BP segment 
2: 2 BP segments 
3: ≥ 3 BP 
segments 
 The scoring system did not 
allow for differentiation of 
which airways were dilated – 
this category therefore 
includes dilatation of both 
small peripheral airways and 
the large central airways. 
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artery outer 
diameter,  
OR 
Airways visible 
in the lung 
periphery,  
OR  
Lack of normal 
tapering 
 
Pattern  
 
(Scored only if 
bronchiectasis seen 
and ‘extent’ score >0) 
1: Cystic 
(Ballooned' 
outline, with 
diameter 
increasing 
towards 
periphery) 
 
2: Cylindrical 
(Regular and 
straight outline, 
with abrupt 
termination) 
 
3: Varicose 
(Irregular 
bronchial outline, 
with bulbous 
termination) 
Score as cystic 
bronchiectasis only 
if appearance 
typical of this, with 
a dilated airway 
connected to an 
area of destroyed 
parenchyma. 
 
Otherwise should 
be scored as a 
slightly dilated 
bronchus related to 
a cavity.  
If bronchiectasis was present, 
only 1 pattern could be 
selected to describe this. In 
reality, multiple patterns of 
airway dilatation were often 
visible in each lobe. In choosing 
which pattern to document, 
the reader could choose either 
the dominant pattern, or the 
pattern considered to be most 
important. The approach to 
this was not specified in the 
SOP and so may have varied 
between readers / scans.    
 
Severity 
 
Maximum degree of 
airway dilatation, to be 
measured by 
comparing diameter of 
airway lumen to 
diameter of adjacent 
vessel.  
 
(Scored only if 
bronchiectasis seen 
and ‘extent’ score >0) 
1: Trivial 
(bronchial lumen 
is <twice 
adjacent vessel 
diameter) 
 
2: Bronchial 
lumen is 2-3 
times adjacent 
vessel diameter 
 
3: Bronchial 
lumen is >3 times 
adjacent vessel 
diameter 
Overall ‘gestalt’ 
impression of 
severity of 
dilatation, including 
both large and 
small airways 
Scores ≥2 were taken to 
denote moderate-severe 
airway dilatation.  
AIRWAY VARIABLES 
Scored at lobar level. All variables independent of each other.  
Bronchial wall 
thickening 
Thickening of bronchial 
walls 
0: Absent 
1: Mild 
2: Moderate  
3: Severe 
Missing: Unable 
to assess 
Score as unable to 
assess if not 
measurable due to 
adjacent collapse / 
consolidation.  
 
Mucous 
plugging 
Mucous seen in 
proximal large airways 
0: Absent 
1: Mild 
2: Moderate  
3: Severe  
 In fact, this category includes 
obstruction of the airway by 
any opacity – it is not possible 
to differentiate the obstructing 
material, and in the context of 
post-TB change, this may be TB 
related granuloma rather than 
mucous.  
 
This category is likely 
mislabelled and should be 
referred to as ‘airway 
plugging’.  
Tree in bud Centrilobular branching 
pattern, resembling a 
budding tree. Most 
pronounced at the 
periphery. 
0: Absent 
1: Mild 
2: Moderate  
3: Severe 
 The scoring system includes 
what others have referred to as 
‘micronodules’ as tree in bud 
change, on the grounds that 
the pathology underlying this is 
likely to be the same 
(inflammatory changes in the 
Centrilobular peripheral small 
airways) 
CAVITY VARIABLES 
Scored at lobar level. Independent of parenchymal scores. Extent scored first, with size and severity scored only if cavities 
seen 
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Cavity 
 
Gas filled space, 
seen as a 
lucency or low-
attenuation 
area within a 
pulmonary 
consolidation, a 
mass, or a 
nodule. 
Consolidation 
may have 
resolved 
leaving a thin 
wall only. 
Mycetoma 
Extent 0: Absent 
1: 1-2 cavities 
2: 3-5 cavities 
3: >5cavities 
 
Any markedly 
dilated airway 
leading to a cavity 
will be scored as 
bronchiectasis, 
rather than a cavity 
 
The category of 
cavity will include 
-Cavities which are 
‘closed’ and 
unrelated to 
airspaces 
-Cavities which are 
‘open’ and related 
to airspaces but 
where the airway is 
not clearly dilated / 
bronchiectatic  
Cavities were scored in 2 ways 
for each lobe, within any given 
scan: 
- % parenchyma affected by 
cavities 
- Extent of cavities seen (absent 
/ 1-2 / 3-5 / >5 cavities)  
 
These variables were not 
‘linked’ within the database 
during initial scoring, which 
generated mismatches 
requiring review in the by the 
consensus reading process.  
 
Maximum size Maximum 
diameter (mm) 
  
 
Mycetoma 
 
Discrete mass of 
hyphae, within a cavity. 
May have air crescent 
sign. May have sponge 
like pattern with areas 
of calcification. 
0: Absent 
1: Present 
If uncertain 
whether this is lung 
necrosis or 
aspergilloma, score 
as the latter.  
 
OTHER LOBAR VARIABLES 
Scores at lobar level 
Nodules Rounded opacities, 
well or poorly-defined, 
>5mm, measuring up 
to 3cm in diameter 
0: Absent 
1: <5 nodules 
2: ≥5 nodules 
3: Miliary 
If multiple 3-5mm 
nodules are seen 
only, to document 
in free text. 
Should be 
documented as an 
alternative, non-TB 
diagnosis.  
Where multiple dense opacities 
were seen, likely related to TB 
rosettes, these were variably 
scored as consolidation in the 
% parenchymal score section, 
or nodules in the categorical 
variables, or as both. The 
extent to which this was done 
differently by readers is not 
possible to identify.  
WHOLE LUNG VARIABLES 
Scored at level of hemithorax / whole lung 
Pleural effusion Accumulation of fluid 
within pleural space 
0: Absent  
1: Present 
  
Pleural 
thickening 
Pleural thickening of 
≥10mm 
0: Absent  
1: Present 
  
Lymph nodes Mediastinal / hilar 
lymph nodes ≥10mm 
diameter 
0: Absent 
1: Present 
  
DOMINANT PATHOLOGY 
Impression of reporting radiologist, after review of individual variables above 
Compatible with resolving PTB – No other pathology These categories presume that 
residual consolidative / nodular 
change was resolving rather 
than active disease, but in 
practice it is of course difficult 
to tell.  
Terminology should be 
changed to denote that 
pathology is consistent with 
‘recent’ PTB instead of 
resolving PTB.  
Compatible with resolving PTB, plus other diagnosis 
Resolving PTB or other diagnosis equally likely 
Not compatible with resolving PTB, other diagnosis likely 
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7.3.2 CT CONSENSUS REVIEW 
Given the large number of variables measured in this study, a pragmatic approach was taken to the 
selection of variables for consensus review: imaging patterns that were rarely seen and felt unlikely to 
have a statistically significant impact on patient outcome (Eg. pleural pathology, airway narrowing), 
and those which are known to be poorly identified using non-contrast HRCT, and had very poor inter-
reader agreement in the original data set (Eg. lymphadenopathy) were not consensus reviewed.  
Consensus review was completed for the scans with the most discrepant scores for the remaining 
variables (Table 3). For continuous variables, the most discrepant ~5% of scans for each variable were 
selected for review: assuming that the difference in scores between readers had a normal distribution, 
this rule identified scans with differences >2 standard deviations away from the mean difference. 
Using this rule, whilst the number of scans re-read for each variable was similar, the magnitude of 
discrepancy tolerated varied widely, according to the spread of differences in reports between original 
readers. For example, only scans reported with differences of ≥160 points between readers for 
mosaicism were re-read, whilst those with differences ≥25 points in emphysema scores were re-read. 
This is, however, in keeping with usual practice in radiology scoring methodology. 
Table 3: Methods used to select scans for consensus review of the CT variables, with both the number of scans reviewed and 
the approach underlying this decision given 
Variable group Variable reported  
(Range of scores 
available for this 
variable at the 
whole lung level) 
Threshold 
difference in 
scores 
between 
readers, at 
which review 
performed 
Number 
of scans 
for r/v 
Method of selecting scans and lobes for consensus 
review 
Parenchymal 
variables  
 
 
Atelectasis  
(integer, 0-600) 
≥60 points 20 Lobar % scores for each parenchymal variable 
were summed across the 6 lobes for each reader, 
so that a minimum score of 0 was allocated if the 
variable was not seen anywhere in the lung, and a 
maximum score of 600 was given if all the lung 
parenchyma was affected by this pathology.  
 
The difference between the total lung scores 
generated by each reader was calculated for each 
scan, for each parenchymal variable. These 
differences were plotted on a histogram, and the 
most discrepant 5% of scans were identified for 
each variable. 
 
If a scan was identified as highly discrepant for a 
given parenchymal variable, this variable was 
reviewed by the consensus reader in all the lobes 
where there had been any disagreement in the % 
score between readers.  
 
Because parenchymal scores for different 
variables were mutually and additive to 100% 
within each lobe, reallocation of scores for one 
variable within a lobe invariably meant that all 
parenchymal variables for this lobe required 
rescoring.  
 
Of note - where % cavities were scored as >0% by 
the consensus reader, the other categorical cavity 
Parenchymal 
banding  
(integer, 0-600) 
≥75 points 22 
Consolidation  
(integer, 0-600) 
≥40 points 18 
Ground glass 
opacification 
(integer, 0-600) 
≥60 points 22 
Mosaicism  
(integer, 0-600) 
≥160 points 22 
Emphysema  
(integer, 0-600) 
≥25 points 18 
Emphysematoid 
destruction 
(integer, 0-600) 
≥15 points 18 
Cavities  
(integer, 0-600) 
≥25 points 23 
Normal lung  
(integer, 0-600) 
≥170 points 21 
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variables for the lobe in question were also 
reviewed and rescored (cavity extent, maximum 
size, mycetoma) to ensure consistency.  
TOTAL 110 scans  Total number of lobes rescored across 
pathologies: RUL  96 (24.9%), RML 71 (18.4%), RLL 
82 (21.2%), LUL 104 (27.0%), LML 93 (24.2%), LLL 
89 (23.1%).  
Bronchiectasis Whole lung 
bronchiectasis 
extent score 
(integer, 0-18) 
≥6 points 20 For bronchiectasis extent and severity scores, the 
lobar scores were summed across all 6 lobes to 
give a minimum score of 0 (variable not seen) and 
a maximum score of 18 (maximum severity / 
extent reported in all lobes) for each reader, for 
each scan.  
 
Differences in the total lung extent / severity 
scores between readers were calculated, and the 
5% of scans with the biggest differences were 
selected for review. For these scans, all lobes with 
any disagreement in severity or extent scores 
between readers were reviewed by the consensus 
scorer.  
Whole lung 
bronchiectasis 
severity score 
(integer, 0-18) 
≥6 points 25 
Whole lung 
presence / absence 
of bronchiectasis 
(binary) 
N/a 79 Any scans with overall disagreement about the 
presence / absence of any bronchiectasis in the 
lung between readers were reviewed.  
Number of lobes 
affected (integer, 0-
6) 
≥3 lobes 30 Because the overall presence / absence of 
bronchiectasis and the number of lobes affected 
by moderate pathology was thought to be of 
clinical relevance, the total number of lobes with a 
severity score ≥2 was summed for each scan, 
giving a total lung score of range 0 (No lobes 
affected by moderate-severe bronchiecatasis) to 6 
(All lobes affected). The 5% of scans with the 
biggest discrepancy in the number of affected 
lobes between readers were identified, and lobes 
in which there was disagreement within these 
scans reviewed.  
Of note - for all reviewed lobes, where 
bronchiectasis was reported as ‘present’ by the 
consensus scorer, details about the severity / 
extent / pattern of bronchiectasis were also 
reviewed by the consensus scorer. 
Whole lung 
bronchiectasis 
pattern score 
(integer, 0-18) 
≥6 points 20 The pattern of bronchiectasis is a nominal rather 
than ordinal variable – whilst there can be a 
progression of pathology from tubular to varicose 
to cystic damage as severity of disease worsens, 
this is not always the case and cannot be 
assumed. 
 
Having said that, for the purpose of identifying 
discrepant scans this simplification was felt to be 
acceptable. The variable was treated as ordinal 
within each lobe, and a whole lung pattern score 
was generated for each scan by summing these 
scores across lobes. The 5% of scans which were 
most discrepant for this score were consensus 
reviewed.  
TOTAL 105 scans 
Cavities / cystic 
airspaces 
Whole lung 
presence / absence 
of cavities or cystic 
airspaces 
N/a 58 The approach to selection of scans for review of 
cavity and mycetoma variables was similar to that 
described above for the whole lung 
presence/absence, and overall extent scores for 
bronchiectasis.  
 
For all reviewed lobes - where cavities were 
reported as present by consensus reader, details 
about maximum size / presence of mycetoma 
were also consensus reviewed.  
Whole lung cavity 
/cystic airspace 
extent score 
(integer, 0-18) 
≥4 points 23 
Whole lung 
presence / absence 
of mycetoma 
(binary) 
N/a 10 
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Maximum cavity 
size 
(size in mm) 
≥22mm 20 The initial plan had been to take one reader’s 
score for cavity size only, with no consensus 
review. However, given the issue identified with 
cavity / cystic bronchiectasis scoring, it was felt 
that large discrepancies in cavity size could be 
used to identify scans with differential 
classification of cystic bronchiectasis and cavities 
between readers. The 5% of scans most 
discrepant for the maximum cavity size were 
therefore also consensus reviewed.  
 
Parenchymal 
change allocated to 
cavities/cystic 
airspaces, but no 
cavities seen, in at 
least 1 lobe 
≥10% 
parenchyma 
in lobe  
7 Cavities were scored in 2 ways for each lobe, 
within any given scan: 
% parenchyma affected by cavities/cystic 
airspaces 
Extent of cavities seen (absent / 1-2 / 3-5 / >5 
cavities)  
Mismatches were seen between the reports given 
by a single reader for a single lobe using these two 
approaches as they were not ‘linked’ within the 
database during initial scoring.  
 
Both the parenchymal % scores and cavity 
variables were therefore consensus reviewed for 
lobes in which cavities > 10mm were reported, 
but no % parenchyma was allocated to cavities, 
and lobes in which >10% parenchyma was 
allocated to cavities but no cavities were reported 
in any lobe. 
Cavity seen, but no 
% parenchyma 
allocated, in at least 
1 lobe 
≥10mm 
cavity seen in 
lobe 
26 
TOTAL 100 scans  
Nodules Whole lung nodule 
extent score 
(integer, 0-18) 
≥5 22 Approach as above, for bronchiectasis extent 
score 
TOTAL 22 scans 
Other airway 
variables 
Whole lung tree in 
bud severity score 
(integer, 0-18) 
≥9 20 Approach as above for bronchiectasis severity 
score 
 
Whole lung airway 
plugging severity 
score (integer, 0-18) 
≥5 18 
Whole lung 
bronchial wall 
thickening severity 
score 
(integer, 0-18) 
≥8  22 There were a number of scans where it was 
deemed ‘not possible’ to report the severity of 
bronchial wall thickening, due to surrounding 
pathology, in at least one lobe.  
 
For the purpose of identifying scans for consensus 
review of this variable, values were generated for 
these ‘missing’ lobes by taking the average score 
across all of the other scored lobes. This assumes 
relative uniformity of the degree of bronchial wall 
thickening across the lung, including the area 
where other pathology was dominant and direct 
scoring not possible. Total lung scores were then 
calculated using these imputed values, and the 5% 
of scans with the most discrepant values for this 
variable reviewed by the consensus reader. 
TOTAL 54 scans 
ALL VARIABLES TOTAL SCANS FOR REVIEW 239 scans, requiring review of at least 1 lobe 
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7.3.3 GENERATION OF FINAL DATA SET FROM ORIGINAL & 
CONSENSUS READS 
The approach used to generate a final dataset, from the 2 original independent reads, and the data 
produced by consensus review of discrepant variables for the 239 scans identified above, is outlined 
below: 
 Where agreement seen between original readers 
Where there was agreement between original readers for a given variable in a given lobe, the agreed-
on score was used as the final result.  
 Where consensus read available 
Where there was discrepancy between original readers, but a consensus read was available for a given 
variable within a given lobe, this consensus read was used as the final data point for this lobe. It was 
noted that some variables (eg. emphysema, emphysematoid destruction) were systematically scored 
higher by the consensus reader. It is accepted that using these reads, available for a subset of the 
scans only, as the ‘correct’ score will have biased the data for these scans towards the consensus’ 
scorers approach, but this is accepted as a limitation of the method.  
 Where neither consensus nor agreement between readers 
As described above, it was not possible to consensus score all scans for all variables – only the most 
discrepant scans for a subset of variables were re-read. For variables where discrepancy was seen but 
no consensus review had been completed, several potential options for deriving a single combined 
data point from the divergent original reads were considered, with different approaches used for 
different variables (Table 4). A pragmatic decision was made not to consider complex imputation 
frameworks / multilevel models, which are time and labour intensive to develop.  
Table 4: Approaches to generating ‘final scores’ for variables where no consensus read, and disagreement between original 
readers 
Approach Details Pros Cons Variables this 
approach used for 
Single reader Use of data from 
one reader only, for 
full analysis 
Can be used for 
sensitivity analysis, to 
check relationships 
identified using 
‘combined’ output – are 
these findings robust, 
across readers.  
Biases towards the 
approach of a single 
reader 
 
Nil 
Average of 
scores between 
readers 
Numerical average 
of scores generated 
by original readers 
Includes data from both 
readers in unbiased way. 
 
Appropriate for 
continuous / ordinal 
variables only.  
Not suitable for 
nominal variables, 
where categories 
cannot be treated as 
sequential / 
incremental.  
 
% parenchymal 
pathology 
 
Airway and cavity 
severity / extent 
scores 
 
Maximum cavity size 
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Where categorical 
variables are treated 
as numerical, there is 
an assumption that 
levels are equidistant 
apart (ie. gap from 
level 1 to 2 is the same 
as distance from level 
2 to 3) 
Random 
selection of 
original reads 
Randomly select 
the reports given by 
one or other 
reader. 
 
 
Can be used for all 
variables – including 
nominal. 
 
Makes no assumptions 
about ‘distance’ between 
categories for categorical 
variables  
 
Can be validated by 
repetition.  
Only makes use of half 
of data.  
 
Difficult to assess the 
impact of any single 
reader’s approach, on 
results.   
Bronchiectasis pattern 
Reader 
agreement 
required 
Pathology counted 
as present only 
when identified by 
both readers 
 
Where 
disagreement, 
pathology classes as 
uncertain OR 
absent 
Provides ‘conservative’ 
estimates of the presence 
of any pathology  
Likely to bias against 
more complex scans, 
where disagreement 
between readers likely 
larger. 
 
Nodule pattern  
 
Mycetoma  
 
Either reader 
can identify 
Pathology counted 
as present if either 
reader identifies 
this 
Provides more lenient 
estimate of the presence 
of a given pathology – 
appropriate where under-
reporting likely 
Gives lenient estimate 
of pathology, so may 
include borderline 
cases 
Pleural pathology 
Discrete variables which were felt to be ordinal (ie. increasing in severity / extent, with each category) 
were treated as numerical: the final score was the average of the scores from the original readers. 
These variables include parenchymal % scores, bronchiectasis severity & extent scores, tree in bud / 
mucus plugging / bronchial wall thickening severity scores, cavity extent & maximum cavity size scores.  
Discrete scores which were non-ordinal and could not be thought of as numeric could not be averaged 
in this way. This included bronchiectasis pattern, nodule pattern, and binary presence/absence scores 
where variable categories likely reflect distinct pathology, and progression between them cannot be 
assumed. Specific approaches were needed for these variables. Specific approaches taken for certain 
variables are described together with the study findings, below: 
 Bronchiectasis pattern 
For lobes in which there was disagreement in bronchiectasis pattern and no consensus review was 
available, a random selection of one of the the patterns reported by the original readers was used. 
This approach assumes that both original readers were equally likely to be the ‘correct’ interpretation 
of the image. 
In lobes deemed to contain moderate to severe bronchiectasis, random selection of pattern was 
required for the following number of scans:  RUL n=37/78 scans, RML n=8/15, RLL n=19/35, LUL 
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n=38/80, LML n=10/39, LLL n=14/39. We must acknowledge that there is some uncertainty about the 
bronchiectasis patterns in these lobes/scans.  
 Bronchial wall thickness score 
As described above, the whole-lung bronchial wall thickness score was missing for 15% of scans 
(58/385). These were a biased sample of scans in which more severe pathology is seen, and imputation 
was therefore not used here. Instead, bronchial wall thickening data was simply acknowledged as 
missing for these ore complex scans, and no ‘final’ score was generated for these.  
 Nodules 
The total number of lobes in which mismatched original reads for the nodule pattern were seen, and 
no consensus reads were available was high: RUL n=118, RML n=65, RLL n=81, LUL n=111, LML n=70, 
LLL n=94. All lobes where miliary pathology was reported had either been consensus read, or had 
agreement between original readers.  
Mismatches between the number of nodules seen were considered less important than differences in 
the overall presence / absence of nodules. A collapsed variable was therefore created here, with 
nodules described as present in a lobe if either the consensus scorer or both original readers reported 
<5/≥5/miliary nodules, and absent if either the consensus reader or both original readers reported 
this as absent. Data were reported as ‘unclear’ where there was no consensus review, and one reader 
had reported nodules as absent / the other had reported as present. One possible cause for this, based 
on discussion with readers and review of the data, is differential classification of lesions as 
consolidation rather than nodules in some cases.  
 Mycetoma 
Mycetoma were a rare finding within the dataset, and were generally small / difficult to identify. A 
conservative estimate of prevalence was therefore obtained with the pathology only said to be 
present if either the consensus or both original readers reported it as such. The pathology was scored 
as absent when there was disagreement.  
 Pleural pathology 
For pragmatic reasons, no consensus reads were completed for pleural pathology. Pleural effusion or 
thickening is relatively easy to detect on imaging. Review of discrepant scans suggested that this in 
cases where discrepant scores were seen, pathology was usually clearly visible on review, suggesting 
likely underscoring. Pleural effusion and thickening on the right and left sides were collapsed down 
into a single variable, and pathology was therefore scored as present if either reader scored it as such.  
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 Lymphadenopathy 
Lymphadenopathy was reported with a high level of inconsistency between readers, and in fact 
reporting on non-contrast HRCT imaging is known to be unreliable. It was therefore decided that no 
attempt would be made to generate a single ‘final’ score for these patterns, and data from the original 
readers are shown here only (Table 5). 
Table 5:  Reporting of lymphadenopathy by the two original CT image readers, using non-contrast HRCT imaging 
Reader 1 Reader 2 
Absent Present Total 
Absent 332 (86.2%) 16 (4.2%) 348 
Present 30 (7.8%) 7 (0.2%) 37 
Total 362 23 385 
 Cavities 
Cavities were reported in two sections of the reporting tool, which were unlinked – the amount of 
parenchymal in each lobe affected by cavities / cystic airspaces, as well as a binary yes/no score for 
the presence / absence of cavities and a measurement made by 1 reader for the size of the largest 
cavity seen. On review of the data, it was felt that the parenchymal score was likely the more accurate 
description of the amount of tissue lost in relation to cavities / cystic airspaces – these features being 
difficult to differentiate – and this value was therefore used in the analysis. 
7.3.4  GENERATION OF NEW CT VARIABLES FOR ANALYSIS 
 Whole lung presence/absence & lobar counts 
Binary presence / absence scores were generated for the airway variables, in order to count the 
number of lobes affected by these pathologies. In the scoring system used here, the severity of 
bronchiectasis, bronchial wall thickening, tree in bud, mucus plugging, and airway narrowing were 
scored in each lobe on a 4-point scale: absent (0), trivial or mild (1), moderate (2) or severe (3). Once 
scores had been averaged between readers, the possible ‘final’ scores ranged from 0-4 with intervals 
of 0.5. A cut off value of 2.0 was chosen to define the presence / absence of pathology: a pattern was 
deemed to be absent if the average final score was <2, and present in a lobe only if the final score was 
≥2. In practical terms, in the absence of a consensus score, this means that only lobes where both 
original readers scored moderate pathology (score of 2) OR where one scored it as trivial (score of 1) 
and the other scored as severe (score of 3) were counted as having this pathology present. Lobes 
where one scored pathology as absent (score of 0) and the other as severe (score of 3) would average 
to 1.5 which is below the required threshold. Whole lung presence/ absence scores, and counts of the 
total number of lobes affected by each of these pathologies, were generated from these lobar 
presence / absence scores. 
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 Extensively damaged or ‘Destroyed’ lobes 
During reporting it was noted that a high proportion of patients have a focal concentration of residual 
parenchymal pathology within the lung, with complete ‘destruction’ of one lobe but relatively normal 
parenchyma seen elsewhere. Such focused pathology may act as a source of infection and clinical 
complications, but may not be captured by the whole lung pathology scores being used here.  
In order to capture this pattern of damage, a composite variable was generated at a lobar level: 
- The amount of atelectasis, parenchymal banding and lung tissue destroyed by cavities/cystic 
airspaces was summed at a lobar level. These pathologies were chosen as they reflect lung tissue 
which is non aerated and non-functioning, and were thought to describe the patterns of damage 
most commonly seen in destroyed lungs most accurately.  
- Lobes were classified as destroyed if ≥90% of parenchyma was occupied by these pathologies. A 
cut off of 90% was selected instead of 100% as even when lobes are almost completely destroyed, 
often a small amount of normal / consolidated tissue remains.  
 
 Atelectasis & parenchymal banding 
Some conflation between atelectasis and banding was noted within the data.  These pathologies are 
similar in aetiology and appearance – both are seen as densities on imaging with volume loss +/- 
anatomical distortion resulting from compressed lung parenchyma. The key difference tends to be in 
volume and shape, with atelectasis tending to be larger in size, and banding often linear in appearance. 
For the purposes of analysis, these variables have been joined, and the amount of tissue affected by 
atelectasis and banding will be reported together.  
 % Abnormal parenchyma 
The amount of abnormal lung tissue seen in each scan was summed, to generate a combined variable 
for the total % of abnormal lung tissue in each scan. A second version of this variable was created, 
including all patterns of pathology except mosaicism – this pattern reflects gas trapping within the 
lung tissue, rather than pathology of the tissue itself, and is therefore somewhat distinct. 
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7.4 APPENDIX 4: CXR METHODOLOGY DEVELOPMENT 
7.4.1 CXR SCORING SYSTEM 
As above, the CXR scoring system is described below together with notes generated by the scoring 
radiologists during reporting and data reviews (Table 6). 
Table 6: CXR scoring variables & definitions – including notes generated during scoring process 
Initial name of 
variable 
Initial definition Scoring options Notes 
PARENCHYMAL VARIABLES  
Scored at lobar level. Mutually exclusive variables, summing to 100% for each lobe. 
Parenchymal bands Linear opacity 1-3mm thick, up to 
5cm long. Usually extends to visceral 
pleura.  
May be accompanied by anatomical 
distortion. 
% of lobe (to 
nearest 5%) 
Bronchial wall thickening should be 
considered for linear changes seen 
centrally and extending out to the 
peripheries, anatomically following 
airways.  
Consolidation / 
ground glass 
Consolidation: Homogeneous 
increase in lung parenchymal 
attenuation which obscures the 
margins of vessels and airway walls. 
An air bronchogram may be present.  
OR 
Ground glass appearance: hazy 
increase in opacification with 
preservation of bronchial and 
vascular margins 
% of lobe (to 
nearest 5%) 
Initially a category for consolidation 
only was included. However, less dense 
areas of opacification were also 
recognized during scoring and difficult 
to clearly differentiate, and as such 
were included here. For these less 
dense areas the % of lung opacification 
was estimated and scored within this 
section.  
Cavities / cystic 
airspaces 
Gas filled space, seen as a lucency or 
low-attenuation area within a 
pulmonary consolidation, a mass, or 
a nodule. Consolidation may have 
resolved leaving a thin wall only. 
% of lobe (to 
nearest 5%) 
Large areas of destroyed lung tissue to 
be scored as cavitation – list 100% if 
full lobe destroyed and absent.  
Atelectasis Reduced volume accompanied by 
decreased opacity in the unaffected 
part of the lung.  
Signs of volume loss should be seen, 
and may include: displaced hila / 
fissures / bronchi, narrowed rib 
spacing, tortuous trachea, hyper-
expansion and linear vessels 
extending through other lung zones 
% of lobe (to 
nearest 5%) 
 
Where a whole lobe is collapsed, this 
lobe should be considered as 1 zone of 
the lung field. The remaining 
uncollapsed lung field on this side 
should be divided into 2 zones for 
scoring.  
Compression of the lung by an external 
feature (e.g. pleural effusion), should 
not be scored as atelectasis. The visible 
parenchyma should instead be scored 
independently, adding up to 100%.   
CAVITY VARIABLES 
Reported at a lobar level 
 
Cavity Gas filled space, seen as a lucency or 
low-attenuation area within a 
pulmonary consolidation, a mass, or 
a nodule. Consolidation may have 
resolved leaving a thin wall only. 
 
0 = Absent 
1 = 1-2 cavities 
2 = 3-5 cavities 
3 = >5cavities 
 
Maximum 
diameter of 
largest cavity, 
in mm 
Not possible to record for hard images, 
where no scale was available.  
Mycetoma Discrete mass of hyphae, within a 
cavity. May have air crescent sign. 
0 = Absent 
1 = Present 
 
OTHER LOBAR VARIABLES 
Nodules 
 
Rounded opacities, well or poorly-
defined, ≥5mm, measuring up to 
3cm in diameter. 
0 = Absent 
1 = <5 
2 = ≥5 
3 = Miliary 
Defined opacities to be called nodules. 
Confluent / poorly defined opacities to 
be called consolidation.  
Ring & tramline 
markings 
Prominent ring-shaped opacities 
representing thickened airways seen 
0 = Absent 
1 = Mild 
2 = Moderate  
If an area of lung is collapsed / opaque 
and it is not possible to judge airway 
thickening, score as absent.  
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end-on, or parallel lines if seen 
longitudinal. 
3 = Severe 
(whole zone) 
WHOLE LUNG VARIABLES 
Hyper-expansion Large lung fields with flattened 
hemidiaphragms.  
0 = Absent 
1 = Present 
 
Pleural thickening Visible pleural thickening ≥10mm 
with any distribution over visceral / 
parietal surfaces. 
 
0 = Absent 
1 = Present 
 
Measure depth from the inside of the 
inner edge of the adjacent rib to the 
edge of the pleura. 
Loss of the CP angle can be attributed 
to thickening if the appearance is not 
typical for ongoing fluid (no clear 
meniscus) and the rest of the image is 
consistent with chronic damage. 
Pleural effusion Accumulation of fluid within the 
pleural space, identified by blunted 
costophrenic angle +/- visible 
meniscus.  
0 = Absent 
1 = Present 
 
 
Lymph nodes Prominent mediastinal or hilar 
lymph nodes. 
0 = Absent 
1 = Present 
 
Dominant pathology   
Compatible with resolving PTB – No other pathology  As per the impression of the reader 
Compatible with resolving PTB, plus other diagnosis 
Resolving PTB or other diagnosis equally likely 
Not compatible with resolving PTB, other diagnosis likely 
 
7.4.2 SELECTION OF IMAGES FOR CXR CONSENSUS REVIEW 
The approach to identifying the most discrepant images / variables for consensus review is shown in 
Table 7 below. As for CT imaging, a pragmatic approach was required to limit the number of images 
requiring review. 
- Cavity size 
During the process of scoring it became clear that specifying the number of cavities on CXR is 
complex and inaccurate. Because a high proportion of images were taken on hard film it was also 
not possible to specify the diameter of cavities on all images. The presence / absence of cavities 
was therefore derived from the % cavity parenchymal score, and data on the number / size of 
lesions was not used and not consensus reviewed.  
- Ring & tramlines 
The level of discrepancy at which consensus review of zonal ring and tramline scores was 
conducted was pre-set at a difference of ≥2 points between readers (the worse severity recorded 
was Absent vs. Moderate, Mild vs. Severe, or Absent vs. Severe). Discrepancies smaller than this 
were felt likely to be clinically meaningless.  
- Hyperexpansion 
Review of a subset of CXRs which were discrepant for this variable showed very clearly that this 
variable was much more consistently reported by the more experienced reader (EJ – the trained 
radiologist). For pragmatic reasons, rather than performing formal discrepancy review of all CXRs 
where there was disagreement for this variable, readings entered by EJ only were used only here.   
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- Lymphadenopathy  
This was rarely reported, and where it was, there was high discrepancy. As for non-contrast CT 
imaging, the reporting of lymphadenopathy on CXR in this population was felt to be highly 
unreliable, and unlikely to influence the study outcomes. For pragmatic reasons no consensus was 
performed for this variable, and data were not used.  
 
243
Table 7: Methods used to select scans for consensus review of the CXR variables, with both the number of scans reviewed and the approach underlying this decision given for baseline and 1-year visit 
Variable group Variable (type, potential scores) 
Baseline visit (n=403) 1-year visit (n=361) 
Identification of scans / lobes for discrepancy review Cut-off 
difference 
for r/v 
Method of deciding 
cut off 
Scans 
for r/v 
Cut-off 
difference 
for r/v 
Method of deciding 
cut off 
Scans for 
r/v 
Parenchymal 
variables  
 
 
Atelectasis  
(integer, 0-600) 
≥40 points 5% cut off 26 ≥40 points 5% cut off 24 As for CT imaging  
Parenchymal banding  
(integer, 0-600) 
≥15 Cut off adjusted 
from 10 to 15 
5 ≥15 Cut off adjusted 
from 10 to 15 
7 
Consolidation / ground 
glass 
(integer, 0-600) 
≥55 5% cut off 23 ≥35 5% cut off 22 
Cavities / cystic 
airspaces 
(integer, 0-600) 
≥25 Cut off adjusted 
from 20 to 25 
20 ≥35 5% cut off 18 
Normal lung  
(integer, 0-600) 
≥60 5% cut off 25 ≥60 5% cut off 19 
TOTAL 61 X-rays 63 X-rays  
Ring & Tramline 
(R&T) 
Whole lung maximal 
severity of R&T (0-3) 
≥2 points Cut off 2 points 
empirically chosen 
59 ≥2 points Cut off 2 points 
empirically chosen 
56 Variable denoting the maximal severity of ring & 
tramline pathology identified across lung generated 
(range 0-3), and the differences between readers 
calculated.  
X-rays where the maximum severity reported 
between readers differed between ‘Absent’ and ‘Mild’ 
were assumed to be ‘Absent’, and no consensus 
review was performed. However,  all X-rays with a 2 
point difference in the maximum severity between 
readers were reviewed. 
Whole lung R&T 
severity score (integer, 
0-18) 
≥6 Cut off adjusted 
from 5 to 6 
13 ≥5 5% cut off 21 Lobar scores for ring & tramline severity were 
summed across 6 lobes, giving a minimum score of 0 
(variable not seen), and a maximum score of 18 
(maximum severity / extent in each lobe). 
 
The 5% most discrepant X-rays for the total severity 
score, across lung, were identified, and zones with 
discrepancy of for R&T severity  within these x-rays 
were  reviewed. 
TOTAL 67 X-rays 66 X-rays  
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Nodules Whole lung presence / 
absence of nodules 
N/a N/a 84 N/a N/a 84 A variable denoting the presence or absence of 
nodules anywhere in the lung was generated, and 
compared between reader. Xrays discrepant for this 
variable were reviewed.  
 
Zones with discrepancy for presence / absence to be 
reviewed. 
Whole lung nodule 
extent score (integer, 
0-18) 
≥3 Cut off adjusted 
from 2 to 3 
15 ≥3 Cut off adjusted 
from 2 to 3 
13 As for whole lung R&T severity score 
Whole lung maximal 
nodule score (0-3) 
N/a N/a 91 N/a N/a 102 As for whole lung R&T maximum nodule score 
TOTAL 98 X-rays 103 X-rays  
Cavities Whole lung presence / 
absence of cavities 
N/a N/a 70 N/a N/a 84 A variable denoting the presence or absence of 
cavities and mycetoma, anywhere in the lung was 
generated, and compared between readers. 
X-rays discrepant for presence / absence of cavities or 
mycetoma were reviewed.  
 
Whole lung presence / 
absence of mycetoma 
(binary) 
N/a N/a 2 N/a N/a 2 
Mismatch between 
parenchymal % and 
categorical cavity 
sections 
N/a  N/a 14 N/a N/a N/a Both the % parenchymal score, and the categorical 
cavity score were compared – zones in which 
mismatch between these variables were seen (one 
reporting the presence of cavities and the other 
reporting absence or 0%) were reviewed. Required for 
baseline visit only.  
TOTAL 75 X-rays   85 X-rays    
Whole lung variables Presence / absence of 
any pleural pathology 
N/a N/a 49 N/a N/a 52 X-rays discrepant for presence / absence of any 
pleural pathology (either pleural thickening or 
effusions) were reviewed.  
TOTAL 49 X-rays  52 X-rays  
ALL VARIABLES TOTAL XRAYS FOR REVIEW 203 X-rays requiring review of at least 1 zone 218 X-rays requiring review of at least 1 zone  
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7.5 APPENDIX 5: A PRIORI PTLD CASE DEFINITION 
In order to determine the relationship between post-TB lung damage (PTLD) as an ‘exposure’ at TB 
treatment completion, and ongoing morbidity over the duration of the 1-year cohort follow-up, a PTLD 
case definition was required. As no validated definitions, measurement systems, or severity scores for 
PTLD were identified in the literature review, a new a priori definition was generated here through 
consensus discussion with the team of respiratory / TB physicians2.  
Although the pattern, extent and severity of lung pathology seen in a post-TB cohort is likely to be 
high, for reasons of study power and in keeping with the study hypothesis it was decided that this a 
priori PTLD definition should be binary and aim to simply differentiate between those with marked 
lung damage likely to be clinically relevant and those with milder/absent damage which may be less 
meaningful.  
7.5.1 PARAMETERS FOR INCLUSION IN PTLD DEFINITION 
As noted in the literature review, established prognostic scores used in other chronic respiratory 
conditions including bronchiectasis, COPD, and pneumonia include multiple measures of respiratory 
pathology to capture disease severity. Spirometry is widely used across scores, with imaging 
parameters included in bronchiectasis prognostic scores, and the decision was taken to include both 
of these as objective measures of damage in the a priori PTLD definition.  
The following parameters were not included, for the reasons given: 
 Clinical parameters such as BMI and 6-minute walk distance – vulnerable to confounding by 
common comorbidities in our study cohort, including HIV co-infection.  
 Symptoms such as MRC-dyspnoea – vulnerable to confounding by co-morbidities, and may reflect 
the consequence of respiratory damage rather than the nature of the damage itself.  
 Respiratory microbiology – not available within this study.  
 History of previous exacerbations – confounded by the recent episode of PTB experienced by 
every member of this cohort, and likely subject to significant recall bias 
 Hypoxia – potentially a sign of severe lung pathology, but marked hypoxia in the absence of the 
imaging or spirometric abnormalities already included within the definition felt to be unlikely. 
  
                                                                
2 Professor E Jane Carter – Respiratory physician, past President of The Union; Dr Jeremiah Chakaya – Respiratory physician, 
current President of The Union; Professor Bertie Squire – Infectious Diseases physician, past President of The Union; Dr Peter 
Macpherson – Intermediate Wellcome Fellow & Senior Lecturer in Public Health; Dr Jamilah Meghji – study PI 
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SPIROMETRY PARAMETERS 
Both airway obstruction and spirometric restriction have been shown to be associated with previous 
TB disease, but the extent to which they are associated with adverse patient outcomes in PTLD is 
unclear. Both of these abnormal patterns were therefore included in the binary PTLD definition (Table 
8). 
Of note – because evidence for adverse outcomes in relation to airway obstruction are stronger if the 
FEV1 is reduced in addition to the FEV1/FVC ratio,147 only those with both an obstructive ratio and a 
reduced FEV1 were included in the PTLD group.   
Table 8: Spirometric PTLD criteria 
Category FEV1/FVC ratio FEV1 FVC 
Obstruction <LLN  
 
<LLN 
 
n/a 
Low FVC ≥LLN 
 
n/a 
 
<LLN 
*LLN: Lower limit of normal, as classified using GLI 2012 reference ranges 
 
 
IMAGING PARAMETERS 
As TB has been shown in previous studies to result in both parenchymal and airway pathology, and 
there is no clear literature on the relationship between these parameters / the relative importance of 
each in determining patient outcomes, both were included in the a priori definition (Table 9). 
 AIRWAYS PATHOLOGY 
Bronchiectasis affecting ≥3 lobes on CT imaging was used as a marker of severity in both the BSI and 
FACED scores.134 135 Whilst these scores were developed and validated in cohorts who are profoundly 
different to the PTB patient population in urban Blantyre, Malawi, it is biologically plausible that similar 
CT features remain poorly prognostic across settings / populations, and this cut off has therefore been 
used to define severe airway disease in PTLD here. Because of the consensus approach used in reading 
the CT imaging, only lobes containing moderate – severe bronchiectasis were included.  
For simplicity, more complex aspects of airway pathology including the type of bronchiectasis (cystic, 
varicose, or tubular) and the degree of bronchial wall thickening were not included within this core 
definition, but were still measured on CT reporting such that their relationship with outcomes can 
explored in the future if required. 
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 PARENCHYMAL PATHOLOGY 
The extent of parenchymal pathology was not included in any of the most widely used prognostic 
scores described above. However, parenchymal damage was a dominant feature in the descriptions 
of PTLD identified in our systematic review, and has been shown to have prognostic implications in 
other studies. In their prospective cohort study of 169 COPD patients, Boutou et al. developed a clinical 
algorithm for prognostic scoring which included both pulmonary function and imaging parameters,245 
They found that the average HRCT emphysema score (ES: the average % of each lobe affected by 
emphysema) and the functional residual capacity (FRC) were the strongest predictors of mortality, and 
developed a clinical prognostic tool whereby patients with  ES<30% were classified as low risk, those 
with ES≥65% were classified as high risk, and those with ES scores between these values were classified 
as low or high risk depending on their FRC volumes. In their prospective study of 215 patients with 
Scleroderma related interstitial lung disease, Goh et al. showed that the % extent of disease on HRCT 
and the % FVC were associated with patient outcome, and a developed a similar prognostic tool where 
those with  <10-20% disease on HRCT were defined as having limited ILD, those with >20-30% disease 
on HRCT defined as having extensive ILD, and those in between defined according to their % FVC 
value.246  
Although these studies relate to ILD and COPD, it is plausible that parenchymal pathology covering a 
similar proportion of the lung parenchyma is significant in the case of PTLD, and the decision was taken 
to include a variable denoting the extent of abnormal parenchyma in our PTLD prognostic score. 
Because the relative importance of each pattern of parenchymal pathology is not known, the decision 
was taken to use a cumulative variable including all patterns of parenchymal pathology. The extent of 
mosaicism, which reflects gas trapping rather than parenchymal damage, was not be included in this 
definition. A cut off for the extent of parenchymal damage of 30% was chosen, to reflect the findings 
of the papers described above.     
Table 9: Structural PTLD criteria 
Category Definition 
Airway pathology Moderate to severe bronchiectasis affecting ≥3 lobes 
on CT imaging 
Parenchymal pathology ≥30% abnormal parenchyma, with any pattern 
excluding mosaicism 
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COMBINED SPIROMETRY & IMAGING PTLD DEFINITION 
The final a priori definition of PTLD is a binary, composite definition, including both spirometry and 
imaging findings (Table 10). Incomplete overlap between these features is expected (Figure 2), such 
that participants can be defined as having PTLD with either abnormal spirometry or imaging, or – 
perhaps in the most severe cases – abnormalities detected using both of these modalities.  
Table 10: Composite a priori definition of PTLD 
Criteria PTLD present 
Abnormal spirometry 
OR 
Airway obstruction with FEV1/FVC ratio<LLN & FEV1<LLN 
OR 
Low FVC with FEV1/FVC ratio≥0.7 & FVC<LLN 
Abnormal CT Imaging Moderate-severe bronchiectasis in ≥3 lobes 
OR 
Parenchymal abnormality of ≥1/3 of the lung tissue 
LLN: Lower limit of normal, as classified using GLI 2012 reference ranges 
 
 
Figure 2: Schematic of a priori PTLD definition 
 
 
 
 
 
249 
 
7.6 APPENDIX 6: FACTORS PREDICTING SPIROMETRY 
FEV1, FVC, AND FEV1/FVC RATIO AT TB TREATMENT COMPLETION 
Table 11: Factors associated with the absolute FEV1 and FVC volume (ml), and the FEV1/FVC ratio (%) at TB treatment completion. ß coefficients (95% CI) presented. Complete case analysis (n=330) 
Variable 
FEV1 (L) (n=330) FVC (L) (n=330) FEV1/FVC percentage#(n=330) 
Univariate 
associations 
‘Standardised” 
univariate^ 
Multivariate model 
R2 0.455 
Univariate 
associations 
‘Standardised” 
univariate^ 
Multivariate model 
R2 0.505 
Univariate 
associations 
‘Standardised” 
univariate^ 
Multivariate 
Model 
R20.165 
Age (yrs) -4.6  (-11.8 – 2.6)   
-12.6  
(-18.6 – -6.7)*** 
4.9  
(-3.3- 13.1)   
-5.3  
(-11.7 – 1.2) -0.3 (-0.4 – -0.2)***   -0.3 (-0.4 – -0.2)*** 
Male gender 690.6  (552.9 – 828.3) ***   
401.1 
(231.2 – 571.0)*** 
911.0  
(761.8 – 
1060.1)*** 
  480.9  (296.2 – 665.6)*** -1.9 (-3.9 – 0.2)   -0.1 (-2.9 – 2.7) 
Height (cm) 50.3  (43.1 – 57.7)***   
37.9 
(28.8 – 47.0)*** 
62.9  
(55.0 – 70.8)***   
47.2  
(37.3 – 57.2)*** -0.0 (-0.2 – 0.1)   -0.0 (-0.2 – 0.1) 
HIV status (vs negative) 
- Positive, CD4≥200 
cells/uL 
- Positive, CD4<200 
cells/uL 
 
-63.5 (-232.5 – 
105.5) 
113.3 (-73.7 – 
300.2) 
 
73.2 (-60.9 – 207.3) 
230.1 (78.4 – 
381.9)** 
 
47.8 (-85.0 – 180.6) 
189.9 (40.4 – 
339.4)* 
 
-76.4 (-269.2 – 
116.4) 
133.7 (-79.5 – 
347.0) 
 
59.8 (-85.2 – 204.9) 
191.6 (27.3 – 
355.8)* 
 
26.5 (-117.8 – 
170.8) 
170.5 (8.0 – 333.0)* 
 
0.4 (-1.9 – 2.6) 
0.5 (-2.0 – 3.0) 
 
1.2 (-1.0 – 3.4) 
2.8 (0.3 – 5.3)* 
 
1.2 (-1.0 – 3.3) 
2.1 (-0.4 – 4.5) 
Positive baseline TB 
microbiology 
21.5  
(-154.0 – 197.1) 
-49.8  
(-188.6 – 88.9) 
22.1  
(-117.2 – 161.5) 
38.9  
(-151.4 – 239.3) 
-15.7  
(-165.2 – 133.7) 
17.0  
(-134..5 – 168.5) -0.4 (-2.7 – 2.0) -1.2 (-3.5 – 1.0) 0.1 (-2.1 – 2.4) 
BMI at TB treatment 
completion (kg/m2) 
21.7  
(-3.7 – 47.1) 
43.5  
(23.5 – 63.6)*** 
38.6  
(18.3 – 58.8)*** 
28.8  
(-0.12 – 57.2) 
51.9  
(30.5 – 73.4)*** 
51.5  
(29..5 – 73.5)*** 0.0 (-0.3 – 0.4) 0.1 (-0.2 – 0.5) -0.0 (-0.4 – 0.3) 
Illness duration ≥1-month 
prior to TB treatment  
-148.6  
(-29.97 – 2.5) 
-119.5  
(-237.9 – -1.0)* 
-116.1  
(-231/8 – 0.3)* 
-113.3  
(-286.2 – 59.7) 
-84.4  
(-212.3 – 43.6) 
-72.6  
(-198.5 – 53.2) -2.1 (-4.0 – -0.1)* -1.9 (-3.8 – 0.0) -2.1 (-4.0 – -0.2)* 
Ever smoking 198.3  (38.5 – 358.1)* 
-128.32  
(-265.8 – 9.3) 
-87.3  
(-226.6 – 52.1) 
382.0  
(202.7 – 561.2)*** 
-45.4  
(-195.7 – 104.9) 
-23.1  
(-174.6 – 128.4) -3.2 (-5.3 – -1.1)** -2.7 (-4.9 – -0.4)* -1.5 (-3.8 – 0.8) 
Poorest 3x SES quintiles -246.9  (-391.7 – -102.2)** 
-139.9  
(-278.8 – -1.0)* 
-99.2 
(-226.4 – 28.0) 
-162.1  
(-329.2 – 5.04) 
-58.8  
(-184.4 – 66.9) 
-12.9  
(-151.2 – 125.4) -3.6 (-5.5 – -1.7)*** -3.4 (-5.2 – -1.5)*** -2.8 (-4.9 – -0.7)** 
Intermittent food 
insecurity 
-254.7  
(-406.5 – -102.9)** 
-155.7 
(-271.3 – 40.0)** 
-10.3 
(-139.8 – 119.2) 
-211.7  
(-386.3 - -37.1)* 
-29.9  
(-161.8 – 102.0) 
36.8  
(-104.0 – 177.6) -2.5 (-4.5 – -0.4)* -2.5 (-4.5 – -0.5)* -1.1 (-3.2 – 1.0) 
*p<.05, **p<.01, ***p<.001; #The FEV1/FVC ratio given as a % rather than a proportion here (eg. 80% rather than 0.8) for ease of interpretation of ß coefficients; ^Standardised univariate: associations between each 
predictor and outcome, controlling / standardizing for age, gender & height 
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PATTERNS OF DEFICIT AT TB TREATMENT COMPLETION 
Table 12: Factors associated with Airway Obstruction or Low FVC at TB treatment completion. OR (95% CI) presented.  
Variable 
Airway obstruction, compared to normal (n=267) Low FVC, compared to normal (n=283) 
Univariate associations Multivariate model  Univariate associations Multivariate model 
Age (yrs) 1.01 (0.98 – 1.04) 1.01 (0.98 – 1.05) 0.95 (0.92 – 0.98)** 0.96 (0.92 – 0.99)* 
Gender 
- Female 
- Male 
 
1.0 
1.03 (0.52 – 2.05) 
 
1.0 
0.84 (0.30 – 2.38) 
 
1.0 
0.67 (0.37 – 1.19) 
 
1,0 
0.99 (0.41 – 2.37) 
Height (cm) 0.99 (0.95 – 1.03) 1.01 (0.95 – 1.07) 0.98 (0.95 – 1.02) 0.99 (0.94 – 1.04) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.59 (0.29 – 1.20) 
0.30 (0.12 – 0.74)** 
 
1.0 
0.50 (0.22 – 1.10) 
0.30 (0.11 – 0.80)* 
 
1.0 
0.74 (0.40 – 1.37) 
0.27 (0.12 – 0.64)** 
 
1.0 
0.82 (0.44 – 1.75) 
0.42 (0.17 – 1.07) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
1.37 (0.62 – 3.02) 
 
1.0 
0.72 (0.29 – 1.78) 
 
1.0 
1.54 (0.75 – 3.16) 
 
1.0 
1.11  (0.50 – 2.46) 
BMI at TB treatment completion (kg/m2) 0.86 (0.75 – 0.98)* 0.91 (0.79 – 1.05) 0.86 (0.76 – 0.97)* 0.89 (0.79 – 1.01) 
Illness duration prior to TB treatment 
- <1-month 
- ≥1-month 
 
1.0 
1.68 (0.84 – 3.36) 
 
1.0 
1.79 (0.86 – 3.74) 
 
1.0 
1.20 (0.67 – 2.15) 
 
1.0 
1.28 (0.68 – 2.39) 
Ever smoking 
- Never 
- Ever 
 
1.0 
1.55 (0.80 – 2.98) 
 
1.0 
1.03 (0.45 – 2.36) 
 
1.0 
0.78 (0.41 – 1.49) 
 
1.0 
0.86 (0.40– 1.86) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
3.91 (1.85 – 8.25)*** 
 
1.0 
3.08 (1.31 – 7.23)* 
 
1.0 
1.61 (0.91 – 2.84) 
 
1.0 
1.31 (0.65 – 2.63) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
2.66 (1.40 – 5.06)** 
 
1.0 
1.91 (0.91 – 4.01) 
 
1.0 
1.91 (1.07 – 3.41)* 
 
1.0 
1.65 (0.83 – 3.26) 
*p<.05, **p<.01, ***p<.001 
Obstruction -  FEV1/FVC ratio <LLN, using GLI-2012 reference range; Low FVC -  FEV1/FVC ratio ≥LLN & FVC<LLN, using GLI-2012 reference range 
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CHANGE IN FEV1 OVER 1-YEAR FOLLOW UP 
 
Table 13: Factors associated with change in absolute FEV1 volumes (ml) over 1-year (n=290) 
 Univariate associations Participant characteristics R2: 0.114 
+ Baseline spirometry 
R2:0.213 
+ Baseline imaging 
R2: 0.127 
+Respiratory events 
R2 :0.126 
Full multivariate model 
R2:0.232 
Age (yrs) -2.6 (-4.9 – -0.2)* -4.1 (-6.6 – -1.7)** -5.7 (-8.1 – -3.3)*** -4.3 (-6.8 – -1.8)** -4.1 (-6.6 – -1.7)** -5.6 (-8.0 – -3.2)*** 
Male gender 72.4  (19.7 – 125.1)* 72.1 (-3.1 – 144.0) 125.9 (55.7 – 196.0)*** 69.6 (-2.2 – 141.3) 72.8 (-1.2 – 144.4)* 131.2 (60.2 – 202.2)*** 
Height (cm) 3.5 (0.5 – 6.6)* 1.4 (-2.5 – 5.3) 6.4 (2.3 – 10.4)** 1.3 (-2.5 – 5.2) 1.2 (-2.7 – 5.1) 6.1 (2.0 – 10.2)** 
HIV positive at TB treatment completion 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
86.1 (30.1 – 142.2)** 
40.6 (-21.2 – 102.3) 
 
103.1 (47.2 – 159.0)**  
68.6 (5.8 – 131.5)* 
 
108.0 (55.2 – 160.8)*** 
93.2 (33.3 – 153.1)** 
 
104.5 (48.6 – 160.5)** 
73.0 (10.2 – 135.8)* 
 
99.9 (43.8 – 156.0)** 
64.7 (-0.4 – 128.9) 
 
105.9 (52.7 – 159.1)*** 
86.4 (25.4 – 147.4)** 
Positive baseline TB microbiology -26.8 (-84.8 – 31.1) -42.9 (-101.2 – 15.4) -38.2 (-93.2 – 16.8) -42.3 (-100.3 – 15.8) -39.5  (-97.7 – 18.7) -33.4 (-88.2 – 21.5) 
BMI at TB treatment completion (kg/m2) -7.5(-16.2 – 1.2) -4.2 (-13.2 – 4.8) 0.9 (-7.7 – 9.6) -2.5 (-11.6 – 6.7) -4.7 (-13.6 – 4.3) 0.21 (-8.5 – 8.9) 
Ever smoking 46.6 (-6.2 – 99.4) 24.7 (-33.4 – 82.7) 12.7 (-42.2 – 67.6) 18.8 (-39.3 – 76.9) 25.3 (-32.7 – 83.4) 10.5 (44.6 – 65.6) 
Poorest 3x SES quintiles 20.8 (-28.2 – 69.8) 16.4 (-37.7 – 70.5) 2.2 (-49.1 – 53.4) 12.1 (-42.0 – 66.2) 15.3 (-38.9 – 69.5) -2.3 (-53.8 – 49.2) 
Intermittent food insecurity 21.6 (-29.7 – 72.9) 17.3 (-37.4 – 72.0) 15.7 (-35.9 – 67.3) 16.7 (-37.8 – 71.3) 17.6 (-36.9 – 72.1) 16.9 (-34.6 – 68.4) 
FEV1 at TBRx completion (ml) -0.04 (-0.08 – -0.01)*  -0.13 (-0.18 – -0.09)***   -0.14 (-0.18 – -0.09)*** 
≥1/3 abnormal parenchyma, except mosaicism 83.0 (17.8 – 148.1)*   72.1 (2.0 – 142.3)*  12.2 (-58.0 – 82.5) 
≥3 lobes with mod-severe bronchiectasis 43.0 (-45.7 – 131.6)   -13.4 (-106.5 – 79.7)  -42.3 (-131.0 – 46.3) 
Any OPD / IP respiratory visits -81.0(-149.1 – -12.8)*    -24.8 (-96.9 – 47.3) -41.1 (-109.2 – 27.0) 
TB retreatment -165.8 (-374.6 – 43.1)    -172.4 (-384.3 – 39.6) -165.4 (-366.0 – 35.2) 
*p<.05, **p<.01, ***p<.001 
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CHANGE IN FVC OVER 1-YEAR FOLLOW UP 
 
Table 14: Factors associated with change in absolute FVC volumes (ml) over 1-year (n=290) 
 Univariate associations Participant characteristics R2: 0.139 
+ Baseline spirometry 
R2:0.261 
+ Baseline imaging 
R2: 0.163 
+Respiratory events 
R2 :0.152 
Full multivariate model 
R2:0.291 
Age (yrs) -1.3 (-4.0 – 1.3) -3.0 (-5.8 – -0.3)* -3.7 (-6.2 – 1.2)** -3.2 (-5.9 – -0.5)* -2.8 (-5.6 – -0.0)* -3.4 (-6.0 - -0.8)** 
Male gender 111.1 (52.1 – 170.0)*** 98.5 (18.5 – 178.5)* 165.3 (88.5 – 242.0)*** 96.8 (17.4 – 176.2)* 100.4 (20.7 – 180.1)* 174.2 (97.3 – 251.1)*** 
Height (cm) 4.5 (1.1 – 8.0)* 1.3 (-3.0 – 5.6) 8.8 (4.3 – 13.4)*** 1.1 (-3.2 – 5.3) 0.8 (-3.5 – 5.2) 8.2 (3.6 – 12.8)** 
HIV positive at TB treatment completion 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
101.3 (38.2 – 164.5)** 
73.3 (3.7 – 142.9)* 
 
126.3 (64.1 – 188.6)*** 
102.9 (32.9 – 172.9)** 
 
126.1 (68.3 – 183.9)*** 
129.9 (64.5 – 195.3)*** 
 
130.5 (68.6 – 192.4)*** 
108.4 (39.0 – 177.9)** 
 
119.7 (57.3 – 182.2)*** 
91.6 (20.1 – 163.1) * 
 
123.2 (65.5 – 180.9)*** 
115.7 (49.6 – 181.8)** 
Positive baseline TB microbiology 5.6 (-59.9 – 71.2) -9.5 (-74.3 – 55.4) -3.1 (-63.4 – 57.1) -8.3 (-72.5 – 55.9) -4.6(-69.3 – 60.2) 4.1 (-55.5 – 63.7) 
BMI at TB treatment completion (kg/m2) -15.8 (-25.6 – -6.0)** -12.3 (-22.3 – -2.4)* -4.4 (-14.0– 5.1) -10.4 (-20.6 – -0.3)* -12.7 (-22.6 – -2.7)* -5.2 (-14.7 – 4.4) 
Ever smoking 67.4 (8.0 – 126.8)* 24.9 (-39.7 – 89.5) 21.3 (-38.6 – 81.3) 15.6 (-48.7 – 79.9) 22.9 (-41.7 – 87.5) 14.0 (-45.7 – 73.8) 
Poorest 3x SES quintiles 41.1 (-14.2 – 96.3) 16.8 (-43.4 – 77.0) 12.8 (-43.0 – 68.7) 9.6 (-50.2 – 69.4) 12.6 (-47.7 – 72.9) 3.0 (-52.7 – 58.7) 
Intermittent food insecurity 37.9 (-19.9 – 95.8) 25.7 (-35.2 – 86.6) 33.6 (-22.9 – 90.2) 26.2 (-34.2 – 86.5) 24.9 (-35.8 – 85.6) 35.6 (-20.3 – 91.6) 
FVC at TBRx completion (ml) -0.04 (-0.08 – -0.00)*  -0.15 (-0.20 – -0.11)***   -0.16 (-0.21 – -0.11)*** 
≥1/3 abnormal parenchyma, except mosaicism 127.2 (54.3 – 200.1)**   109.8 (32.2 – 187. 5)**  40.6 (-35.0 – 116.1) 
≥3 lobes with mod-severe bronchiectasis 39.6 (-60.6 – 139.8)   -56.3 (-159.3 – 46.8)  -92.8 (-189.0 – 3.4) 
Any OPD / IP respiratory visits -115.6 (-192.2 – 39.0)**    -61.5 (-141.7 – 18.7) -79.9 (-153.8 – -6.0)* 
TB retreatment -120.3 (-356.9 – 116.2)    -109.5 (-345.4 – 126.3) -114.4 (-332.0 – 103.2) 
*p<.05, **p<.01, ***p<.001 
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FEV1 AT 1-YEAR 
 
Table 15: Factors associated with absolute volumes of FEV1 (ml) 1-year after TB treatment completion (n=290) 
 Univariate associations ‘Standardised’ univariate Basic multivariate model R2: 0.513 
+ Baseline spirometry 
R2: 0.924 
+ Baseline imaging 
R2: 0.580 
+Respiratory events 
R2 :0.517 
Full multivariate model 
R2: 0.926 
Age (yrs) -6.5 (-14.1 – 1.05)  -15.5 (-21.4 – -9.6)*** -5.7 (-8.1 – -3.3)*** -14.4 (-19.9 – -8.8)*** -15.0 (-21.0 – -9.0) -5.6 (-8.0 – -3.2)*** 
Male gender 772.1 (625.5–918.7)***  468.2 (196.2 – 640.3)*** 125.4 (55.1 – 195.7)** 506.9 (345.9 – 667.9)*** 473.3 (301.7 – 645.0)*** 130.8 (59.5 – 202.0)*** 
Height (cm) 53.5 (45.8 – 61.2)***  39.2 (29.9 – 48.4)*** 6.4 (2.4 – 10.4)** 38.7 (30.0 – 47.3)*** 38.1 (28.7 – 47.4)*** 6.1 (2.0 – 10.2)** 
HIV positive at TBRx end 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
28.6 (-153.6 – 210.7) 
175.3 (-25.4 – 376.0) 
 
154.4 (19.1 – 289.7)* 
282.4 (129.6 – 435.1)*** 
 
127.1 (-7.0 – 261.3) 
243.7 (93.1 – 394.3)** 
 
107.1 (54.0 – 160.1)** 
92.5 (32.4– 152.6)** 
 
141.6 (15.8 – 267.3)* 
212.2 (71.5 – 353.0)** 
 
113.4 (-21.3 – 248.1) 
218.1 (64.2 – 372.0)** 
 
105.3 (51.8 – 158.8)*** 
86.0 (24.0 – 147.2)** 
Positive baseline TB 
microbiology 26.9 (-159.8 – 213.7) -77.0 (-217.3 – 63.4) -12.7 (-152.0 – 126.6) -38.6 (-93.7 – 16.6) -12.2 (-142.1 – 117.7) -2.6 (-141.9 – 136.7) -33.6 (-88.7 – 21.4) 
BMI at TB treatment 
completion (kg/m2) 16.3 (-12.1 – 44.6) 40.4 (19.0 – 61.7)*** 33.9 (12.4 – 55.3)** 0.9 (-7.7 – 9.6) 18.6 (-1.9 – 39.1) 33.4 (12.0 – 54.8)** 0.2 (-8.5 – 8.9) 
Illness duration ≥1-month 
prior to treatment -177.6 (-339.7 – -15.4)* -138.2 (-259.2 – -17.1)* -123.8 (-241.3 – -6.20)* -9.4 (-56.3 – 37.5) -80.8 (-191.3 – 29.6) -117.4 (-234.8 – 0.01) -5.6 (-52.5 – 41.3) 
Ever smoking 255.8 (87.8 – 423.9)** -109.8 (-249.7 – 30.2) -64.5 (-203.2 – 74.1) 12.7 (-42.3– 67.8) -35.6 (-202.6 – 40.1) -70.6 (-209.4 – 68.2) 10.5 (-44.7 – 65.7) 
Poorest 3x SES quintiles -214.4 (-370.3 – -58.5)** -155.0 (-273.0 – -36.95)* -103.2 (-232.8 – 26.4) 1.2 (-50.4 – 52.7) -81.2 (-202.6 – 40.1) -112.7 (-242.6 – 17.3) -2.8 (-54.6 – 49.0) 
Intermittent food 
insecurity -200.4 (-364.0 – -36.8)* -76.3 (-200.3 – 47.7) 11.3 (-119.5 – 142.0) 16.2 (-35.6– 67.9) 24.4 (-97.7 – 146.5) 8.5 (-121.9 – 139.0) 17.2 (-34.4 – 68.8) 
FEV1 (ml) at TBRx 
completion 0.96 (0.92 – 0.99)*** 0.88 (0.83 – 0.92)***  0.87 (0.82 – 0.91)***   0.86 (0.82 – 0.91)*** 
FVC (ml) at TBRx 
completion 0.76 (0.71 – 0.81)*** 0.68 (0.62 – 0.75)***      
FEV1/FVC ratio (%) at TBRx 
completion 28.9 (20.8 – 36.9)*** 30.2 (24.3 – 36.1)***      
≥1/3 abnormal 
parenchyma, except 
mosaicism 
-407.4  
(-613.9 – -201.0)*** 
-549.2  
(-695.4 – -402.9)***   
-406.0  
(-563.3 – -248.8)***  12.5 (-57.9 – 82.9) 
≥3 lobes with mod-severe 
bronchiectasis 
-492.4 
(-772.4 – -212.5)** 
-497.7  
(-703.7 – -291.7)**   
-243.1  
(-452.0 – -34.3)*  -41.7 (-130.6 – 47.3) 
Any OPD / IP respiratory 
visits 
-357.1  
(-574.7 – -139.5)** 
-189.8 
(-355.2 –  -24.3)*    -139.1 (-311.6 – 33.3) -40.8 (-109.1 – 27.5) 
TB retreatment -260.7  (-934.9 – 413.6) 
-361.0 
(-863.7 – 141.7)    -131.5 (-638.4 – 375.4) -165.1 (-366.1 – 35.9) 
*p<.05, **p<.01, ***p<.001 
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Table 16: Factors associated with absolute volumes of FVC (ml) 1-year after TB treatment completion (n=290) 
 Univariate associations ‘Standardised’ univariate Basic multivariate model R2: 0.576 
+ Baseline spirometry 
R2: 0.929 
+ Baseline imaging 
R2:0.628 
+Respiratory events 
R2: 0.583 
Full multivariate model 
R2: 0.932 
Age (yrs) 3.9 (-4.7 – 12.5)  -7.2 (-13.4 – -0.9)* -3.7 (-6.3 – -1.1)** -6.0 (-11.9 – -0.12)* -6.5 (-12.8 – -0.19)* -3.4 (-6.0 – -0.9)** 
Male gender 1014.6 (859.4 – 1169.7)***  526.3 (344.4 – 708.2)*** 165.7 (88.8 – 242.7)*** 567.5 (395.7 – 739.2)*** 532.7 (351.6 – 713.8)*** 175.5 (98.3 – 252.7)*** 
Height (cm) 67.7 (59.7 – 75.7)***  50.4 (40.6 – 60.2)*** 8.8 (4.2– 13.4)*** 49.7 (40.5 – 58.9)*** 49.1 (39.2 – 58.9)*** 8.1 (3.5 – 12.8)** 
HIV positive at TBRx end 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
22.4 (-183.5 – 228.2) 
240.7 (13.9 – 467.5)* 
 
143.6 (2.3 – 284.9)* 
282.6 (123.1 – 442.0)** 
 
117.4 (-24.5 – 259.2) 
272.1 (112.9 – 431.4)** 
 
126.8 (68.7 – 184.9)*** 
130.5 (64.8 – 196.1)*** 
 
136.0 (1.84 – 270.1)* 
241.1 (91.0 – 391.2)** 
 
100.2 (-41.9 – 242.3) 
240.0 (77.7 – 402.4)** 
 
124.5 (66.5 – 182.6)*** 
116.6 (50.3 – 182.8)** 
Positive baseline TB 
microbiology 96.2 (-115.3 – 307.6) 1.7 (-144.9 – 148.3) 28.7 (-118.6 – 176.1) -2.9 (-63.3 – 57.5) 30.0 (-108.6 – 168.5) 41.2 (-105.8 – 188.1) 4.7 (-55.1 – 64.4) 
BMI at TB treatment 
completion (kg/m2) 16.7 (-15.4 – 48.9) 39.3 (17.0 – 61.6)** 38.5 (15.8 – 61.1)** -4.4 (-14.0 – 5.1) 23.0 (1.17 – 44.9)* 38.0 (15.4 – 60.6)** -5.1 (-14.7 – 4.4) 
Illness duration ≥1-month 
prior to treatment -136.7 (-321.4 – 47.9) -92.2 (-219.0 – 34.6) -70.0 (-194.3 – 54.3) 6.6 (-44.5 – 57.7) -26.0 (-143.8 – 91.8) -62.1 (-186.0 – 61.8) 12.7 (-38.0 – 63.4) 
Ever smoking 456.9 (270.8 – 643.0)*** -5.9  (-152.3 – 140.5) 2.7 (-143.9 – 149.4) 21.3 (-38.8 – 81.4) 28.0 (-110.6 – 166.6) -5.0 (-151.4 – 141.5) 13.9 (-45.9 – 73.7) 
Poorest 3x SES quintiles -95.5 (-274.1 – 83.2) -33.6 (-158.0 – 90.8) -15.7 (-152.8 – 121.3) 13.4 (-42.8 – 69.6) 2.9 (-126.5 – 132.4) -27.7 (-164.7 – 109.4) 4.1 (-51.8 – 60.1) 
Intermittent food insecurity -114.8 (-301.7 – 72.0) 35.1 (-94.4 – 164.6) 80.5 (-57.7 – 218.8) 33.3 (-23.5 – 90.0) 95.5 (-34.7 – 255.8) 77.1 (-60.6 – 214.7) 35.0 (-21.1 – 91.1) 
FEV1 (ml) at TBRx 
completion 0.99 (0.93 – 1.06)*** 0.79 (0.72 – 0.86)***      
FVC (ml) at TBRx completion 0.96 (0.92 – 0.99)*** 0.85 (0.80 – 0.89)***  0.85 (0.80 – 0.89)***   0.84 (0.79 – 0.89)*** 
FEV1/FVC ratio (%) at TBRx 
completion -0.89 (-10.77 – 8.99) 1.61 (-5.51 – 8.73)      
≥1/3 abnormal parenchyma, 
except mosaicism 
-309.2  
(-546.7 – -71.8)* 
-497.1  
(-653.1 – -341.1)***   
-368.0  
(-535.7 – -200.2)***  39.7 (-36.1 – 115.4) 
≥3 lobes with mod-severe 
bronchiectasis 
-517.1  
(-835.4 – -198.8)** 
-531.1  
(-745.3 – -316.8)***   
-309.1  
(-531.9 - -86.3)**  -94.4 (-191.0 – 2.1) 
Any OPD / IP respiratory 
visits 434.2 (-680.2 – -188.2)* 
-243.7  
(-415.2 – 72.1)**    -174.1 (-356.0 – 7.87) -80.6 (-154.7 – -6.5)* 
TB retreatment -306.9 (-1071.2 – 457.4) 
-356.1 
(-880.1 – 167.9)    -150.1 (-684.8 – 384.7) -114.8 (-332.8 – 103.1) 
*p<.05, **p<.01, ***p<.001 
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FEV1/FVC RATIO AT 1-YEAR 
Table 17: Factors associated with the absolute FEV1/FVC ratio (%), 1-year after TB treatment completion (n=290) 
 Univariate associations 
 
‘Controlled’ univariate 
 
Basic multivariate model 
R2: 0.204 
+ Baseline spirometry 
R2: 0.841 
+ Baseline imaging 
R2:0.216 
+Respiratory events 
R2: 0.204 
Full multivariate model 
R2: 0.843 
Age (yrs) -0.3 (-0.4 – 0.2)***  -0.3 (-0.4 – -0.2)*** -0.1 (-0.1 – -0.0)** -0.3 (-0.4 – -0.2)*** -0.3 (-0.4 – -0.2)*** -0.1 (-0.1 – -0.0)*** 
Male gender -1.5 (-3.9 – 0.9)  1.2 (-1.9 – 4.2) 0.1 (-1.3 – 1.4) 1.3 (-1.7 – 4.4) 1.2 (-1.9 – 4.2) -0.0 (-1.4 – 1.4) 
Height (cm) -0.0 (-0.2 – 0.1)  -0.0 (-0.2 – 0.1) 0.0 (-0.1 – 0.1) -0.0 (-0.2 – 0.12) -0.0 (-0.2 – 0.1) -0.0 (-0.1 – 0.1) 
HIV positive at TBRx end 
- CD4≥200 cells/uL 
- CD4<200 cells/uL 
 
0.6 (-2.0 – 3.1) 
-0.2 (-3.0 – 2.6) 
 
1.5 (-0.9 – 3.9) 
2.3 (-0.4 – 5.0) 
 
1.3 (-1.1 – 3.6) 
1.4 (1.3 – 4.0) 
 
0.2 (-0.9 – 1.2) 
0.0 (-1.2 – 1.2) 
 
1.3 (-1.1 – 3.6) 
1.2 (-1.5 – 3.8) 
 
1.2 (-1.2 – 3.6) 
1.3 (-1.5 – 4.0) 
 
-0.1 (-0.9 – 1.2) 
-0.2 (-1.1 – 1.4) 
Positive baseline TB microbiology -1.7 (-4.3 – 0.9) -2.6 (-5.1 – 0.2)* -1.3 (-3.8 – 1.1) -1.1 (-2.2 – -0.0)* -1.3 (-3.8 – 1.1) -1.3 (-3.8 – 1.2) -1.2 (-2.3 – -0.0)* 
BMI at TB treatment completion 
(kg/m2) 
0.2 (-0.2 – 0.5) 0.4 (0.0 – 0.7) 0.2 (-0.2 – 0.5) 0.2 (0.0 – 0.4)* 0.1 (-0.2 – 0.5) 0.2 (-0.2 – 0.5) 0.2 (0.0 – 0.4)* 
Illness duration ≥1-month prior to 
treatment 
-2.2 (-4.4 – 0.1) -2.1 (-4.2 – -0.1) -2.1 (-4.2 – -0.1)* -0.3 (-1.2 – 0.7) -1.9 (-4.0 – 0.2) -2.1 (-4.2 – -0.0)* -0.3 (-1.2 – 0.7) 
Ever smoking -2.9 (-5.2 – -0.5)* -2.5 (-4.9 – -0.0)* -1.2 (-3.7 – 1.3) 0.1 (-1.0 – 1.2) -1.0 (-3.4 – 1.5) -1.2 (-3.7 – 1.3) 0.2 (-0.9 – 1.3) 
Poorest 3x SES quintiles -4.4 (-6.5 – -2.3)*** -4.1 (-6.1 – -2.0)*** -3.0 (-5.3 – -0.7)* -0.3 (-1.4 – 0.7) -2.8 (-5.1 – -0.5)* -3.1 (-5.4 – -0.7)* -0.2 (-1.3 – 0.8) 
Intermittent food insecurity -3.2 (-5.5 – -1.0)** -3.1 (-5.2 – -0.9)** -1.4 (-3.7 – 0.9) -0.2 (-1.2 – 0.9) -1.4 (-3.7 – 0.9) -1.4 (-3.8 – 0.9) -0.2 (-1.2 – 0.9) 
FEV1 (ml) at TBRx completion 0.01 (0.00 – 0.01)*** -0.01 (-0.01 – -0.01)***      
FVC (ml) at TBRx completion -0.00 (-0.00 – 0.00) 0.00 (-0.00 – 0.00)      
FEV1/FVC ratio (%) at TBRx 
completion 0.95 (0.90 – 1.00)*** 0.92 (0.87 – 0.98) ***  0.91 (0.86 – 0.96)***   0.91 (0.86 – 0.97)*** 
≥1/3 abnormal parenchyma, 
except mosaicism 
-4.7 (-7.6 – -1.8)** -4.4 (-7.1 – -1.6)**   -3.0 (-6.0 – -0.0)  -0.3 (-1.7 – 1.1) 
≥3 lobes with mod-severe 
bronchiectasis 
-2.7 (-6.7 – 1.2) -2.5 (-6.2 – 1.2)   -0.2 (-4.1 – 3.8)  0.9 (-0.8 – 2.7) 
Any OPD / IP respiratory visits -1.0 (-4.0 – 2.1) -0.5 (-3.4 – 2.4)    -0.5 (-3.6 – 2.6) 0.6 (-0.8 – 2.0) 
TB retreatment -0.7 (-10.§ – 8.6) -2.7 (-11.5 – 6.1)    -0.3 (-9.3 – 8.8) -2.7 (-6.8 – 1.4) 
*p<.05, **p<.01, ***p<.001 
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PATTERNS OF DEFICIT AT 1-YEAR 
Table 18: Factors associated with Airway Obstruction (n=48) or Low FVC (n=40) at 1-year post TB treatment completion, compared to normal spirometry (n=202). OR (95% CI) presented  
Obstruction -  FEV1/FVC ratio <LLN, using GLI-2012 reference range; Low FVC -  FEV1/FVC ratio ≥LLN & FVC<LLN, using GLI-2012 reference range 
Variable 
Airway obstruction, compared to normal (n=250) Low FVC, compared to normal (n=242) 
Univariate associations Basic multivariate model Full multivariate model Univariate associations Basic multivariate model Full multivariate model 
Age (yrs) 1.01 (0.98 - 1.04) 1.02 (0.98 – 1.05) 1.02 (0.98 – 1.08) 0.94 (0.90 – 0.98)** 0.96 (0.91 – 1.01) 1.00 (0.93 – 1.08) 
Gender 
- Female 
- Male 
 
1.0 
1.03 (0.51 – 2.09) 
 
1.0 
0.84 (0.30 – 2.31) 
 
1.0 
1.35 (0.31 – 5.96) 
 
1.0 
0.47 (0.23 – 0.94)* 
 
1.0 
0.41 (0.14 – 1.20) 
0.06 (0.01 – 0.50)* 
Height (cm) 0.98 (0.95 – 1.02) 0.99 (0.93 – 1.04) 0.95 (0.87 – 1.03) 0.99 (0.94 – 1.03) 1.02 (0.95 – 1.08) 1.12 (0.98 – 1.28) 
HIV status  
- Negative 
- Positive, CD4>=200 cells/uL 
- Positive, CD4<200 cells/uL 
 
1.0 
0.56 (0.27 – 1.17) 
0.53 (0.24 – 1.19) 
 
1.0 
0.53 (0.24 – 1.18) 
0.58 (0.93 – 1.04) 
 
1.0 
0.9 (0.32 – 3.50) 
1.5 (0.38 – 5.71) 
 
1.0 
0.52 (0.25 – 1.10) 
0.19 (0.06 – 0.60) ** 
 
1.0 
0.61 (0.27 – 1.41) 
0.34 (0.10 – 1.16) 
 
1.0 
0.16 (0.04 – 0.70)* 
0.21 (0.03 – 1.59) 
Baseline TB microbiology 
- Negative 
- Positive 
 
1.0 
2.08 (0.88 – 4.93) 
 
1.0 
1.44 (0.57 – 3.64) 
 
1.0 
3.36 (0.83 – 13.56) 
 
1.0 
1.68 (0.70 – 4.02) 
 
1.0 
1.30 (0.50 – 3.39) 
 
1.0 
1.82 (0.35 – 9.46) 
BMI at TB treatment completion (kg/m2) 0.86 (0.75 – 0.99) 0.91 (0.78 – 1.05) 1.00 (0.81 – 1.24) 0.83 (0.71 – 0.97)* 0.87 (0.75 – 1.02) 0.96 (0.77 – 1.20) 
Illness duration prior to TB treatment 
- <1-month 
- ≥1-month 
 
1.0 
1.59 (0.80 – 3.15) 
 
1.0 
1.60 (0.78 – 3.26) 
 
1.0 
1.54 (0.54 – 4.39) 
 
1.0 
1.53 (0.74 – 3.18) 
 
1.0 
1.40 (0.64 – 3.08) 
 
1.0 
0.43 (0.11 – 1.67) 
Ever smoking 
- Never 
- Ever 
 
1.0 
1.55 (0.81 – 2.98) 
 
1.0 
1.30 (0.59 – 2.89) 
 
1.0 
1.63 (0.52 – 5.10) 
 
1.0 
0.79 (0.36 – 1.71) 
 
1.0 
1.04 (0.40 – 2.70) 
 
1.0 
1.25 (0.24 – 6.45) 
Urban SES quintile 
- Least poor quintiles x2 
- Poorest quintiles x3 
 
1.0 
2.86 (1.43 – 5.72)** 
 
1.0 
1.79 (0.80 – 3.98) 
 
1.0 
0.74 (0.23 – 2.36) 
 
1.0 
1.44 (0.72 – 2.85) 
 
1.0 
1.19 (0.51 – 2.78) 
 
1.0 
0. 67 (0.14 – 3.09) 
Food insecurity 
- Never 
- Sometimes / often 
 
1.0 
2.70 (1.42 – 5.13)* 
 
1.0 
1.95 (0.95 – 4.03) 
 
1.0 
1.59 (0.53 – 4.70) 
 
1.0 
2.03 (1.02 – 4.06)* 
 
1.0 
2.03 (0.88 – 4.65) 
 
1.0 
1.48 (0.35 – 6.30) 
Baseline spirometry pattern 
- Normal 
- Obstruction 
- Low FVC 
 
1.0 
78.26 (28.29 – 215.92)*** 
2.68 (0.68 – 10.51) 
 
 
1.0 
117.91 (31.26 – 444.73)*** 
2.92 (0.64 – 13.40) 
 
1.0 
Empty^ 
121.28 (33.97 – 432.96)*** 
 
 
1.0 
Empty^ 
216.98 (37.87 – 1243.21)*** 
Parenchyma, except mosaicism 
- <1/3 abnormal 
- ≥1/3 abnormal 
 
1.0 
4.4 (2.0 – 9.5)*** 
 
 
1.0 
1.38 (0.36 – 5.26) 
 
1.0 
5.19 (2.32 – 11.58)*** 
 1.0 1.53  (0.31 – 7.62) 
Mod-severe bronchiectasis 
- <3 lobes 
- ≥3 lobes 
 
1.0 
4.9 (1.7 – 13.7)** 
 
 
1.0 
2.58 (0.41 – 16.20) 
 
1.0 
6.06 (2.12 – 17.31)** 
 
 
1.0 
15.37 (1.19 –199.01)* 
Any OPD / IP respiratory visits 
- No 
- Yes 
 
1.0 
0.9 (0.3 – 2.2) 
 
 
1.0 
0.33 (0.07 – 1.67) 
 
1.0 
1.49 (0.63 – 3.56) 
 
 
1.0 
0.94 (0.16 – 5.39) 
TB retreatment 
- No 
- Yes 
Empty#  Empty 
 
1.0 
1.70 (0.17 – 16.78) 
 
 
1.0 
1.31 (0.00 – 512.60) 
*p<.05, **p<.01, ***p<.001; #No patients with airway obstruction at 1-year had received TB retreatment; ^No patients in the low-FVC group at 1-year had been classed as obstructed at baseline 
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